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Summary 
 
Many chemotherapy drugs act by inducing DNA damage leading to cell death, and 
the platinum analogue class of anticancer drugs are the most commonly used DNA 
damaging chemotherapeutic drugs. Despite extensive analysis of platinum-DNA 
interactions, particularly characterising the individual adducts and their effects on 
DNA replication, transcription and cell survival, measurement of these adducts in 
cells with higher sensitivity and precision is necessary. Previous work studying 
platinum-DNA adduct formation has been performed using DNA damage assays such 
as immuno-slot-blots to detect whole genome DNA damage, or with combinations of 
chromatography and mass spectrometry to characterise each adduct individually. The 
ability to measure platinum-induced DNA damage genome-wide with high resolution 
in human cells could have profound implications for basic mechanistic research, as 
well as clinical translational research and treatment stratification, by providing a tool 
with the potential for predicting clinical response to these agents. 
 The achievement of this PhD was developing an assay to measure platinum-
induced DNA damage induction at high resolution, density and precision within the 
genome of human cells. This was achieved using DNA immunoprecipitation coupled 
with analysis using DNA microarrays, allowing measurements of platinum-induced 
DNA damage to be made at high resolution throughout the human genome for the 
first time. This assay was initially developed to measure cisplatin and oxaliplatin 
induced DNA damage in the genome of the yeast model organism Saccharomyces 
cerevisiae and experimental profiles of cisplatin and oxaliplatin-induced DNA 
damage were validated by demonstrating close correlation with mathematically 
generated predicted profiles for platinum-induced DNA damage.  
 The assay was then applied and validated to measure cisplatin, oxaliplatin and 
ultraviolet-induced CPD formation in human fibroblast cells, and again, experimental 
profiles of cisplatin and oxaliplatin-induced DNA damage and UV-induced CPD 
formation were shown to correlate well with predicted profiles of DNA damage. 
Novel comparative analytical approaches for studying microarray data from these 
genome-wide DNA damage datasets are demonstrated and further validation of the 
assay is provided by demonstrating the contrast between platinum-induced DNA 
damage and UV-induced CPD formation genome-wide and in the context of repeat 
sequences of DNA. 
 Finally, cisplatin and oxaliplatin-induced histone H3 acetylation changes are 
examined and histone H3 K14 acetylation is demonstrated to be a prominent histone 
modification following exposure to platinum analogues. Novel analysis is performed 
to investigate the influence of chromatin on platinum adduct formation, and greater 
platinum-induced DNA damage is demonstrated in DNA samples treated in vitro 
compared with DNA samples taken from cells treated in culture. Comparisons were 
also performed between histone H3 acetylation in yeast cells following exposure to 
cisplatin or UV irradiation and this comparison revealed very similar patterns of 
histone acetylation following exposure to these two different genotoxins. 
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Chapter 1. Introduction 
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Chapter 1 
Introduction 
 
 
1.1 DNA & Chromatin 
 
1.1.1 DNA discovery 
Deoxyribonucleic acid (DNA) contains the genetic information that codes the proteins 
that govern the function and development of cellular life and all living organisms. 
This molecule also allows the genetic information to be passed from one generation to 
the next, explaining the physical basis of heredity. DNA was first isolated in 1869, by 
the Swiss physician Friedrich Miescher, from leucocytes present in pus on discarded 
surgical bandages (Dahm, 2005). Following chemical analysis of its composition 
Miescher noted that this novel molecule was not a protein and since it had been 
isolated from the cell nucleus he named it ‘nuclein’. It wasn’t until the mid-1940s and 
early 1950s that DNA was shown to be the carrier of genetic information in living 
organisms (Avery et al., 1944, Hershey and Chase, 1952). Until this point it had been 
believed that since the DNA molecule comprised only four different nucleotides it 
was incapable of storing the enormous amount of genetic information required for 
heredity. Equally, whilst it was known that the DNA molecule was comprised of 
phosphate groups, sugars and nitrogenous bases, the structure of the molecule, and 
how it conveyed genetic information was unknown. 
 The structure of the DNA molecule was co-discovered in 1953 by James 
Watson and Francis Crick in the Cavendish Laboratory at Cambridge University. 
Their approach to discovering this structure had been to build physical models of the 
DNA molecule, however this approach alone was proving unsuccessful. Two pivotal 
pieces of work performed by Rosalind Franklin, who along with Maurice Wilkins was 
pioneering x-ray crystallography to study DNA structure at King’s College Hospital, 
London, proved crucial in assisting Watson and Crick to construct their model. 
Firstly, Franklin observed that the hydrophilic phosphate-containing backbone of the 
DNA molecule should be positioned on the outside of the molecule so as to allow 
interaction with water molecules, rather than at the centre where they had been placed 
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in Watson and Crick’s original molecular model in 1951. Secondly, a high quality x-
ray diffraction image of the DNA molecule (known as photograph 51), produced in 
1952 by Franklin and her student Raymond Gosling, and was passed to Watson and 
Crick by Maurice Wilkins without Franklin’s permission, allowed Franklin to confirm 
the helical structure of the molecule. Watson and Crick’s interpretation of these 
observations, allied to their own modelling insights, led them to develop the double-
helix molecular model for DNA, which was presented in 1953 (Watson and Crick, 
1953). The Kings group published their interlocking work in two other papers in the 
same issue of Nature (Wilkins et al., 1953, Franklin and Gosling, 1953). Watson, 
Crick and Maurice Wilkins were awarded the Nobel Prize for Physiology or Medicine 
in 1962 for their discovery but having died 4 years previously, Rosalind Franklin was 
ineligible for nomination.  
 In the years following the discovery of the structure of DNA Crick proceeded 
to make fundamentally important observations, which he outlined in a seminal 
address to the British Society of Experimental Biology and in an accompanying paper 
‘On Protein Synthesis’ (Crick, 1958). Here he proposed the ‘Sequence Hypothesis’ 
whereby the order of the bases represented a code for the amino acid sequence of a 
particular protein, and the ‘Central Dogma’ whereby the genetic information could 
pass from DNA to RNA and to proteins but not in the reverse direction. 
 The discovery of DNA and the description of its structure represented the 
beginning of modern molecular biology and remains one of the most significant 
scientific discoveries ever made. By the late 1960s the genetic code had been 
translated (Singer, 1968) paving the way for molecular genetic research to identify 
individual genes and study their function. By the turn of the millennium the Human 
Genome Project had completed the sequencing map of the human genome (Lander et 
al., 2001, Venter et al., 2001). Huge advances in the field of genomic research 
continue to be made and it remains at the forefront of pioneering scientific and 
medical research 60 years on from the discovery of Watson and Crick. 
 
1.1.2 DNA structure 
DNA comprises two polynucleotide strands that run in antiparallel direction and are 
organised in the shape of a double helix. Each nucleotide comprises a nucleobase 
(base for short), deoxyribose sugar and a phosphate group. The strands have 
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asymmetric ends, defined by the position of the carbon atom of the deoxyribose 
molecule, and these ends describe the orientation of the strand. One end has a 
terminal phosphate group and is called the 5ʹ′ (five prime) end, whilst the other end 
has a terminal hydroxyl group and is called the 3ʹ′ (three prime) end. 
 The DNA ‘backbone’ consists of alternating sugar and phosphate residues. 
The sugars are bound to one another via phosphate groups, which bind between the 
third and fifth carbon atoms of adjacent deoxyribose groups by covalent 
phosphodiester bonds (figure 1.1). Bound to each sugar via a N-glycosyl bond is a 
base, which are classified into two types: purine bases comprising adenine (A) and 
guanine (G), and pyrimidine bases comprising cytosine (C) and thymine (T). Bases 
form hydrogen bonds with bases on the other strand and each base binds with just one 
other type on the opposing strand; A binds to T involving two hydrogen bonds and G 
binds to C involving three hydrogen bonds. This is referred to as complementary base 
pairing and the significance of this was immediately recognised by Watson and Crick 
who wrote “If only specific pairs of bases can be formed, it follows that if the 
sequence of bases on one chain is given, then the sequence on the other chain is 
automatically determined”. They also interpreted that base pairing provided the basis 
for DNA replication, writing “It has not escaped our notice that the specific pairing 
we have postulated immediately suggests a possible copying mechanism for the 
genetic material” (Watson and Crick, 1953). 
 The two strands of the DNA double helix are therefore joined together by 
hydrogen bonds, which are weaker than covalent bonds and these two strands can be 
pulled apart or separated either by mechanical force, high temperatures or changes in 
pH. Since the GC base pairing forms three hydrogen bonds, DNA with higher GC-
content is considered more stable than low GC-content DNA.  
 DNA can exist in alternate structural conformations, termed A-DNA, B-DNA 
and Z-DNA, and it is the B-DNA from that is predominantly seen in the well-
hydrated environment within cells. B-DNA exists as a right handed helix with an 
angle of 36° between adjacent base pairs, meaning there are 10 base pairs per 
complete revolution of the helix, and the structure repeats itself after 10 bases on each 
chain (Watson and Crick, 1953). The A-DNA conformation occurs under non-
physiological, dehydrated conditions and involves an altered helical conformity with a 
wider helical spiral and deeper major groove. Alternatively, segments of DNA that 
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have been modified, particularly by methylation, can exist in a Z-DNA form, which 
involves a larger change in conformation. 
 
 
Figure 1.1 - Chemical structure of the double-stranded DNA molecule. Two antiparallel phosphate-
deoxyribose backbone strands consisting of sugars bound to one another via phosphate groups and 
covalent phosphodiester bonds. Bound to each sugar is a nucleobase and these bases form hydrogen 
bonds with bases on the other strand of DNA. C - carbon atom, H - hydrogen atom, O - oxygen atom, 
N - nitrogen atom, P - phosphorous atom, 3ʹ′  - three prime, 5ʹ′  - five prime.  
 
1.1.3 Chromatin structure and organisation 
In mammalian cells genomic DNA, when fully extended, is around 2 metres long. A 
sophisticated level of organisation is therefore required allowing the DNA molecule 
to be packaged and compacted within the cell nucleus. This is achieved through a 
highly conserved series of structural arrangements and interactions with DNA-binding 
proteins, which collectively is termed chromatin.  
 The nucleosome is the fundamental repeating sub-unit of chromatin 
(Kornberg, 1974). Each nucleosome is composed of two copies of the histone proteins 
H2A, H2B, H3 and H4, forming a histone octamer, 170-240 base pairs (bp) of DNA 
and a single linker histone H1 protein. Approximately 146bp of this segment of DNA 
is tightly wrapped in about 1.5 turns around the histone octamer comprising the 
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nucleosome core particle (NCP) (Luger et al., 1997). Neighbouring NCPs are joined 
to one another via a connecting segment of linker DNA of around 20-90 bp in length 
giving the typical “beads on a string” appearance seen on electron microscopy (Olins 
and Olins, 1974) (figure 1.2). Nucleosomes represent the first step in DNA 
compaction; the next step in organisation is formed when adjacent nucleosome cores 
form short-range interactions with each other, assembling into higher order structures, 
which are stabilised by the linker histone H1. This compacts linear DNA by a factor 
of 30-40 and additional compaction and folding produces the highly condensed, 
higher order, helical structure of chromatin typical of metaphase chromosomes 
(Felsenfeld and Groudine, 2003) (figure 1.3). 
 
 
Figure 1.2 - Schematic illustration of the nucleosome core particle with connecting strand of 
linker DNA. The histone octamer comprising two copies of the histone proteins H2A, H2B, H3 and H4 is 
represented by the cylindrical disks and the DNA as a ribbon, with shading to distinguish core DNA 
(dark) from linker DNA (light). Figure reproduced from (Kornberg and Lorch, 1999). 
 
 Cytological studies have identified two different forms of chromatin: 
heterochromatin and euchromatin. Originally, these two forms were distinguished by 
how intensely they stained - heterochromatin is the portion of the genome that is 
tightly packed and highly condensed and stains intensely whilst euchromatin is more 
lightly packed and stains less intensely. Euchromatin is a more open form of 
chromatin, rich in gene concentration, often under active transcription and represents 
the vast majority of the human genome. More recently, these forms have been 
distinguished based on function and epigenetic characteristics, which in the case of 
DNA methylation has been shown to be stable and heritable between cell divisions 
(Wigler et al., 1981). Euchromatin, where the individual nucleosomes are loosely 
wrapped and decondensed, is enriched in certain epigenetic motifs or histone tail post-
translational modifications (PTMs) such as histone 3 lysine 4 trimethylation 
(H3K4me3) and histone 3 acetylation (Margueron and Reinberg, 2010). This loose, 
unfolded structure is thought to promote accessibility of gene regulatory proteins 
Cell
286
Figure 1. Schematic of Nucleosome Core
Particle and Linker
The histone octamer is represented as a disk,
and the DNA as a ribbon, with shading to
distinguish core DNA (dark) from linker DNA
(light).
shorter fragment of 110 base pairs, produced upon ex- 15–30 residues at the amino termini of all the histones
are unstructured and commonly referred to as “tails.”tended micrococcal nuclease digestion (Sahasrabud-
The high-resolution structure of the core particledhe and van Holde, 1974), was explained by subsequent
(Luger et al., 1997) shows details of the histone–DNAcharacterization of the “coreparticle” of the nucleosome
interaction, which is confined to the phosphodiester(see below). Finally, electron microscopists early noted
backbones of the DNA strands on the inner surface ofa “knobby” appearance of chromatin fibers (Bram and
the superhelix (Figure 2). A set of contacts is made everyRis, 1971), which came into clearer focus with improved
10 base pairs where theminor g oove of he double helixmethods of specim n preparation, r vealing a beaded
faces inward. Electrostatic interactions and hydrogensubstructure of the fibers (Olins and Olins, 1974; Wood-
bonding ith the DNA phosphates, as well as nonpolarcock et al., 1976). Soon after, electron microscopy of
contacts with the deoxyribose groups, are observed.reconstituted histone–DNA complexes (Oudet et al.,
The lack of contacts with DNA bases is in accord with1975) and of chromatin digested with microccocal
the lack of sequence specificity of the histone–DNA in-nuclease (Finch et al., 1975; Oudet et al., 1975) identified
teraction, evident from the capacity of the histone oc-the beads as nucleosomes.
tamer to package virtually any DNA. Two further pointsSubsequent solution studies provided further support
that relate to nucleosome function are also noteworthy.for the nucleosome. Physical isolation proved the exis-
First, the two turns of the DNA superhelix are in register,tence of the proposed histone octamer (Thomas and
with grooves aligned, creating sufficient gaps for theKornberg, 1975). Digestion of chromatin with DNase I
amino-terminal tails of both H2B and H3 to pass throughsupported the proposed wrapping of the DNA around
to the outside of the core particle. H2A and H4 tails passthe octamer (Noll, 1974). Topoisomer analysis quanti-
across the superhelix on the flat faces of the particle totated the wrapping (Germond et al., 1975). Additional
the outside as well. Thus, the histone tails are exposed,studies of histone–DNA complexes completed the char-
a feature crucial for the role of the nucleosome in tran-acterization of the nucleosome (reviewed by Pederson
scriptional regulation. The second point of functionalet al., 1986).
inter st concerns the twist of theDNAdouble helix asso-
ciated with the core particle. A stretch of about 10 base
Structure of the Nucleosome pairs of slightly alter d twist, with about 1 fewer base
Micrococcal nuclease digestion of chromatin paved the pair per turn, is readily accommodated at various loca-
way to structure determination of the nucleosome. After tions within the core particl . This structural plasticity
cleaving the DNA between nucleosomes, micrococcal may underlie the remodeling of chromatin for transcrip-
nuclease digests the ends of the DNA protruding from tion (see below).
the nucleosome to a metastable limit at 146 base pairs
(van Holde et al., 1975; Noll and Kornberg, 1977). The Structure of Chromatin Fibers
resulting complex, containing all four histones in associ- The DNA between core particles, connecting one nu-
ation with the residual DNA, has come to be known as cleosome to the next in chromatin, is referred to as
the “core particle” of the nucleosome (Figure 1). Core “linker” (Figure 1). Variation in the length of linker DNA
particles are homogeneous enough to be crystallized. (Spadafora et al., 1976) is important for the diversity
Analysis at 7 A˚ resolution by a combination of X-ray and of gene regulation. Despite this variation, a chain of
electron crystallography revealed the coiling of DNA in nucleosomes can still coil or fold in a regular manner,
1 3/4 left-handed superhelical turns around the histones to form a chromatin fiber. How variability is reconciled
(Finch et al., 1977). Details of histone arrangement and with regularity underlies a mechanism of great signifi-
structure came from crystallographic analysis of the oc- cance, the decondensation of chromatin for transcrip-
tamer alone. The histones were seen to form a left- tion, and its modulation by posttranslational modifica-
handed protein superhelix matching that of the DNA in tions of the histone tails.
the core particle (Klug et al., 1980; Arents et al., 1991). The length of linker DNA varies in many cases almost
The (H3)2(H4)2 tetramer lay at the center, with H2A-H2B at random, but the locations of nucleosomes are some-
dimers at the ends of the DNA path. Each of the histones times constrained by barriers, such as sequence-spe-
exhibits a similar polypeptide chain fold (the “histone cific DNA-binding proteins on the DNA, as well as by
fold,” Figure 2), based on a long central a helix, flanked more subtle effects, such as sequence dependence of
on both sides by shorter helices and loops that interact the energy of bending DNA. As a consequence, nucleo-
somes often appear at preferred positions in the vicinitywith DNA (Arents and Moudrianakis, 1995). Finally,
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involved in DNA transcription. In contrast, heterochromatin is tightly packed 
throughout the cell cycle, is gene-poor and largely contains repetitive sequences of 
DNA including centromeres, telomeres and satellite sequences. Heterochromatin is 
thought to protect genes when they are not being transcribed and is enriched in 
histone PTMs such as histone H3, lysine 9 trimethylation (H3K9me3) (Margueron 
and Reinberg, 2010). Accessibility of proteins to DNA is therefore reduced in 
heterochromatin and processes such as DNA repair often occur more slowly in 
heterochromatin than in euchromatin, and require modification of the chromatin 
structure to facilitate normal functioning. 
 
 
Figure 1.3 - Organisation of DNA within the chromatin structure. DNA is organised into 
nucleosomes as the lowest order of organisation where DNA is wound around histone proteins as 
demonstrated in figure 1.2. The next level of organisation involves a string of nucleosomes folded into 
a 30nm diameter chromatin fibre. These fibres then undergo further folding into higher-order structures 
forming chromatin and chromosomes. Figure reproduced from (Felsenfeld and Groudine, 2003). 
feature
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may facilitate gene activation, by promoting specific structural 
interactions between distal sequences, or repression, by occluding
binding sites for transcriptional activators. 
We suggest that the function of archaeal histones reflects their
ancestral function, and therefore that chromatin evolved originally
as an important mechanism for regulating gene expression. Its use in
packaging DNA was an ancillary benefit that was recruited for the
more complex nucleosome structure that subsequently evolved in
the ancestors of modern eukaryotes, which had expanded genome
sizes. Although their compactness might seem to suggest inertness,
chromatin structures are in fact a centre for a range of biochemical
activities that are vital to the control of gene expression, as well as
DNA replication and repair.
Packaging DNA into chromatin
The fundamental subunit of chromatin is the nucleosome, which
consists of approximately 165 base pairs (bp) of DNA wrapped in two
superhelical turns around an octamer of core histones (two each of
histones H2A, H2B, H3 and H4). This results in a five- to tenfold
compaction of DNA6. The DNA wound around the surface of the 
histone octamer (Fig. 1) is partially accessible to regulatory proteins,
but could become more available if the nucleosome could be moved
out of the way, or if the DNA partly unwound from the octamer. The
histone ‘tails’ (the amino-terminal ends of the histone protein
chains) are also accessible, and enzymes can chemically modify these
tails to promote nucleosome movement and unwinding, with 
profound local effects on the chromatin complex.
Each nucleosome is connected to its neighbours by a short 
segment of linker DNA (~10–80 bp in length) and this polynucleo-
some string is folded into a compact fibre with a diameter of ~30 nm,
producing a net compaction of roughly 50-fold. The 30-nm fibre is
stabilized by the binding of a fifth histone, H1, to each nucleosome
and to its adjacent linker. There is still considerable debate about the
finer points of nucleosome packing within the chromatin fibre, and
even less is known about the way in which these fibres are further
packed within the nucleus to form the highest-order structures.
Chromatin regulates gene expression 
Regulatory signals entering the nucleus encounter chromatin, not
DNA, a d the rate-limiting biochemical response that leads to 
activation of gene expression in most cases involves alterations in
chromatin structure. How are such alterations achieved?
The most compact form of chromatin is inaccessible and 
therefore provides a poor template for biochemical reactions such as
transcription, in which the DNA duplex must serve as a template for
RNA polymerase. Nucleosomes associated with active genes were
shown to be more accessible to enzymes that attack DNA than those
associated with inactive genes7, which is consistent with the idea that
activation of gene expression should involve selective disruption of
the folded structure.
Clues as to how chromatin is unpacked came from the discovery that
components of chromatin are subject to a wide range of modifications
that are correlated with gene activity. Such modifications probably
occur at every level of organization, but most attention has focused on
the nucleosome itself. There are three general ways in which chromatin
structure can be altered. First, nucleosome remodelling can be induced
by complexes designed specifically for the task8; this typically requires
that energy be expended by hydrolysis of ATP. Second, covalent modifi-
cation of histones can occur within the nucleosome9. Third, histone
variants may replace one or more of the core histones10–12.
Some modifications affect nucleosome structure or lability
directly, whereas others introduce chemical groups that are recog-
nized by additional regulatory or structural proteins. Still others may
be involved in disruption of higher-order structure. In some cases,
the packaging of particular genes in chromatin is required for their
expression13. Thus, chromatin can be involved in both activation and
repression of gene expression.
Chromatin remodelling
Transcription factors regulate expression by binding to specific DNA
control sequences in the neighbourhood of a gene. Although some
DNA sequences are accessible either as an outward-facing segment
on the nucleosome surface, or in linkers between nucleosomes, most
30-nm chromatin
fibre of packed
nucleosomes 
Section of
chromosome in an
extended form
Condensed section
of chromosome
Entire mitotic
chromosome
C entromere
Short region of
DNA double helix
2 nm
11 nm
700 nm
1,400 nm
30 nm
300 nm
" Beads on a string "
form of chromatin
a
b
Figure 1 Packaging DNA. a, The organization of DNA within the chromatin structure.
The lowest level of organization is the nucleosome, in which two superhelical turns of
DNA (a total of 165 base pairs) are wound around the outside of a histone octamer.
Nucleosomes are connected to one another by short stretches of linker DNA. At the
next level of organization the string of nucleosomes is folded into a fibre about 30 nm
in diameter, and these fibres are then further folded into higher-order structures. At
levels of structure beyond the nucleosome the details of folding are still uncertain.
(Redrawn from ref. 41, with permission). b, The structure of the nucleosome core
particle was uncovered by X-ray diffraction, to a resolution of 2.8Å (ref. 42). It shows
the DNA double helix wound around the central histone octamer. Hydrogen bonds
and electrostatic interactions with the histones hold the DNA in place.
© 2003 Nature Publishing Group
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Histone Structure 
Details of the histone structure and arrangement came from crystallographic analysis 
of the octamer within the NCP. These studies demonstrated the octamer composed of 
two H2A-H2B dimers flanking a centrally located (H3-H4)2 tetramer. Each of these 
histones, whilst bearing little sequence homology, do share structural similarity.  Each 
histone comprises a polypeptide chain based on a central α helix called the histone 
fold. The fold is flanked on either side by shorter helices and loops that interact 
directly with DNA (Kornberg and Lorch, 1999). The histone fold motif contains 
highly homologous residues governing histone-histone dimer assembly and the 
pairing of two folds generates paired element motifs (PEMs) that serve as docking 
pads for histone-DNA binding (Arents and Moudrianakis, 1995). This histone fold 
domain is also referred to as the globular domain.  
 At either end of the histone protein there is an amino-terminal domain and a 
carboxyl terminal domain. The amino-terminal domain is composed of 15-30 amino 
acid residues and is commonly referred to as the histone “tail”. High resolution 
studies have demonstrated that these histone tails lie to the outside of the NCP, 
passing through channels in the DNA helix, and are therefore exposed, a crucial 
feature facilitating the role of the core particle in chromatin remodelling (Luger et al., 
1997). These tail regions contain the sites for PTM such as acetylation, which allows 
remodelling during processes such as transcription and DNA repair. Histone tails can 
be the subject of many other PTMs including phosphorylation, methylation and 
ubiquitination. Far less commonly, the globular domains of histone proteins can also 
undergo PTM. The histone tail regions are involved in higher-order structural 
arrangement of the chromatin fibre through interactions between histone tails of 
neighbouring nucleosomes.  
 
Nucleosome Structure 
The packaging of DNA into nucleosomes condenses the genome but generally 
inhibits the binding of non-histone DNA-binding proteins such as transcription factors 
and DNA repair proteins by occluding regulatory DNA sequences. The restriction 
imposed may be due to the physical blockage of binding sites by the histone proteins 
themselves but more so to do with the tight structural compaction of the DNA helix 
achieved by the nucleosome arrangement (Ataian and Krebs, 2006). This can limit the 
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accessibility of DNA to binding proteins but also to physical agents for example DNA 
damaging drugs, such as the platinum analogues, commonly used in cancer 
chemotherapeutics (in this thesis the term platinum analogues refers to the platinum 
class or family of anticancer agents). It has been demonstrated experimentally that 
nucleosomes exert an inhibitory effect on transcription in vivo and that nucleosome 
loss can activate transcription (Han and Grunstein, 1988). Repressing histone H4 
synthesis in yeast (and the subsequent reduction in nucleosome assembly) leads to 
promoter activation and transcription initiation in previously inactive genes (Han and 
Grunstein, 1988).  
 The structural organisation of chromatin therefore needs to be altered to allow 
access to these DNA-binding proteins to perform intrinsic cellular processes. This is 
achieved by ATP-dependent chromatin remodelling complexes acting in concert with 
histone-modifying enzymes and other chromatin proteins. The chromatin remodellers 
comprise four families of complexes, including the switching defective/sucrose 
nonfermenting (SWI/SNF) family, which alters chromatin structure by unwrapping, 
moving/sliding, ejecting or restructuring nucleosomes (Clapier and Cairns, 2009). 
Therefore, rather than acting as a barrier or having an inhibitory role chromatin may 
be viewed as having an active, participatory role in the regulation of DNA 
transcription, replication and repair and that it is through chromatin remodelling that 
these DNA metabolic processes are able to proceed effectively (Teng et al., 2009). 
This also raises the interesting possibility of pharmacologically altering chromatin 
structure to potentiate damage caused by therapeutic DNA damaging agents. 
 
 
1.2 DNA damage 
 
Preservation of the structure of cellular DNA is fundamental for the accurate transfer 
of genetic information from parent to daughter cells. However, the integrity of DNA 
is constantly under threat and alterations to the chemical structure of DNA can occur 
following exposure to genotoxic sources arising from within the cell, (endogenous 
DNA damage), or from extra-cellular sources, (exogenous DNA damage). 
Endogenous DNA damage arises as a consequence of normal cellular metabolism and 
occurs spontaneously at high rates and typically involves base modifications such as 
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deamination, oxidation and alkylation or base losses such as depurination or 
depyrimidination. It is estimated that each cell can face up to 105 spontaneous 
endogenous DNA damage lesions per day and much of these are repaired by the base 
excision repair (BER) pathway (Maynard et al., 2009). Exogenous DNA damage 
occurs less frequently and is due to chemical, physical or radiation insults arising 
outside the cell. This type of damage typically involves DNA alkylation and the 
formation of intra- and interstrand crosslinks and single-strand breaks (SSBs) or 
double-strand breaks (DSBs). 
 Unrepaired DNA damage can have widespread deleterious complications. At 
the genomic and cellular level DNA damage can impede cellular DNA processes such 
as transcription and replication resulting in senescence, cell cycle arrest, apoptosis, 
genome instability and mutation (Jackson and Bartek, 2009). DNA damage at the 
level of the organism can lead to chromosomal abnormalities, carcinogenesis and 
ageing (de Boer and Hoeijmakers, 2000). In order to maintain the integrity of the 
genome, prevent these detrimental consequences and to protect their survival, cells 
have developed a sophisticated network of DNA repair pathways (Friedberg, 2003).  
 The most prevalent environmental DNA-damaging agent is ultraviolet 
irradiation, which causes DNA damage directly in the form of dimer formation at 
dipyrimidines and less commonly indirectly, via chemical intermediates such as free 
radicals. The link between deficiency in DNA repair pathways and human disease and 
cancer predisposition is particularly highlighted by the rare recessively inherited 
syndrome xeroderma pigmentosum (XP), characterised by extreme UV sensitivity 
and skin cancer predisposition. This disease has been demonstrated to arise due to 
defective nucleotide excision repair (NER) as a consequence of mutations in any one 
of the seven XP complementation group genes (designated XP-A to XP-G) (Cleaver, 
1968, De Weerd-Kastelein et al., 1972, Friedberg et al., 2006). 
 In the following section the different types of DNA damage will be outlined. 
Firstly, damage events that modify single bases, secondly events that alter the 
structure of the DNA molecule and thirdly events which lead to DNA strand breaks. 
 
1.2.1 DNA base modifications 
Base modification or base loss occurring at single bases can result in alterations to the 
DNA sequence and typically these are caused by spontaneous deamination, 
Chapter 1. Introduction 
 10 
hydrolysis, oxidation or alkylation reactions as a consequence of normal cellular 
metabolism. Exogenous sources of DNA damage, such as ionising radiation, 
however, can also be implicated. Base modification disrupts replication and 
transcription and can lead to the insertion of incorrect bases into the genetic sequence 
during DNA replication. Such mutations are classed as transitions if a base is 
substituted for another of the same class, i.e. a purine for a purine or a pyrimidine for 
a pyrimidine, or a transversion if different classes of bases are substituted, i.e. a 
purine for a pyrimidine or vice versa. Physiological processes such as DNA 
mismatches, introduced during erroneous DNA replication, can also lead to 
alterations to the base sequence. 
 
Deamination 
Three of the four bases in DNA contain exocyclic amine groups and a common base 
modification is deamination, characterised by the removal of the amine group from 
the nucleotide via a hydrolysis reaction. Cytosine, adenine, guanine and 5-
methylcytosine each undergo spontaneous deamination resulting in conversion to 
uracil, hypoxanthine, xanthine and thymine respectively. Cytosine is the most 
frequently deaminated base, which produces uracil, one way in which this base, 
normally confined to RNA, can occur in DNA. Uracil pairs with adenine and 
therefore during replication this leads to a C:G to T:A mutation. Each of the 
deaminated products are recognised as abnormal and can be repaired by the cell apart 
from thymine (produced by 5-methylcytosine) as thymine is not recognised as an 
abnormal base by cells. 5-methylcytosine is therefore considered a vulnerable region 
for DNA damage and a mutation hot spot (Denissenko et al., 1997). 5-methylcytosine 
accounts for around 1-6% of nucleotides within the human genome and imparts an 
added layer of heritable information on the DNA code (Lister and Ecker, 2009). 
Cytosine methylation is important for a number of biological processes including 
gene transcription and embryogenesis, is directly involved in modulating 
transcription, and is often referred to as the “fifth base”. 
  
Depurination & Depyrimidination 
Base loss from DNA can also occur through spontaneous hydrolytic reactions. 
Depurination and depyrimidination reactions generate apurinic or apyrimidinic (AP) 
sites via hydrolysis reactions which release bases by cleaving the N-glycosyl bond 
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between base and sugar. AP sites are frequently encountered spontaneous lesions in 
DNA and unrepaired AP sites can block DNA replication and transcription and can 
yield single base-pair substitutions (Loeb, 1985). AP sites are primarily repaired by 
the BER pathway, generating temporary SSBs, and the genetic information can be 
recovered from the complementary strand in double stranded DNA. Conversely, 
unrepaired AP sites can stall replication forks initiating potentially mutagenic 
translesion DNA synthesis (Boiteux and Guillet, 2004).   
 
Oxidation 
Reactive oxygen species (ROS) derived from aerobic respiration and other sources are 
an important source of endogenous DNA, RNA and protein damage. Excessive 
production of intracellular free radicals result in accumulative oxidative damage and 
oxidation of all 4 bases can occur. Oxidation is most commonly seen at guanine 
residues where it can produce 7,8-dihydro-8-oxoguanine (commonly known as 8-
oxoguanine), often used as a cellular biomarker for oxidative stress. This is a 
particularly deleterious lesion because of its ability during replication to functionally 
mimic thymine and for DNA polymerase to pair it with adenine, producing a G:C to 
T:A mutation. Other types of ROS-related oxidative DNA damage include AP sites, 
single strand breaks, protein-DNA adducts and intra- or interstrand crosslinks.  
  
Alkylation 
DNA alkylation occurs with the transfer of an alkyl group, most commonly a methyl 
group, to the base. The most vulnerable site for alkylation to occur is carbon atom 6 
of the guanine base, producing O6-methylguanine. This often mispairs with thymine, 
inducing a G:C to A:T mutation. Other commonly alkylated bases include N7-
methylguanine, N7-methyladenine. There are a variety of alkylating agents occurring 
endogenously as well as exogenously. Of particular importance are the alkylating 
agents used in cancer therapeutics such as the nitrogen mustards and nitrosoureas as 
well as environmental alkylating agents such as those found in cigarette smoke. 
 
1.2.2 Structural alterations to DNA 
Whilst the majority of DNA damage affects the primary structure of DNA, i.e. the 
bases themselves, other types of damage can disrupt and alter the helical structure. 
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Structural alterations can occur at single bases, as is the case with base substitutions, 
or at multiple bases, as is the case with intra- and interstrand crosslinks, and can occur 
following exposure to endogenous or exogenous sources of DNA damage. As with 
base modifications structural alterations can also block transcription and replication. 
Some examples of structural alterations include base substitution, DNA intercalation 
and crosslink or adduct formation. 
 
Base substitution 
Base substitution entails misincorporation of bases or the incorporation of molecules 
with similar structure to bases, base analogues, into the DNA molecule. Whilst base 
analogues are similar enough to traditional bases to be processed and incorporated 
into the DNA molecule, once they have been incorporated they can cause replicative 
errors. A common source of base analogues is cancer therapeutics with the use of the 
antimetabolite family of chemotherapeutic agents, which include fluoropyrimidines 
such as 5-fluorouracil (5-FU), purine analogues such as fludarabine and pyrimidine 
analogues such as cytarabine and gemcitabine. These agents have the ability to be 
directly misincorporated, or to produce metabolites that can be misincorporated, into 
the DNA molecule and subsequently inhibit DNA replication. These agents can also 
deplete cells of nucleotide pools by inhibiting nucleotide metabolic pathways. For 
example, 5-FU is metabolised to fluorodeoxyuridine monophosphate (FdUMP), 
which inhibits thymidylate synthase, which in turn inhibits thymidine monophosphate 
(dTMP) formation, resulting in the cell existing in a ‘thymineless state’. 
 
DNA Intercalation 
DNA intercalation occurs when molecules of an appropriate size and nature fit 
themselves between the base pairs of the DNA. This induces structural distortion of 
the DNA molecule causing helical unwinding and base pair separation that can inhibit 
transcription and replication. Intercalating agents include polycyclic aromatic 
hydrocarbons, as found in cigarette smoke and aflatoxins. The anthracycline family of 
chemotherapy agents such as doxorubicin and epirubicin, used commonly to treat 
Hodgkin’s lymphoma, sarcoma and breast cancer are also potent DNA intercalators. 
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DNA adducts, intra- and interstrand crosslinks 
Rather than sliding between components of the DNA helix as seen with the DNA 
intercalators some molecules are able to form covalent bonds with nucleotides, 
forming bulky adducts. Such adducts can be monofunctional, binding to a single 
nucleotide, or bifunctional, binding to two different nucleotides forming crosslinks. 
Crosslinks are termed intrastrand if they form on the same strand of the helix or 
interstrand if they form between two nucleotides on opposing strands of the helix. 
These crosslinks have the effect of unwinding and bending the helical structure, 
blocking DNA polymerases, inhibiting replication and forming strand breaks. The 
platinum analogue family of chemotherapy agents form adducts at purine bases and 
are discussed extensively in subsequent sections. Absorption of ultraviolet irradiation 
can also cause covalent linking of adjacent pyrimidines bases, creating adducts 
including cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs). 
 
1.2.3 DNA strand breaks 
DNA strand breaks can be induced by ionising radiation as well as cellular metabolic 
and repair processes such as abortive topoisomerase I or topoisomerase II activity. 
Strand breaks form due to breaks in the phosphodiester DNA backbone, which can 
occur in single or both strands of the DNA. 
 
Single strand breaks 
Single strand breaks (SSBs) involve breaks to single strands of the phosphodiester 
backbone of the DNA double helix. These typically occur due to reactive oxygen 
species production during cellular metabolism, radiation exposure or during other 
DNA repair processes. The DNA molecule remains intact as a result of the second, 
unbroken, strand of DNA. When two SSBs occur in close proximity to one another or 
when a SSB encounters a DNA replication fork SSBs can be converted into double 
strand breaks (DSBs). Timely and effective repair of SSBs is therefore crucial. 
 
Double strand breaks 
DNA DSBs can arise following endogenous damage from reactive oxygen species 
generated during cellular metabolism and collapsed replication forks and from 
exogenous sources including exposure to ionising radiation and DNA-damaging 
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chemicals. DSBs do not occur as frequently as SSBs, however these lesions are 
extremely toxic and if left unrepaired are lethal events for the cell. If misrepaired 
DSBs can lead to chromosomal translocations, rearrangements and deletions, causing 
genomic instability and promoting tumorigenesis (Khanna and Jackson, 2001). 
 
 
1.3. DNA repair 
 
To mitigate the threat posed by DNA damage, and to protect cellular DNA, 
mechanisms collectively known as the DNA-damage response (DDR) have evolved 
to detect DNA damage lesions, signal their presence and promote their repair (Harper 
and Elledge, 2007). Due to the diversity of the DNA damage lesions a variety of 
distinct DNA repair mechanisms have evolved. Broadly, these DNA repair pathways 
can be divided into two types; those that excise the damage and those that repair DNA 
strand breaks. The excision repair pathways include base excision repair (BER), 
mismatch repair (MMR) and nucleotide excision repair (NER) and the pathways that 
repair DNA strand breaks include the SSB repair pathway and the DSB repair 
pathways homologous recombination (HR) and non-homologous end joining (NHEJ). 
In the context of using therapeutic DNA damaging agents for the treatment of cancer, 
however, these protective mechanisms comprising the DDR can be a hindrance, and 
can promote treatment resistance and limit efficacy. 
 
1.3.1 Excision repair pathways  
These are inherent protective mechanisms, designed to protect the genome from the 
array of endogenous and exogenous DNA damaging agents encountered by the cell. 
These pathways act by recognising the damage lesion, excising damaged bases or 
segments of DNA and repairing the gaps in DNA.  
 
Base excision repair 
Base excision repair (BER) repairs many of the base modifications and structural 
alterations described in section 1.2 and is active throughout the cell cycle. This 
pathway is initiated by DNA glycosylase enzymes which recognise and remove the 
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damaged base by cleaving the N-glycosyl bond between the sugar and the base 
forming an AP site (Memisoglu and Samson, 2000). Several different DNA 
glycosylase enzymes exist which differ in their base substrate specificity and the 
damage lesions that they recognise (Krokan et al., 2000). Glycosylases can be specific 
for certain lesions or individual glycosylases can recognise more than one type of 
damage which maintains an enormous diversity along with an element of redundancy 
in the action in BER in mammalian cells (Maynard et al., 2009). For spontaneous AP 
or abasic damage types the base removal step is not needed.  
 The AP site can be processed in two ways. Firstly, the phosphodiester bond of 
the DNA backbone can be cleaved by an AP endonuclease resulting in a 3ʹ′-OH 
adjacent to a 5ʹ′-abasic deoxyribose phosphate (dRP), subsequently removed by the 
dRPase activity of DNA polymerase β. Alternatively, the AP site can be cleaved by 
bifunctional DNA glycosylases which also have AP lyase activity resulting in the 
formation of a 5ʹ′-phosphate and a 3ʹ′-fragmented deoxyribose which is then removed 
by the 3ʹ′-diesterase activity of the AP endonucleases (Memisoglu and Samson, 2000) 
(figure 1.4). BER is completed and the resulting gap is repaired by short-patch repair, 
which replaces the single removed nucleotide in both cases by a combination of DNA 
polymerase β and DNA ligases I and III to seal the break. Often, if the 5ʹ′-abasic 
deoxyribose phosphate (dRP) is refractory to the dRPase activity of DNA polymerase 
β, long-patch repair occurs which involves extension of the 3ʹ′-OH group and 
displacement of the strand containing the 5ʹ′-dRP. This is termed long-patch repair, 
replaces 2-10 nucleotides, and requires the combined activity of the flap endonuclease 
(FEN1) to remove the displaced strand along with proliferating cell nuclear antigen 
(PCNA), DNA polymerases β, δ and ε and DNA ligase I/III (figure 1.4). 
 The significance of defective BER in human disease was first demonstrated 
when a direct link between mutations in the gene encoding a DNA glycosylase - the 
human MutY homologue (MUTYH) - and colorectal cancer was uncovered (Al-
Tassan et al., 2002). MUTYH is known to be a critical glycosylase processing the 8-
oxoguanine base modification and preventing the G:C to T:A transversion, and the 
observation that inherited defects in this gene lead to somatic mutations in 
adenomatous polyposis gene (APC) established a novel mechanism for colorectal 
cancer predisposition and was termed MUTYH-associated polyposis (Sampson et al., 
2005, Cheadle and Sampson, 2007, David et al., 2007). 
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Figure 1.4 – Diagram of the base excision repair (BER) pathway. The BER pathway corrects DNA 
damaged bases initially through the activity of DNA glycosylases. Subsequently, alternative pathways 
are activated causing SSBs and the removal and repair of the damaged base through two different 
mechanisms leading to short patch repair and a separate mechanism leading to long patch repair. See 
text for full details. PCNA - Proliferating cell nuclear antigen, Pol β, δ and ε - DNA polymerases β, δ 
and ε. Figure reproduced from (Memisoglu and Samson, 2000).  
 
Mismatch repair 
The mismatch repair (MMR) pathway is a highly conserved, strand-specific repair 
process that corrects single base substitution mismatches and insertion-deletion 
mismatches generated during DNA replication that escape proofreading (Kunkel and 
Erie, 2005). For example, mismatched base pairs can arise due to incorrect nucleotide 
insertion during replication or as a result of base modification such as the deamination 
of 5-methylcytosine to thymine. Inactivation of MMR proteins can have profound 
biological consequences including increased rates of genome-wide point mutations 
arising from unrepaired DNA synthesis errors. In mammals, loss of MMR activity can 
lead to cells developing a mutator phenotype, a hypothesis whereby mutations are 
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required in genes that control DNA fidelity to allow the greatly increased mutation 
rates required for the initiation and promotion of carcinogenesis (Loeb et al., 2003). 
 Microsatellites are short repeating sequences of 2-6 base pairs of DNA. 
Repetitive regions of the genome, such as microsatellites, are inherently unstable, due 
primarily to inefficient DNA proofreading which leads to gains or losses of short 
repeat units within microsatellites and the ensuing ‘microsatellite instability’ (MSI) 
phenotype (Jascur and Boland, 2006). This makes MMR the major repair pathway 
guarding against MSI and, therefore, the increased presence of MSI is now an 
established marker for loss of MMR activity in tumour cells (Burgart, 2005). 
Approximately 15% of colorectal carcinomas develop through loss of MMR and 
germline mutations in some MMR genes underlie one of the most prevalent cancer 
syndromes in humans, hereditary nonpolyposis colorectal cancer (HNPCC), also 
known as Lynch syndrome (Peltomaki, 2003). This is an autosomal dominant 
syndrome characterised by early age onset, predominantly colon cancer neoplastic 
lesions along with a spectrum of extracolonic cancers, and MSI. MSI testing therefore 
now forms an important component of identifying patients with HNPCC (Umar et al., 
2004). The commonest germline mutations seen in HNPCC arise from inherited 
mutations in the MutS homologue 2 (MSH2) and MutL homologue 1 (MLH1) genes, 
components of the MMR pathway. 
 As well as inherited defects in MMR genes, dysfunctional MMR may occur 
through epigenetic silencing of the same genes through promoter hypermethylation. 
Many genes in mammalian genomes have a high concentration of cytosine-guanine 
dinucleotide repeat sequences, termed CpG islands, at the start of the gene or 
promoter region. Cytosines in CpG islands can be methylated to form 5-
methylcytosine which can lead to reduced transcription of the gene and gene 
silencing. Methylated DNA can cause gene silencing by physically impeding the 
binding of transcription factors (Choy et al., 2010) and also by promoting the 
formation of a transcriptionally repressive form of chromatin characterised by the 
binding of methylcytosine-binding proteins and histone deacetylases and tightly 
compacted nucleosomes (Herman and Baylin, 2003). Epigenetic silencing of MMR 
genes occurs most often through MLH1 promoter hypermethylation (Esteller, 2000) 
and this has been demonstrated in ovarian and colorectal carcinoma among others 
(Bignami et al., 2003, Peltomaki, 2003). 
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Mismatch repair mechanism 
Mammalian MMR follows a stepwise process requiring at least six different proteins 
and is initiated by recognition of DNA damage. It is broadly a sensory system that 
scans DNA and when a nucleotide mismatch is detected removes the error resulting in 
a single strand incision and triggering the recruitment of proteins and polymerases to 
resynthesise the strand and correct the error. In order for the error to be correctly 
detected the MMR machinery needs to correctly distinguish the newly synthesised, 
daughter (and erroneous) strand from the template, parental strand. In bacteria, this is 
achieved by hemimethylation, whereby the parental strand is methylated whilst the 
daughter strand is not. In eukaryotes the process is less clear but is thought that the 
daughter strands contain nicks which direct the MMR machinery to the correct strand 
(Jiricny, 2006, Kunkel and Erie, 2005). Mismatched or unmatched DNA base pairs or 
insertion-deletion loops (IDLs) are recognised by Mut proteins, which recruit and 
initiate the assembly of a protein repair complex to excise the affected area and 
resynthesise the missing portion of DNA using a DNA polymerase.  
 Five MutS homologues (MSH) have been identified in human cells and of 
these MSH2, MSH3 and MSH6 participate in MMR and recognise mismatches in the 
form of heterodimers (Kunkel and Erie, 2005). Depending on the nature of the 
mismatch, different recognition heterodimers are recruited. The most abundant, 
MSH2-MSH6, often referred to as MutSα, recognises base-base mismatches and 
IDLs whilst larger IDLs are recognised by the MSH2-MSH3 heterodimer, referred to 
as MutSβ (Jiricny, 2006). Human MutL homologues (MLH) are then recruited to co-
ordinate repair, which also form heterodimers. The MLH1-PMS2 heterodimer 
coordinates the assembly of the mismatch recognition complex and the other proteins 
necessary for DNA repair synthesis. These additional proteins, include exonuclease 1 
(EXO1), PCNA, replication protein A (RPA), DNA polymerase δ or ε and DNA 
ligase and govern excision, DNA synthesis and ligation (Peltomaki, 2003). 
 The MMR pathway activates other cell-cycle regulators such as p53 and c-
ABL, which mediate the induction of cell cycle arrest and apoptosis (Bellacosa, 
2001). Furthermore, cisplatin induced activation of these regulators depends on 
functional MSH2 and MLH1 proteins and a functional MMR pathway (Nehme et al., 
1997). 
 
Chapter 1. Introduction 
 19 
Nucleotide Excision Repair 
Nucleotide excision repair (NER) is a highly conserved DNA repair pathway and is 
the most versatile of all the repair systems operating in eukaryotic cells enabling cells 
to remove a wide spectrum of helix-distorting DNA damage lesions, caused by 
different exogenous sources. These include damage induced by bulky platinum-
induced adducts, UV-induced photoproducts and dimers and many other chemical-
induced helix-distorting damage lesions (Friedberg et al., 2006). NER consists of two 
distinct subpathways that operate, in contrast to BER for example, via a series of 
conserved multiprotein complexes capable of recognising many different damage 
types. Global genome repair (GG-NER) removes lesions from the entire genome in 
regions that are transcriptionally silent, and transcription-coupled repair (TC-NER) 
repairs damage only within regions of the genome that are actively transcribed and is 
initiated by RNA polymerase stalling at a damage site (Guo et al., 2010). These two 
pathways are identical other than the molecular mechanism involved in the initial 
damage recognition step, and involve several biochemical steps including damage 
recognition, dual incision, excision of the damaged oligonucleotide, gap-filling DNA 
synthesis and finally DNA ligation (Petit and Sancar, 1999). 
 In prokaryotic organisms the whole NER process has been elucidated whilst in 
eukaryotes some of the precise details in higher organisms, particularly its function in 
the context of chromatin, is not fully understood. In prokaryotes NER involves three 
proteins, UvrA, UvrB and UvrC which are collectively responsible for DNA damage 
recognition and its excision in an ATP-dependent reaction (Truglio et al., 2006). A 
complex of UvrA and UvrB molecules, either as a heterotrimer or a heterotetramer, 
directly recognises damaged DNA. UvrA then leaves the complex and UvrC is 
recruited and dimerises with UvrB forming the preincision complex that initiates dual 
incision and excision of the damaged region. UvrD (DNA helicase II) removes the 
damaged fragment of DNA, DNA polymerase I fills the gap generated and DNA 
ligase joins the newly synthesised DNA ends.  
 A similar sequence of events occurs for NER in eukaryotic cells but is a more 
complex process requiring more than 30 different proteins for successful completion. 
Most of the core enzymatic activities have been characterised in detail for NER in 
eukaryotes but it is its function in the context of chromatin, particularly lesion 
recognition, that remains incompletely understood and is the current focus for 
research in this area (Waters et al., 2009). The biological importance of NER is 
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highlighted in patients with the rare autosomal recessive disease xeroderma 
pigmentosum (XP), characterised by extreme UV sensitivity and strong disposition to 
developing skin cancers. XP is caused by inheritance of mutations in one of the seven 
genetic complementation groups, designated XPA to XPG, involved in all stages of 
NER and required for successful NER in mammalian cells (Cleaver, 1968, De Weerd-
Kastelein et al., 1972, Friedberg et al., 2006).  
 Cockayne’s syndrome (CS) and trichothiodystrophy (TTD) are two other 
diseases associated with congenital defects in the NER pathway but, importantly, 
neither of these conditions are characterised by cancer predisposition (Lehmann and 
O'Driscoll, 2010). XPB and XPD are helicases and are two of the subunits of 
transcription factor II human complex (TFIIH). TFIIH consists of a core complex 
comprising ten different proteins and a subcomplex which includes a cyclin-
dependent kinase-activating kinase (CAK), and acts as a transcription factor required 
for the initiation of transcription mediated by RNA polymerase II as well as being 
integral to NER. Mutations in XPB and XPD can result in XP or TTD, with different 
mutations in each responsible for these conditions. It is generally accepted that the 
features of XP result from defective repair (also accounting for the cancer 
predisposition), whilst the features of TTD are caused by more subtle abnormalities in 
transcription (Lehmann, 2001). CS is associated with mutations in genes coding for 
the CSA and CSB proteins involved in TC-NER and, as for TTD, CS is primarily 
caused by abnormalities in transcription with failure to restore RNA synthesis the 
primary molecular phenotype (Mayne and Lehmann, 1982, Fousteri et al., 2006). 
Other rarer diseases include cerebro-oculo-facio-skeletal (COFS) syndrome, which 
results from mutations in the CSB gene and PIBIDS which is considered a 
photosensitive variant of TTD and characterised by photosensitivity, icthyosis, 
intellectual impairment, decreased fertility and short stature (Friedberg et al., 2006). 
 
Nucleotide excision repair mechanism 
During GG-NER two different DNA damage recognition complexes, firstly involving 
the XPC/HR23B/Centrin 2 proteins and the other involving the DDB1/DDB2 
heterodimer, are implicated (Nouspikel, 2009). Whether both complexes are always 
involved in damage recognition in NER regardless of the mode of DNA damage is 
less clear, however both recognition complexes are known to be involved in sensing 
UV-induced DNA damage (Fei et al., 2011).  
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 UV-induced DNA damage triggers the binding of the DDB1/DDB2 
heterodimer to sites of damaged DNA, which activates a ubiquitin ligase complex that 
recruits XPC to the damage site and promotes ubiquitination of DDB2 and XPC 
(Sugasawa et al., 2005). Ubiquitinated DDB2 loses its ability to bind DNA, whilst 
ubiquitinated XPC shows enhanced DNA binding (Guo et al., 2010). XPC is essential 
for the recruitment of downstream NER factors including TFIIH, which comprises 
XPB and XPD (Volker et al., 2001). The second damage recognition process involves 
recruitment of TFIIH via interaction with the XPC/HR23B/Centrin 2 protein complex. 
 Unwinding of the DNA helix and strand separation around the sites of DNA 
damage is initiated by the XPB and/or XPD ATPase/helicase function of TFIIH 
(Volker et al., 2001). This allows XPA and RPA to be recruited, promoting the 
disassembly of the CAK subcomplex of TFIIH and leading to further unwinding of 
DNA around the site of damage (‘bubble formation’) and the release of 
XPC/HR23B/Centrin 2 (Coin et al., 2008). Dual incision then occurs either side of 
this ‘bubble’ through the sequential action of two endonucleases, firstly the 
ERCC1/XPF complex which cuts the damaged DNA strand 5ʹ′, followed by the XPG 
endonuclease which cuts it 3ʹ′ (Staresincic et al., 2009). This produces a single strand 
oligonucleotide fragment ∼24 -32 nucleotides in length and the resulting gap is filled 
by the combined actions of DNA polymerase δ or ε, PCNA and RPA and DNA ligase 
I joins these newly synthesised DNA ends. 
 As mentioned, GG-NER and TC-NER differ only by the molecular 
mechanism of the initial damage recognition step. Damage recognition during TC-
NER is initiated by the stalling of RNA polymerase II at sites of DNA damage on the 
transcribed strand, which then forms a complex and recruits CSB protein, an ATP-
dependent chromatin remodelling factor (Hanawalt and Spivak, 2008). CSB fulfils an 
important role in recruiting and coupling a number of additional proteins to the stalled 
RNAPII complex, including the histone acetyltransferase p300, the CSA-DDB1 E3-
ubiquitin ligase/COP9 signalosome complex (Fousteri et al., 2006), TFIIH and RPA. 
CSA protein, in conjunction with CSB, assists in recruiting further proteins such as 
high-mobility group N nonhistone nucleosome-binding protein (HMGN1), XAB2, 
TFIIS and XPA. The subsequent steps, of dual incision, strand repair synthesis and 
ligation, occur as previously described for GG-NER. 
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Figure 1.5 – Diagram of nucleotide excision repair pathway in eukaryotes. NER consists of two 
distinct subpathways that operate via a series of conserved multiprotein complexes capable of 
recognising many different damage types. Global genome repair (GG-NER) removes lesions from the 
entire genome in regions that are transcriptionally silent, and transcription-coupled repair (TC-NER) 
repairs damage only within regions of the genome that are actively transcribed and is initiated by RNA 
polymerase stalling at a damage site. The diagram demonstrates that these two pathways are identical 
other than the molecular mechanism involved in the initial damage recognition step, and both involve 
several biochemical steps including damage recognition, dual incision, excision of the damaged 
oligonucleotide, gap-filling DNA synthesis and finally DNA ligation. See text for full description and 
abbreviations. Figure reproduced from (Guo et al., 2010). 
SnapShot: Nucleotide Excision Repair
Caixia Guo,1,3 Tie-Shan Tang,2 and Errol C. Friedberg3
1Beijing Institute of Genomics, 2SKLBMB, Institute of Zoology, CAS, 100101 Beijing, China; 3UT Southwestern Medical Center, Dallas, TX 75390, USA
S
ee o
nlin
e versio
n fo
r leg
en
d
 an
d
 referen
ces.
754 
C
ell 140, M
arch 5, 2010 ©
2010 E
lsevier Inc. 
D
O
I 10.1016/j.cell.2010.02.033
Chapter 1. Introduction 
 23 
1.3.2 DNA strand break repair 
 
Single strand break repair 
Poly (ADP-ribose) polymerases (PARPs) are a large family of enzymes found in the 
cell nucleus whose main role is to detect and signal the presence of SSBs to other 
proteins involved in their repair. PARP binds DNA and synthesises a poly (ADP-
ribose) chain that acts as a signal to recruit the other repair machinery including the 
enzymes DNA ligase III, DNA polymerase β and the scaffolding protein X-ray cross-
complementing gene 1 (XRCC1). 
 Recently, understanding of the role of PARP in SSB repair has been exploited 
clinically with the development of PARP inhibitors. If they remain unrepaired SSBs 
can be converted to DSBs when they encounter replication forks and at this stage the 
DSBs can be repaired by homologous recombination (HR) (see next section). 
Inhibition of SSB repair alone is therefore unlikely to be cytotoxic unless HR is also 
defective. Patients who are carriers of germline mutations in BRCA1 or BRCA2 are at 
risk of acquiring a second mutation leading to loss of heterozygosity (LOH) and 
tumour formation as a result of a defective HR DNA repair pathway. It has been 
shown that in such cells and patients a targeted approach using PARP inhibitors is 
effective (Fong et al., 2009, Iglehart and Silver, 2009, Farmer et al., 2005, Bryant et 
al., 2005). This is an example of synthetic lethality, a concept involving a form of 
genetic interaction, often applied to aberrant DNA repair pathways, whereby the 
combination of a mutant gene along with the therapeutic inhibition of another 
pathway is lethal for the cell (Gottipati et al., 2010). 
 
Double strand break repair 
DSB repair pathways are highly conserved and can be divided into two basic groups: 
firstly, homologous recombination (HR), which requires the presence of a template 
identical or homologous sequence, and secondly, non-homologous end joining 
(NHEJ) which does not require the presence of homologous sequences (Friedberg et 
al., 2006). Whether HR or NHEJ is used to repair DSBs is largely determined by the 
phase of the cell cycle. HR requires the presence of a homologous sequence on a 
sister chromatid and therefore occurs during and after DNA replication, during the S 
and G2 phases of the cell cycle. NHEJ occurs predominantly in the G1 phase of the 
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cell cycle when cells are growing prior to DNA replication and cell division, although 
maintains some activity throughout the cell cycle (Shrivastav et al., 2008). 
 
Homologous Recombination 
HR, or recombination repair, includes two models for the repair of DSBs - the double-
strand break repair (DSBR) pathway which involves the formation of double Holliday 
junctions (HJs) and the synthesis-dependent strand annealing (SDSA) pathway (Sung 
and Klein, 2006). Both pathways involve similar initial stages of strand resection, 
strand invasion and DNA synthesis (figure 1.6). These stages initially involve the 
MRN-complex (a protein complex consisting of Mre11, Rad50 and Nbs1) which 
recognises and binds to DNA either side of the DSB. The MRN-complex activates 
and recruits other repair complexes, in particular the ATM complex, which through 
its kinase function, is important for further signalling. ATM and ATR kinases act as 
both recruiters and additional scaffold upon which the repair complex is assembled. 
Enzymatic digestion of the 5ʹ′ ends of the DNA strands then occurs resulting in 
overhanging 3ʹ′ ends of single-stranded DNA. RPA binds these overhangs and Rad51 
forms a nucleic acid/protein filament which searches for homologous sequences, and 
a complex of BRCA1, BRCA2 and Rad52 interact with Rad51 at this point (Sung and 
Klein, 2006). Rad51 recombinase plays a central role in HR, and BRCA2, in 
conjunction with Rad51, is also essential for effective HR (Moynahan et al., 2001). 
 After these common initial stages two distinct models diverge for the 
completion of DSB repair - the DSBR and SDSA pathways (figure 1.6). The DSBR 
pathway involves the overhanging end invading the sister chromatid to find its 
homologous sequence, pairing with this sequence and displacing the complementary 
strand forming a displacement loop (D-loop). DNA polymerase then extends the 3ʹ′ 
end of the invading strand based on the sequence of the complimentary strand of the 
sister chromatid. This leads to the formation of a cross-shaped structure, the HJ, 
connecting the two DNA molecules. The second 3ʹ′ overhanging end, not involved in 
strand invasion, also forms a HJ with the sister chromatid resulting in double HJs. HJs 
are resolved and converted to recombination products by restriction endonucleases 
which cut either the crossing or non-crossing strand of DNA followed by ligation by 
DNA ligase I. Resolution of both HJs at the crossing strands (black arrowheds in 
figure 1.6) results in a non-crossover product whilst resolution of one HJ at the 
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crossing strand and one at the non-crossing strand (green arrowheads in figure 1.6) 
results in a crossover chromosomal product (Alberts et al., 2002). In the SDSA 
pathway recombination occurs via direct extension of the overhanging single strand 
end to the ssDNA on the other break end followed by gap filling DNA synthesis and 
ligation. SDSA repair results in non-crossover products (Sung and Klein, 2006). 
Using the homologous sequence to initiate repair and DNA synthesis in this fashion is 
largely preserved and provides a repair process that is error free and leads to no loss 
of genetic material. 
 
 
 
 
Figure 1.6 - Diagram of the homologous recombination repair pathway. HR repairs DSBs in DNA 
during and shortly after DNA replication before the cell enters mitosis and requires the presence of 
homologous sequences. Following the common first steps of end resection, strand invasion and DNA 
synthesis (a) DSB repair is completed by two different models. Firstly, the double strand break repair 
(DSBR) pathway which involves the formation of double HJs (b) and secondly the synthesis dependent 
strand annealing (SDSA) pathway (c). The DSBR pathway can result in chromosomal crossover, whilst 
the SDSA pathway always ends with non-crossover products. See text for full details. Figure 
reproduced from (Sung and Klein, 2006). 
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DNA-crosslinking chemicals, that directly or indirectly 
lead to the formation of DSBs. Early work in the 1960s 
from several laboratories28–33 led to the isolation of 
X-ray-sensitive mutants of S. cerevisiae. It was decided 
at the IVth International Yeast Genetics Conference in 
1970 to refer to these mutants as rad mutants and to 
reserve the numbers 50 (rad50) and onwards for these 
mutants. A detailed examination of the initial collec-
tion of 64 mutants from laboratories around the world 
resulted in the classification of the various RAD genes as 
the RAD52 epistasis group30. Since then, four additional 
genes have been added to the RAD52 epistasis group: 
RAD59, MRE11, XRS2 and RDH54/TID1 (REFS 33–38). 
Mutation in any of the RAD52 group of genes results in 
DNA-damage sensitivity and defective HR.
The known biochemical attributes and functions of 
the proteins that are encoded by the RAD52 group genes 
and their human orthologues are summarized in TABLE 1. 
Of particular interest is the RAD51 gene, the product of 
which is structurally related to the E. coli RecA protein 
and, similarly to RecA, possesses a recombinase activity 
that mediates the linkage of recombining chromosomes 
via DNA joint formation39. RAD51 and other members 
of the RAD52 epistasis group are needed for meiotic 
HR and chromosome segregation in meiosis I. The 
efficiency of HR is enhanced by mediator proteins 
that promote the loading of Rad51 onto ssDNA and 
is attenuated by the Srs2 helicase that dismantles the 
Rad51–ssDNA complex (see below). Other helicases 
control HR at the level of crossover formation. The 
Mer3 helicase ensures that enough crossovers are made 
during meiosis, whereas the Sgs1 and BLM helicases 
suppress spurious crossovers (see below).
The meiotic recombinase Dmc1 and its associated factors. 
A study that was aimed at uncovering genes the expres-
sions of which are enhanced or restricted to meiosis led 
to the isolation of a gene, DMC1, that encodes a RecA/
Rad51-like recombinase enzyme40. Further genetic, 
cell-biological and biochemical analyses have unveiled 
protein factors that physically and functionally interact 
with Dmc1 (TABLE 1). Overall, the mechanistic attributes 
of the Dmc1-associated HR machinery are not as well 
defined as the Rad51-associated machinery.
Formation of recombinase filaments on ssDNA
As discussed above (and depicted in FIG. 2a), the sub-
strate of the HR machinery is ssDNA that stems from 
the processing of a DSB (or another lesion). The ssDNA 
serves to attract the recombinase, either Rad51 or Dmc1, 
and its associated ancillary factors. Studies that are 
directed at deciphering the recombinase mechanism have 
been guided by knowledge of the prokaryotic prototype 
E. coli RecA protein (BOX 1). RecA and its orthologues, 
including Rad51 and Dmc1, possess protein motifs that 
enable them to bind and hydrolyse ATP. Both Rad51 and 
RecA exist as a protein ring that consists of six and seven 
monomers, respectively. RecA and Rad51 polymerize on 
ssDNA to form a highly ordered, right-handed helical 
protein filament41–43, which is commonly known as the 
presynaptic filament. The presynaptic filament has a 
pitch of 95–100 Å, comprising 6 recombinase molecules 
and 18 nucleotides of the DNA ligand per helical repeat 
(FIG. 3). Notably, the ssDNA is held in an extended for-
mation in the presynaptic filament, being stretched by 
as much as 50% of the length of a B-form duplex DNA 
mole cule42–45. Assembly of the presynaptic filament 
requires ATP binding, but not ATP hydrolysis46, 47.
The catalytic core of the HR machinery. The assembly 
of the presynaptic filament is the most important step 
in HR reactions as it provides the catalytic centre for 
the formation of DNA joints between the two recom-
bining DNA molecules. Extensive biochemical studies 
with the RecA presynaptic filament have uncovered two 
DNA-binding sites: the ‘primary’ site accommodates the 
Figure 2 | Repair of DNA double-strand breaks by DSBR and SDSA. Double-strand 
breaks (DSBs) can be repaired by several homologous recombination (HR)-mediated 
pathways, including double-strand break repair (DSBR) and synthesis-dependent strand 
nnealing (SDSA). a | In both pathways, repair is initi ted by resection of a DSB to provide 
3′ single-stranded DNA (ssDNA) v rhangs. Strand invasion by these 3′ ssDNA overhangs 
into a homologous sequence is f llowed by DNA synthesis at the invading end. b |After 
strand invasion and synthesis, the second DSB end can be captured to form an 
intermediate with two Holliday junctions (HJs). After gap-repair DNA synthesis and 
ligation, the structure is resolved at the HJs in a non-crossover (black arrow heads at both 
HJs) or crossover mode (green arrow heads at one HJ and black arrow heads at the 
other HJ). c | Alternatively, the reaction can proceed to SDSA by strand displacement, 
annealing of the extended single-strand end to the ssDNA on the other break end, 
followed by gap-filling DNA synthesis and ligation. The repair product from SDSA is 
always non-crossover.
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 Congenital mutations in components of the HR pathway can cause genetic 
disorders associated with increased cancer predisposition. For example mutations in 
the BRCA1 and BRCA2 genes result in defective HR and are linked to familial breast 
cancer syndromes, which also have increased risks of developing ovarian cancer 
(King et al., 2003). A group of rare autosomal recessive disorders, characterised by 
chromosomal instability and cancer predisposition, are also associated with mutations 
in genes coding for elements of the HR repair pathway and also the DNA damage 
signalling transduction machinery leading to defective HR. Examples of these are 
ataxia-telangiectasia and the ataxia telangiectasia-like disorder which are caused by 
mutations in the ATM gene coding for the ATM kinase and seckel syndrome which is 
associated with ATR mutations. Nijmegen breakage syndrome is caused by mutation 
in NBS1 (Varon et al., 1998), which codes for a constitutive protein of the MRN 
complex. Finally, Werner’s syndrome and Bloom syndrome are associated with 
mutations in RecQ genes (WRN and BLM genes respectively), which code for DNA 
helicases involved in HR. As well as promoting HR these genes also protect against 
excessive recombination and the number of human diseases associated with defects in 
the signalling cascade demonstrates that regulation of the repair process is essential. 
 
Non-homologous end joining 
The homology-independent mode of DSB repair is called NHEJ and generally occurs 
when the sister chromatid is not present, i.e before DNA replication has taken place. 
This is the predominant process for repairing DSBs in human cells and occurs 
following ionising radiation induced DSBs. The importance of NHEJ in human cells 
is thought to relate to the size and repetitive nature of its genome complicating the 
search for suitable homologous sequences to allow HR. In NHEJ short regions of 
homologous sequences, called microhomologies, are often present at the end of DSBs 
and if compatible these can be directly joined together without the need of a sizeable 
homologous sequence (Critchlow and Jackson, 1998).  
 NHEJ requires a largely different set of proteins to HR. A heterodimeric 
complex consisting of Ku70 and Ku80 binds initially to the strand ends and recruits 
the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) generating the 
DNA-PK complex (Boulton and Jackson, 1996). If the damaged strand ends are not 
already compatible some processing occurs of the ends by Artemis, which forms a 
functional complex with DNA-PK and possesses intrinsic single strand exonuclease, 
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as well as endonuclease activity. This is followed by resynthesis by DNA polymerase 
β. Artemis provides an important processing activity in preparing and stabilising the 
strand ends which facilitates the joining of DNA ligase IV and the XRCC4 cofactor to 
perform the ligation step (Wilson et al., 1997). XLF/Cernunnos protein interacts 
directly with XRCC4 stimulating XRCC4-DNA ligase IV joining of the DNA ends 
facilitated by XRCC4-XLF performing a stable bridging function between the DNA 
molecules (Sekiguchi and Ferguson, 2006, Andres et al., 2012). This process results 
in loss of small amounts of genetic material either side of the DSB and is therefore 
error-prone. However, given the large amount of non-coding DNA within the human 
genome these losses and errors are generally tolerated. Another potential source of 
error with this process is that it can potentially lead to free ends being ligated to 
strands that were not joined prior to the DSB, leading to chromosomal 
rearrangements, one of the known hallmarks of cancer. 
 
 
1.4 Molecular basis of cancer 
 
A tumour describes an abnormal proliferation of cells and it is the ability of a tumour 
to invade locally into surrounding tissues, or metastasise to separate organs, which 
distinguishes a malignant tumour from a benign one. Cancer is a medical term 
referring to malignant tumours and comprises a group of diseases characterised by 
unregulated cell growth. Over 100 different types of cancer have been classified, with 
different origins and features, and many different molecular mechanisms have been 
shown to be involved in carcinogenesis and metastasis. Despite these differences, the 
net end result of unregulated cell growth is the same.  
 A number of steps are required for normal cells to transform into malignant 
cells. In 2000, Hanahan and Weinberg described six essential alterations in cell 
physiology acquired by most, if not all, cancers during their development that dictate 
malignancy (figure 1.7a). These were described as acquired functional capabilities, or 
hallmarks, essential for carcinogenesis, and are: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion 
and metastasis (Hanahan and Weinberg, 2000). In 2011 the same authors updated this 
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concept to include two emerging hallmarks in addition to the six hallmarks previously 
established: the reprogramming of cellular metabolism and the avoidance of immune 
destruction (Figure 1.7b) (Hanahan and Weinberg, 2011).  
 Two fundamentally important factors, comprising genome instability and 
tumour promoting inflammation, and called enabling characteristics were also 
described. These underpin carcinogenesis and are crucial to the acquisition of each of 
the hallmark capabilities described (Hanahan and Weinberg, 2011). Each of the 
hallmarks can be viewed as representing the successful breaching of an anticancer 
defence mechanism and a brief description of each of these capabilities is given here. 
 
 
 
Figure 1.7 - The acquired capabilities or hallmarks of cancer cells and their enabling 
characteristics as outlined by Hanahan & Weinberg. In 2000 six acquired functional capabilities, or 
hallmarks, essential for carcinogenesis were described (figure 1.7a). In 2011 this was updated to 
include two emerging hallmarks - the reprogramming of cellular metabolism and the avoidance of 
immune destruction - along with two enabling characteristics crucial to the acquisition of each of the 
hallmarks - genome instability and tumour promoting inflammation. Figure reproduced from (Hanahan 
and Weinberg, 2000, Hanahan and Weinberg, 2011). 
 
1.4.1 Self-sufficiency in growth signals 
Normal cells require stimuli from external growth signals to divide and these are 
provided by growth factors transmitted into the cell by transmembrane receptors. 
Normal cells rely on such signals to proliferate and are under the careful control of 
growth-promoting signals which govern their progression through the cell growth and 
division cycle. Cancer cells develop mechanisms that ensure they become less 
dependent on these external signals for their growth, disrupting the normal 
a b 
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homeostatic mechanism that controls cellular proliferation. This growth autonomy is 
achieved in different ways but all involve either the alteration of extracellular growth 
factor signalling, modulation of the transmembrane apparatus or alteration of the 
intracellular transduction of these signals. Many of the known cancer oncogenes act 
by mimicking these growth-promoting signals.  
 Whilst normal cells tend to produce growth factors to stimulate proliferation 
of another cell, cancer cells can acquire the capability to produce their own growth 
factor ligands, which they can respond to by expressing corresponding receptors, 
termed autocrine stimulation (Witsch et al., 2010). Cancer cells also send stimulatory 
signals to surrounding normal cells within the stroma, which not only respond by 
proliferating, but also by supplying the cancer cells with growth factors (Cheng et al., 
2008). Transmembrane receptor tyrosine kinases (RTK) can also be overexpressed in 
different cancers (Lemmon and Schlessinger, 2010) rendering cancer cells 
hyperresponsive to normal, or even limited, levels of growth factor ligand. Examples 
of this include the epidermal growth factor receptor (EGFR/ErbB1) in brain, stomach 
or lung carcinomas and the ErbB2/HER2 receptor in stomach and breast carcinomas. 
Receptor deregulation can also occur through structural alterations in RTKs leading to 
constitutively activated receptors or ligand-independent receptor activation.  
 Finally, downstream intracellular signalling pathways can be altered, again 
triggering constitutive signal activation independent of ligand-mediated receptor 
activation. KRAS mutation is an example of a clinically relevant activating mutation 
resulting in a constitutively activated intracellular signalling pathway and is present in 
30-40% of colorectal carcinomas (De Roock et al., 2011, Maughan et al., 2011). This 
mutation results in constituent activation of the RAS-RAF-MAP kinase signal 
transduction pathway from cell receptor to nucleus and renders cells resistant to 
therapy aimed at blocking the cell surface receptor with anti-EGFR monoclonal 
antibodies such as cetuximab (Karapetis et al., 2008, De Roock et al., 2010).  
  
1.4.2 Insensitivity to growth-inhibitory signals 
Within normal tissues, in addition to the growth-promoting signals, there are 
antiproliferative signals operating to maintain cellular and tissue homeostasis. Like 
the growth-promoting signals their growth-inhibitory counterparts generally involve 
soluble growth inhibitory factors acting on transmembrane receptors allied to the 
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intracellular signalling cascade. Generally, growth-inhibitory signals limit 
proliferation by forcing cells into the quiescent growth state (G0), or by inducing cells 
to enter into postmitotic states. Cancer cells overcome these antiproliferative signals 
mainly through the actions of tumour suppressor genes, and the inactivation of dozens 
of these have been implicated in human cancers. 
 The two most established suppressor genes code the retinoblastoma (RB) and 
TP53 proteins. These two proteins are of great importance in regulating proliferation 
within the cell, governing key complimentary regulatory circuits determining whether 
cells remain quiescent or enter a postmitotic state. RB was originally thought to 
function largely by arresting cells in G1 by inhibiting the E2F transcription factor, but 
is now believed to have many diverse cellular roles including control of cellular 
differentiation, regulation of apoptosis and preservation of chromosomal stability 
(Burkhart and Sage, 2008). RB responds to signals from many extracellular and 
intracellular sources, whereas TP53 tends to respond predominantly to intracellular 
signals such as DNA damage, fluctuations in nucleotide pools and disturbances in 
glucose or oxygen metabolism. Both pathways act as suppressors of cellular 
proliferation and disruption in either contributes to cancer initiation and progression 
in many human cancers (Sherr and McCormick, 2002). 
 Another mechanism for growth inhibition is via cell-to-cell contacts with 
coupling between cell-surface molecules and transmembrane receptors on 
neighbouring cells. An example is the cell membrane-based protein, Merlin, coded for 
by the suppressor gene NF2, which acts by coordinating such cell-to cell contact, and 
has been shown to be defective in neurofibromatosis type 2 (Curto et al., 2007). 
 
1.4.3 Evasion of programmed cell death (apoptosis) 
For tumour cell populations to expand in number requires not only an increase in 
cellular proliferation but also a reduction in programmed cell death or apoptosis, and 
impaired apoptosis has been shown to be a critical hallmark of cancer development. 
Apoptosis can be broadly divided into two components – sensors and effectors. The 
sensing component can be divided into those that process signals of extracellular 
origin, such as the insulin-like growth factor 1/2 (IGF1/2) survival signal and the FAS 
ligand and TNFα death signals which bind to corresponding transmembrane 
receptors, and those that respond to signals of intracellular origin, and are primarily 
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regulated by the Bcl-2 family (Adams and Cory, 2007). These sensor signals 
culminate in activation of an array of intracellular proteases termed caspases which 
coordinate cellular death.  
 Members of the Bcl-2 family of proteins have either proapoptotic (Bax, Bak, 
Bid, Bim) or antiapoptotic function (Bcl-2, Bcl-XL, Bcl-W) and TP53 can trigger 
apoptosis via an increase in Bax expression. Resistance to apoptosis can be acquired 
through a variety of mechanisms and is present in virtually all cancer cells. The most 
common mechanism is through loss of TP53 function, which results in removal of a 
critical DNA damage sensor component of the intracellular proapoptotic signalling 
pathway (Harris, 1996, Junttila and Evan, 2009). Similar outcomes can be achieved in 
cancer cells by increasing expression of antiapoptotic regulators, eg the Bcl-2 
oncogene, or of the extracellular survival factors IGF-1/2 (Evan and Littlewood, 
1998) or by downregulating proapoptotic factors such as Bax/Bim or by loss of the 
tumour suppressor gene pTEN (Cantley and Neel, 1999).  
 
1.4.4 Limitless replicative potential 
Aside from the three acquired capabilities discussed, which provide the cancer cell 
with an autonomous growth programme independent of signals from the 
microenvironment, a further barrier to tumour formation must be overcome. Cells 
have finite replicative potential that must be disrupted for cancer cells to proliferate 
sufficiently to produce macroscopic tumours. Cultured cells are shown to have finite 
replicative capacity before reaching senescence and crisis or apoptosis (Hayflick, 
1997), whilst most types of tumour cells appear immortalised, exhibiting limitless 
replicative potential. Telomere maintenance plays a critical role in achieving this 
immortal phenotype, with upregulated telomerase demonstrated in 90% of cancers 
(Shay and Bacchetti, 1997). Telomerase is a specialised DNA polymerase which 
maintains telomere ends by adding telomere repeat 3’-TTAGGG-5’ hexanucleotide 
segments, ensuring that cells avoid senescence and apoptosis. An alternative, 
telomerase-independent, mechanism of maintaining telomere length has also been 
described, called ALT (alternative lengthening of telomeres) (Henson et al., 2002).  
 Telomere length and telomerase function have long been known to be 
important factors in the biology of human disease, and whilst telomerase and telomere 
related proteins are known to be upregulated in most cancers, telomere shortening has 
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also been demonstrated in many age-related pathologies as well as many late-stage 
cancers (Blasco, 2005). Recent advances in understanding has described transient 
telomere deficiency leading initially to genomic alterations and tumour-promoting 
mutations before upregulated telomerase stabilises these mutations and confers 
unlimited replicative capacity required by tumour cells. This phenomenon of initial 
telomere shortening associated with chromosomal aberrations followed by telomerase 
overexpression and telomere lengthening has been demonstrated in breast tissue as 
premalignant lesions develop into malignant carcinomas (Raynaud et al., 2010). 
 
1.4.5 Sustained angiogenesis 
Cellular function and survival is dependent on the supply of oxygen and nutrients 
through the vasculature. During normal tissue growth and organ formation the growth 
of new blood vessels, known as angiogenesis, is a critical and carefully regulated 
event. Neoplastic growth must also develop similar angiogenic ability, however this is 
not such a well-regulated process - rather tumours first develop hypoxic regions due 
to inadequate vessel growth followed subsequently by disordered, poorly regulated 
and aberrant angiogenesis. Part of normal tissue angiogenic regulation is that in 
normal tissues, angiogenesis is turned on transiently before the vasculature returns to 
quiescence. In contrast to this, in neoplastic tissue, the “angiogenic switch” is turned 
on and remains on continuously to support tumour growth and the vasculature never 
returns to the quiescent state (Hanahan and Folkman, 1996).  
 The “angiogenic switch” is under the counterbalance of dozens of soluble 
protein factors that act on cell surface receptors stimulating or opposing angiogenesis. 
Two of the most well established endogenous regulators of this process are the 
stimulatory vascular endothelial growth factor-A (VEGF-A) (Ferrara, 2009), and 
inhibitory thromospondin-1 (TSP-1) (Ribatti, 2009). Part of the early proof of 
principle for the importance of angiogenesis to the establishment of tumours came 
with the observation that anti-VEGF antibodies inhibited tumour growth in mice (Kim 
et al., 1993). Several such antibodies have now been developed and approved as 
therapeutic agents that inhibit VEGF and are used in the treatment of advanced cancer 
and neovascular age-related macular degeneration, demonstrating the importance of 
angiogenesis for tumour development and confirming its relevance as a therapeutic 
target. 
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1.4.6 Tissue invasion and metastasis 
As mentioned previously, the hallmark that differentiates a malignant tumour from a 
benign one is its ability to invade adjacent tissues and metastasise to distant sites. It is 
this invasion and metastatic spread which proves lethal, rather than the cellular 
proliferation of the primary tumour, with around 90% of human cancer deaths caused 
by metastatic disease (Sporn, 1996). A sequence of steps, termed the invasion-
metastatic cascade has been described which involves local invasion, intravasation 
into blood or lymphatic vessels, travel to distant sites and extravasation from the 
vessels to the parenchyma of distant tissues to form metastatic lesions (Fidler, 2003).  
 Invasion and metastases occur when cells develop alterations in their ability to 
remain attached to host tissues and extracellular matrix. E-cadherin has been the most 
well characterised cell adhesion molecule implicated in this process. It has been 
demonstrated that increased E-cadherin expression reduces tumour cell invasion or 
metastases whilst reduction of its expression promotes these processes and 
furthermore it has been shown to be downregulated in many human carcinomas (Berx 
and van Roy, 2009). Recently, an increasing body of research work has demonstrated 
the importance of signalling and crosstalk between cancer cells and the cells of the 
surrounding stroma and shown how this is involved in acquiring the capability for 
invasion and metastases (Egeblad et al., 2010, Qian and Pollard, 2010).   
 
1.4.7 Emerging hallmarks 
As mentioned, the seminal text by Hanahan and Weinberg in 2000 was updated in 
2011, when two further emerging hallmarks were defined. These emerging hallmarks 
described themes where more recent research developed and substantiated familiar 
theories and established their importance to the cancer cell phenotype (Hanahan and 
Weinberg, 2011). Firstly, reprogramming the energy metabolism of cancer cells, 
whereby cells adjust their glucose metabolism and energy production primarily to 
glycolysis such that they exist in a state of “aerobic glycolysis”. This effect was first 
outlined in the 1950s by Warburg (Warburg, 1956a, Warburg, 1956b), but recently 
this work has been substantiated, particularly in studies into the role of hypoxia and 
hypoxia inducible factor-1 (HIF-1α) (Semenza, 2010a, Semenza, 2010b).  
 The second emerging hallmark is the evasion of immune destruction. This 
hallmark is built around the long-standing theory that immune surveillance of cells 
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and tumours manages to eliminate the majority of cancer cells, and that tumours that 
do develop have somehow managed to avoid this surveillance. Research work 
supporting the evasion of antitumour immune responses as an emerging hallmark 
comes from many sources including analysis of virus-induced cancers, tumour 
transplantation studies in genetically engineered immunodeficient mice (Kim et al., 
2007), clinical epidemiology studies of human cancers (Nelson, 2008) and 
immunosuppressed organ transplant patients (Strauss and Thomas, 2010). 
 
1.4.8 Enabling characteristics 
The acquisition of each of these hallmarks is facilitated by two enabling 
characteristics, primarily, genome instability, and tumour-promoting inflammation 
(Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011). It was accepted that 
the acquirement of the hallmarks of cancer was primarily dependent on a succession 
of alterations in the genomes of neoplastic cells and that genomic instability was 
integral to this (Hanahan and Weinberg, 2011). The importance of TP53 as the 
“guardian of the genome” has long been known (Lane, 1992) and this remains an 
integral part of the surveillance system that monitors genome integrity. More recently, 
the loss of telomeric DNA has been shown to be a source of genomic instability by 
generating karyotypic instability and chromosomal deletions (Artandi and DePinho, 
2010). Recent work performed at Cardiff University analysing single-molecule 
telomere length and telomere fusion in patients with chronic lymphocytic leukaemia 
(CLL) identified the shortest telomeres recorded in human tissue, reinforcing the 
concept that significant cell division occurs in CLL and that telomere shortening, 
dysfunction and fusion contribute to disease progression (Lin et al., 2010). The 
importance of telomerase therefore is clear, not only in promoting the limitless 
replicative phenotype as discussed earlier, but also for maintaining genome integrity.  
 The second feature now considered to be an enabling characteristic is tumour-
promoting inflammation. Tumours have been shown to contain many immune and 
inflammatory cells and the functional role that these inflammatory cells have on 
tumour growth, by supplying them with factors that help sustain cell growth, survival, 
angiogenesis, invasion and metastases has been clearly demonstrated (Colotta et al., 
2009, Grivennikov et al., 2010).  
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1.4.9 Cancer and modern genomics 
During much of the early genomic era, attention focused on the function and variation 
of particular genomic sequences. Work in this area continues in the form of genome-
wide association studies (GWAS), which permit the comparison of genomes between 
different individuals and populations to allow the recognition of disease causing 
mutations and polymorphisms. Recent attention has also focused on how findings 
from GWAS relate to dynamic aspects of cellular genomics such as gene transcription 
and expression, epigenetic changes and DNA repair, termed functional genomics. 
Much of this work has been conducted by functional genome-wide analysis using 
chromatin immunoprecipitation-DNA microarray (ChIP-chip) and chromatin 
immunoprecipitation-DNA sequencing (ChIP-seq) techniques and information from 
such approaches is currently being applied to improving disease diagnosis, prognosis 
and tailor personalised treatment approaches. The clinical area where these 
approaches are being applied most frequently and having most impact is in oncology 
and cancer research.  
 Whole cancer genomes have been sequenced revealing several thousand 
somatic mutations, however the biological meaning of such mutations are difficult to 
decipher and the current thinking is that the majority of these may have little 
biological relevance (Shah et al., 2009, Pleasance et al., 2010, Puente et al., 2011). 
Somatic mutations have been classified according to their consequences for cancer 
development as “driver” mutations of oncogenesis, those that confer a growth 
advantage for the cancer and therefore have been positively selected during its 
evolution, and “passenger” mutations that happen to be present within the cancer 
genome but do not confer a growth advantage (Stratton et al., 2009). Such mutations 
are now being catalogued globally from more than 25,000 cancer genomes by an 
international consortium in an effort to co-ordinate different large-scale cancer 
genome projects (Hudson et al., 2010). The somatic mutations that are present in 
cancer cells will reflect and provide insights to the DNA damage and repair processes 
that have been operative during cancer development, and will be a cumulative result 
of all mutations and mutational processes encountered during the cellular lineage 
from fertilised egg to final cancer cell (Stratton, 2011).  
 Developing this theme, recent studies have been able to demonstrate cancer as 
a dynamically evolving series of clonal expansions driven by mutational processes, 
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and by sequencing cancer genomes and using algorithms to model clonal mutations 
the clonal life history of a cancer can be deciphered (Nik-Zainal et al., 2012a, Nik-
Zainal et al., 2012b). These studies demonstrate many driver mutations accumulated 
in the lineage of tumour cells in genes, such as P53, EGFR and MYC, all implicated in 
Hanahan and Weinberg’s hallmarks of cancer, before the appearance of the “most-
recent common ancestor” cell with the full complement of somatic mutations found in 
all the cancer cells. This is followed by a final expansion of a dominant subclonal 
lineage prior to diagnosis of cancer - in the case of this study, breast cancer (Nik-
Zainal et al., 2012b). Another recent important development has been to map and 
catalogue somatic mutations present in cancer genomes of different cancer types. By 
doing this, distinct mutational signatures have been isolated and related to cancer type 
and shown to be associated with different mutagenic exposures or different DNA 
repair defects (Alexandrov et al., 2013a, Alexandrov et al., 2013b). Modelling cancer 
development in such a way raises the intriguing possibility of being able to measure 
DNA damage and repair processes in precursors to cancer cells as a potential 
opportunity to assess cancer susceptibility or predisposition in an individual. 
 These studies build on concepts of cancer stem cells (CSCs) and clonal 
heterogeneity in solid tumours and the understanding that cancers evolve as a result of 
a series of processes of clonal cell expansion, genetic diversification and clonal 
selection. CSCs are cells found within tumours that mimic normal stem cells, 
particularly the ability to develop into any cell type within the tumour, and also 
possess the ability for self-renewal. These concepts have important therapeutic 
relevance by highlighting how therapeutic failure and resistance can occur if 
therapeutic intervention only acts on certain clones whilst providing selective impetus 
for the expansion of the resistant clones (Greaves and Maley, 2012). Additionally, 
recent studies using mouse models have demonstrated how skin, intestinal and brain 
tumours contained CSCs capable of self-renewal. Such cells are able to produce 
daughter (non-stem) cells capable of proliferation that constitute the bulk of tumours 
and these studies demonstrate how targeting the CSCs could improve therapeutic 
outcome and is required for complete tumour eradication (Chen et al., 2012, Driessens 
et al., 2012, Schepers et al., 2012). 
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1.5. Principles of cancer therapies for solid tumours 
 
There are three modalities of cancer therapy - surgery, radiotherapy and systemic 
therapy. Traditionally, systemic therapy has comprised only chemotherapy but over 
the past two decades this now also includes the novel agents or targeted therapies. 
Each of these treatments can be used alone (single modality) or in any combination of 
the three (multimodality) and this treatment can be given concurrently in the case of 
chemo-radiotherapy or sequentially. Outcome and response to treatment depends 
primarily on the stage at which the cancer is detected, with earlier detected cancers 
having a better outcome than later presentations. Whilst there are certain notable 
exceptions such as lymphoma and testicular cancer, generally, if at the time of 
diagnosis the cancer has metastasised to other parts of the body then the treatment 
intent is palliative rather than radical. Recent advances in cancer management have, 
however, demonstrated that in patients with isolated metastatic disease, for example 
in the liver, regional treatments using surgery can result in improved long-term 
disease control and cure (Kopetz et al., 2009). Further advances include studying the 
use of novel techniques such as radio-embolisation in combination with 
chemotherapy for inoperable liver metastases (FOXFIRE clinical trial). 
 
1.5.1 Surgery 
Surgery was the earliest therapeutic strategy used against solid cancers. It is often a 
curative procedure for early stage disease but it is often impossible to surgically 
remove all of the cancer depending on its site or position. Obviously surgery only 
removes the macroscopically visible tumour based on radiological assessments and 
what the surgeon can visualise at the time of surgery. It obviously does not address 
treatment at a cellular level, and whilst a margin of normal tissue is removed around a 
tumour to increase the likelihood of tumour clearance it is impossible to address cells 
that may have already metastasised from the primary site at the time of surgery. For 
these reasons chemotherapy is often given with surgery, either pre-operatively (neo-
adjuvant chemotherapy) with the intention of shrinking tumours and treating 
metastatic cells or post-operatively (adjuvant chemotherapy) to treat metastatic cells. 
For haematological malignancies such as leukaemia, lymphoma and myeloma there is 
little role for surgery. 
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1.5.2 Radiotherapy 
At least 50% of all patients with cancer in the UK receive radiation therapy. 
Radiotherapy can be delivered in different ways; from outside the body using beams 
of ionising radiation such as X-rays generated by linear accelerators (external beam 
radiotherapy, EBRT), or particles such as electrons or protons, or from within the 
body using sealed source radioisotopes (brachytherapy) or unsealed systemic 
radioisotopes. Radiotherapy involves delivering ionising radiation to tumours and the 
bulk of ionisations produced are in intracellular water molecules. This generates free 
radicals that damage DNA causing single and double strand breaks, leading to cell 
death.  
 The dose and delivery of radiation therapy is limited by the dose received by 
the surrounding normal tissue and structures. By incorporating modern imaging 
techniques, such as computerised tomography (CT) and magnetic resonance imaging 
(MRI) into radiotherapy treatment planning algorithms, and with improved 
technology within linear accelerators for the delivery of EBRT, the targeting and 
delivery of EBRT to the tumour has become more precise. This has allowed greater 
sparing of normal tissue. The delivery of external radiotherapy has further evolved 
recently, again mitigating damage to surrounding normal tissue, by using techniques 
such as intensity modulated radiotherapy (IMRT) and stereotactic radiotherapy.  
 Another way of increasing tumour dose and limiting dose received by 
surrounding structures is to place the radioactive source within, or in direct proximity 
to, the tumour itself, known as brachytherapy. This is established treatment for a 
variety of tumours, particularly prostate (NICE, 2005a) and cervical cancers (Nag et 
al., 2000). Systemic radioisotope therapy involves delivering these radioisotopes 
either orally or as an intravenous infusion and are commonly used to treat thyroid 
cancers (RCP, 2002).  
 When delivered as curative, radical, treatment radiotherapy is often given with 
concurrent chemotherapy. In the metastatic setting radiotherapy can be given for 
palliation of certain symptoms. 
 
1.5.3 Chemotherapy 
Traditional cytotoxic chemotherapeutic agents are given in three distinct clinical 
scenarios; firstly, as curative treatment for certain malignancies such as testicular 
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cancer, Hodgkin and non-Hodgkin lymphoma, secondly, as postoperative (adjuvant) 
or pre-operative (neoadjuvant) treatment of localised malignancies and thirdly as 
palliative treatment in advanced malignancies. The goal of cytotoxic chemotherapy is 
to inflict damage in the cancer cell triggering apoptosis or direct cell killing, and 
whilst the targets are non-specific, and therefore the effects of these agents occur in 
normal tissue as well as the cancer cells, their effect is greater in rapidly dividing 
cancer cells. Since cancer cells proliferate more rapidly the majority of cancer 
treatments target the cell cycle and the therapeutic index of a cytotoxic agent refers to 
its ability to kill cancer cells in preference to cells in normal tissues. 
 Cytotoxic agents currently used in clinical practice have differing modes of 
action and different cellular targets, including DNA, RNA and proteins. The majority 
of cytotoxic agents target DNA, often forming covalent adducts or transferring alkyl 
groups to the DNA. These can cause cell cycle arrest and direct cell death, or can 
disrupt DNA function and metabolism and inhibit DNA replication, triggering 
apoptosis. Replicating cells (i.e. rapidly proliferating) will therefore be more 
susceptible to DNA-damaging agents leading to greater cell killing in these cells. The 
effect of DNA damaging agents can be mitigated by DNA repair pathways which can 
remove the DNA damage lesions before they cause toxicity causing drug resistance 
(Helleday et al., 2008). Conversely DNA repair pathways are often inactivated in 
cancer cells making them more susceptible to DNA-damaging agents than normal 
cells. 
 Examples of such DNA damaging drugs include platinum analogues (eg 
cisplatin, carboplatin and oxaliplatin) and alkylating agents such as nitrogen mustards 
(eg cyclophosphamide and ifosfamide) or nitrosoureas (carmustine, lomustine). 
Antineoplastic agents demonstrate varying efficacy in different tumour types, even 
within families of antineoplastic agents. For example the newer platinum analogue 
oxaliplatin is effective against colorectal cancer, whilst the older platinum agents 
cisplatin and carboplatin are ineffective against this.  
 The first chemotherapy agents used were nitrogen mustards, derivatives of 
mustard gas originally used in warfare. Post-mortem examination of mustard gas 
victims during world war I revealed low levels of white blood cells in the bone 
marrow, suggesting it to be a potent inhibitor of haematopoiesis (Krumbhaar and 
Krumbhaar, 1919). This observation highlighted the potential therapeutic benefit of 
these agents and they were therefore developed for administration to patients with 
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haematological malignancies (Lawley, 1995). These agents primarily target the N7 
position of deoxyguanosine residues, which it alkylates and forms covalent 
monoadducts and interstrand crosslinks.  
 Other examples of agents that form toxic adducts with DNA are the platinum 
analogues, the subject of this thesis. These also target the N7 position of guanine and 
adenine residues to form a variety of bulky, covalent, mono and bifunctional adducts. 
Similar to the nitrogen mustards the potential anticancer effect of the platinum 
analogues was discovered fortuitously (see section 1.6.1). 
 Anthracyclines, a type of antitumour antibiotic, work by intercalating between 
base pairs on the DNA strand but also by inhibiting topoisomerase II and forming free 
radicals that damage DNA. The anti-metabolites, such as 5-fluorouracil inhibit DNA 
synthesis and generate metabolites that become mis-incorporated into DNA. The 
topoisomerase inhibitors target enzymes involved in regulating and maintaining the 
topology of DNA and these act by interfering with DNA transcription and replication. 
Non-DNA targeting antineoplastic agents include the microtubule-targeting cytotoxic 
agents, which target the mitotic spindle and therefore target cell division directly.  
Examples of these are the taxanes which inhibit microtubule depolymerisation and the 
vinca alkaloids which inhibit microtubule formation.  
 Cytotoxics are often delivered clinically in combinations of two or more 
different drugs in an attempt to maximise response. Combinations of anticancer 
agents form the basis of treatment of most solid organ and haematological 
malignancy. The desirable effect of combination therapy is synergistic interaction - 
where the combined effect surpasses the additive effect. The principles for combining 
different anticancer agents involve combining drugs with different modes of action, 
different side effect profiles or drugs that act at different stages of the cell cycle. An 
example of a common combination chemotherapy regime is the combination of the 
platinum analogue oxaliplatin and the antimetabolite 5-Fluorouracil (5-FU). These 
have differing modes of action, different side effect profiles and 5-FU is S-phase 
specific whilst oxaliplatin is cell-cycle non-specific.  
 
1.5.4 Targeted therapies 
Cytotoxic agents have often been used with limited understanding of their molecular 
mode of action, but as understanding improves, and as more is learnt about the 
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molecular action of cancer cells, targeted therapies have been designed and developed 
to exploit these known characteristics. Endocrine therapies have been in clinical 
practice for many decades and are examples of early targeted therapies, used to inhibit 
the endocrine growth signals for hormonally driven tumours such as breast and 
prostate cancer. Novel targeted therapies developed in the last two decades include 
receptor tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, which are 
designed to inhibit a specific molecular target, typically within the growth signalling 
pathways, known to be over expressed or functionally active within cancer cells.  
 The first such agent in this class was imatinib (Glivec), a TKI of the bcr-abl 
protein product of the Philadelphia chromosome translocation, shown to have 
significant activity in chronic myeloid leukaemia (CML) (Goldman and Melo, 2003). 
Because the bcr-abl enzyme only exists in the cancer cell this agent was regarded as 
the first molecularly targeted agent and acted as a paradigm for the molecular era of 
cancer therapeutics. This drug has subsequently been shown to inhibit the tyrosine 
kinase domain of the c-kit receptor and as such has been used to treat gastrointestinal 
stromal tumours (GISTs) (van Oosterom et al., 2001). Subsequently, many different 
TKIs have now been developed and are used clinically to treat most common solid 
and haematological malignancy. Many of these TKIs comprise small molecules that 
compete with ATP for binding to a receptor’s intracellular tyrosine kinase domain. 
This blocks receptor activation and prevents transduction of downstream signalling.  
 The other major class and approach of novel targeted therapies are the 
monoclonal antibodies and these are often antibodies generated against a receptor’s 
ligand-binding extracellular domain which block the binding of receptor-activating 
ligands. Some important examples include trastuzumab (Herceptin) an antibody 
designed to inhibit the HER2 receptor and licensed for use in patients with early or 
late stage HER2 positive breast cancer (Cobleigh et al., 1999). Other monoclonal 
antibodies include cetuximab (Erbitux), licensed for use in colorectal (Cunningham et 
al., 2004) and head and neck (Bonner et al., 2006) malignancies and designed to 
inhibit the EGFR, and bevacizumab (Avastin) an anti-VEGF monoclonal antibody 
used in patients with advanced colorectal cancer (Hurwitz et al., 2004).   
 Important advances have been made in therapeutic outcomes and molecular 
understanding of tumour biology and treatment resistance with the development of 
these agents. However despite these obvious advances, and whilst these agents are 
undoubtedly efficacious in some patients and in some circumstances, they have not 
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shown the sort of improvements in survival expected. Again, similar to the traditional 
chemotherapy agents, it is evident that their efficacy can be enhanced by improved 
knowledge of their molecular mode of action, patterns of resistance and ultimately by 
stratifying their use to those patients most likely to respond. An example of where 
improved biological and mechanistic understanding combine to improve treatment 
efficacy is with the use of the EGFR TKIs in non-small cell lung cancer (NSCLC). 
EGFR is overexpressed in 40 - 80% of patients with NSCLC (Arteaga, 2003) 
however, simply adding the EGFR TKI gefitinib to standard chemotherapy to 
pharmacologically inhibit EGFR had no clinical efficacy (Giaccone et al., 2004, 
Herbst et al., 2004). A subpopulation of patients were shown to be responding to 
gefitinib and an activating mutation in EGFR was then identified in this 
subpopulation (Lynch et al., 2004). It was then confirmed in a phase 3 clinical trial 
that the presence of this activating mutation was a strong predictor of response to 
gefitinib, such that gefitinib monotherapy offered improved outcome compared with 
standard chemotherapy treatment (Mok et al., 2009). 
 
1.5.5 Conclusion 
Despite significant advances in our understanding of the molecular biology of cancer 
and despite the development of new, targeted therapies, cures for most types of cancer 
remain elusive. Whilst developing new therapies based on our improved 
understanding of cancer biology is one approach to improving treatment outcome, 
another is to use this understanding to improve the use of traditional and existing 
cancer cytotoxic agents. This requires improved mechanistic understanding of how 
these traditional therapies work and better phenotypic and clinical assays that will 
allow existing therapies to be individualised to patients most likely to respond to 
them. Through this improved understanding new approaches, new therapeutic agents 
and new treatment combinations may be developed to exploit these intrinsic 
mechanisms and improve drug efficacy. 
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1.6 Platinum analogues 
 
1.6.1 Platinum analogues in cancer therapeutics 
The platinum-based family of compounds are among the most established and potent 
chemotherapeutic agents and are widely used to treat a variety of malignant tumours 
including ovarian, testicular, head and neck, lung and colorectal carcinoma (Cohen 
and Lippard, 2001). The 3 major platinum-based compounds in clinical use are 
cisplatin, carboplatin and oxaliplatin and they share structural similarities (figure 1.8) 
but have marked differences in therapeutic use, pharmacokinetics and adverse effect 
profiles. Oxaliplatin has demonstrated reduced toxicity along with a lack of cross-
resistance with cisplatin (Chaney, 1995, Raymond et al., 1998, Kelland and McKeage, 
1994) and is the first platinum-based chemotherapeutic agent approved for the 
treatment of colorectal cancer.  
 
 
Figure 1.8 – The chemical structures of cisplatin, carboplatin and oxaliplatin. Cisplatin [cis-
diamminedichloroplatinum(II)] consists of two amine and two chloride ligands attached to a central 
platinum atom in a square planar structure. Carboplatin [cis-diammine(1,1-
cyclobutanedicarboxylato)platinum(II)] has a bidentate dicarboxylate (CBDCA) ligand replacing the 
chloride ions as the leaving group. Oxaliplatin [oxalate(trans-1,2-diamminocyclohexane) platinum(II)] 
has a diamminocyclohexane (DACH) ligand replacing the amine groups as the carrier ligand and an 
oxalato- ligand replacing the chloride leaving groups present in cisplatin.  
 
Cisplatin 
The first platinum analogue to be developed was cisplatin. The biological activity of 
cis-diamminedichloroplatinum(II) or cisplatin was discovered by chance by 
Rosenberg in 1965 during studies on the effects of electric currents on bacterial 
growth. During these studies he noticed that an electric field caused Escherichia coli 
cells to form long filaments, up to 300 times the length of a normal cell, suggesting 
that whilst cell growth continued, cell division was stalled (Rosenberg et al., 1965). 
Further work indicated that platinum salts produced at the electrode during 
 Cisplatin                                                Carboplatin                                                           Oxaliplatin 
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electrolysis were the active agents for this phenomenon (Rosenberg et al., 1967). A 
number of platinum compounds were subsequently assessed for their ability to induce 
filamentous growth in bacteria, and several of these, including cisplatin, demonstrated 
such activity (Howle and Gale, 1970). It was concluded that filamentation was 
indicative of DNA damage and that these agents may therefore have biological 
antitumour activity. This was demonstrated by Rosenberg et al, who demonstrated 
that cisplatin inhibited the growth of sarcoma 180 cells and leukaemia L1210 cells in 
mice (Rosenberg et al., 1969). 
 Demonstration of cytotoxic activity against a broad spectrum of cancer cell 
lines and animal tumours meant that clinical studies of these agents’ safety and 
efficacy soon commenced. The Food and Drug Administration (FDA) approved 
cisplatin for clinical use in 1978 for the treatment of metastatic testicular and ovarian 
carcinoma. Cisplatin is a small inorganic molecule comprising a central platinum 
atom surrounded by two amine ligands (carrier groups) and two chloride ligands 
(leaving groups) arranged in a square planar molecular structure (figure 1.8). 
 Cisplatin is now one of the most effective and widely used chemotherapeutic 
agents treating solid organ malignancies. It is used as part of combination 
chemotherapy regimes to treat a variety of malignancies including carcinomas of the 
oesophagus, stomach, head and neck, lung, bladder and cervix and is often used in 
combination with radiotherapy as a radiosensitising agent for example to treat 
oesophageal, head and neck and cervical carcinomas. Transplatin is the trans 
stereoisomer of cisplatin and has not demonstrated biological activity. 
 
Carboplatin 
The second generation platinum analogue carboplatin [cis-diammine(1,1-
cyclobutanedicarboxylato)platinum (II)] was introduced in the mid–1980s. It differs 
from cisplatin as it has a bidentate dicarboxylate (CBDCA) ligand replacing the 
chloride ion leaving groups (figure 1.8). This structure confers greater chemical 
stability compared with cisplatin, accounting for its lower reactivity with nucleophilic 
sites of DNA. This lower reactivity may explain the higher drug doses necessary to 
obtain similar antitumour effects to cisplatin (van der Vijgh, 1991, Murry, 1997). 
Carboplatin has fewer side effects than cisplatin and has replaced cisplatin in the 
chemotherapy regimes of some tumours, such as ovarian and lung carcinoma, 
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however it remains unclear whether carboplatin has equivalent efficacy to cisplatin 
across all disease types. 
 
Oxaliplatin 
Oxaliplatin, or oxalate(trans-1,2-diamminocyclohexane) platinum(II), is a third 
generation platinum analogue and is the most recent platinum analogue developed for 
clinical use. It differs from cisplatin in that the amine carrier ligands are replaced by a 
diamminocyclohexane (DACH) ligand whilst the chloride ligands are replaced by an 
oxalate leaving group (Figure 1.8). This structure is important since it accounts for 
some of oxaliplatin’s unique chemical properties. Whereas cisplatin structure is stable 
in plasma and becomes activated within the low chloride environment of the cell, 
oxaliplatin is rapidly transformed into the reactive compound in plasma by having the 
oxalate leaving group displaced.  
 Limitations of cisplatin include its significant side effects (see next section) 
and its lack of activity against colorectal cancer, one of the commonest malignancies. 
For these reasons an alternative to cisplatin was sought and oxaliplatin was 
developed. Phase 1 trials with oxaliplatin interestingly did not demonstrate 
nephrotoxicity but did begin to characterise another important dose-limiting toxicity - 
peripheral neuropathy (Extra et al., 1990). Nevertheless, oxaliplatin demonstrated an 
improved toxicity profile and, critically, phase II trials demonstrated modest activity 
in patients against colorectal cancer as a single agent (Machover et al., 1996, Diaz-
Rubio et al., 1998) and synergistic action with 5-FU (Levi et al., 1992). Oxaliplatin is 
now a mainstay of treatment for patients with both early and late stage colorectal 
carcinoma (de Gramont et al., 2000), although peripheral neuropathy continues to be a 
well recognised, troublesome, cumulative toxicity associated with its use. 
 
1.6.2 Toxicities 
Despite their widespread use, the platinum analogues are associated with significant 
toxicities. Cisplatin is significantly more toxic than the newer agents, causing side 
effects ranging from mild to severe, and include nephrotoxicity, myelosuppression, 
ototoxicity and neuropathy (Hartmann and Lipp, 2003). Cisplatin causes ototoxicity 
in approximately 25-55% of patients (Rybak and Whitworth, 2005) and similar levels 
of nephrotoxicity. Carboplatin is less toxic and rarely causes nephrotoxicity or 
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peripheral neuropathy, but does cause myelosuppression (Wagstaff et al., 1989). The 
commonest toxicity associated with oxaliplatin is peripheral neuropathy, which can be 
acute and transient or cumulative and chronic (Argyriou et al., 2008). Generally 
oxaliplatin does not cause ototoxicity or nephrotoxicity but does cause 
myelosuppression (Alcindor and Beauger, 2011).  
 Cisplatin related nephrotoxicity and ototoxicity are regarded to be mediated by 
production of reactive oxygen species within the cells of the proximal tubule and the 
cochlea respectively (Lee et al., 2004, Lieberthal et al., 1996). Oxaliplatin-induced 
peripheral neuropathy has two distinct mechanisms. Firstly, the acute peripheral 
neuropathy is considered to be due to decreased sensory nerve conduction due to 
chelation of calcium ions by oxalate groups as well as sodium and calcium channel 
toxicity and dysfunction. Conversely, the chronic neuropathy component is due to 
accumulation of platinum adducts within the dorsal root ganglia of the spinal cord of 
the central nervous system, accounting for the primarily sensory neuropathy observed 
(Argyriou et al., 2008, Pachman et al., 2011). The recently reported phase III 
randomised controlled trial, the COIN trial, investigated patients with metastatic 
colorectal carcinoma and is the largest such trial performed and recorded rates of 20-
25% of severe peripheral neuropathy in patients treated with a combination of 
oxaliplatin and 5-FU (Maughan et al., 2011). 
 Toxicity is therefore commonly observed with these agents, is dose-limiting 
and whilst co-existing medical co-morbidities can increase people’s susceptibility to 
these side effects (such as diabetes with neuropathy and nephrotoxicity) they are 
essentially unpredictable. There is a spectrum of toxicity observed, from mild to 
severe and can be acute and reversible or chronic and irreversible. 
 
1.6.3 Clinical Response 
In clinical practice, when treating cancers, response to a particular therapy is often 
judged by the degree of shrinkage seen in a cancer on imaging following treatment. 
Alternative means of judging clinical responses are by assessing improvements in 
symptoms or reduction in tumour blood markers on serial blood tests. Clinical 
responses observed to platinum analogues are variable and are limited by drug 
resistance, which may be inherent or acquired and can vary between individuals, 
tumour types and drugs. For example, recent randomised clinical trials have reported 
Chapter 1. Introduction 
 47 
response rates of 48% for a carboplatin-containing regime in patients with ovarian 
carcinoma (Perren et al., 2011), 64% for a cisplatin-containing regime in patients with 
head and neck cancer (Posner et al., 2007) and 57% in patients with colorectal 
carcinoma treated with an oxaliplatin-containing regime (Maughan et al., 2011). It is 
probable that different degrees of sensitivity to platinum agents exist and in the 
treatment of ovarian carcinoma four different categories of disease have been defined 
based on how soon after treatment with platinum agents the disease relapses. These 
have been categorised as platinum-sensitive ovarian cancer if relapse occurs after 12 
months, partially platinum-sensitive ovarian cancer if relapse occurs between 6 and 
12 months and platinum-resistant ovarian cancer if relapse occurs less than 6 months 
after initial response to platinum-based treatment. Finally, platinum-refractory ovarian 
cancer describes disease that does not respond to platinum-based treatment (NICE, 
2005b). In these cases rechallenge with platinum-based therapy is recommended for 
platinum sensitive disease but not for platinum-resistant disease. Resistance to these 
agents develops as a result of many different mechanisms and these will be outlined 
briefly in section 1.6.5. 
 
1.6.4 Mechanism of action 
The antineoplastic activity and the dose-limiting toxicity of cisplatin and oxaliplatin 
result from the formation of adducts in DNA. On entering the cell, cisplatin undergoes 
biotransformation whereby the chloro- ligands are exchanged to hydroxo- ligands and 
these molecules react with nucleophilic molecules including DNA, RNA and proteins. 
DNA is the preferential target, where they bind covalently to the N7 atoms of the 
imidazole rings of guanine and adenine forming adducts. There is an initial fast 
formation of a monofunctional adduct with the purine base followed by a slower 
conversion into the bifunctional intrastrand or interstrand adduct over a few hours 
(Kartalou and Essigmann, 2001a).  
 Three different types of adducts form on purine bases of DNA; monoadducts 
binding to a single guanine residue, bifunctional intrastrand crosslinks which form on 
adjacent guanine (1,2-d(GpG)), adjacent adenine guanine residues (1,2-d(ApG)) or 
adjacent guanine residues separated by a single nucleotide (1,3-d(GNG)) on the same 
strand and interstrand (G-G) crosslinks which form on guanine residues on opposing 
strands (figure 1.9) (Eastman, 1983, Fichtinger-Schepman et al., 1985b, Rabik and 
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Dolan, 2007). Crosslinks between adjacent adenine and guanine residues only form 
when the adenine lies 5ʹ′ to the guanine (Fichtinger-Schepman et al., 1985b). 
Intrastrand crosslinks comprise 90% of the damage induced by cisplatin with roughly 
65% of these being 1,2-d(GpG) crosslinks, 25% being (1,2-d(ApG)) and 5-10% being 
1,3-d(GNG) and interstrand crosslinks comprise roughly 1-2% of total adduct 
formation (Jung and Lippard, 2007). Oxaliplatin has been shown to produce adducts 
that share the sequence specificity of cisplatin (Woynarowski et al., 1998) but forms 
significantly fewer adducts than cisplatin at equimolar concentrations (Woynarowski 
et al., 1998, Woynarowski et al., 2000). Despite fewer total adducts, oxaliplatin exerts 
similar or greater cytotoxicity (Woynarowski et al., 2000), suggesting a greater 
lethality of oxaliplatin adducts. It has been suggested that oxaliplatin adducts are 
bulkier and more hydrophobic than cisplatin, leading to greater effects in cells (Di 
Francesco et al., 2002).  
 Once DNA had been implicated as the primary intracellular target for these 
agents and platinum adducts on DNA the critical step in causing platinum-induced 
cytotoxicity then interest grew in studying the mode of cell death. Studies using 
murine leukaemia L1210 and Chinese hamster ovary cell lines demonstrating that 
cells treated with cisplatin arrested in G2 phase provided information about the 
mechanism of cell death (Sorenson and Eastman, 1988b, Sorenson and Eastman, 
1988a). It was observed following exposure to cisplatin and arrest in G2 that the fate 
of cells was dependent on the dose of cisplatin. Fewer cells are shown to recover from 
cell cycle arrest and survive with increasing concentrations of drug, whilst greater 
numbers of cells repair their damage and survive with lower drug concentrations. It 
was suggested that G2 arrest resulted from the inability of cells to transcribe the 
required genes for passage into mitosis rather than inhibition of DNA synthesis 
(Sorenson and Eastman, 1988a). In these studies the microscopic appearances of cells 
treated with cisplatin demonstrated the classic hallmarks of apoptosis such as DNA 
degradation, reduced cell volume and plasma membrane blebbing (Sorenson et al., 
1990). This suggested that exposure to cisplatin resulted in inhibition of transcription, 
G2 cell cycle arrest, followed by apoptosis. Alternatively, cells could circumvent cell 
cycle arrest by repair and processing of platinum-induced DNA damage. Inhibition of 
DNA replication, cell cycle arrest in S phase followed by apoptosis was also 
considered to be important and apoptosis was thus confirmed to be the primary 
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mechanism by which platinum agents kill cells (Jamieson and Lippard, 1999). A 
reduction or alteration in the cellular apoptotic response has therefore been linked to 
resistance to cisplatin, discussed in section 1.6.5.3. Cancers contain greater 
proportions of cells actively replicating compared to many tissues which contain large 
numbers of cells in G0. From the mechanisms of action described in this section it can 
be seen how replicating cells are more sensitive to DNA damaging chemotherapeutic 
agents such as the platinum agents compared with non-replicating cells. This provides 
the basis for selectivity of cancer cells to chemotherapy agents and it is the degree of 
this selectivity which defines the therapeutic index of a treatment. 
 
  
 
Figure 1.9 - Platinum analogue adduct formation in DNA. Platinum analogues react with purine 
bases in DNA to form monoadducts at guanine residues, intrastrand crosslinks (1,2-d(GpG)), (1,2-
d(ApG)) and (1,3-d(GpXpGp)), interstrand crosslinks (G-G) and DNA-protein crosslinks. G=guanine, 
A=adenine. Figure reproduced from (Rabik and Dolan, 2007). 
 
1.6.5 Platinum Resistance 
Along with dose-limiting toxicity, the development of resistance leading to 
therapeutic failure represent the two major obstacles limiting clinical efficacy of the 
platinum analogues. Furthermore, clinical efficacy of the platinum analogues vary 
Background
Cisplatin [cis-diammine-dichloroplatinum(II)]4 (Fig. 1) is a
commonly used chemotherapeutic agent that was discov-
ered in 1970 as an inhibitor of growth in Eschericia coli.1
The clinical benefits of cisplatin as an anti-cancer agent
have been recognized for over 30years. Cisplatin is consid-
ered to be curative treatment for testicular cancer, when
combined with bleomycin and etoposide. It is closely re-
lated to its second generation analog carboplatin; the two
compounds share a mechanism of action, are fully crossre-
sistant, and form identical lesions on DNA. Both agents are
used for many other types of cancer, including ovarian, cer-
vical, head and neck, non-small cell lung, and lymphoma.
However, for many, particularly head and neck, lung, and
relapsed lymphomas, cisplatin treatment is plagued by
problems – including toxicities and resistance, both intrin-
sic and acquired.2 Oxalate (trans-l-1,2-diamminocyclohex-
ane) platinum(II) (oxaliplatin) is an analog which does not
share the same mechanism as cisplatin, and likewise does
not share in crossresistance (reviewed in Ref. 3).
In this review, we will focus on the most commonly used
platinating agents – cisplatin, carboplatin, and oxaliplatin.
It is worth mentioning, however, that a fourth platinating
agent, satraplatin (bis(aceto)amminedichloro(cyclohexyl-
amine) platinum(IV)), is available, and is currently the only
orally available platinating agent. Satraplatin does not share
crossresistance with cisplatin, which is thought to be due to
a different detoxification mechanism, and it shows activity
in advanced hormone-refractory prostate cancer.4,5
Mechanism of action
DNA Lesions
Upon entering a cell, all platinating agents become aqua-
ted, losing chloride or oxalate ions, and gaining two water
molecules. This positively charged molecule is then able
to interact with nucleophilic molecules within the cell,
including DNA, RNA, and proteins. It is generally agreed that
DNA is the preferential and cytotoxic target for cisplatin and
other platinating agents (reviewed in Ref. 6). When binding
to DNA, platinating agents favor the N7 atoms of the imidaz-
ole rings of guanosine and adenosine. Three different types
of lesions can form on purine bases of DNA: monoadducts,
intrastrand crosslinks, and interstrand crosslinks (Fig. 2).
Monoadducts are first formed as one molecule of water is
lost from aquated platinating agents; however, greater than
90% of monoadducts then react to form crosslinks. Almost
all of these crosslinks are intrastrand, with the majority
being 1,2-d(GpG) crosslinks. Additional DNA lesions include
interstrand crosslinks. Oxaliplatin forms fewer crosslinks
than cisplatin at equimolar concentrations; however, it is
equally as potent at these concentrations7,8 and is able to
induce similar numbers of single-strand and double-strand
breaks on DNA.9
All crosslinks result in contortion of the DNA (reviewed in
Ref. 10). Cisplatin and carboplatin intrastrand crosslinks
bend the double helix by 32–35! toward the major groove,
whereas oxaliplatin treatment bends the helix even fur-
ther.11 Both 1,2-d(GpG) and 1,2-d(ApG) intrastrand cross-
links unwind DNA by 13!, while the 1,3-d(GpXpG)
intrastrand lesion unwinds DNA by 34!. Interstrand lesions
induce even more steric changes in DNA, with extrusion of
the cytosines at the crosslinked d(GpC)d(GpC) sites, bend-
ing of the double helix toward the i or groove by 20–
40!, and extensive DNA unwinding of up to 80!. Oxaliplatin
adducts are bulkier and more hydrophobic than those
formed from cisplatin or carboplatin, leading to different
effects in the cell (reviewed in Ref. 12).
HMG involvement
There are different theories as to which lesion is responsible
for cytotoxicity. Some believe that the interstrand crosslink
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from patient to patient, largely because of drug resistance (Graham et al., 2004). 
Resistance to platinum chemotherapy can be intrinsic or acquired and is 
multifactorial. It can develop as a consequence of reduced intracellular accumulation 
of the drug, which can be caused by reduced drug influx, increased drug efflux, or 
increased drug inactivation within the cell due to cytoplasmic drug detoxification, 
conjugation with glutathione or sequestration with metallothionine. Each of these 
processes has the effect of reducing the drug concentration able to bind and damage 
DNA and trigger apoptosis. Finally, DNA repair pathways can repair the platinum-
DNA damage modulating cell death and defective apoptotic responses can also lead 
to resistance. Whilst each of the processes affecting cellular platinum accumulation 
and detoxification contribute to platinum resistance, it is principally through DNA 
repair pathways that drug resistance manifests (Shellard et al., 1993). 
 Resistance, both intrinsic and acquired, to these drugs is a frequent event and a 
better understanding of this would help explain and predict the variation in inter-
individual response to these treatments encountered clinically. Whilst there may be 
many different contributory mechanisms to platinum resistance ultimately it is 
through the DNA damage sustained that cytotoxicity is achieved. Therefore 
developing new techniques to measure the damage level itself sensitively within the 
genome would represent a major advance which could allow treatment to be stratified 
and modified to improve treatment outcome and toxicity. 
 
1.6.5.1 Cellular uptake and efflux of platinum analogues 
For successful therapeutic response to platinum analogue therapy adequate drug 
accumulation within the cell is critical. Reduced cisplatin accumulation due to either 
decreased influx or increased drug efflux has been demonstrated in resistant cell lines 
(Kelland, 1993, Lin et al., 2002, Siddik, 2003). It was initially assumed that cisplatin 
entered the cell largely by passive diffusion, since its uptake was not saturable and 
was governed primarily by platinum concentration (Hromas et al., 1987, Binks and 
Dobrota, 1990, Kartalou and Essigmann, 2001a). Subsequent evidence, however, has 
suggested a role for active transporters in the uptake and efflux of cisplatin and the 
other platinum analogues (Gately and Howell, 1993, Safaei and Howell, 2005). 
 Many studies have now indicated the importance of expression of copper 
transporter 1 (CTR1) for cisplatin uptake, accumulation and sensitivity. This is the 
main copper transporter found in the cell membrane of human and yeast cells. 
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Experiments initially conducted in yeast demonstrated that deletion of the CTR1 gene 
led to a significantly reduced accumulation of cisplatin, and increased resistance 
(Ishida et al., 2002). Further work in CTR1-deficient yeast cells also confirmed 
reduced accumulation of carboplatin and oxaliplatin (Lin et al., 2002). Reduced influx 
of cisplatin, carboplatin and oxaliplatin and increased platinum resistance was shown 
in CTR knockout mouse embryonic fibroblasts (Larson et al., 2009). Several 
subsequent studies have confirmed that the same correlations between platinum 
uptake and sensitivity are seen with human CTR1 (hCTR1) for each of the platinum 
analogues in different human cancer cells (Holzer et al., 2004a, Holzer et al., 2004b, 
Zisowsky et al., 2007, Kalayda et al., 2012). 
 Copper homeostasis in mammalian cells also depends on two copper-activated 
P-type ATPases, ATP7A and ATP7B, and studies have demonstrated the importance 
of these proteins in promoting the efflux of cisplatin, reducing cellular accumulation 
and promoting resistance (Komatsu et al., 2000). Mammalian fibroblasts expressing 
neither ATP7A nor ATP7B showed increased sensitivity to cisplatin and carboplatin 
compared to cells expressing either protein individually (Samimi et al., 2004a). These 
proteins have also been implicated in affecting platinum accumulation and resistance 
in many different cancer cell lines, with resistance associated with increased ATP7A 
or ATP7B expression in human ovarian and prostate carcinoma cell lines (Katano et 
al., 2002, Komatsu et al., 2000). Overexpression of ATP7A in ovarian cancer cell 
lines has been shown to mediate resistance to cisplatin, carboplatin as well as 
oxaliplatin (Samimi et al., 2004b). Overexpression of ATP7B in clinical tumour 
samples has also been reported to correlate with inferior outcome in cisplatin-treated 
patients with oral squamous cell carcinoma (Miyashita et al., 2003), ovarian 
carcinoma (Nakayama et al., 2004) and gastric carcinoma (Ohbu et al., 2003).  
 Whilst these studies suggest that alterations in copper transporters affect 
platinum accumulation and sensitivity to platinum analogues, it has also been reported 
that increased cellular cisplatin accumulation does not correlate with increase 
cisplatin-induced DNA damage (Holzer et al., 2004b). Equally, a recent study 
observed that cisplatin uptake over a range of drug concentrations is non-saturable, 
suggesting once again that platinum drug uptake is occurring predominantly via 
passive diffusion through the cell membrane and that hCTR1 is not the predominant 
route for cisplatin cellular uptake (Ivy and Kaplan, 2013). Some uncertainty therefore 
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remains regarding the clinical significance of facilitated drug uptake in platinum 
resistance, and this remains to be fully addressed. 
 
1.6.5.2 Inactivation of platinum analogues within the cytoplasm 
A further potential mechanism for platinum analogue resistance is their inactivation 
within the cytoplasm of cells by forming complexes with sulphur/thiol-containing 
molecules. Following uptake to the cell, the lower chloride concentration in the 
cytoplasm enables activation of cisplatin to its reactive complex by aquation, where 
the chloride ions are replaced by water ligands (Bancroft et al., 1990). Conversely, 
oxaliplatin is readily transformed into its reactive compound in plasma by having the 
oxalate group displaced. This activation allows the platinum complex to react with 
DNA and form adducts. Activation also allows the platinum complex to react with 
thiol-containing molecules within the cytoplasm of cells, of which the most abundant 
is glutathione (GSH) (Meister and Anderson, 1983), followed by the metallothioneins 
(MTs) (Endo et al., 2004), which co-ordinate, inactivate and detoxify the platinum 
complex (Sadowitz et al., 2002, Volckova et al., 2002).  
 Evidence from cultured human bladder carcinoma cells has shown that 
depleting GSH increases cisplatin sensitivity but that for cisplatin-resistant cell lines 
this only partially restores cisplatin sensitivity (Byun et al., 2005). Studies in human 
ovarian carcinoma cell lines have shown a correlation between cisplatin resistance 
and elevated GSH levels (Godwin et al., 1992). Glutathione S-transferases (GSTs) are 
a family of enzymes that catalyse the conjugation of glutathione with toxins to 
inactivate them. Inconsistent observations have been made correlating GST 
expression and resistance to cisplatin in cell lines and in clinical samples. A positive 
correlation has been shown between GST expression and resistance to cisplatin in a 
variety of human cancer cell lines (Goto et al., 2002) as well as in human ovarian and 
head and neck cancer tumour samples (Nishimura et al., 1996, Mayr et al., 2000, 
Satoh et al., 2001). Conversely clinical samples from patients with ovarian, cervical 
and lung tumours have failed to demonstrate correlation (Ikeda et al., 2003, van der 
Zee et al., 1995, Konishi et al., 1998, Miyatake et al., 2003).  
 Genetic studies of the GST genes have demonstrated polymorphisms in a 
number of these genes. One such polymorphism (GSTP1) has been demonstrated to 
be significantly associated with response in patients with NSCLC (Pillot et al., 2006) 
and the development of oxaliplatin-induced neuropathy in patients being treated for 
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colorectal cancer (Lecomte et al., 2006, Ruzzo et al., 2007). Equally, patients with 
this same polymorphism demonstrated improved responses to carboplatin compared 
with wild type.  
 The second major component of these inactivating proteins are MTs. Elevated 
levels of MTs have been shown to correlate with cisplatin resistance in human cancer 
cell lines (Siegsmund et al., 1999, Peng et al., 2012) and correlations between MTs 
and poorer outcomes have also been shown in primary tumours of patients (Surowiak 
et al., 2005, Muramatsu et al., 2000, Meijer et al., 2000).  
 Whilst it is likely that GSH/GST and MTs play some role in platinum 
resistance in certain tumours, given the conflicting findings presented here their 
importance in platinum resistance is unclear and they have not in themselves proven 
to be predictive of response to platinum analogues. Equally, most work in this area 
has been performed in tissue culture samples and therefore needs to be fully addressed 
in clinical samples. 
 
1.6.5.3 Defective apoptotic response 
The p53 tumour-suppressor gene codes for a transcription factor involved in the 
transcription of a number of proteins including p21, which mediates cell-cycle arrest, 
and Bax, which promotes apoptosis. Disruption of normal p53 activity occurs in 
around a half of human cancers and the role of p53 as a regulator of apoptotic 
response in tumour cells to antineoplastic therapy, has been extensively studied. This 
work has established that the p53 protein can determine cell susceptibility to 
apoptosis induction through a diverse range of apoptotic stimuli (Fisher, 1994). 
Interestingly, some of the most platinum sensitive cancers, namely testicular tumours, 
rarely contain mutated p53 genes (Levine, 1997), supporting the apoptotic mechanism 
for cell killing following cisplatin treatment. The role of p53 in platinum resistance 
has been examined and loss of p53 function has been associated with resistance in 
ovarian and lymphoma cell lines, presumably as a result of reduced apoptosis 
(Jamieson and Lippard, 1999).  
 Human lymphoma cell lines with mutant p53 demonstrated defective 
apoptotic responses to cisplatin, with reduced DNA fragmentation and plasma 
membrane blebbing, and an associated reduced cytotoxicity (Fan et al., 1994). Similar 
differences in morphological cellular response and sensitivity to cisplatin were seen 
between wild type and p53 mutants in human ovarian carcinoma cell lines and 
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testicular teratocarcinoma cells (Fajac et al., 1996, Lutzker and Levine, 1996). A 
further study investigating the relationship between cisplatin sensitivity and p53 status 
in human ovarian carcinoma cell lines confirmed the same pattern as described in the 
previous studies (Perego et al., 1996). This study also correlated these findings with 
expression of the apoptosis-inducing gene, Bax, and found that p53 mutant cells 
demonstrating cisplatin resistance showed a loss of the ability of p53 to transactivate 
Bax. Expression of p53 was shown, in a panel of human cells, to correlate with cell 
sensitivity for each of the three platinum analogues (Vekris et al., 2004). Conversely, 
other studies have shown that cisplatin cytotoxicity is enhanced by p53 mutation 
whilst others have shown that cytotoxicity is not influenced by p53. A study of human 
breast cancer cell lines highlighted the importance of the biological context of the cell 
line, whereby these cells, which did not readily undergo apoptosis, became sensitised 
to cisplatin following disruption of p53 (Fan et al., 1995). Another study showed that 
the presence of mutant p53 in human ovarian cancer cell lines did not affect cisplatin 
cytotoxicity (De Feudis et al., 1997) whilst a study of mouse testicular 
teratocarcinoma cells demonstrated that p53 mutation did not lead to resistance in 
these cells (Zamble et al., 1998).  
 The results of these studies again show that, as with the other mechanisms of 
platinum resistance discussed, conflicting results exist for the role of p53 mutation 
and defective apoptotic response in platinum resistance. It is likely, again to be only 
one of many factors governing and affecting platinum sensitivity and that these 
effects may be different between tumour types. It is important to recognise that p53 
protein not only regulates the expression of genes involved in the apoptotic response 
such as the pro-apoptotic factor Bax along with the apoptotic inhibitory factor Bcl2, 
but it also regulates genes that control the cell cycle such as p21, and also genes 
involved with DNA repair such as GADD45. Since apoptosis is involved in 
cytotoxicity following platinum-drug treatment considering defects in apoptotic 
response is obviously an important component when assessing platinum drug 
sensitivity. However, whilst these studies all provide evidence that cisplatin can 
induce cells to undergo apoptosis and that alterations in these apoptotic pathways are 
obviously important considerations for platinum drug sensitivity, the absolute 
significance of this within tumours in vivo remains unclear.  
 
 
Chapter 1. Introduction 
 55 
1.6.5.4 DNA repair of platinum adducts 
Whilst resistance to platinum analogues is influenced by variation in cellular rates of 
drug influx, export and detoxification it is principally through intrinsic DNA repair 
pathways that drug resistance manifests itself (Shellard et al., 1993). Platinum-DNA 
adducts can trigger DNA damage recognition and repair, leading to the continued 
viability of the cell and platinum resistance. Heterogeneity in DNA repair capacity is 
a feature of normal cells as well as tumour cells and can be affected by factors such as 
the age of the cell and the cell type. Variation in radiosensitivity, for example, has 
been demonstrated in normal fibroblasts for similar levels of DSBs and large 
differences observed in cellular radiosensitivity resulting from small variations in 
DSB repair capacity (Kasten-Pisula et al., 2005). Whilst tumour cells can have 
intrinsic differences in DNA repair mechanisms compared with their normal cell 
counterparts, these differences may also be acquired. 
 The main DNA repair pathways involved in removing platinum-induced 
intrastrand crosslinks are NER and MMR and these are key in mediating resistance 
and reducing efficacy of the platinum agents (Martin et al., 2008). Activity of both of 
these pathways has been shown to relate to response and sensitivity to the platinum 
analogues and this will be outlined in the next sections. Repair of platinum-induced 
interstrand crosslinks is different and more complex and involves a combination of 
NER and homologous recombination (HR) (McHugh et al., 2001). 
 
NER and platinum analogues 
Repair of intrastrand platinum adducts occurs principally through NER, and platinum 
adducts are recognised by both subpathways of NER (Crul et al., 1997). The 1,2-
intrastrand crosslinks are repaired less efficiently than the minor 1,3-intrastrand 
crosslinks, supporting the hypothesis that these are the more relevant lesions leading 
to cytotoxicity (Moggs et al., 1997, Zamble et al., 1996). This is thought to be due to 
structural elements such as the greater helical distortion and unwinding seen with the 
1,3-intrastrand crosslink favouring lesion recognition by cellular proteins and DNA 
repair factors (Kartalou and Essigmann, 2001b). Equally, repair of the 1,2-intrastrand 
crosslink is inhibited by binding of the high-motility group (HMG) proteins, which 
shield these adducts from repair (Huang et al., 1994, Zamble et al., 1996).  
 Xeroderma pigmentosum (XP) human fibroblast cell lines are 5 - 30 times 
more sensitive to cisplatin than normal cells, based on D37 values (dose increment 
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reducing survival to 37% of original value) (Poll et al., 1984, Dijt et al., 1988, Furuta 
et al., 2002) and cell extracts from these cells have shown no repair activity toward 
cisplatin-modified DNA (Dijt et al., 1988, Hansson et al., 1991). Equally, cisplatin 
resistant NSCLC cell lines have displayed over 2-fold higher expression levels of 
NER proteins such as XPC, XPA and ERCC1 (Weaver et al., 2005) with 
corresponding increased repair activities in human cancer cell extracts compared to 
wild type cells (Ferry et al., 2000).  
 Demonstrating increased expression of different NER genes in cisplatin 
resistant tumours highlighted the clinical relevance of this pathway in platinum 
therapy. Firstly, human ovarian cancer tumour samples with overexpression of XPA 
and ERCC1-XPF proteins were shown to be resistant to platinum treatment 
(Dabholkar et al., 1994, Li et al., 2000) and XPA, XPB and ERCC1 mRNA was also 
shown to be higher in platinum resistant ovarian tumours compared with platinum 
sensitive human tumour samples (Dabholkar et al., 2000). Similar correlations have 
also been demonstrated in patients with gastric cancer tumours between ERCC1 
mRNA levels and cisplatin response and survival (Metzger et al., 1998), whilst low 
levels of XPA and ERCC1-XPF proteins have been demonstrated in cell lines derived 
from patients with testicular cancer, which is generally very sensitive to cisplatin 
(Koberle et al., 1999, Welsh et al., 2004). Likewise, for oxaliplatin, moderately 
elevated levels of ERCC1 mRNA was seen in oxaliplatin resistant human colon 
carcinoma cells and exposure to oxaliplatin induced XPA and ERCC1 expression 
(Hector et al., 2001). Also, the rate of NER has been shown to be similar between 
cisplatin and oxaliplatin (Reardon et al., 1999). Finally, an approach using synthetic 
siRNAs to target ERCC1 and XPA has been used successfully for in vitro sensitising 
of prostate cancer cell lines to cisplatin (Cummings et al., 2006). 
 The effect of nucleosomes on NER has also been investigated and their 
presence has been shown to significantly impede efficient NER of intrastrand 
crosslinks. Comparison of NER by mammalian cell extracts of free and nucleosomal 
DNA shows that for the (1,3-d(GNG)) crosslink the nucleosome inhibits NER to 
about 10% of the level obtained with free DNA, and roughly 30% for the (1,2-
d(GpG)) crosslink (Wang et al., 2003). The same study also demonstrated a ∼2-fold 
more efficient repair process in nucleosomes that contain acetylated histones. This 
provides evidence linking histone post-translational modification and the NER 
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process and supports the intrinsic importance of chromatin structure on the DNA 
repair process (Reed, 2005). The effect of chromatin structure on platinum-induced 
DNA damage and its repair will be discussed in further detail in chapter 6. 
 
MMR and platinum resistance 
1,2-intrastrand d(GpG) platinum-DNA adducts are recognised by the MutSα 
heterodimer recognition proteins of the MMR pathway (Duckett et al., 1996). A 
functional MMR pathway is required to detect cisplatin and carboplatin-induced DNA 
damage, however the platinum adducts impede normal MMR activity and prevent 
repair of the platinum adduct from being completed, leading to apoptosis (Aebi et al., 
1996, Plumb et al., 2000). Equally, MMR proteins are not involved in the repair of 
platinum adducts by NER (Moggs et al., 1997). If MMR is deficient then cells 
continue to proliferate despite damage caused by platinating agents, and are therefore 
resistant. MMR deficiency confers resistance to cisplatin and carboplatin but not 
oxaliplatin (Fink et al., 1996, Aebi et al., 1997, Francia et al., 2005). 
 MLH1 and MSH2 genes are particularly important for the normal function of 
MMR. In a series of 24 ovarian carcinoma clinical samples a correlation was shown 
between the presence of MSI and down-regulation of hMLH1 expression, and this 
group also showed the transition from microsatellite stable tumours to MSI following 
cisplatin treatment (Watanabe et al., 2001). Another in vitro and in vivo study 
investigating cisplatin and carboplatin also demonstrated that cisplatin treatment leads 
to an enriched MMR-deficient cell population, supporting the hypothesis that these 
repair-deficient Chinese hamster ovary cells are resistant to platinum agents (Fink et 
al., 1998). Further studies have demonstrated a correlation between cisplatin 
resistance and MSI in human colon and ovarian carcinomas (Fink et al., 1996, Cai et 
al., 2004, Geisler et al., 2003) and have also shown that ovarian carcinomas which 
show hMLH1 promoter hypermethylation are platinum resistant (Strathdee et al., 
1999). Reversal of this MLH1 methylation using 5-azacytidine has been shown to 
reverse MMR deficiency (Cameron et al., 1999). 
 A retrospective study reviewing the outcome of 93 patients with non-small 
cell lung carcinoma treated with either a cisplatin or oxaliplatin-containing 
chemotherapy regime showed that hMSH2 deficiency was associated with 38% 
response rates in patients treated with oxaliplatin, compared with 0% for oxaliplatin 
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treated patients without a loss of hMSH2 expression (Scartozzi et al., 2006). This 
again suggested a difference between platinum analogue activity in MMR deficient 
cells and that oxaliplatin is active in cells with MMR deficiency. This is particularly 
relevant in the treatment of colorectal carcinoma, which is known to be resistant to 
cisplatin but sensitive to oxaliplatin, as MMR is often deficient in these tumours.  
 Plasma samples have been taken from 138 patients with advanced ovarian or 
primary peritoneal carcinoma and DNA analysed for the presence of methylation of 
hMLH1. In this study methylation of hMLH1 was shown to be greater at relapse, 
associated with increased MSI and to correlate with poor overall survival following 
platinum-based chemotherapy treatment (Gifford et al., 2004). 
 There are some notable exceptions however, to these studies presented so far 
which show a clear correlation between dysfunctional MMR pathway and cisplatin 
resistance (Wang and Lippard, 2005). One such study of ovarian cancer tumour 
samples showed that immunohistochemical staining for hMLH1 and hMSH2 
expression showed no correlation between expression of these MMR proteins and 
overall survival (Samimi et al., 2000). Furthermore, another study using the Cre-lox 
system and embryonic stem cells, in which the hMSH2 gene was inactivated de novo 
before being reactivated, showed no change in cisplatin sensitivity when hMSH2 was 
inactivated (Claij and te Riele, 2004). The reason for this discrepancy may be that 
there is a requirement for other gene changes to occur, in addition to MMR 
deficiency, to affect cisplatin sensitivity. For example, one report concluded that 
defective MMR may only be a minor contributory factor to cisplatin resistance, less 
than 1.3-fold increase in resistance, but that loss of p53 was the main determinant of 
resistance (Branch et al., 2000). The MMR pathway is only one of several pathways 
linked to cisplatin action, and its influence on platinum sensitivity is likely to vary, 
depending on experimental conditions. 
 
Platinum-induced interstrand crosslink repair 
Covalent DNA interstrand cross-links (ICLs) are produced by several different 
anticancer agents, greatly distort the structure of DNA and represent a highly toxic 
form of genomic damage. These pose a critical threat to the integrity of the cell by 
blocking processes that require the separation of the two strands of DNA such as 
replication and transcription (Dronkert and Kanaar, 2001). The covalent crosslinking 
of both strands of DNA makes repair of ICLs particularly challenging, and generally 
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ICL repair remains poorly understood. Cellular ICL repair and processing is known to 
involve the coordinated action of different repair pathways including NER, HRR, 
translesion DNA synthesis (TLS) and the Fanconi anaemia (FA) pathway (De Silva et 
al., 2000, McHugh et al., 2000, Raschle et al., 2008, Long et al., 2011, Knipscheer et 
al., 2009). Whilst the mechanistic details of how these pathways act and are 
coordinated remains a subject of research, some elements are now well understood. 
 In eukaryotic cells, DNA ICL repair is coupled to DNA replication and, as 
discussed, involves the co-ordinated action of different DNA repair pathways 
(McHugh et al., 2001). When a replication fork converges on the ICL, the 
combination of the block and the torsional stress induced by this block, leads to 
collapse of the replication fork and the formation of a DSB. This acts as the signal to 
complete repair by incorporating recombination repair (Nakanishi et al., 2011). The 
precise role for HR in ICL repair remains unclear but one model for this repair has 
been presented by Long et al, and will be discussed here (Long et al., 2011). Two 
replication forks converge on the ICL, with the leading strand of one fork extending 
to within one nucleotide of the ICL. Subsequently, dual incisions, mediated by 
ERCC1-XPF and RPA, surrounding the ICL create a DNA DSB in one sister 
chromatid, and translesion DNA synthesis restores the other chromatid by inserting a 
nucleotide opposite the base with the adduct followed by strand extension beyond the 
ICL site. The sister chromatid is then repaired via Rad51-dependent strand invasion 
and recombination with the intact chromatid, which has been shown to occur 
downstream of FANCI-FANCD2 (Long et al., 2011). This highlights the functional 
link between the Fanconi anaemia pathway and the HR repair machinery during ICL 
repair. The ICL adduct is finally removed by NER. 
 Studies have demonstrated that XPF and ERCC1 mutant cell lines are greatly 
sensitive to cross-linking agents whilst mutants in other NER components are often 
less sensitive (De Silva et al., 2000). Cells deficient in a TLS polymerase or Fanconi 
anaemia complementation groups (FANC) show enhanced sensitivity to cisplatin 
compared with wild type cells (Nojima et al., 2005). The DSB repair capabilities has 
also been investigated and it has been shown that cells lacking in members of the 
Rad52 proteins lacked the ability to repair ICLs whilst cells defective in ku80, and 
therefore NHEJ defective, retained their ability to repair ICLs (De Silva et al., 2000, 
McHugh et al., 2001). Similarly, cells with mutations in XRCC3, and defective in the 
HR pathway, demonstrated increased cisplatin and radiation sensitivity whilst cells 
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with a knockout of the NHEJ pathway resulted in increased radiation sensitivity only 
(Raaphorst et al., 2005). These studies confirmed homology-driven events as being 
responsible for the processing recombination and repair of ICLs. 
 
HR and platinum therapy 
BRCA2-deficient cancer cells are hypersensitive to DNA-crosslinking agents such as 
cisplatin (Sakai et al., 2009) and patients with BRCA1/2-mutated ovarian cancer have 
been shown to have a better prognosis if they receive platinum-based therapy (Chetrit 
et al., 2008).  
 The importance of BRCA-1 and BRCA-2 proteins in homologous 
recombination and the repair of double strand breaks (DSBs) has been given as an 
explanation for increase cancer risk in patients who carry germ-line mutations of 
BRCA-1 or BRCA-2 (Wooster and Weber, 2003). The same explanation has been 
given for the role of BRCA-1 or BRCA-2 in mediating the response to chemotherapy 
treatment in certain cancers (Quinn et al., 2003). In vitro inhibition of the Fanconi 
anaemia/BRCA pathway can enhance sensitivity to cisplatin in cancer cell lines and 
that reversal of this induces cisplatin resistance (Taniguchi et al., 2003). 
 
 
1.7 Measuring DNA damage 
 
Many different approaches have been developed to investigate and measure DNA 
damage and its subsequent repair in cells or tissues. These approaches involve 
methods or assays that can be broadly divided, based on their ability to locate the site 
at which damage occurs, into two categories: high or low resolution. Low resolution 
techniques provide methods for determining total genomic damage levels within 
genomes but offer no information on location or site within the genome of this 
damage. High resolution approaches, in contrast, allow DNA damage to be measured 
and for the location of that damage to be determined within the genome, up to a 
resolution of a few base pairs. These high resolution approaches allow short sections 
of the genome or single genes (up to 1kb) to be investigated at very high resolution or 
for longer sections (up to 10kb) to be measured at medium resolution. These 
techniques can also be used to indicate repair by taking repeat measurements of DNA 
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damage at sequential time points following treatment or exposure to the DNA-
damaging agent to detect reductions in level of damage. 
 
1.7.1 Low resolution techniques for detecting DNA damage 
Early studies measuring DNA damage were conducted using low resolution 
approaches to analyse global genome DNA damage. In the 1960s, radioactive 
labelling approaches were developed to measure DNA SSBs induced by X-rays 
(McGrath and Williams, 1966). This sucrose gradient sedimentation technique 
involved exposing cells to [14C]thymidine to label DNA, lysing the cells and exposing 
to an alkaline solution to denature DNA. Samples are then spun in a high-speed 
centrifuge with the resulting profile of the 14C concentration in the sucrose gradient 
reflecting the amount of strand breaks and DNA damage. This approach was initially 
used to observe whole genome strand breaks and to follow changes in the number of 
these breaks over time in Escherichia coli. It has also been applied to measuring 
damage associated with platinum-induced ICLs (Woynarowski et al., 2000) and used 
extensively to measure strand breaks produced by ionising radiation (Steel, 2002). 
 Techniques were subsequently developed to measure DNA DSBs including 
pulsed field gel electrophoresis (PFGE), the alkaline unwinding assay and the comet 
assay. PFGE was developed in 1984 (Schwartz and Cantor, 1984) and was first used 
to examine X-ray-induced DSBs and their repair in Saccharomyces cerevisiae (S. 
cerevisiae) (Contopoulou et al., 1987). This technique of pulsing electric fields at 60° 
to the axis of migration allowed improved fragment separation and movement through 
the gel providing an improved resolution such that individual chromosomes could be 
resolved. The alkaline unwinding assay, was based on the principal of providing cells 
with the conditions to allow helical unwinding and strand separation to occur at sites 
of SSBs (Elkind and Chang-Liu, 1972). The amount of single stranded DNA present 
indicates the amount of damage or number of SSBs present. This assay has also been 
adapted to measure the short excised single strand fragments generated during UV-
induced NER to monitor NER activity and examine its kinetics (Erixon and 
Ahnstrom, 1979). Another technique is the ‘comet’ assay, first described in 1990 
(Olive et al., 1990), and still commonly used particularly in the field of genotoxicity 
testing for drug development. This uses an electrophoretic gel to detect DNA damage 
in single cells by separating broken strands based on their strand length. Shorter 
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damaged DNA fragments, indicating SSBs or DSBs, migrate further producing the 
‘tail’ region whilst the longer undamaged fragments remain in the ‘head’, giving the 
appearance of a comet. Computer software can then be used to interpret the shape and 
features of the comet and to relate it to the degree of DNA damage. Variations on the 
lysis conditions can allow the detection of different lesions, for example, alkaline 
conditions assess SSBs whilst neutral conditions assess DSBs. The ‘halo’ assay is a 
variation on the ‘comet’ assay whereby cells are lysed and damaged DNA is allowed 
to migrate out of the cell by diffusion and sedimentation occurs in a sucrose gradient. 
Again, this assay is named after the resulting shape adopted by the damaged 
fragments, which form the appearance of a halo around the cell.  
 Combinations of chromatography techniques with mass spectrometry have 
been widely used, particularly in relation to platinum-induced DNA damage, and 
these will be discussed in more detail in chapter 3. Another important area of low 
resolution DNA damage assays involve immunochemical methods whereby an 
antibody raised against the DNA damage of interest is used. The commonest of these 
is the immuno-slot-blot (ISB), or dot blot, a simple alternative to the western blot, 
whereby no electrophoretic separation is required and samples are applied directly to 
a membrane. This assay provides a sensitive, quick and widely used method for 
detecting whole genome DNA damage. Alternative immunochemical methods include 
the enzyme linked immunosorbant assay (ELISA) (Engvall and Perlmann, 1971). In 
these immunochemical assays, quantitative antibody binding to antigen occurs which 
is detected by increasing optical density or fluorescent units in the output, producing 
quantitative immunochemical assays.   
 
1.7.2 High resolution techniques for detecting DNA damage 
The development of alternative techniques allowed measurement of gene-specific 
DNA damage or for DNA damage to be detected and examined in particular regions 
of the genome. This allowed researchers to concentrate on certain areas of the genome 
at high resolution and the first of these approaches was used to measure UV-induced 
CPDs and their repair in the dihydrofolate reductase gene in Chinese hamster ovary 
cells using a Southern blot technique (Bohr et al., 1985). This gene specific approach 
used a UV-endonuclease to produce DNA strand incisions at sites of pyrimidine 
dimers followed by electrophoresis, transfer of DNA to nitrocellulose filters followed 
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by detection of specific restriction fragments by using radiolabelled sequence-specific 
probes and autoradiography. A subsequent development used an adaption to the 
quantitative PCR assay termed the PCR-stop assay. This technique was first 
employed to measure UV-induced DNA damage in human lymphocytes (Govan et al., 
1990) and exploited the principle that DNA polymerases could be blocked by the 
presence of certain types of DNA damage and that replication would be unable to 
continue beyond these sites. The subsequent reduction in PCR product between an 
undamaged and damaged sample would indicate the degree of DNA damage in that 
region. Again, this allowed DNA damage to be probed in particular genomic regions 
of interest, thereby offering a high resolution approach, albeit the assay was not able 
to identify the locations of the damage lesions. This approach is ideally suited to 
detecting larger, bulky damage lesions bound to DNA and, indeed has been widely 
used to detect cisplatin and oxaliplatin-induced DNA damage (Oshita et al., 1998, 
Woynarowski et al., 1998). 
 Alternative methods were also developed allowing UV-induced pyrimidine 
dimers to be detected at specific nucleotides within genes in mammalian cells. The 
first of these methods mapped pyrimidine (6-4) pyrimidone photoproducts [(6-4) 
photoproducts] in mammalian cells following in vivo UV treatment (Pfeifer et al., 
1991). In this technique DNA is cleaved at sites of damage and gene-specific 
fragments are amplified using ligation-mediated PCR (LM-PCR). Amplified 
fragments are then separated, blotted onto nylon membranes and detected by 
hybridisation with gene-specific single strand probes. The sites of DNA damage are 
identified by sizing the cut DNA fragments on sequencing gels by comparing to 
reference DNA sequences. The LM-PCR technique was, however, technically 
challenging and relied upon the site at which DNA damage is cut to produce ligatable 
structures. An adaption to this assay was developed in our laboratory to measure sites 
of UV-induced CPD formation at the MFA2 locus in S. cerevisiae, and which didn’t 
rely on LM-PCR (Teng et al., 1997). This assay uses a CPD-specific T4 endonuclease 
enzyme to cut DNA strands at the sites of damage and strands of DNA of particular 
interest were separated from genomic DNA by using primer probes specific to the 
MFA2 region. The lengths of each of these fragments are different and represent the 
cut position at the damage site. The fragments are radiolabelled, assessed by 
electrophoresis, and fragment length is sized by comparing to a DNA reference 
sequence ladder, allowing the detection of CPDs, and their repair, to be located at a 
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very high single nucleotide resolution. This technique also allows each strand to be 
analysed separately. 
 A more recent development in technology in our laboratory has allowed 
precise high resolution measurements to be made of DNA damage over whole 
genomes. This involves a technique whereby the commonly used chromatin 
immunoprecipitation-DNA microarray (ChIP-chip) technique has been modified and, 
rather than chromatin, DNA is measured directly by DNA immunoprecipitation (DIP) 
to characterise global genomic DNA damage events (called DIP-chip) (Teng et al., 
2011). This was developed in S. cerevisiae to measure UV-induced CPD distribution 
using an antibody against the CPD damage lesion. After capturing fragments of 
damaged DNA these are hybridised to DNA microarrays producing a profile of CPD 
induction that has the advantage of being both genome-wide and high resolution. 
Using DNA microarrays for DNA damage detection is a novel concept and is the 
major focus of this thesis and will be discussed further in the next section. 
 
 
1.8 Functional Genome-wide Analysis 
 
Interactions between proteins and chromatin are fundamental to cellular functions and 
mediate a variety of cellular processes, including gene transcription, DNA replication 
and DNA repair. An important area of research has concentrated on investigating and 
characterising these interactions, and over the past decade the advent of genome-wide 
location analysis assays, in particular, has facilitated this. The emergence of these 
assays has revolutionised modern molecular genomics by being able to characterise 
protein-chromatin interactions in great detail and at a high resolution throughout the 
genome. The resulting research has significantly improved our mechanistic 
understanding of these interactions. 
 Traditional methods for investigating protein-chromatin interactions have 
often involved in vitro gel-based assays on short oligonucleotide sequences at very 
high resolution (described in section 1.7.2) and conclusions have often been drawn 
from such studies and their relevance to the in vivo context inferred. However, given 
that DNA binding sequence motifs may occur at hundreds of locations throughout the 
genome even in the simplest of organisms, such studies are often poor predictors of in 
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vivo protein binding at the genome scale (Lieb et al., 2001). Where DNA sequences 
can be identified for particular protein binding then ChIP followed by quantitative 
PCR may be used. However, this technique is limited and can only be applied to small 
numbers of selected genetic loci. 
 Combining ChIP with DNA microarray chips (ChIP-chip) has circumvented 
these limitations by allowing genome-wide characterisation of in vivo interactions 
between proteins and chromatin at high resolution. This has been the most commonly 
used technique in this field over the past decade and the ability to characterise these 
interactions genome-wide at high resolution and map binding sites and protein 
binding characteristics across the genome has led to a huge advance in understanding 
in this area.  
 
1.8.1 DNA microarrays 
A DNA microarray is an ordered arrangement of oligonucleotide fragments (probes) 
printed on the surface of a glass slide. Many probes, of the same sequence, are 
grouped together at features, and one way that microarrays are classified is by the 
number of features printed on the microarray. DNA fragments or sequences present 
within DIP or ChIP samples can then be identified by their hybridisation to 
complimentary DNA probes on the microarray. The first published work using DNA 
microarrays was in 1995 and was a gene expression microarray study where 
messenger RNA was applied to a microarray printed with complimentary DNA 
probes and the differential expression of 45 genes was studied in the plant 
Arabidopsis thaliana (Schena et al., 1995). This microarray contained only a very 
small fraction of what can now be printed on modern microarrays and DNA 
microarrays have subsequently been used extensively to investigate mRNA levels to 
characterise gene expression in many diverse biological processes and organisms.  
Following on from this pivotal work by Schena et al, with the development of ChIP-
chip, DNA microarrays have been extensively employed to characterise the physical 
properties of the genome, for example, by mapping transcription factor binding sites 
(Ren et al., 2000, Iyer et al., 2001) and histone modifications (Kurdistani et al., 2002, 
Bernstein et al., 2002). Since its introduction ChIP-chip has been developed and used 
extensively to map these physical properties in both model organisms and mammalian 
cells (Buck and Lieb, 2004). A diagram of a standard two channel ChIP-chip 
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experimental technique is presented in figure 1.10 and the experimental method for 
this technique is discussed in detail in section 1.8.3 of this chapter. 
 Examples of areas that have been widely investigated include histone 
modification and histone binding proteins in both yeast (Liu et al., 2005, Pokholok et 
al., 2005) and mammalian cells (Bernstein et al., 2005, Kim et al., 2005). Further 
recent developments of ChIP-chip have seen it used, with certain key modifications, 
to analyse genomic alterations directly such as methylated DNA (Weber et al., 2005, 
Weber et al., 2007) and DNA damage events (Teng et al., 2011). 
 Whilst the traditional application of ChIP-chip continues with important work 
analysing DNA-binding proteins, this technique is being increasingly applied, 
modified and developed to directly analyse different aspects of genetic and epigenetic 
changes that occur in the cell. This has important translational potential with clear 
implications for cancer research and therapeutics, in particular when considering 
novel drug combinations and for treatment stratification (this is discussed later in this 
chapter, in section 1.8.5). 
 
1.8.2 Development of ChIP-chip 
Since being established as a research tool around a decade ago, ChIP-chip has been 
used to characterise many important DNA-binding proteins including RNA 
polymerases, transcription factors and co-factors, histone proteins and the DNA repair 
machinery. These microarray approaches have, in turn, led to many important 
discoveries related to transcriptional regulation (Lee et al., 2002) and epigenetic 
regulation through histone modification (Pokholok et al., 2005). 
 ChIP-chip was first employed to identify and characterise the genome-wide 
locations and binding of DNA-binding proteins. Early and important studies in S. 
cerevisiae identified DNA binding sites for the transcriptional activators Gal4 and 
Ste12 (Ren et al., 2000) and for the transcription factors SBF and MBF (Iyer et al., 
2001). This was a novel approach for identifying these targets and, for the first time, 
allowed researchers to capture and analyse gene promoters where the protein factor of 
interest was directly bound. As well as providing new information on the genome-
wide locations of the binding sites of these proteins, analysing the binding sequences 
offered new mechanistic and functional insights into their behaviour.	  A subsequent 
larger study, again in S.cerevisiae, used c-myc epitope tagging of transcription factors 
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Figure 1.10 - Example of chromatin immunoprecipitation-DNA microarray (ChIP-chip) 
experimental workflow. This demonstrates the workflow for a standard two channel ChIP-chip 
experiment using an antibody against a particular protein of interest. Two channel ChIP-chip 
experiments allow an input (IN) sample of background DNA, to be processed in tandem with the 
immunoprecipitated sample (IP) throughout the experimental procedure to act as experimental control. 
 
to map the binding profile of over 100 transcription factors (Lee et al., 2002). Other 
ChIP-chip studies with S.cerevisiae have led to important discoveries in epigenetic 
regulation, for example, through histone modification (Robyr et al., 2002, Kurdistani 
et al., 2002, Bernstein et al., 2002) and nucleosome organisation (Ng et al., 2002). 
 ChIP-chip has also been applied to mammalian cells to identify binding sites 
of transcription factors. One of the first ChIP-chip studies conducted in the 
mammalian context identified and examined binding sites for the E2F transcription 
factor using CpG island promoter microarrays. This study identified 68 unique target 
loci for E2F, with many of these genes coding for proteins not previously associated 
with E2F (Weinmann et al., 2002). Among the subsequent early studies binding sites 
for other transcription factors, including c-Myc and Rb were mapped (Wells et al., 
2003, Li et al., 2003). These pioneering early studies were conducted using human 
promoter microarrays that, by including gene promoter regions, coverage for only 
short and dispersed sections of the total genome was included. An alternative 
Chapter 1. Introduction 
 68 
approach was used to characterise binding of the GATA-1 transcription factor to the 
β-globin locus (Horak et al., 2002). This study used a ‘tiling’ microarray with 
coverage across the regulatory region of interest at high resolution, resulting in a 
small, comprehensive and high resolution array but specific to a single regulatory 
region. 
 The type of applications for which ChIP-chip experiments can be employed 
depends somewhat on the microarray technology. Microarrays are now commercially 
available for most common model organisms and mammalian genomes. For 
mammalian studies a number of alternative microarray products are available 
including CGH microarrays, DNA methylation arrays, microRNA arrays, gene 
expression arrays, promoter arrays and ENCODE ChIP-chip arrays. Recent advances 
in microarray printing technology have allowed the production of high-density, high 
resolution ‘tiling’ microarrays, where the coverage of adjacent probes partially 
overlap each other, and with customised 1,000,000 feature microarrays now routinely 
available. These high-density arrays, in turn, require corresponding improved high 
resolution scanning facilities. 
 Some of the key variables with ChIP-chip experiments are antibody quality, IP 
efficacy, microarray hybridisation and data normalisation and analysis (Kurdistani 
and Grunstein, 2003). Important consideration should be given to each of these steps 
and also to the use of control samples. Control samples or experiments are important 
to account for experimental variation in chromatin immunoprecipitation or microarray 
preparation caused by nonbiological reasons, such as sample handling, differential 
PCR amplification, differential labelling and non-specific amplification. A commonly 
used control method is to measure a reference signal using a sample of background 
genomic DNA as an input (IN) sample and dividing the immunoprecipitation (IP) 
signal by this reference signal (Siebert et al., 2009). IN samples undergo the same 
sample preparation and processing as the IP sample, and are used throughout the 
ChIP-chip experimental procedure to correct the IP sample values (see figure 1.10). 
The use of IN samples will be discussed and highlighted throughout the work 
presented in this thesis. Alternative suitable control methods include a mock IP 
experiment, whereby the protocol is repeated exactly but with the antibody omitted, 
or an unrelated antibody is used for which there is no corresponding epitope (Buck 
and Lieb, 2004). The best control, if available, is a cell which lacks the IP epitope but 
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otherwise isogenic, so that there is no target for the antibody to bind specifically 
(Buck and Lieb, 2004). 
 
1.8.3 Overview of the ChIP-chip experimental technique 
Generally, there is little variation in published ChIP-chip experimental techniques, 
regardless of the species it is performed in or the factor of interest (Buck and Lieb, 
2004). As outlined in section 1.8.2 ChIP-chip has been applied in a number of species 
including yeast and mammalian cells to examine a range of factors. Typically, cells 
are cultured under the desired experimental condition before being fixed with 
formaldehyde (Wells and Farnham, 2002). Formaldehyde forms crosslinks between 
primary amino groups in amino acids and amino groups in other proteins or DNA, 
and these reactions take place within minutes of adding formaldehyde to cells 
(Orlando, 2000). Alternative crosslinking agents have been used in combination with 
formaldehyde, for example dimethyl adipimidate, however formaldehyde remains the 
most commonly used fixative (Kurdistani and Grunstein, 2003). Formaldehyde 
remains a desirable fixative because it is heat reversible and therefore can be easily 
reversed following ChIP to allow downstream sample processing (Das et al., 2004). 
The formaldehyde fixation ChIP approach is often referred to as X-ChIP (Orlando, 
2000). Following extraction, the chromatin is fragmented to the required length, 
typically using sonication, although an enzymatic method may also be used (Carey et 
al., 2009). The fragment length is dictated by both the resolution of the microarray, 
and the technique used to fragment the DNA, but can range from <200bp to 1kbp in 
length.  
 Fixation and chromatin fragmentation can introduce bias, with the potential 
for certain histone modifications to be ‘masked’ by chromatin proteins that can bind 
modified histones. In view of this, alternative techniques for mapping proteins of 
interest have been proposed which partially overcome these issues. NChIP uses native 
chromatin prepared and fragmented by micrococcal nuclease digestion of cell nuclei, 
and doesn’t require cross-linking (O'Neill and Turner, 2003). One drawback of this 
approach is the potential for nucleosome and histone rearrangement during digestion 
(Das et al., 2004). Biotin tagged purification of histones tagged with biotin ligase 
recognition peptide coupled with micrococcal nuclease has also been described (Mito 
et al., 2005). Another alternative technique is DamID, whereby the proteins are fused 
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to a DNA adenine methylase and the binding sites identified with adenine 
methylation-sensitive enzymes (van Steensel et al., 2001). However, these alternative 
methods are not widely used and with optimised formaldehyde fixation, and the 
development of better quality antibodies with increasing epitope precision, X-ChIP 
remains the favoured method for capturing genomic regions of interest (Carey et al., 
2009). 
 DNA fragments crosslinked to the protein of interest can be captured either 
through IP using a primary protein-specific antibody or via an epitope tagged protein 
of interest using an antibody against the tag (Buck and Lieb, 2004). The efficacy of 
this IP step can vary between antibodies and tags, and it is crucial that effective 
enrichment is achieved at this stage (Das et al., 2004). Careful evaluation of the 
suitability of the antibody, and optimisation of its binding characteristics, at the outset 
are therefore critically important. Following IP the formaldehyde crosslinks are 
reversed and the resulting DNA is purified. This sample may then be analysed by 
quantitative PCR, to study the presence, absence or relative enrichment of a particular 
gene, or applied to DNA microarrays for analysis of the whole genome or sections 
thereof. 
 Even using a standard number of 1 x 107 cells, the yield of 
immunoprecipitated DNA is too low for DNA microarray hybridisation. Some groups 
have solved this problem by pooling multiple IP samples (Martone et al., 2003, Wells 
et al., 2003), however, this requires a large amount of starting material. Generally, 
DNA amplification with PCR is the preferred method for producing the microgram 
quantities of DNA required for hybridisation to DNA microarrays. Commonly-used 
approaches for amplification are random primer PCR (Bohlander et al., 1992), 
ligation-mediated PCR (LM-PCR) (Mueller and Wold, 1989) or whole genome 
amplification (WGA) (O'Geen et al., 2006). LM-PCR involves ligating a short 
common section of linker DNA to the ChIP DNA fragments followed by PCR 
amplification using the linker sequence for priming. LM-PCR amplification is very 
effective and is widely used, but has been shown to produce high background levels 
particularly when samples are analysed on high resolution arrays. WGA has been 
compared directly to LM-PCR and has shown to produce superior signal to noise 
ratios following hybridisation (O'Geen et al., 2006). The random primer procedure 
involves an initial round of DNA synthesis using a primer that contains a random 
sequence at its 3ʹ′ end and a defined sequence at its 5ʹ′ end, followed by PCR 
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amplification with the defined sequence as the primer. WGA uses a proprietary 
amplification technology based on conversion of the small fragments to PCR-
amplifiable library molecules flanked by universal priming sites. The library is then 
PCR amplified using universal oligonucleotide primers. 
 As mentioned, one method for internal control within a microarray protocol is 
to prepare IN samples alongside IP samples. IN samples are samples of genomic 
DNA that do not undergo IP and reflect all background fragmented genomic DNA. 
They represent purified, total genomic DNA taken prior to the IP process and are used 
to correct individual IP samples for differences in background DNA. During the 
microarray preparation stages both IP and IN samples are amplified and samples are 
then differentially labelled using fluorescent molecules of different fluorescence 
emission wavelengths, such as Cy5 for the IP sample and Cy3 for the IN sample. Both 
samples are combined and hybridised to a single DNA microarray and scanned to 
visualise the fluorescence of the two fluorophores after excitation with a laser beam of 
a defined wavelength. Computer software then converts this image into numerical 
values for data analysis. This is an example of a two channel or two colour microarray 
system, typically used in the Agilent Technologies’ microarray platform. The IN 
sample acts as an internal control within the ChIP-chip protocol and the benefits of 
using this two channel approach is that it allows the IP sample to be corrected by the 
IN sample to account for changes occurring between samples due to non-biological 
reasons, such as sample handling, differential PCR amplification, differential 
labelling and non-specific amplification. Single channel or one colour microarray 
systems are also available, and are typically used in gene expression microarray 
experiments. Affymetrix, Nimblegen and Illumina all offer commercially available 
DNA microarray platforms, mostly providing one channel microarray systems. 
 
1.8.4 Variations on typical ChIP-chip methodology 
Recently the traditional ChIP-chip methodology as described above has been 
developed and modified, allowing researchers to concentrate on the genome itself as 
well as on the DNA-binding proteins or the epigenome. The main areas where this 
technique has been developed has been to characterise DNA damage events using UV 
irradiation as a paradigm (Teng et al., 2011), and for analysing methylated DNA 
(Jacinto et al., 2008). For these techniques the broad methodology and principles are 
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the same as outlined for ChIP-chip except that DNA is the template rather than 
chromatin. This obviates the need for crosslinking with formaldehyde and its 
subsequent reversal. Instead, naked DNA is extracted from cells with the DNA 
modification or factor of interest covalently bound. IP and microarray preparation 
proceeds as previously described, however, in this case it is critically important that 
the DNA lesions are repaired prior to amplification, labelling and hybridisation. 
 These approaches introduce the novel possibility of comparing changes 
observed in the genome with those observed in the epigenome in order to develop 
integrative approaches to improving mechanistic understanding. One of the big 
challenges in ChIP-chip data analysis is to develop bioinformatic tools and algorithms 
that allow us to make robust comparisons between datasets generated under different 
biological conditions, and this is discussed in section 1.8.6. Establishing these 
bioinformatic tools is a current key focus of research underway in our laboratory and 
will be a pivotal development to increasing the scope, significance and application of 
the ChIP-chip assay and technique. 
 
1.8.5 Recent and novel applications of functional genome-wide 
analysis using ChIP-chip and DIP-chip 
 
The epigenome  
As discussed, extensive work has been conducted using ChIP-chip, providing global 
genome insights into histone modifications. The technique is well suited to studying 
these epigenetic modifications because data is not restricted to annotated open reading 
frames (ORFs) but also the transcriptional regulatory elements. Moreover, this 
continuous global data output allows the boundaries and extent of regions with 
modified histones to be defined. This work has been conducted in both model 
organisms and mammalian cells and data normalisation is a particularly important 
consideration for these studies. 
 The most common histone modifications mapped by ChIP-chip have been 
histone H3 lysine 9 acetylation (H3K9ac), histone H3 lysine 14 acetylation 
(H3K14ac) and histone H4 hyperacetylation. With microarrays available containing 
complete coverage of the yeast genome, its histone modification patterns have been 
studied extensively. Studies in S. cerevisiae have painted a picture of reduced 
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nucleosome occupancy and elevated histone acetylation at the promoter regions of 
active genes, which correlates closely with transcription (Pokholok et al., 2005, Liu et 
al., 2005, Sekinger et al., 2005, Yuan et al., 2005). In the same studies, elevated levels 
of histone H3K4 trimethylation were also detected around transcription start sites, 
again with a correlation between this modification and transcription, confirming co-
localisation of certain histone modifications. These approaches began to allow the 
examination of how cellular events, such as gene transcription or DNA repair, are 
processed in the context of chromatin. Studies using ChIP-chip characterising global 
histone modifications in mammalian systems have also been performed, again 
providing important insights into the relationship between epigenetic modifications 
and genetic processes (Bernstein et al., 2005, Kim et al., 2005).  
 Whilst these epigenetic studies have been hugely informative, they only begin 
to describe the hugely complex regulatory function performed by the epigenome. 
Characterising this and developing a greater understanding of this area, particularly in 
disease development and treatment response, remain important challenges. ChIP-chip 
remains a crucial tool for interrogating these epigenetic responses, whilst DNA 
sequencing-based methods can also be used (Roh et al., 2006, Roh et al., 2005). 
Studying the relationship between genome and epigenome, understanding how 
information is transferred from one to the other and the role of DNA sequence in 
defining the epigenome are all areas of great interest that can be investigated through 
the use of ChIP-chip. Equally, questions such as how the presence of DNA damage 
triggers epigenetic changes and understanding the corresponding chromatin 
remodelling and how this can potentially be targeted therapeutically are important 
translational research elements that could be exploited with this technique. 
 
The Methylome - MeDIP-chip 
Whilst both are considered epigenetic traits, it is important to draw a distinction 
between cytosine methylation and methylated histones. The latter can be studied 
using traditional ChIP-chip whereas the former requires certain changes to this 
method whereby genomic DNA, rather than chromatin, is initially extracted before 
carrying out methylated DNA immunoprecipitation (MeDIP-chip) (Weber et al., 
2005). In normal tissues, most promoter-associated CpGs are unmethylated, and those 
that are methylated generally cause transcriptional silencing. CpG dinucleotide 
methylation has been demonstrated to be an important mechanism in carcinogenesis, 
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whereby critical genes normally involved in tumour suppression may be switched off. 
Inactivation of gene expression by CpG dinucleotide methylation of the promoter 
region of these genes has been observed in cancer cell lines and human tumours 
(Esteller, 2007). Paradoxically, despite this promoter hypermethylation, globally, the 
genome of a cancer cell can display 20-60% less methylation than a normal cell. This 
global hypomethylation typically occurs in coding regions as well as gene-poor 
regions and results in gene activation and chromosomal instability. This phenomenon 
of genome-wide hypomethylation is also thought to have a causal role in tumour 
development (Feinberg and Tycko, 2004, Esteller, 2008). 
 Much of our understanding of this subject has come from genome-wide 
analyses of DNA methylation profiles (Weber et al., 2005, Weber et al., 2007). 
Typically these experiments involve IP of methylated CpGs using an anti-5-
methylcytosine antibody (MeDIP), followed by DNA amplification and hybridisation 
to human CpG island or promoter arrays. These assays studying genome-wide 
methylation profiles, as well as increasing our understanding of methylation states, 
have also offered insights into the issue of the size of the starting sample. It has been 
demonstrated in one study of in vitro methylated DNA, whereby naked DNA from a 
cancer cell line was incubated with methyltransferase in vitro, that accurate genome-
wide methylation data could be reproducibly obtained from a starting amount of as 
little as 2µg of genomic DNA (Jia et al., 2010). This important evaluation of starting 
material amount has allowed many subsequent studies where this assay has been 
applied to clinical samples from tumours and cultured tumour cells (Gloss et al., 
2012, Yalcin et al., 2012, Heller et al., 2012), where DNA from a tumour biopsy may 
be limited. Establishing MeDIP-chip has been an important development and 
application of the traditional ChIP-chip technology, an area which will prove useful in 
identifying new therapeutic targets and prognostic markers in translational cancer 
research. 
 
DNA damage events - DIP-chip 
One particularly interesting development in this field over the past few years has seen 
ChIP-chip methodology further modified and applied to DNA to directly characterise 
global genomic DNA damage events (called DIP-chip) (Teng et al., 2011). As for 
MeDIP-chip, DNA is the template for these studies rather than chromatin and 
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therefore crosslinking with formaldehyde is not required. Secondly, careful 
consideration needs to be given, not to reversing the protein crosslinks, but to 
reversing the DNA damage prior to amplification and hybridisation.  
 The application of DIP-chip technology primarily allows the sensitive 
measurement of DNA damage induction and repair throughout whole genomes. This 
is a novel area of genomics that has huge potential, particularly in the field of 
pharmacogenomics where these assays may be applied to clinical samples and 
findings correlated with response and toxicity to different DNA damaging agents. If 
the example of the platinum analogues is considered, where platinum-DNA adduct 
formation correlates with cell death, it is recognised that a significant number of 
patients treated with these agents demonstrate inherent or acquired resistance to them. 
The ability to sensitively measure DNA damage induction and repair genome-wide in 
these patients may allow the use of these agents to be stratified based on an 
individual’s adduct induction and DNA repair capacity. Another area where these 
assays may be employed is as an alternative to traditional methods of genotoxicity 
testing of novel compounds during drug development. Such assays could provide 
more mechanistic information than traditional assessments of genotoxicity, such as 
comet and other current assays. This has the potential to be developed as an in vitro 
alternative to existing animal-based genetic toxicology assays for use in the chemical, 
cosmetic and pharmaceutical industries. The development of this DIP-chip assay to 
measure and characterise platinum-induced DNA damage in human cells is the focus 
of the work presented in this thesis. 
 
 
1.8.6 Microarray data processing and bioinformatic challenges 
Microarray experiments produce large amounts of data and different strategies can be 
applied to process this data depending on the type of microarray and the research 
context. This processing is important for the reliability of the data generated from 
these experiments and also to allow comparisons between datasets. Detailed accounts 
of the bioinformatic data analysis for DNA microarrays, and in particular for making 
comparisons between ChIP-chip studies, are provided elsewhere (Butte, 2002, Buck 
and Lieb, 2004, Zheng et al., 2007, Johannes et al., 2010, Wu and Ji, 2010) and is 
discussed in further detail in section 3.2.7, chapter 3. Some of these key areas will 
now be outlined here. 
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 Firstly, microarray data require robust normalisation if replicate datasets of the 
same experimental condition are to be compared or to allow comparisons between 
biologically distinct datasets of different experimental conditions. Distinct microarray 
datasets will contain biological variation, representing genuine differences in the 
biological measurements of interest related to different experimental conditions, and 
inherent random technical variation based on experimental procedure. These two 
types of variation need to be distinguished such that biological variation is captured 
and technical variation is minimised or discarded and this is achieved by the 
application of an appropriate data normalisation procedure (Johnson et al., 2008). The 
need for normalisation is well recognised and different approaches to normalisation 
have been taken, particularly with respect to gene expression microarray datasets 
(Quackenbush, 2002, Bolstad et al., 2003) and, latterly, ChIP-chip datasets (Buck and 
Lieb, 2004, Johnson et al., 2008). However, despite these different approaches, 
quantitative comparisons between the enrichment of different ChIP-chip microarray 
datasets have not been possible. 
 One common approach to analysing ChIP-chip datasets has been to define 
peaks within the dataset which signify the binding location and presence of a factor of 
interest. This approach is appropriate for certain studies of discrete DNA-protein 
binding. However, certain ChIP-chip datasets, such as histone acetylation studies, 
contain greater information than simply the binary determination of the ‘presence’ or 
‘absence’ of a particular factor. In these cases each microarray feature can produce a 
range of signal intensities reflecting the different amounts of factor binding each 
microarray probe. These data are therefore capable of providing far greater depth of 
information on the relative levels of binding that could allow, with robust 
normalisation, quantitative comparisons of enrichment levels. 
 One of the fundamental differences between ChIP-chip datasets and other 
microarray datasets, such as those from gene expression arrays, is that the microarray 
signal intensities are not normally distributed but follow a skewed distribution offset 
in the direction of enrichment. This raises different bioinformatic and statistical 
challenges and means that normalisation procedures applicable to gene expression 
microarray data are not applicable to ChIP-chip data (Buck and Lieb, 2004, Johnson 
et al., 2008). A method to normalise ChIP-chip datasets has been developed by a 
colleague in our research group (Dr M Bennett, PhD thesis, 2012) which now allows 
comparisons to be made between biologically distinct ChIP-chip datasets. This is a 
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novel and robust normalisation procedure and is discussed further in section 3.2.7, 
chapter 3 and is then applied in chapter 6 of my thesis. The DIP-chip datasets 
generated in chapter 3 and 4 of my thesis require an alternative method of 
normalisation again and this is discussed in the relevant chapters. 
 
1.8.7. Limitations of DNA microarrays and future solutions 
Limitations exist to working with DNA microarrays, such as the relatively large 
amounts of DNA that are required and that experimental work is constrained by the 
availability of microarrays. An alternative to DNA microarrays and a solution to some 
of these limitations, and where genomic sequence information for an entire genome is 
available, is to use DNA sequencing methods instead of microarrays. A number of 
alternative sequencing-based genome-wide platforms have been developed for 
studying protein-DNA interactions. 
 ChIP followed by direct analysis by DNA sequencing of the IP fragments 
(ChIP-seq), was developed and was demonstrated to be an effective, high throughput 
and direct assay (Johnson et al., 2007). In this study a sequencing method was used to 
map in vivo binding of the neuron-restrictive silencer factor (NRSF) to locations in 
the human genome. Very briefly, for ChIP-seq methodology, ChIP samples can be 
used directly, following a limited amplification step, for sequencing by a genome 
sequencer following protocols for library and cluster generation.  
 It is generally accepted that ChIP-seq produces profiles that offer greater 
spatial resolution and genomic coverage than ChIP-chip, allowing greater sensitivity 
and specificity in terms of protein binding site identification (Ho et al., 2011). 
Furthermore, unlike ChIP-chip where work is constrained by the availability of 
organism-specific microarrays, ChIP-seq may be used to analyse any organism where 
the genomic sequence is known and is not limited by the more restrictive DNA 
microarray coverage to a fixed number of microarray probes.  
 ChIP-seq protocols are able to work with smaller starting amounts of material 
and offer a higher throughput alternative compared with ChIP-chip and therefore are 
more suited to research using clinical samples. The main limitation to sequencing 
work has traditionally been cost, expertise and access to sequencing technology. 
However, particularly with the advent of next generation sequencing (NGS), cost 
effectiveness and access to sequencing machinery have improved. This has led to a 
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large increase in the use of this technique, which is likely to transfer to widespread 
adoption of this technology both in the fields of basic research and clinical practice. 
 Chip-seq therefore provides a number of practical advantages that make it an 
attractive alternative to ChIP-chip. Direct comparison between these two platforms 
has been performed using pairs of ChIP-chip/ChIP-seq profiles of technical replicates 
for eight different IP factors (coactivator CBP, RNA Polymerase II and six different 
histone modifications) (Ho et al., 2011). This demonstrated that ChIP-seq generates 
profiles with higher signal-to-noise ratios and a larger number of more localised 
peaks, confirming improved spatial resolution and dynamic range with ChIP-seq. It is 
likely that these advantages will make ChIP-seq a more appropriate tool for mapping 
DNA damage lesions, which are more ubiquitous than protein-binding events, and 
occur in the context of fewer ‘background’ regions of undamaged DNA. One 
drawback with DNA sequencing has traditionally been that a very large number of 
sequencing reads have been required, particularly for adequate coverage of the human 
genome, however with the development of latest technologies, particularly NGS this 
is now less problematic. 
 Despite these potential benefits to sequencing, DNA microarrays remain an 
established technique, with a clear experimental workflow. There is also a clearer 
understanding of the limitations, such as the bioinformatic challenges, associated with 
DNA microarrays than for sequencing. Therefore whilst there may be a number of 
potential practical advantages to developing DNA sequencing based approaches in 
place of microarrays, when developing novel genome-wide technologies and 
establishing their feasibility then DNA microarrays are the more established platform. 
 
 
1.9 Aims of the current study 
 
Despite extensive analysis of platinum-DNA interactions, in particular in 
characterising the individual adducts and their effects on DNA replication, 
transcription and cell survival, measurement of these adducts in cells with higher 
sensitivity, and precision is still necessary. Much of the work previously conducted 
studying platinum-DNA adduct formation has been performed using low resolution 
DNA damage assays such as immuno-slot-blots or ELISA to detect whole genome 
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DNA damage at low resolution, or with combinations of chromatography and mass 
spectrometry to characterise the individual adducts. The ability to measure platinum-
induced DNA damage genome-wide with high sensitivity in human cells would have 
profound implications for basic mechanistic research as well as clinical translational 
research, particularly for individualisation of treatment. The development of such an 
assay to then measure and detect other DNA damaging agents would also have major 
implications in developing novel therapies in the field of genotoxicity testing.  
 The aim of this PhD was to develop an assay to allow measurements of 
platinum-induced DNA damage induction to be made at high resolution, density and 
precision within the genome of human cells. This was developed using DNA 
immunoprecipitation coupled with analysis on DNA microarrays (DIP-chip), which 
allowed these measurements to be made throughout the human genome for the first 
time. This now provides a novel assay that may be further developed to apply to 
clinical samples with the potential for predicting response in an individual to platinum 
agents and thus allowing individualisation of treatment. The DIP-chip assay was 
initially developed and validated in the yeast model organism S. cerevisiae and this is 
presented in chapter 3. The assay was then developed and validated in human 
fibroblast cells and applied to measuring both platinum-induced DNA damage and 
UV-induced CPD formation and this is presented in chapter 4. Another aim of this 
study was to present novel comparative analytical approaches to studying microarray 
data from these genome-wide datasets and examples are given in chapter 5 of such 
approaches. Finally, epigenetic responses following platinum treatment are examined 
in chapter 6 where findings from ChIP-chip studies of cisplatin-induced histone 
acetylation in S. cerevisiae are presented.  
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Chapter 2  
Materials and Methods 
 
 
In this chapter materials and methods employed for the culture and maintenance of 
Saccharomyces cerevisiae (S. cerevisiae) yeast and human cells are detailed along 
with the routine techniques employed for DNA and chromatin preparation, drug and 
UV treatments, DNA fragmentation with sonication, quantitative real-time PCR and 
immuno-slot-blot assays. The detailed methodology related to the DIP-chip and ChIP-
chip assays along with the methods developed during this study and the 
computational and bioinformatic methods are each outlined in the relevant sections of 
chapters 3, 4 and 6. The constituents of all liquid solutions are given in Appendix I. 
 
 
2.1 Platinum analogue chemotherapy drugs  
 
Cisplatin and oxaliplatin were obtained courtesy of the pharmacy department of 
Velindre Cancer Centre, Cardiff. The clinical formulations, at a concentration of 3.3 
mM for cisplatin and 12.6 mM for oxaliplatin, were stored at 4°C. 
 
 
2.2 Yeast cell culture, treatments and preparation 
 
2.2.1 Yeast strains, culture and storage 
The haploid, wild-type, S.cerevisiae strain used in these studies was BY4742 (MATα 
his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0). Equipment and Yeast Extract Peptone Dextrose 
(YPD) media was sterilised by autoclaving at 121°C for 15 minutes, and all 
manipulations were undertaken in standard sterile conditions. All incubations were 
conducted at 30°C at 180rpm in an Infors HT multitron standard incubator unless 
otherwise stated. 
 BY4742 cells were stored and grown in YPD media. For long-term storage, 
cells were grown to logarithmic-phase in YPD, glycerol was added to a final 
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concentration of 30%, and cells were frozen at -80°C. Pre-cultures were formed by 
inoculating cells in 10 ml of YPD, incubating until cells reached stationary phase and 
storing these at 4°C. Pre-calculated amounts of pre-culture were then used to 
inoculate large volumes of YPD media as required for each experiment. For all 
experiments cultures were incubated overnight to a density of 2 x 107 cells/ml. Cell 
density was calculated using a Nebauer cell counting chamber (Hawksley). 
 
2.2.2 Platinum treatment of yeast cells in culture 
Wild-type yeast BY4742 cells were grown to logarithmic-phase in YPD and collected 
by centrifugation at 5000rpm for 5 minutes and resuspended in chilled phosphate-
buffered saline (PBS) at a concentration of 2 x 107 cells/ml. 250 ml of resuspended 
cells were incubated with the required concentration of cisplatin or oxaliplatin in PBS 
for 4 hours, and untreated cells were incubated in PBS alone. Following incubation, 
cells were immediately collected by centrifugation at 5000rpm for 5 minutes at room 
temperature and washed twice with chilled PBS ready for DNA preparation. For 
repair studies with chromatin, following treatment in PBS and collection, cells were 
resuspended in YPD and placed in the incubator for the required amount of repair 
time. 
 
2.2.3 Preparation of yeast DNA 
Both untreated and platinum treated cells were resuspended in 5 ml of sorbitol-Tris-
ethylenediamine tetracetate (sorbitol-TE) solution and mixed well. 0.5 ml of 
zymolyase 20T (10 mg/ml in sorbitol solution) and 0.5 ml of 0.28 M β-
mercaptoethanol were added and samples mixed by shaking. Cells were incubated 
overnight at 4°C. Spheroplasts were collected by gentle centrifugation at 2000rpm for 
5 minutes at 4°C and resuspended in 5 ml of lysis buffer/PBS 1:1(v/v) solution. 500 
µl of 10 mg/ml RNase A was added and samples were vortexed and incubated at 
37°C for 1 hour. Following incubation, 200 µl of proteinase K (10 mg/ml in TE 
buffer) solution was added and samples were incubated for 2 hours at 65°C with 
occasional shaking. Two phenol/chloroform (6 ml) DNA extractions and one 
chloroform (6 ml) extraction were carried out to ensure complete deproteinisation. 
Equal volumes of phenol/chloroform were added (1:1 v/v), and samples shaken 
vigorously followed by centrifugation at 10,000rpm (Beckman-Coulter centrifuge, 
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JA-20 rotor) for 10 minutes and transfer of the upper aqueous phase to 15 ml Falcon 
tubes. DNA was recovered by precipitation using two volumes (12 ml) of pre-chilled 
100% ethanol and storing at -20°C overnight. DNA pellets were collected by 
centrifugation at 4000rpm for 15 minutes at 4°C and resuspended in 1 ml of TE 
buffer. After being completely dissolved, the DNA was reprecipitated by adding 1 ml 
of pre-chilled 100% isopropanol, with gentle shaking. DNA precipitate was removed 
by pipette tip, resuspended in 1 ml of TE buffer and DNA checked for purity and 
amount by non-denaturing agarose gel electrophoresis and UV spectrophotometry 
(NanoDrop-1000, NanoDrop Technologies, Thermo Scientific).  
 
2.2.4 In vitro platinum treatment of yeast DNA 
For in vitro platinum treatment, extracted naked genomic yeast DNA in TE was 
incubated with cisplatin or oxaliplatin, added from stock solution giving the required 
final drug concentration. DNA was incubated with cisplatin or oxaliplatin for 2 hours 
at 37°C and DNA recovered by ethanol precipitation. Precipitation was conducted by 
adding 2.5 x volume 100% ethanol, incubating at -80°C for 20 minutes, then at -20°C 
for 30 minutes, followed by centrifugation at 13500rpm (Beckman-Coulter Microfuge 
22R) for 20 minutes at 4°C. DNA pellets were washed with 75% ethanol and 
centrifuged a second time at 13500rpm for 20 minutes at 4°C. Pellets were dried 
using a SpeedVac system (Thermo Savant) and resuspended in 100 µl TE prior to 
sonication and DIP. 
 
2.2.5 Preparation of yeast chromatin 
Wild-type yeast BY4742 cells were grown to logarithmic-phase in YPD and treated in 
culture as described above in section 2.2.2. Cells were treated with 250 µM cisplatin 
or oxaliplatin for four hours and following treatment resuspended in YPD for the 
required repair time. Cells were crosslinked using 3 ml of 37% formaldehyde, per 100 
ml culture, for 10 minutes at room temperature on a shaking platform. Crosslinking 
was quenched using 5.5 ml of 2.5 M glycine for 5 minutes at room temperature on a 
shaking platform. Cells were collected by centrifugation at 5000rpm for 5 minutes at 
4°C (Beckman-Coulter centrifuge, JA-10 rotor), and washed twice by resuspending in 
40 ml of ice cold PBS and collecting by centrifugation as before. Cells were 
resuspended in 1 ml FA/SDS (+PMSF) and transferred to a 2 ml microcentrifuge 
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tube. Cells were collected by centrifugation at 13500rpm for 5 minutes at 4°C 
(Beckman-Coulter Microfuge 22R), the supernatant was removed and the pellet was 
resuspended again in 0.5 ml FA/SDS (+PMSF) in a 2 ml microcentrifuge tube. Cells 
were mechanically lysed by adding 500 µl of glass beads to each sample and 
vortexing for 10 minutes at 4°C. The cell lysate was retrieved by puncturing a hole in 
the 2 ml microcentrifuge tube with a hot needle and placing it in a 15 ml Falcon tube 
and centrifuging briefly at 2000rpm for 2 minutes at 4°C (Eppendorf centrifuge 
5810R). The glass beads were washed with 500 µl of FA/SDS (+PMSF) and 
centrifuged again at 2000rpm for 2 minutes at 4°C. Cell lysate was transferred to a 2 
ml microcentrifuge tube and centrifuged at 4000rpm for 20 minutes at 4°C (Beckman-
Coulter Microfuge 22R) to remove any soluble, non-crosslinked proteins. The 
supernatant was removed and the pellet was resuspended in 1 ml FA/SDS (+PMSF) 
and sonicated using a BioRuptor sonicator (Diagenode) with power set at the ‘high’ 
position for 8 cycles of 30 seconds on and 30 seconds off at 4°C (as described in 
section 2.6). Following sonication a further centrifugation was performed at 
13000rpm for 10 minutes at 4°C and the supernatant was collected and centrifuged 
again at 13000rpm for 20 minutes at 4°C (both using Beckman-Coulter Microfuge 
22R). The supernatant containing the chromatin was snap frozen in liquid nitrogen 
and stored at -80°C. 
 
 
2.3 Human cell culture, treatments and preparation 
 
2.3.1 Human cell lines 
AG16409 (normal human dermal fibroblast) cells were obtained from the Coriell Cell 
Repository (Camden, NJ, USA). AG16409 cells were transduced with an amphotropic 
retrovirus expressing the catalytic subunit of telomerase, human telomerase reverse 
transcriptase (hTERT). Telomerase activity was confirmed by the telomeric repeat 
amplification protocol (TRAP) assay, ensuring immortalisation of fibroblasts 
(AG16409)tert (Tivey et al., 2013). These cells were obtained courtesy of Dr Terence 
Davis, Cardiff University and hTERT transformation was performed by his team. The 
MDA-MB-231 epithelial breast adenocarcinoma cell line was used for the in vitro 
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immuno-slot-blot studies presented in section 4.3.1, chapter 4 and some preliminary 
DIP studies presented in figures 4.5 and 4.6, chapter 4, but these cells were not used 
for human microarray experiments. This cell line was supplied by the ATCC® and 
was obtained courtesy of Dr Zara Poghosyan, Cardiff University. The culture 
conditions for the MDA-MB-231 cells, and their treatment with the platinum 
analogues, were as described in the next section for the dermal fibroblast cell line.  
 
2.3.2 Human cell culture 
All manipulations were undertaken in standard sterile conditions and all glassware 
was sterilised by autoclaving at 121°C for 15 minutes. Fibroblasts were grown as 
monolayers at 37°C in a humidified incubator, under an atmosphere containing 5% 
CO2. Fibroblast growth media comprised Dulbecco’s Modified Eagle Medium 
(DMEM: Gibco by Life Technologies, Invitrogen, Paisley, UK), supplemented with 
10% fetal calf serum, 1% L-Glutamine and 1% penicillin-streptomycin (all Sigma-
Aldrich, Dorset, UK). Fibroblasts were cultured in 10 ml of growth media in T75cm2 
cell culture flasks or in 5 ml of media in T25cm2 cell culture flasks and replenished 
with fresh growth medium approximately every 3 days. Cells were reseeded and 
maintained in new cell culture flasks approximately every 4 weeks and were seeded 
and cultured on tissue culture dishes for drug treatments.  
 Fibroblasts were routinely passaged close to confluence (~80-90% confluent) 
every 7-10 days, when cells were trypsinised and ~2 x 105 - 4 x 105 cells were 
reseeded. Briefly, cells were trypsinised by removing growth media from the flask 
followed by washing with 2 ml of warmed PBS to remove residual media and serum. 
2 ml of 1 X trypsin-EDTA (Gibco by Life Technologies, Invitrogen) was added and 
fibroblasts were returned to the incubator at 37°C for 15-30 minutes. When cells had 
detached from the surface of the flask they were resuspended in the required amount 
of growth media for reseeding. Cells were counted using an Improved Neubauer 
haemocytometer (Hawksley) and 10 µl of cell suspension was pipetted under the 
coverslip of the haemocytometer. Cells in the 4 big corner squares (divided into 16 
smaller squares) of the haemocytometer were counted and cells that touched the 
bottom and right sides of the square were counted whilst those touching the top and 
left sides were discounted. The total number of cells in the four big squares was 
divided by four, giving the number of cells x 104 per ml of cell suspension. The total 
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cell number could therefore be calculated knowing the volume of cell suspension. By 
knowing the initial number of cells seeded and the total number of cells following 
trypsinisation the population doubling time (PD) for each passage could be calculated. 
For these cells the PD was ~0.4 PD/day and this remained constant throughout these 
experiments. 
 
2.3.3 Human cell storage – cryopreservation of cells 
During the exponential phase of growth, when cells were trypsinised, fibroblasts that 
were not re-seeded were frozen and stored as viable stocks. After trypsinising, the cell 
suspension was transferred to a 15 ml Falcon tube and the tube centrifuged for 5 
minutes at 1000rpm at room temperature. The supernatant was discarded and the cell 
pellet re-suspended evenly in 0.5 ml of cell medium with serum and 0.5 ml of 
freezing mixture giving a total of 1 ml. The freezing mixture contained Dimethyl 
Sulfoxide (DMSO) mixed with fetal calf serum in a proportion of 1:4, giving a final 
DMSO concentration of 20%. This mixture was transferred to a freezing CryoTube™ 
ampoule and placed in a freezing container containing isopropanol, for 4 hours at -
80°C, before the ampoule was transferred for long-term storage in liquid nitrogen. 
 To thaw cell cultures from liquid nitrogen, the freezing ampoule was 
transferred to a waterbath at 37°C. When thawed, the cell suspension was transferred 
to a 15 ml Falcon tube and 9 ml of warmed growth medium was slowly added, drop-
wise. The cell suspension was centrifuged as before and the media removed and 
replaced with fresh media. The cells were gently mixed by pipetting and the cell 
suspension was transferred to a T25cm2 cell culture flask.  
 
2.3.4 Preparation of human DNA and platinum treatment and UV 
irradiation of human cells in culture 
Approximately 2 x 105 - 4 x 105 cells were seeded on to tissue culture dishes (100 x 
20mm), yielding approximately 2 x 106 cells following growth for 7-10 days. 
Alternatively, larger tissue culture dishes (150 x 25mm) would yield 4-5 x 106 cells 
after 10 days incubation. Cells were grown to confluence before treatment in each 
case.  
 Stock solutions of cisplatin and oxaliplatin were diluted to the required 
concentration using serum-free media. Growth media was removed from cells in 
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tissue culture dishes, cells were washed twice with 2 ml of warmed PBS (5 ml PBS 
used for the larger tissue culture dishes), and serum-free media containing the 
platinum analogue at the required concentration was added. Dishes were returned to 
the incubator for 2 hours at 37°C. Untreated cells were also incubated for 2 hours in 
serum-free media. Following incubation, cells were harvested with 1 x trypsin-EDTA 
as described in section 2.3.2. PBS was added to the cell suspension and this was 
transferred to a 15 ml Falcon tube and centrifuged at 1000rpm for 5 minutes at room 
temperature (Eppendorf centrifuge 5810R). The supernatant was removed from the 
cell pellet and the cells processed directly for DNA extraction using the Qiagen 
DNeasy Blood & Tissue Kit (Qiagen No. 69504). 
 For UV treatment, growth media was removed and cells were washed twice 
with 2 ml of warmed PBS. 5 ml of PBS was then added to the tissue culture dish for 
UV treatment, and untreated cells were also placed in 5 ml of PBS. Cells were 
irradiated with 254nm UVC irradiation from a calibrated germicidal VL-21G 
mineralight lamp (UV products, San Gabriel, CA, USA) at a fluence of 10 J/m2/s for 
5 seconds, giving a total dose of 50 J/m2. Following treatment cells were immediately 
harvested using trypsin, as described in section 2.3.2, and genomic DNA was 
extracted using the Qiagen DNeasy Blood & Tissue Kit. 
 
2.3.5 Human DNA treated in vitro with platinum and UV irradiation 
Cisplatin or oxaliplatin was added from stock solution to genomic DNA (suspended 
in buffer AE, the elution buffer solution of the Qiagen DNeasy Blood & Tissue 
Kit), to give the required final drug concentration. DNA was incubated with cisplatin 
or oxaliplatin for 2 hours at 37°C and recovered by ethanol precipitation. Precipitation 
was conducted by adding 2.5 x volume 100% ethanol, incubating at -80°C for 20 
minutes, then at -20°C for 30 minutes, followed by centrifugation at 13500rpm for 20 
minutes at 4°C (Beckman-Coulter Microfuge 22R). DNA pellets were washed with 
75% ethanol and centrifuged a second time, at 13500rpm for 20 minutes at 4°C. 
Pellets were dried using the SpeedVac system (Thermo Savant) and resuspended in 
100-200 µl of the buffer AE elution buffer prior to sonication and DIP or to immuno-
slot-blot (ISB) analysis. 
 For UV treatment genomic DNA, in buffer AE, was transferred to 35 x 10mm 
tissue culture dishes and irradiated as described in section 2.3.4 with UV at a dose of 
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300 J/m2. Following treatment, DNA was returned to microcentrifuge tubes 
(Eppendorf) for fragmentation with sonication followed by DIP. 
 
 
2.4 Assessment of DNA purity 
 
DNA purity is of critical importance for the accuracy and reproducibility of 
downstream applications, in this case, DIP, quantitative real-time PCR (qRT-PCR) 
and microarray preparation. The methods for these applications are described in 
chapters 3, 4 and 6. Accurate assessment of the purity and quality of extracted DNA 
was therefore crucial prior to commencing downstream experimental work. Purity 
was assessed using the NanoDrop-1000 spectrophotometer to measure absorbance at 
230nm, 260nm and 280 nm, and by agarose gel electrophoresis. 
 Nucleic acids have absorbance maxima at 260nm, and the ratio of absorbance 
maximum to the absorbance at 280nm was used as a measure of DNA purity for DNA 
extractions. Generally, a 260/280 ratio of ~1.8 was accepted as “pure” for DNA. A 
ratio of ~2.0 would be accepted as “pure” for RNA.  
 Absorbance at 230nm is generally accepted as being the result of 
contamination and therefore the 260/230 ratio was also calculated and used as a 
secondary measure of nucleic acid purity. The 260/230 ratio for “pure” nucleic acids 
is often higher than the respective 260/280 ratio, and expected 260/230 ratio values 
for “pure” nucleic acids are within the range of 2.0-2.2. A ratio lower than this 
indicates the presence of contaminants that absorb at 230nmn such as phenol and 
protein. 
 Following extraction of genomic DNA, if 260/280 ratio was greater than 1.85 
or if RNA contamination was visible on gel electrophoresis further treatment with 
RNase A followed by DNA purification was performed. Equally, if 260/230 ratio was 
below 2.0-2.2 an extra purification step was performed. 
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2.5 DNA gel electrophoresis 
 
Gel electrophoresis was used to assess the quality, amount and purity of extracted 
DNA and chromatin and to assess the fragmentation and uniformity of DNA and 
chromatin fragments following sonication. It was also used to assess PCR products. 
The same technique was used to assess human and yeast samples. 
 
2.5.1 Non-denaturing agarose gel electrophoresis 
Double-stranded DNA was assessed using non-denaturing agarose gels. For genomic 
DNA 1.0% agarose gel was prepared and for sonicated DNA 1.2% agarose gel was 
prepared. For 1% or 1.2% gel, 1 or 1.2 grams of agarose was added to 100 ml of 1 x 
TAE buffer respectively, and dissolved by heating in a microwave and mixing well. 5 
µl of ethidium bromide (10mg/ml) was added and mixed thoroughly. Gels were cast 
at a thickness of ∼0.5-1cm in a tray and allowed to cool and set at room temperature.  
 For DNA, electrophoresis samples consisted of 2 µl of DNA (50-200 ng), 8 µl 
of water and 2 µl of non-denaturing loading buffer, whilst for chromatin, samples 
consisted of 4 µl of chromatin, 6 µl of water and 2 µl of loading dye. Gels were 
placed in a horizontal gel electrophoresis tank containing 1 x TAE buffer and 10 µl of 
the electrophoresis DNA samples were loaded into the wells and run at 75-90V for 
30-60 minutes at room temperature using an Amersham pharmacia biotech power 
pack. A DNA ladder was loaded to one well - either GeneRuler™ 1kb DNA ladder 
(Thermo Scientific) or FastRuler™ low range DNA ladder (Fermentas). Following 
electrophoresis DNA was visualised using a BioDoc-It Imaging System UV 
transilluminator (UV products, San Gabriel, CA, USA) with UV-B at 302nm. 
 
 
2.6 DNA and chromatin fragmentation by sonication 
 
DNA and chromatin were fragmented using a BioRuptor sonicator (Diagenode). Four 
1.5 ml microcentrifuge tubes, each containing 200 µl of DNA or chromatin sample, 
were placed in a 1.5 ml microtube unit, and the unit placed in a cooling waterbath. For 
human DNA each sample was diluted to 100 ng/µl prior to sonication to ensure 
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reproducibility. Power was set at the ‘high’ position and sonication was conducted at 
4°C. The number of cycles of sonication employed was different between samples, 
firstly because chromatin fragments more readily than naked DNA and therefore 
fewer cycles are required. Secondly, for human samples a shorter fragment length was 
required to improve microarray resolution (described in detail in chapter 4). For yeast 
studies, a fragment length of 3-500 bp was used, whilst for human studies a shorter 
fragment length of 2-300 bp was required. Sonication schedules employed were as 
follows:- 
Yeast DNA - 20 cycles of 30 seconds on, 30 seconds off 
Yeast chromatin - 8 cycles of 30s on, 30s off 
Human DNA - 25 cycles of 30s on, 30s off 
Satisfactory sonication was confirmed by gel electrophoresis using a 1.2% agarose gel 
and using the FastRuler™ low range DNA ladder (Fermentas) for reference. 
 
 
2.7 Quantitative real-time PCR (qRT-PCR) 
 
qRT-PCR was used to determine relative amounts of immunoprecipitated DNA or 
chromatin between untreated and treated samples and with different doses of drug. In 
these studies, qRT-PCR was used to quantify platinum-induced DNA damage in yeast 
and human DNA, UV-induced CPD formation in human DNA and histone H3K14 
acetylation in yeast chromatin. For qRT-PCR studies immunoprecipitated (IP) and 
input (IN) samples were used and the importance of using IN samples as a control for 
starting DNA amounts in qRT-PCR is discussed in section 3.1.3 of chapter 3. 
Samples were amplified using the iQ™ SYBRgreen supermix (Bio-Rad) and the 
iCycler MyiQ™ real-time PCR detection system (Bio-Rad). SYBRgreen dye exhibits 
minimal fluorescence when free in solution, but when bound to dsDNA, its 
fluorescence increases up to 1000-fold, thus the fluorescence emitted is proportional 
to the amount of DNA in the well. Fluorescence was measured during each PCR cycle 
of amplification. 
 During each qRT-PCR experiment a set of standards were included, where 
one input (IN) sample was serially diluted 10-fold to provide a range of dilutions from 
10-1 to 10-4. These standards were used as a reference for relative DNA quantification 
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between samples. For quantification of yeast samples, IN samples were diluted 1000-
fold and the immunoprecipitated (IP) samples diluted 5-fold, and for quantification of 
human samples, IN samples were diluted 1000-fold and the IP samples diluted 4-fold. 
All dilutions were conducted in water. 10 µl of these diluted samples were added to a 
10 µl mix of SYBRgreen and primer pair to achieve a final primer concentration in 
the well of 500 nM, and a final volume in each well of 20 µl. For yeast qRT-PCR 
studies, primers for the MFA2, POL30 and PSK1 genes were used and for human 
studies primers for the human 28s ribosomal RNA gene were used. qRT-PCR 
reactions were performed in 96 well PCR plates (Type: LW2215, Alpha Laboratories) 
and each PCR reaction was performed in triplicate including the standards. Plates 
were sealed with plastic film, mixed briefly by vortexing and centrifuged at 2000rpm 
for 2 minutes. For yeast studies the qRT-PCR reaction was performed under the 
following conditions: 
 
 
1. 95°C for 3 minutes 
2. 95°C for 15 seconds 
3. 55°C for 20 seconds 
4. 55°C for 20 seconds – followed by optical image 
5. Go to step 2 x 44 times 
6. 95°C for 1 minute  
7. 55°C for 30 seconds 
8. Melt curve from 55°C 
 
 
Midway through this work a new qRT-PCR machine was purchased, the CFX 
Connect™ Real-Time PCR Detection System (Bio-Rad), which was used for the later 
human qRT-PCR studies. Additionally, a new iTaq™ Universal SYBRgreen 
Supermix (Bio-Rad) was used for studies with this machine. The same sample 
preparation protocol was followed, as outlined above, on the new machine other than 
the total volume of sample in each well could be reduced to 10 µl rather than 20 µl. 
Therefore all dilutions and constituent reagents remained the same except half the 
volume was used. qRT-PCR reactions were still performed in 96 well PCR plates, but 
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different plates were used (Hard-Shell 96 well PCR plates, Bio-Rad) and some 
reactions were performed in duplicate rather than triplicate to allow DNA samples to 
be conserved for DNA microarray studies. For human studies the qRT-PCR reaction 
was performed under the following conditions: 
 
 
1. 95°C for 3 minutes 
2. 95°C for 10 seconds 
3. 60°C for 20 seconds - followed by optical image 
4. Go to step 2 x 44 times 
5. 95°C for 10 seconds  
6. 65°C for 5 seconds 
7. Melt curve from 65°C 
 
 
2.8 Immuno-slot-blot assay 
 
The immuno-slot-blot (ISB) assay was used to detect platinum-induced DNA damage 
in yeast and in human DNA samples using the CP9/19 antibody, as a preliminary test 
of the antibody’s sensitivity. In vitro treated naked DNA or genomic DNA extracted 
from cells treated in culture with cisplatin or oxaliplatin, as described in section 2.2 
and 2.3, was used. 
 The Bio-Dot SF Microfiltration apparatus (Bio-Rad) was assembled and a 
VacuGene pump (Pharmacia Biotech, UK) was attached to the outlet valve. Two 
layers of Bio-Dot SF (Bio-Rad) filter paper were placed on the apparatus as a base 
followed by a layer of GeneScreen Plus™ hybridisation transfer membrane, soaked 
for 2 minutes in 0.4 M NaOH solution. The lid was placed on the apparatus and 
secured tightly.  The vacuum pump was started and allowed to reach a pressure of 50-
60mbar. Once the required pressure was reached, 200 µl of DNA solution was loaded 
into each well and left for 5 minutes. For human ISB assays each DNA solution 
contained 200 ng DNA and yeast ISB assays contained 300 ng of DNA, in a final 
solution concentration of 0.4 M NaOH and 1 x TE buffer. Once the DNA solution had 
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been absorbed into the membrane a rinse was performed with 200 µl of 0.4 M NaOH 
added to each well.  
  The membrane was removed from the apparatus and washed quickly with 1 x 
TBST solution. The membrane was blocked by immersing it in 3% non-fat milk/1 X 
TBST solution overnight on a platform shaker at 4°C. Following overnight 
incubation, the membrane was placed in a plastic envelope and incubated with 1-2 µg 
of CP9/19 antibody, made up in 10 ml of 1 x TBST/3% non-fat milk solution, for 2 
hours at room temperature on a platform shaker. Following incubation with the 
primary antibody the membrane was washed 3 times in 1 x TBST solution, first wash 
for a few seconds followed by 2 x 10 minute washes where the membrane was 
immersed in 1 x TBST and placed on a platform shaker. The membrane was then 
placed again in a plastic envelope and incubated with 0.5 µl (1:20,000) of alkaline 
phosphatase-linked Goat anti-Rat IgG secondary antibody (Sigma-Aldrich, A8438) in 
10 ml of 1 x TBST/3% milk solution for 1 hour at room temperature. A further 3 
washes were conducted following incubation with secondary antibody as previously 
described. The membrane was covered with 2 ml of ECF (enhanced 
chemifluorescence) detection solution (GE Healthcare), made by adding 36mg of 
ECF substrate to 60 ml of ECF dilution buffer, and incubated for 2 minutes at room 
temperature. The fluorescent emission was detected using the Typhoon TRIO 
Variable Mode Imager (Amersham Biosciences) and quantification of the image 
bands was performed using ImageQuant software. 
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Chapter 3  
Development of DNA immunoprecipitation-DNA 
microarray (DIP-chip) assay to measure platinum-
induced DNA damage in Saccharomyces cerevisiae 
 
 
3.1 Introduction 
 
In this chapter the development of a technique combining DNA immunoprecipitation 
with DNA microarrays (DIP-chip) for measuring cisplatin and oxaliplatin-induced 
DNA damage in the yeast model organism Saccharomyces cerevisiae (S. cerevisiae) 
is presented. As described in section 1.6, chapter 1, the platinum analogues are 
commonly used chemotherapeutic agents and act by forming covalent, predominantly 
bifunctional, adducts with DNA. The DIP-chip technique developed here is a novel 
assay allowing the sensitive detection of platinum-DNA adducts genome-wide at a 
resolution not previously possible. The methods undertaken to develop this assay in 
the model organism are described in this chapter and its validation using a 
mathematical model to generate predicted profiles for platinum-induced damage 
induction is also presented.  
 The combination of immunoprecipitation (IP) with microarray technology is 
not a new concept, with chromatin immunoprecipitation coupled with DNA 
microarrays (ChIP-chip) developed primarily for genome wide protein binding now 
widely used and well established (see section 1.8, chapter 1). The concept of using 
this technology to examine DNA damage and repair events genome-wide is novel and 
was first presented by Teng et al who examined cyclobutane pyrimidine dimer (CPD) 
induction following exposure of S. cerevisiae cells to ultraviolet (UV) light irradiation  
(Teng et al., 2011). In this chapter this technique is further developed and refined to 
examine DNA damage induced by the platinum analogue family of cytotoxic agents. 
The major benefit of this assay is that it allows platinum-induced DNA damage events 
to be examined, for the first time, throughout the whole genome at high resolution. 
Developing this assay in the model organism provided valuable genomic platinum-
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induced DNA damage datasets that are analysed in this chapter, and also allowed 
comparative and integrative analysis to be performed between these and other 
genomic and epigenetic datasets, work that is described and presented in chapter 5. 
This work also provided a huge amount of guidance and insight for the next stage of 
development for this assay, its development in the human context and this work is 
presented in chapter 4. 
 In order to accurately detect the formation of platinum-DNA adducts in 
experimental systems and clinical samples and to improve molecular understanding of 
the mechanism of action and cytotoxicity of the platinum analogues, many different 
analytical laboratory techniques have previously been developed. Historically, the 
commonest method for determining total amount of platinum adducts in isolated 
DNA has been with a combination of enzymatic degradation, chromatography and 
atomic absorption spectroscopy (AAS) (Fichtinger-Schepman et al., 1985b, Reed et 
al., 1993). Other spectroscopic procedures have also been used such as nuclear 
magnetic resonance (NMR) (Fichtinger-Schepman et al., 1982) and inductively 
coupled mass spectroscopy (ICP-MS) (Bonetti et al., 1996). Subsequently, many 
immunochemical techniques have been developed, using polyclonal and monoclonal 
antibodies, and have been directed either against platinum adducts in whole DNA or 
against the individual adducts in digested DNA (Plooy et al., 1985, Reed et al., 1990). 
These early immunochemical studies had certain drawbacks, including that the 
techniques had limited sensitivity and that they had difficulty distinguishing between 
the different individual adducts (Parker et al., 1991). Additionally, polyclonal 
antibodies can lack specificity and are unable to quantify and differentiate between 
the various DNA adducts. To overcome this, new techniques were developed that 
allowed the quantitative detection of individual DNA adducts. Initially, these 
involved using polyclonal antibodies and digested DNA samples, coupled with 
chromatography and immunochemical enzyme linked immunosorbant assay (ELISA) 
methods, (Fichtinger-Schepman et al., 1985a, Fichtinger-Schepman et al., 1987). 
These methods, whilst sensitive, were laborious, required large amounts of DNA and 
had the drawbacks of limited antisera.  
 More recent quantitative assays have been developed including the 32P-
postlabelling technique (Blommaert and Saris, 1995, Welters et al., 1997). This 
technique allowed quantification of the two major intrastrand adducts (the 1,2-d(GpG) 
and 1,2-d(ApG) adduct) from smaller (∼10µg) starting amounts of DNA and was 
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applied to DNA isolated from cultured cells, tumour xenografts from cisplatin-treated 
mice and from white blood cells taken from patients treated with cisplatin. This assay 
provided a sensitive and quantitative approach for detecting these lesions, which 
compared favourably to the existing methods of AAS, competitive ELISA and 
immunohistochemistry.  
 More recent qualitative analytical methods for detecting platinum-induced 
DNA damage include coupled techniques such as high-performance liquid 
chromatography (HPLC) (Iijima et al., 2004) or capillary electrophoresis (Kung et al., 
2001) with mass spectrometry (Iannitti-Tito et al., 2000). Recently, accurate 
quantitative analysis of platinum adducts has been achieved through the development 
of an assay based on ICP-MS methodology coupled with isotope dilution analysis 
(IDA) (Garcia Sar et al., 2009). Whilst these later techniques offer alternative 
strategies for the assessment of adduct formation, the quantitative determination 
remains complex. Another limitation of these techniques is that they generally aren’t 
commercially available and do not lend themselves easily to being applied to the high 
throughput assessment of clinical samples necessary for use within the clinical 
environment.  
 
3.1.1 Saccharomyces cerevisiae as a model organism 
The budding yeast S. cerevisiae is used in a variety of fermentation industries 
including bread making, and brewing and has also been used extensively by the 
research community as a model organism for scientific research. It is one of the most 
well studied eukaryotic microorganisms, was the first eukaryotic organism to have its 
genomic sequence determined and it shares considerable genetic homology with 
mammalian cells including human cells. 
 In this chapter S. cerevisiae was used as a model system to develop and study 
the validity and reproducibility of the DIP-chip assay for detecting platinum-induced 
DNA damage. Studies were conducted using logarithmically growing S. cerevisiae 
cells treated with cisplatin and oxaliplatin as described in section 2.2, chapter 2. 
Developing this work first in the simpler model organism allowed each of the 
different elements of the assay to be developed and characterised; firstly, the IP stage 
using the CP9/19 antibody (see section 3.1.2), secondly, the sample preparation for 
microarray hybridisation and, thirdly, the bioinformatic tools to allow the processing 
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and validation of the data output. This work in the model system provided a 
significant amount of information for each of these three crucial elements that could 
then be applied to help understand and overcome some of the challenges encountered 
when developing the assay in the more complex human system. This work also 
provided genomic platinum-induced DNA damage datasets that were used for 
comparative analyses with UV-induced DNA damage datasets (presented in chapter 
5), and for integrative analysis with epigenetic platinum-induced histone acetylation 
datasets (presented in chapter 6), generated in S. cerevisiae  
 S. cerevisiae is a desirable model organism for use in this context for a number 
of reasons. Firstly, yeast cells are sensitive to platinum analogues enabling platinum-
induced DNA damage to be successfully induced following drug exposure. 
Additionally, the yeast and human genome have extensive homology and many of the 
basic cellular processes in yeast are conserved in human cells, particularly those 
involved in DNA damage response and repair pathways. This emphasises the 
relevance for first developing this work in yeast cells. Also, the doubling time of yeast 
cells is ~90 minutes compared with >48 hours for the cultured human fibroblast cell 
lines used for the work presented in chapter 4, making it a useful, pragmatic approach 
to increasing the DNA yield and throughput for these initial studies. Additionally, the 
size of the yeast genome, roughly 12 x 106 base pairs, make this a far simpler system 
to develop microarray approaches in compared with the 3.2 x 109 base pair size of the 
human genome. Despite the desirability of this organism one potential drawback from 
using yeast for this work is the prohibitive effect of the presence of the cell wall in 
ensuring adequate cellular accumulation of the platinum agent. Previous published 
work, however, using S. cerevisiae has demonstrated that this is not a significant 
barrier to the accumulation of cisplatin (Ishida et al., 2002) or oxaliplatin (Wu et al., 
2004). Equally, with the studies presented here, drug uptake did not prove to be a 
significant problem since platinum-DNA adducts were readily detected following 
both cisplatin and oxaliplatin treatment of yeast cells in culture (see section 3.3.1, 
figure 3.4). Therefore no additional measures were taken to increase yeast cell wall 
permeability.  
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3.1.2 Anti-cisplatin modified DNA antibodies 
Many attempts have been made to detect, measure and quantify platinum-induced 
DNA modifications using immunological methods. The CP9/19 monoclonal antibody 
was developed by Tilby et al in 1991 and has been demonstrated to recognise DNA 
adducts formed by cisplatin and carboplatin (Tilby et al., 1991). The CP9/19 antibody 
was raised in rats exposed to cisplatin treated polymeric DNA and was proven by 
Tilby et al to efficiently detect cisplatin and carboplatin modified DNA by ELISA. 
Prior to this, other groups had raised polyclonal antisera in rabbits against cisplatin-
modified calf thymus DNA and were used experimentally with varying degrees of 
success. In one case the antiserum was shown not to react with in vivo modified DNA 
(Malfoy et al., 1981) whilst others showed greatly reduced sensitivity to cisplatin-
modified DNA in vivo compared with DNA modified in vitro (Poirier et al., 1982, 
Fichtinger-Schepman et al., 1989). For one of these antibodies (Poirier et al., 1982), 
the reduced sensitivity was attributed to the low levels of platinated DNA used to 
raise the antiserum (Fichtinger-Schepman et al., 1989, Reed et al., 1990). Another 
polyclonal antiserum raised against cisplatin-modified calf thymus DNA showed 
good sensitivity for detection of cisplatin-DNA adducts in immunocytochemistry 
studies applied to tissue taken from cisplatin treated rats and mice, but has not been 
characterised for other techniques (Terheggen et al., 1987). Subsequently, Terheggen 
et al raised a further four rabbit antisera, one against cisplatin modified DNA, and 
another three against cisplatin-modified (di)nucleotides (1,2-d(GpG), 1,2-d(ApG) and 
monofunctional guanine adduct) and characterised these using ELISA (Terheggen et 
al., 1991). More recently, two other monoclonal antibodies have been established and 
characterised - the R-C18 antibody which recognises the 1,2-d(GpG) intrastrand 
crosslink and R-B3 which recognises the 1,2-d(ApG) intrastrand crosslink. Both of 
these antibodies were demonstrated to be sensitive and were employed in immuno-
cytological assays allowing the quantification of adducts in cells and in tissue biopsies 
taken from patients with gastric cancer (Liedert et al., 2006). 
 The CP9/19 antibody proved sensitive for use in ELISA assays and its 
sensitivity was confirmed to be independent of frequency of DNA modification and 
of whether the DNA was exposed to drug in vivo or in vitro (Tilby et al., 1991). Non-
competitive ELISA showed no detectable binding of CP9/19 antibody to native 
control DNA, and clear binding of the antibody with cisplatin-modified DNA. 
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Competitive ELISA was then performed, whereby the CP9/19 antibody was incubated 
with serial dilutions of cisplatin-modified DNA prior to being applied to a plate-
coated with control or modified DNA, followed by washing of the plate to remove the 
unbound antibody. The drop in immunofluorescence recorded as a result of the 
competitor antigen allows for improved characterisation of the affinity, and relative 
affinity, of the antibody for cisplatin-modified DNA versus control DNA. Control 
DNA caused slight inhibition within the competitive ELISA but only at very high 
concentrations, and generally CP9/19 distinguished between cisplatin-modified DNA 
and control DNA with great specificity in competitive assays (Tilby et al., 1991). The 
CP9/19 was also tested against carboplatin-modified DNA in vitro, and its 
immunoreactivity was found to be similar to cisplatin-modified DNA (Tilby et al., 
1991).  
 Clearly, detailed knowledge of the specificity of this antibody is important 
given the different classes of adducts that the platinum analogues can yield. Whilst 
Tilby et al did not formally characterise the antibody epitope in their initial paper, 
they observed that since CP9/19 recognised adducts caused by the trans isomer of 
cisplatin, (trans-diamine-dichloroplatinum(II), trans-DDP is incapable of forming 
1,2-d(GpG) crosslinks) far less efficiently, if at all, it was likely that CP9/19 was 
primarily recognising the intrastrand 1,2-d(GpG) crosslink. Also, they showed that 
CP9/19 recognised carboplatin adducts almost as efficiently as cisplatin adducts. A 
study using defined sequence synthetic oligodeoxynucleotides to restrict the type of 
adducts able to form during reaction with cisplatin was used to clearly define the 
epitope and the exact adduct recognised by CP9/19. This confirmed that in the 
competitive ELISA situation the only adduct recognised by CP9/19 were the 
crosslinks between adjacent guanine residues (Meczes et al., 2005). This work 
therefore confirmed the specificity of the CP9/19 antibody for recognising the 1,2-
d(GpG) intrastrand crosslink. 
 Recently, the trapped in agarose DNA immunostaining (TARDIS) assay was 
developed as a means of detecting and quantifying cisplatin DNA adducts in single 
cells (Cowell et al., 2011). Using this method cisplatin-DNA adducts are detected by 
sensitive immunofluorescence using adduct-specific antibodies. This approach was 
developed using the CP9/19 antibody, and worked well initially but subsequently 
developed problems related to persistently high levels of non-specific binding of 
CP9/19 to DNA. It is unclear why this situation arose and may represent an assay 
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specific limitation, possibly related to adduct detection within agarose. The authors 
also discussed technical issues and limitations relating to excessive background 
fluorescence detected by the camera system. 
 CP9/19 has been widely used, predominantly in competitive ELISA assays, 
for varying experimental research investigations, and been shown to recognise 
cisplatin-modified DNA in human ovarian cancer cell lines (Mellish et al., 1995) rat 
thymocytes (Evans et al., 1994), rat hepatocytes (Cross et al., 1996) and Chinese 
hamster ovary cell lines (De Silva et al., 2002). The CP9/19 antibody has also been 
used and shown to recognise cisplatin and carboplatin-induced adducts in peripheral 
blood leucocytes in clinical samples again using immunological approaches such as 
competitive ELISA (Peng et al., 1997, Ghazal-Aswad et al., 1999, Veal et al., 2001). 
Therefore, despite being raised against cisplatin-modified DNA this antibody has 
been shown to sensitively detect adducts formed by both cisplatin and carboplatin. It 
was developed before oxaliplatin had been established, and therefore had not 
previously been used to detect oxaliplatin-induced DNA damage, however, given the 
structural similarities of the platinum analogues (figure 1.8) as well as the similarities 
of the adduct profile generated by each of the platinum analogues (discussed in 
section 1.6.4, chapter 1) it was reasoned that CP9/19 might also demonstrate 
immunoreactivity against oxaliplatin. For these reasons, along with the fact that it was 
readily commercially available through Abcam®, this antibody was chosen for use in 
these studies. 
 
3.1.3 DNA immunoprecipitation-DNA microarray (DIP-chip) 
experimental overview 
An overview of the ChIP-chip experimental technique is outlined in section 1.8.3 and 
figure 1.10, chapter 1 and the key difference between it and the DIP-chip assay 
described in this chapter is that DNA is the starting template and not chromatin. 
Consequently, crosslinking of chromatin proteins is not required for DIP-chip. 
Broadly, the DIP-chip technique employed for these studies involved capturing 
platinum-damaged fragments of DNA through immunoprecipitation (DIP), 
quantitative real-time PCR (qRT-PCR) analysis at the MFA2 promoter gene locus 
followed by sample preparation for hybridisation to the DNA microarray. The qRT-
PCR step is an important quality control checkpoint as it provides additional 
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assessment that the DNA prepared is of good quality. It also allows the first 
assessment that the DIP step has worked effectively and confirms that samples are of 
sufficient quality to proceed with DNA microarray preparation. Throughout the 
experimental workflow for each immunoprecipitated DNA sample (IP) a separate 
input (IN) sample was used. The IN sample acts as an internal control and represents 
purified, total background genomic DNA taken prior to the IP process and does not 
undergo IP but does undergo amplification by qRT-PCR. For each sample the values 
obtained following qRT-PCR are presented as the ratio of IP to the corresponding IN 
sample to correct individual IP samples for differences in initial or background DNA 
amounts (see table 3.1). During the development of this work qRT-PCR also allowed 
careful characterisation of the sensitivity of the CP9/19 antibody by testing its 
performance within dose titration studies using cisplatin and oxaliplatin.  
 Following satisfactory qRT-PCR, the paired IP and IN samples were prepared 
for DNA microarray hybridisation. This involved blunting of the ends of the DNA 
strands, ligation of a common linker sequence of DNA, ligation-mediated PCR 
followed by fluorescent labelling and microarray hybridisation (figure 3.1). The 
methods for each of these steps is described in the following section, section 3.2.5. 
Importantly, for the DNA microarray method used in these studies a two channel 
microarray method is used and these two channels consist of the IP sample along with 
the corresponding IN sample. This allows the final microarray hybridisation sample to 
consist of a mix of the IP and IN samples differentially labelled with separate 
fluorescent dyes (Cy5 and Cy3 fluorophores respectively). In this case the IN samples 
again act as an internal control within the microarray protocol and are prepared 
alongside the IP sample, undergoing all of the same manipulations. This allows 
differences that occur within the sample due to non-biological, technical reasons, such 
as sample handling, differential PCR amplification or labelling to be corrected for. 
Following hybridisation, each microarray probe will therefore generate two signals, 
one signal representing bound IP fragments and a separate signal representing bound 
IN fragments. These signals are converted to numerical values using Feature 
Extraction software and the value obtained at each microarray probe is presented as 
the IP/IN ratio at that probe. For these studies, Agilent Technologies’ DNA 
microarray system was used since this is a well-established two channel microarray 
platform.  
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Figure 3.1 - Diagram demonstrating the workflow and stages for the two channel DNA 
immunoprecipitation-DNA microarray (DIP-chip) protocol. This figure is updated from figure 1.10 
to reflect the specific workflow of the platinum DNA damage DIP-chip protocol. Platinum-induced 
damaged DNA samples are extracted and fragmented using sonication. DNA samples are then 
processed for immunoprecipitation (IP sample), using the CP9/19 antibody in conjunction with 
Dynabeads and a separate input sample (IN sample) is taken as a control which does not undergo IP. 
Paired IP and IN samples are then analysed using qRT-PCR and if satisfactory these samples are 
prepared for DNA microarray hybridisation with DNA amplification and differential labelling of the 
fragments with Cy5 or Cy3 fluorophore dyes. Following hybridisation the microarray is scanned and a 
file with the microarray image is created. Feature Extraction software is then used to convert the probe 
intensity at each microarray probe into a numerical value and this data is then analysed. 
 
 
3.2 Methods 
 
The constituents for all liquid solutions referred to in this section are given in 
Appendix I. 
 
3.2.1 Preparation of platinum-treated yeast DNA 
Cisplatin or oxaliplatin-treated DNA was extracted from S. cerevisiae cells treated in 
culture, or naked DNA was treated in vitro, and DNA samples then used for immuno-
slot-blot or DIP studies. DNA was checked for purity and concentration using the 
NanoDrop-1000 spectrophotometer and agarose gel electrophoresis and samples 
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fragmented using sonication. This resulted in a mean DNA fragment length of 
approximately 400 base pairs (figure 3.2). Each of these methods were conducted as 
described in sections 2.2 - 2.6, chapter 2. 
 
 
Figure 3.2 - Examples of extracted and sonicated genomic DNA from wild type Saccharomyces 
cerevisiae yeast cells treated in culture and demonstrated by agarose gel electrophoresis. The 4 
lanes represent, from left to right, oxaliplatin treated DNA (lane 1), 2 lanes of cisplatin treated DNA 
(lanes 2 and 3) and a lane of untreated DNA (lane 4). The FastRuler™ low range DNA ladder 
(Fermentas) was used for reference and the fragment length in base pairs is displayed in figures to the 
right of the sonicated gel image. In 3.2 (a) whole, extracted, genomic DNA is presented whilst 3.2 (b) 
shows the same samples having been sonicated for 20 cycles of 30 second cycles of intermittent 
sonication. 
 
 
3.2.2 DNA immunoprecipitation of platinum-induced DNA damage 
Fragmented yeast DNA extracted from cells treated in culture, or treated in vitro, with 
platinum analogues, as described in section 2.2, was used for DIP using the anti-
cisplatin modified DNA, CP9/19, antibody (ab103261, Abcam). 40 µl of Dynabeads 
(Sheep anti-Rat IgG, Invitrogen) per sample were washed three times using 500 µl 
PBS-BSA (0.1% of BSA). Washed Dynabeads were resuspended in 50 µl of PBS-
BSA (0.1% of BSA) per sample and 0.5 µg of CP9/19 antibody was added per 40 µl 
of Dynabeads for the detection of cisplatin-induced DNA damage or 1.5 µg of 
antibody added per 40 µl of Dynabeads for the detection of oxaliplatin-induced 
damage. Dynabeads and antibody were incubated at 30°C for 30 minutes at 1300rpm 
in a thermomixer (Eppendorf). Dynabeads were collected, washed three times with 
500 µl of chilled PBS-BSA (0.1% of BSA) and resuspended in 50 µl of PBS-BSA 
(0.1% of BSA) per sample. 30 µl of 10 X PBS-BSA (1% of BSA) and 6 µg of 
sonicated DNA were added to each tube containing the Dynabeads, and the final 
volume made up to 300 µl with PBS. Samples were incubated at 21°C for 3 hours at 
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1300rpm in a thermomixer. Following incubation, samples underwent a series of 
washes as follows: first wash with 500 µl of freshly prepared FA/SDS buffer. This 
was followed by three washes with 500 µl of FA/SDS containing 0.5 M NaCl, one 
wash with 500 µl of LiCl solution and one wash with 500 µl of cold TE. DNA was 
eluted from the Dynabeads in 125 µl of 1 x pronase buffer at 65°C at 900rpm for 30 
min in a thermomixer (Eppendorf). 6.25 µl of pronase (20 mg/ml) was added and 
samples incubated in a waterbath at 65°C overnight. IN samples of 0.6 µg (1/10 of IP 
sample) of sonicated DNA were made up to 100 µl with TE buffer followed by the 
addition of 25 µl of 5 x pronase buffer and 6.25 µl of pronase (20 mg/ml) and 
incubated in a waterbath at 65°C overnight. Following overnight incubation, IP and 
IN samples were processed for removal of the DNA damage (see section 3.2.3), and 5 
µl of DNase-free RNase A (10 mg/ml) was added during this process. DNA was then 
purified using the PureLinkTM Quick PCR Purification Kit (Invitrogen) and eluted 
with 50 µl of elution buffer. 
 
3.2.3 Removal of platinum adducts prior to qRT-PCR and 
microarray preparation 
DIP DNA fragments detected by the CP9/19 antibody and the corresponding IN DNA 
samples will contain platinum adducts (apart from untreated samples), which are 
known to inhibit DNA polymerase function and interfere with microarray 
hybridisation. These samples therefore require processing for removal of these 
adducts prior to downstream applications. Platinum-DNA adducts are very stable over 
a long period of time, but in the presence of cyanide ions most platinum residues are 
known to be removed from DNA (Lemaire et al., 1991). Sodium cyanide (NaCN) has 
been proven to be the most effective chemical for disrupting platinum-DNA adducts 
(Lemaire et al., 1991, Olinski et al., 1992, Blommaert and Saris, 1995), and in the DIP 
studies described in this thesis, NaCN was used to remove platinum adducts. 
Following overnight incubation of the IP and IN samples with pronase DNA samples 
were incubated with 0.2 M NaCN for 2 hours at 65°C. 5 µl of RNase A (10 mg/ml) 
was added for the last 45 minutes of this incubation. Following incubation DNA 
samples were purified using the PureLinkTM Quick PCR Purification Kit (Invitrogen) 
and eluted with 50 µl of elution buffer. 
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3.2.4 Quantitative real-time PCR (qRT-PCR) 
Following DIP, IP and IN samples underwent qRT-PCR, conducted as described in 
section 2.7, chapter 2. This allowed quantification of the amount of DNA in the 
platinum-treated and untreated IP and IN samples. These values represent relative 
amounts of DNA determined by the use of a standard curve (figure 3.3). Since 
platinum-induced DNA damage was likely to occur throughout the genome the locus 
used to examine this damage during qRT-PCR could be chosen arbitrarily. The 
promoter of the MFA2 gene was chosen as this has been used extensively in yeast 
model organism work to study UV-induced CPD damage and repair (Teng et al., 
1997, Teng et al., 2002, Yu et al., 2005). 
 
The MFA2 promoter primer sequence:- 
Primer 
Forward: 5ʹ′ - AAAGCAGCATGTTTTCATTTGAAACA - 3ʹ′                                     
Reverse: 5ʹ′ - TATGGGCGTCCTATGCATGCAC - 3ʹ′                                       
 
 
 
Figure 3.3 - Melt curve and standard curve for typical qRT-PCR experiment using primers for 
the promoter of the MFA2 gene. This demonstrates qRT-PCR data from a DIP experiment of a dose 
titration study of cisplatin treated yeast DNA. 3.3 (a) shows a typical example of a melt curve produced 
using the MFA2 promoter primers. The single, sharp peak represents a single melting temperature, 
confirming the formation of a single PCR product. 3.3 (b) demonstrates the standard curve for this PCR 
experiment. Here, 4 standards are displayed, as green spots, representing serial 10-fold DNA dilutions 
plotted from -1 to -4 on the x axis, with the threshold cycle values given on the y axis. Threshold cycles 
for each sample are represented by the green crosses plotted along the standard curve and DNA starting 
amounts are calculated relative to these standards. Samples containing relatively little DNA, such as an 
untreated IP sample will lie to the lower end, left, of the curve, whilst samples containing relatively 
high amounts of DNA will lie at the higher end, right, of the curve. 
! !
a b 
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3.2.5 Sample Preparation for DNA microarray hybridisation 
Yeast DIP and ChIP and input samples were processed for microarray hybridisation 
as described in the Agilent Technologies Yeast ChIP on chip protocol (Agilent 
Technologies Yeast ChIP-on-chip Analysis Protocol, version 9.2), and as outlined in 
the paper by Teng et al (Teng et al., 2011). The steps required are blunting of the ends 
of the DNA fragments followed by ligation of a common linker sequence of DNA to 
the ends of these fragments, ligation-mediated PCR amplification (LM-PCR), 
labelling and hybridisation to 4 x 44k format Agilent yeast microarrays. This format 
signifies that 44,000 features are imprinted on a single microarray to represent the 
entire yeast genome and that 4 microarrays are printed on each glass slide. The 
method for each of the preparatory microarray steps were conducted similarly to 
previously published (Teng et al., 2011) and will be outlined in the following 
sections. qRT-PCR demonstrated that the IN samples contained greater amounts of 
DNA than the IP samples, usually 10 - 100 fold greater. Therefore, to balance the two 
microarray channels and to standardise microarray preparation equal amounts of 
DNA were used in the IP and IN channels at the outset. To achieve this, IN samples 
were diluted, (normally 10 -100 x) dependent on qRT-PCR results, to equalise the 
DNA concentration of both samples. 
 
Blunting 
To allow the ligation of a linker hybrid DNA sequence, the DNA ends must first 
undergo blunting. Blunting of the DNA ends was performed using the endonuclease 
function of the T4 DNA polymerase (New England Biolabs, NEB). 70 µl of blunting 
mix (see table) was added to 50 µl of IP or IN sample. These samples were mixed by 
pipetting and incubated in a waterbath at 12°C for 20 minutes. Following this, 12 µl 
of sodium acetate (NaAc 3 M, pH 5.2) and 0.5 µl of glycogen (20 mg/ml) were added 
followed by 130 µl of phenol/chloroform; samples were mixed thoroughly by vortex 
and subsequently centrifuged for 10 minutes at 13000rpm at room temperature. The 
upper phase was transferred and DNA retrieved by precipitation with 260 µl 100% 
ethanol for 1 hour at -20°C. Following precipitation samples were centrifuged at 
13500rpm for 20 minutes at 4°C (Beckman-Coulter Microfuge 22R), supernatant 
removed and the DNA pellet washed with 500 µl of cold 75% ethanol and centrifuged 
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again at 13500rpm for 10 minutes at 4°C. The supernatant was discarded and DNA 
pellet dried for 5 minutes using the SpeedVac system (Thermo Savant). 
 
Blunt end mix 
T4 DNA polymerase buffer 12 µl 
BSA (10 mg/ml) 1.2 µl 
dNTP (10 mM) 1 µl 
T4 DNA polymerase 0.2 µl 
Water 55.6 µl 
Total 70 µl 
 
 
Ligation 
After blunting the ends of the DNA fragments a ligation mixture was made and DNA 
pellets were resuspended in 25 µl of H2O and 25 µl of the ligation mix (see table). 
Samples were mixed with pipetting and incubated in a waterbath at 16°C overnight. 
Ligation of a common linker hybrid DNA to the ends of each DNA fragment allows 
amplification of all fragments to occur using a single set of primers. 
 
Ligation mix 
DNA ligase buffer 5 µl 
Linker hybrid DNA 6.5 µl 
T4 DNA ligase (NEB) 0.5 µl 
Water 13 µl 
Total 25 µl 
 
 
Sequence for linker hybrid DNA:- 
oligo JW102 5ʹ′- GCGGTGACCCGGGAGATCTGAATTC - 3ʹ′ 
oligo JW103 5ʹ′- GAATTCAGATC - 3ʹ′ 
  
Ligation-mediated PCR (LM-PCR) 
DIP does not yield sufficient quantities of DNA required for efficient DNA 
microarray hybridisation experiments. Microgram quantities of DNA are required for 
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hybridisation to DNA microarrays and, normally, a single DIP experiment will only 
yield a few nanograms of IP DNA. Therefore, amplification of the IP and IN samples 
are required, and this was achieved using LM-PCR. 
 Following ligation overnight, 6 µl of NaAc (3 M) was added to each sample 
followed by ethanol precipitation. 100% ethanol was added and samples stored at -
80°C for 30 minutes followed by -20°C for 30 minutes. Following precipitation 
samples were centrifuged at 13500rpm for 20 minutes at 4°C (Beckman-Coulter 
Microfuge 22R), supernatant was removed and the DNA pellet washed with 500 µl of 
cold 75% ethanol and centrifuged again at 13500rpm for 10 minutes at 4°C. The 
supernatant was discarded and the DNA pellet dried for 5 minutes using the 
SpeedVac system (Thermo Savant). The DNA pellet was resuspended in 25 µl H2O 
and 15 µl of PCR mix A (see table below) was added and PCR 1 commenced (See 
PCR 1 conditions below). The PCR reaction was paused after 2 minutes and 10 µl of 
PCR mix B was added and PCR continued following the PCR 1 conditions detailed 
below. During LM-PCR the oligo102 component acts as a primer for the linker 
hybrid, which has been ligated during the previous step. This ensures that a single 
primer set can potentially amplify all the genomic fragments.  
 To ensure sufficient quantities of DNA were produced for labelling, 
amplification was conducted in 2 stages. 0.5 µl of the product from PCR 1 was taken 
and 49.5 µl of PCR 2 mix added (see table below) and a second expansion was 
performed following the PCR 2 conditions detailed below. After PCR 2 DNA samples 
were precipitated by adding 25 µl of ammonium acetate (7.5 M) and 225 µl of 100% 
ethanol and stored overnight at -20°C. Following overnight precipitation, samples 
were centrifuged at 13500rpm for 20 minutes at 4°C (Beckman-Coulter Microfuge 
22R), supernatant removed and the DNA pellet washed with 500 µl of cold 75% 
ethanol and centrifuged again at 13500rpm for 10 minutes at 4°C. The supernatant 
was discarded and the DNA pellet dried for 5 minutes using the SpeedVac system 
(Thermo Savant). DNA pellets were resuspended in 13 µl of water and DNA 
concentration was measured using the NanoDrop-1000 Spectrophotometer and 
adjusted to 150 ng/µl with water. 
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PCR 1 mix A 
5 x HF Buffer (Phusion) 8 µl 
dNTP (10 mM) 1.25 µl 
Oligo 102 (40 µM) 1.25 µl 
Water 4.5 µl 
Total 15 µl 
 
PCR 1 mix B 
5 x HF Buffer (Phusion) 2 µl 
Phusion DNA polymerase 1 µl 
Water 7 µl 
Total 10 µl 
 
 
PCR 1 conditions: 
1. 55.0°C for 4 minutes  
2. 72.0°C for 3 minutes 
3. 98.0°C for 1 minute 
4. 98.0°C for 10 seconds 
5. 55.0°C for 30 seconds 
6. 72.0°C for 1 minute 
7. Go to 4. x 14 times 
8. 72.0°C for 5 minutes 
 
PCR 2 mix 
5 x HF Buffer (Phusion) 10 µl 
dNTP (10 mM) 1.25 µl 
Oligo 102 (40 µM) 1.25 µl 
Phusion DNA polymerase 0.5 µl 
Water 36.5 µl 
Total 49.5 µl 
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PCR 2 conditions: 
1. 98.0°C for 1 minute  
2. 98.0°C for 10 seconds 
3. 55.0°C for 30 seconds 
4. 72.0°C for 1 minute 
5. Go to 2. x 24 times 
6. 72.0°C for 5 minutes 
 
 
DNA labelling 
In order to detect DNA fragments when hybridised to the DNA microarray and to 
determine the relative level of binding between IP and IN samples these were 
fluorescently labelled with different fluorophores. 10.5 µl of the IP and IN samples 
were differentially fluorescently labelled with Cy5 and Cy3 fluorophores respectively 
using the BioPrime Total Genomic Labelling Module (Invitrogen). This yielded 
sufficient quantities of labelled DNA for hybridisation to microarrays. The labelling 
reaction mix was made as outlined in the table below, mixed with pipette and 
incubated at 95°C for 5 minutes in the dark. Samples were then placed on ice for a 
further 5 minutes during which time 2 µl of Exo-Klenow fragment was added, 
followed by incubation for 2 hours at 37°C. Labelled DNA was purified using the 
Invitrogen columns provided with the BioPrime Labelling Module and labelling 
efficiency was determined using the MicroArray Measurement Module on the 
NanoDrop-1000 Spectrophotometer. 
 Following labelling, corresponding 50 µl paired IP and IN samples were 
combined, giving a total of 100 µl, to which 12 µl of NaAc (3 M) and 5 µl 
polyacrylamide (2.5 µg/ml) were added. DNA was then precipitated with 290 µl of 
absolute ethanol at -20°C overnight. After precipitation samples were centrifuged at 
13500rpm for 20 minutes at 4°C, supernatant removed and the DNA pellet washed 
with 500 µl of cold 75% ethanol and centrifuged again at 13500rpm for 10 minutes at 
4°C. The supernatant was discarded and the DNA pellet dried for 5 minutes using the 
SpeedVac system (Thermo Savant). At this stage DNA pellets were stored 
overnight at -20°C. 
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Labelling mix  
DNA sample in water (150 ng/µl) 10.5 µl 
EDTA (5 mM) 2.5 µl 
Alexa Fluor Cy3 or Cy5 reaction mix 15 µl 
Total 28 µl 
 
 
Microarray hybridisation, washing and scanning 
Pellets of labelled DNA were resuspended in 39 µl of water, and to each sample, and 
in the following order, the following hybridisation reagents were added; 5 µl of 
human Cot-1 DNA (1.0 mg/ml) (Invitrogen), 11 µl of Agilent 10x blocking agent and 
55 µl of Agilent 2 x hybridisation buffer. Human Cot-1 DNA comprises fragmented 
placental DNA 50-300bp in size, enriched for repetitive DNA sequences and is used 
to block nonspecific microarray hybridisation. The hybridisation mix was incubated at 
95°C for 3 minutes followed immediately by another incubation at 37°C for 30 
minutes. 110 µl of hybridisation DNA sample was then applied to each microarray on 
the glass slide and the slide transferred to a rotating hybridization oven at 65°C and 
incubated for 24 hours.  
 Following hybridisation, slides were washed for 5 minutes in wash buffer I 
(300 ml of 20 x SSPE, 250 µl of 20% sarcosine and 700 ml of H2O), followed by a 
second wash for a further 5 minutes in wash buffer II (3 ml of 20 x SSPE, 997 ml of 
H2O). After washing, the microarrays were scanned using an Agilent microarray 
scanner (Agilent technologies G2565BA microarray scanner). This records the 
intensity of the fluorescence for both IP and IN samples at each feature and produces 
an image of the microarray as a tagged image file format (TIFF) file. The scanned 
image is then analysed by Agilent Feature Extraction computer software, which 
converts the fluorescence intensities at each feature within the image into numerical 
values for data analysis.   
 Yeast Whole Genome ChIP-on-chip Microarrays, 4 x 44K format, were used 
(Agilent Technologies, Catalogue number G4493A). The 4 x 44K format entails 4 
microarrays on one glass slide, each microarray imprinted with approximately 44,000 
features. These microarrays actually contain 45,219 features, of which 41,775 contain 
probes corresponding to the yeast genome. The remainder include various technical 
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probes, including positive and negative controls and probes used by the Feature 
Extraction software for correct alignment of the DNA microarray. 
 
3.2.6 Data analysis of platinum-induced DNA damage DIP-chip 
datasets 
As described in section 3.1.3, the two channel microarray format records two different 
fluorescence intensity values at each microarray feature. These represent the red 
fluorescence from the IP sample and the background green fluorescence from the IN 
sample and the intensity of the fluorescence emitted for each is proportional to the 
amount of DNA hybridised at each feature. These two different fluorescence 
intensities are represented in the image produced by the microarray scanner. Feature 
Extraction software then converts each of these fluorescence intensities into 
numerical values at each microarray feature. The data from the feature extraction are 
loaded into the R statistical programming language (R version 2.15.2), and analysed 
using Sandcastle, a suite of tools written in R which allows data to be analysed using 
bioinformatic approaches developed by Dr M Bennett, PhD thesis 2012. This allows 
all of the analyses performed in this thesis to be conducted and also allows the 
compilation of each of the graphical outputs presented in this thesis. The Sandcastle 
software and full documentation are available for download from 
http://reedlab.cf.ac.uk. 
 As discussed in section 3.1.3, with the two channel microarray system the red 
IP fluorescence values are corrected by the background green IN fluorescence values 
to produce a single numerical value, the IP/IN ratio. IP/IN ratios are calculated for 
each probe on the microarray and this value represents the relative level of platinum-
induced DNA damage at the genomic location represented by that feature. Since the 
data covers a large range, following loading of the data into R the IP/IN ratios are 
converted into log2 format in order to compress the range. In each case in this thesis 
where microarray data is presented it is the log2 IP/IN value that is used. 
 
3.2.7 Microarray data normalisation for comparisons between 
platinum-induced DNA damage DIP-chip datasets  
Fundamental and different bioinformatic challenges exist to analysing the genome-
wide microarray data from DIP-chip assays presented here studying platinum-induced 
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DNA damage events compared with ChIP-chip datasets studying protein-chromatin 
interactions. Contrary to protein-chromatin interactions, these DNA damage events 
occur at reasonably uniform distributions throughout the genome, with no genomic 
regions refractory to damage, and therefore no obvious regions of ‘background’ 
undamaged DNA. This poses a different set of key bioinformatic challenges that 
require careful consideration and need to be overcome for successful application of 
DIP-chip technology in this context. 
 As discussed in section 1.8.6, chapter 1, microarray data requires robust 
normalisation to allow comparisons to be made between datasets from different 
experimental conditions and to adjust for differences in hybridisation signal intensity 
between samples. Whilst many different normalisation procedures have been applied 
depending on the nature of the microarray dataset being analysed, for example gene 
expression array data or ChIP-chip data, there is currently no standardised method of 
normalising and making comparisons between ChIP-chip datasets.  
 A novel and robust data normalisation method for ChIP-chip datasets has 
however been developed in our research group by Dr M. Bennett, PhD thesis, 2012, 
and this is applied to the epigenetic ChIP-chip datasets presented in chapter 6. This 
method relies on the principle that ChIP-chip datasets demonstrate two distinct 
subpopulations – a background data population and an enriched population. However, 
this is not the case with the DIP-chip microarray data being analysed in these studies. 
 Therefore, for a DIP-chip experiment a density plot of the distribution of the 
total log2 IP/IN values from a single microarray dataset forms a normal distribution 
whereby all the data falls into the ‘enriched’ portion. This is in contrast to a ChIP-chip 
dataset where the data consists of a significant non-enriched or background portion 
along with an enriched portion which positively skews the data resulting in a bi-modal 
distribution (see example figure 1, appendix II). This background sub-population can 
then be used to normalise the data and ‘set the baseline’ from which increases can be 
judged and comparisons can be made between datasets. 
 In our laboratory, a method for normalisation of DIP-chip datasets, which 
involves using external reference fragments of undamaged DNA or ‘spike-in’ 
standards to artificially provide the background population of undamaged DNA is 
being developed. This is an approach that has been used by other groups to normalise 
gene expression microarray data (Fardin et al., 2007, Loven et al., 2012). For this 
method an exogenous source of DNA is being used to ensure no sequence similarity 
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to the studied genome and in this case spike-in DNA from the Escherichia coli 
organism is being used. Sequences of E. coli DNA have been amplified by PCR and 
complimentary E. coli probes have been included on custom-designed yeast and 
human DNA microarrays. These spike-in standards will provide a method for data 
normalisation which will allow quantitative comparisons to be made between 
datasets, but also to evaluate several other microarray parameters such as the 
reproducibility and variability of microarray hybridisation. This element of the work 
is a collaborative piece of work by all of the members of the research group and is 
currently on-going and therefore this work will not be presented in this thesis other 
than by broadly outlining here the approach being taken. 
 For the purposes of the assay development phase of this work, presented in 
this thesis, quantile normalisation has been applied to normalise the DIP-chip datasets 
presented in chapters 3, 4 & 5. Quantile normalisation implements the methods 
described by Bolstad et al, which aims to make the distribution of microarray feature 
intensities for each microarray within a set of arrays the same (Bolstad et al., 2003). 
This has the effect of transforming all normalised datasets to follow the same 
distribution, which can be considered as the average distribution of the datasets. 
Whilst the distributions are made the same, the absolute values within the data remain 
different. This is an appropriate normalisation method to apply to analysing datasets 
from replicate samples and the quantile normalise function forms part of the 
Sandcastle bioinformatics suite (Dr M Bennett, PhD thesis 2012). This approach 
cannot be applied to DIP-chip datasets from different experimental conditions, such 
as different DNA repair times, as this would remove the actual biological differences 
between them. However, this approach does allow biological replicate samples to be 
compared for the purposes of data validation and does allow comparative studies to be 
performed. However, for the development of quantitative assays, for example for 
comparisons to be made between DNA damage in different cell lines, different DNA 
repair times or between clinical samples the more robust DNA ‘spike-in’ 
normalisation method will be required.  
 
 
 
 
Chapter 3. Development of DIP-chip in S. cerevisiae 
 
 114 
3.3 Results  
 
The data presented in each of the figures in this section are presented in Appendix II 
and the raw complete datasets are included in the electronic appendix in the 
accompanying CD. 
 
3.3.1 Immuno-slot-blot analysis of platinum-induced DNA damage in 
yeast cells treated in culture 
At the outset a single scouting experiment was performed to evaluate two preliminary 
but important questions. Firstly, being aware of the potential inhibitory effect of the 
cell wall to platinum drug accumulation in yeast, it was important to ensure that 
platinum-induced DNA damage could be induced in wild-type S. cerevisiae cells, 
following treatment in culture with both cisplatin and oxaliplatin. Secondly, since the 
CP9/19 antibody had not previously been used to detect oxaliplatin-induced damage, 
it was important to assess that, following treatment of cells in culture, damage 
induced by both cisplatin and oxaliplatin could be detected. Rather than proceed 
directly to DIP studies these questions were addressed using the more established and 
simpler immuno-slot-blot (ISB) assay.  
 Wild-type S. cerevisiae cells were treated in culture with cisplatin and 
oxaliplatin and the ISB assay was conducted as described in sections 2.2 & 2.8 of 
chapter 2. Quantification of ISB band intensities was performed using ImageQuant 
software. Following drug treatment of S. cerevisiae cells in culture both cisplatin and 
oxaliplatin-induced DNA damage were clearly detected using the CP9/19 antibody 
(figure 3.4). This experiment ensured that DNA damage induction with cisplatin and 
oxaliplatin could be achieved and detected when treating yeast cells in culture and 
that the CP9/19 antibody could recognise DNA damage induced by oxaliplatin as well 
as cisplatin. 
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Figure 3.4 - Immuno-slot-blot (ISB) analysis of platinum-induced DNA damage in S. cerevisiae 
cells. Cells were treated in culture with cisplatin or oxaliplatin and an ISB experiment was performed 
to detect global genomic DNA damage. 300 ng of DNA was used for each experiment and 1 µg of 
primary antibody and 0.5 µl (1:20,000 dilution) of secondary antibody was used. 3.4 (a) demonstrates 
the image of the ISB membrane taken by the Typhoon TRIO Imager and 3.4 (b) presents the 
quantification of these ISB bands using ImageQuant software. 
 
3.3.2 DNA immunoprecipitation and qRT-PCR of cisplatin and 
oxaliplatin-induced DNA damage at MFA2 promoter 
For each of the studies discussed in this section qRT-PCR results at the MFA2 
promoter gene locus are presented and for each qRT-PCR experiment the amount of 
DNA in the IP and IN samples were calculated relative to the standard curve (as 
described in section 3.2.4 and figure 3.3). In each case, unless otherwise stated, the 
value for the IP samples were corrected for differences in starting amount of DNA by 
dividing by the corresponding IN sample (as described in section 3.1.3). The ratio of 
IP to IN values was first calculated and the fold increase or ‘enrichment’ in IP/IN 
ratio for cisplatin and oxaliplatin treated samples relative to untreated samples was 
calculated (example presented in table 3.1). For the DIP results, treated samples were 
therefore normalised to the untreated samples in each case. 
 
 
IP IN IP/IN Enrichment 
Untreated 0.000012 0.000964 0.012448 1 
Cisplatin 0.5mM 0.000212 0.003420 0.061988 4.98 
Cisplatin 1mM 0.000095 0.000729 0.130316 10.47 
 
Table 3.1 - Example of analysis of qRT-PCR results. Results from a dose titration study of S.	  
cerevisiae	  cells treated in culture with cisplatin. The figures in the table are the relative starting amounts 
of DNA as determined by qRT-PCR. For each sample an IP and IN value is obtained and the IP/IN 
ratio is calculated. The final enrichment is calculated and presented as the fold change or increase 
relative to the untreated sample.  
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CP9/19 antibody titration studies for DIP experiments 
Studies of the antibody-DNA binding efficiency, such as antibody titration assays and 
DNA amount titration assays were performed with human DNA and these are 
presented in section 4.3.2, chapter 4. Since antibody-DNA interactions always occur 
on naked DNA the antibody characteristics are likely to be consistent between human 
and yeast DNA. Therefore to maximise antibody usage and to limit the number of 
different batches of antibody used, these studies were conducted with human DNA 
and these results extrapolated and applied to the yeast context.  
 
Capturing cisplatin and oxaliplatin-induced DNA damage using DNA 
immunoprecipitation 
Whilst the results presented in section 3.3.1 had shown that the CP9/19 antibody was 
capable of detecting genomic platinum-induced damage in the context of ISB assays, 
this antibody had yet to be used in the context of DIP studies. Therefore, to begin 
with, DIP studies were performed to assess how the CP9/19 antibody would perform 
in this assay and if it could be used to detect platinum-induced DNA damage. 
Additionally, it was important to assess the antibody and DIP assay to evaluate if 
these would be sensitive enough to detect DNA damage induced by both cisplatin and 
oxaliplatin and be able to detect different DNA damage amounts related to different 
drug doses. 
 For in vitro treated platinum dose titration studies, equal amounts of DNA 
were taken from the same starting DNA sample for 3 biological repeat experiments. 
Repeat samples were treated independently, and all DNA samples were processed 
similarly, being recovered with ethanol precipitation and resuspended to the same 
concentrations based on NanoDrop readings. 3 DIP studies were then conducted in 
parallel. For this reason, in these in vitro dose titration assays no IN samples were 
judged to be necessary and results presented in figure 3.5 (a) represent fold 
enrichment of treated IP values over untreated. These data, presented in figure 3.5 (a), 
represent the mean values for three repeat experiments. More limited dose titration 
studies were also performed studying platinum-induced DNA damage following yeast 
cell treatment in culture and the results for these are presented in figure 3.5 (b). In 
some studies in this figure if replicate samples were treated and processed for DIP in 
parallel then single input samples were used. In each case the error bars represent the 
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standard error of the mean and these demonstrate the variation between experiments 
in this assay. 
 These studies confirm that the DIP assay using the CP9/19 antibody is able to 
detect platinum-induced DNA damage for both cisplatin and oxaliplatin treated DNA 
in vitro and yeast cells treated in culture. Equally, a dose-dependent platinum-induced 
DNA damage enrichment is demonstrated for cisplatin and oxaliplatin treated DNA 
samples over untreated for both in vitro and cells in culture treatments. Oxaliplatin is 
known to form fewer adducts than cisplatin at equimolar doses (Saris et al., 1996, 
Woynarowski et al., 1998, Woynarowski et al., 2000) and this is reflected in both the 
in vitro and in culture studies presented in figure 3.5. Note is made of the marginally 
lower enrichment level seen in the 2 mM oxaliplatin-treated DNA in vitro sample 
than the 1mM samples. It is possible that for oxaliplatin-induced damage induction 
that a saturation point has been reached in this experiment under the conditions tested. 
Comparatively lower levels of DNA damage are observed in DNA extracted from 
cells treated in culture compared with DNA treated in vitro, which may reflect lower 
drug levels reaching the DNA due to differences in drug uptake or intracellular 
platinum metabolism.  
 
 
 
Figure 3.5 - DNA immunoprecipitation studies capturing cisplatin and oxaliplatin-induced DNA 
damage using CP9/19 antibody. 3.5 (a) displays the data from a dose titration DIP study of cisplatin 
and oxaliplatin treated yeast DNA in vitro and data presented are means of 3 biological repeat studies. 
3.5 (b) displays a more limited dose titration study for cisplatin and oxaliplatin treated yeast cells in 
culture and data presented are means of 2 biological replicate studies, except for the single cisplatin 0.5 
mM data point and the cisplatin treated 1mM data which represents 3 replicate samples. In each case 
the mean value of these studies is presented and the error bars represent +/- the standard error of the 
mean. 
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Removing platinum-induced adducts from DNA using sodium cyanide 
As discussed in section 3.2.3 removal of the platinum adducts from the DNA 
following DIP is necessary to ensure reproducible and efficient qRT-PCR, DNA 
labelling and microarray hybridisation. To assess the effectiveness of NaCN in 
removing platinum adducts, cisplatin and oxaliplatin treated DNA samples were 
incubated with NaCN prior to DIP. Following exposure to NaCN, platinum treated 
samples show little enrichment when compared to the same sample not treated with 
NaCN (figure 3.6). When using DNA obtained from cells treated in culture with 
cisplatin or oxaliplatin for DIP without NaCN treatment, a roughly ten-fold 
enrichment is seen. When comparing the same samples treated prior to DIP with 
NaCN no enrichment is evident. This confirms adequate removal of platinum adducts 
using this method. 
 
   
Figure 3.6 - Studies demonstrating effect of treatment of IP and IN samples with sodium cyanide 
(NaCN) on DIP enrichment. DIP studies were performed on the same genomic platinum-damaged 
DNA samples before or after incubation with NaCN. Overall enrichment levels are plotted in each case 
and samples demonstrate no enrichment between untreated and treated samples for DNA samples that 
have been incubated with NaCN pre-DIP. The same DNA samples not treated with NaCN demonstrate 
good enrichment for damage. 
 
3.3.3 DNA microarray studies 
Affinity capture, using DIP, of platinum-damaged DNA samples is discussed and 
presented in the previous section and demonstrated to be consistent and reproducible. 
These samples can now therefore be used and prepared for DNA microarray studies to 
reveal the genomic distribution of the platinum adducts. 
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Platinum-induced DNA damage sample preparation for DNA microarray 
hybridisation 
To convert the nanogram quantities of DNA contained in the DIP sample into the 
microgram quantities required for efficient DNA microarray hybridisation a PCR step 
is required. This is achieved by LM-PCR as described in section 3.2.5. Approximately 
3-5 µg of DNA is obtained following two rounds of PCR (see table 3.2) and 1.5 µg of 
DNA is used for labelling. Following labelling roughly 3-5 µg of IP and IN labelled 
DNA is then applied to microarrays (table 3.3). Samples are processed for microarray 
hybridisation with the IP and IN samples differentially labelled with cy5 and cy3 
fluorophores respectively and hybridised to Agilent 4 x 44k yeast microarrays. The 
LM-PCR followed by differential labelling protocol proved to be an efficient and 
consistent approach for achieving the amounts of labelled platinum damaged yeast 
DNA necessary for microarray hybridisation. 
 
Sample ng/µl A260 A280 260/280 260/230 
Untreated IN 389.38 7.788 4.661 1.67 2.28 
Untreated IP 423.96 8.479 5.038 1.68 2.29 
Cisplatin IN 385.28 7.706 4.591 1.68 2.32 
Cisplatin IP 357.49 7.150 4.191 1.71 2.27 
 
Table 3.2 - DNA concentration measured following LM-PCR using the NanoDrop-1000 
Spectrophotometer. DNA concentration was measured following LM-PCR for IP and IN samples for 
untreated yeast DNA and yeast DNA treated in vitro with cisplatin are presented. Samples are in 13 µl. 
A260 - absorbance at 260 nm, A280 - absorbance at 280 nm. 
 
 
Sample Dye 1 Dye 1 pmol/µl Dye 2 Dye 2 pmol/µl ng/µl 
Untreated IN Cy3 2.03 Cy5 0.00 63.09 
Untreated IP Cy3 0.31 Cy5 2.99 68.20 
Cisplatin IN Cy3 2.23 Cy5 -0.03 74.12 
Cisplatin IP Cy3 0.43 Cy5 3.13 74.46 
 
Table 3.3 - DNA labelling efficiency assessed using MicroArray Measurement Module on 
NanoDrop-1000 Spectrophotometer. The DNA samples presented in table 3.2 were differentially 
labelled with Cy3 and Cy5 fluorophores using the BioPrime Total Genomic Labelling Module 
(Invitrogen). IP samples were labelled with Cy5 fluorophore and IN with Cy3. Samples are in 50 µl. 
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Data validation of platinum-induced DNA microarray datasets 
Following scanning of the microarray, Agilent Feature Extraction software converts 
the fluorescent signal from the IP and IN channels to numerical values at each 
microarray feature. The log2 of the ratio of the values for the IP to IN channels is then 
calculated which produces single values for each microarray feature. These log2 IP/IN 
values indicate the relative level of platinum adducts detected at each region of the 
genome that the microarray feature locate. In view of the different levels of adduct 
formation seen following qRT-PCR for different doses of cisplatin and oxaliplatin, 1 
mM cisplatin samples and 2.5 mM oxaliplatin samples were used for microarray 
studies. This was done based on the qRT-PCR DIP results (such as those presented in 
figure 3.5), with the intention of trying to use samples with equivalent levels of DNA 
damage at the outset. Again, this was done with the intention of trying to standardise 
the methodology whilst developing the assay. 
 The first method used to validate the microarray data output was to plot log2 
IP/IN values for all of the microarray probe ratios for two biological repeat 
experiments on a scatter plot to assess the reproducibility of microarray datasets. A 
linear association between biological repeat samples for cisplatin and oxaliplatin 
treated DNA in vitro (Pearson's product moment correlation coefficient 0.72 and 0.58 
respectively) and cisplatin and oxaliplatin treated yeast cells in culture (Pearson's 
correlation 0.57 and 0.57 respectively) was demonstrated, confirming reproducibility 
(figure 3.7). The reproducibility of the pattern of platinum adduct formation appeared 
closer for in vitro treated samples compared with samples treated in culture, and in the 
case of the in vitro studies the correlation was higher between cisplatin repeats than 
oxaliplatin repeats. The higher correlation seen for the in vitro situation may represent 
structural differences between adduct formation in DNA taken from cells treated in 
culture, where DNA exists as chromatin, compared with in vitro treatments where 
DNA exists in the naked form. This is considered in more detail in the discussion.  
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Figure 3.7 - Scatter plots displaying the association between biological repeat microarray 
datasets for platinum treated yeast cells and DNA. Log2 values of the IP/IN ratios at each 
microarray feature for two biological repeat microarray datasets are plotted against each other and 
these plots are presented as ‘heat plots’ whereby the darker blue regions represent the greater density of 
data. In each case the Pearson's product moment correlation coefficient is displayed on the scatter plot. 
In 3.7 (a) and (b) two repeat microarray datasets for cisplatin and oxaliplatin treated yeast DNA in vitro 
are presented demonstrating Pearson’s correlation coefficients of 0.72 and 0.58 respectively. 3.7 (c) 
and (d) show two repeat datasets for cisplatin and oxaliplatin treated yeast cells in culture 
demonstrating Pearson’s correlation coefficients of 0.57 and 0.57 respectively. r - Pearson's product 
moment correlation coefficient. In each plot the line of x = y is shown.	  
 
Distribution of platinum adducts throughout the yeast genome  
To demonstrate the genomic pattern and distribution of platinum-induced DNA 
adduct induction a snapshot of chromosome 4 for each treatment profile is presented, 
which is representative of the total genomic DNA damage profile. Microarray 
genome profiles are presented demonstrating the platinum adduct distribution in a 
section of chromosome 4 for cisplatin and oxaliplatin treated naked DNA in vitro and 
cisplatin and oxaliplatin treated cellular DNA in culture (figure 3.8). Log2 IP/IN 
values are presented and the peaks represent regions of high platinum levels and 
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troughs represent regions of low platinum levels. In the case of cisplatin treated DNA 
in vitro the data presented are the mean of three biological repeat experiments, in each 
other case the data represent the mean of two biological repeats. The black profile 
represents the experimental platinum-induced DNA damage data whereas the red 
profile represents the predicted or theoretical distribution of platinum-induced 1,2-
d(GpG) adduct formation based on a mathematical algorithm (discussed in detail in 
next section). It is evident from these profiles that, in each case, cisplatin and 
oxaliplatin-induced DNA damage across the genome is distributed heterogeneously. 
In figure 3.9 the profiles for cisplatin and oxaliplatin treated yeast DNA in vitro are 
presented again, this time including error bars on the platinum treated profiles 
representing the standard error of the mean. This again indicates the reproducibility of 
the assay, and demonstrates smaller error bars for the cisplatin dataset, which includes 
the mean of three biological repeat samples compared with the two biological repeat 
experiments included for the oxaliplatin treated samples. The smaller error bars for 
the cisplatin treated samples therefore partly reflects the greater numbers of samples 
averaged in this case. 
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Figure 3.8 - Genome plot of distribution of platinum-induced DNA damage in a section of 
chromosome 4. In each of these figures the log2 IP/IN ratio values for each microarray feature are 
plotted as a genome plot displaying the distribution of platinum-induced DNA damage (black profile) 
and the predicted distribution of platinum-induced 1,2-d(GpG) adduct formation (red profile) in a 
section of chromosome 4. 3.8 (a) shows the mean of 3 repeat experiments for cisplatin-treated yeast 
DNA in vitro, two of which were presented in figure 3.7 (a) (Pearson's product moment correlation 
coefficient with the predicted profile is 0.71 for the probes presented, 0.59 for the whole genome) and 
3.8 (b) shows the mean of 2 repeat experiments for oxaliplatin-treated DNA in vitro presented in figure 
3.7 (b) (Pearson’s correlation with the predicted profile is 0.65 for probes presented and 0.52 for the 
whole genome). 3.8 (c) shows the mean of the 2 repeat experiments for cisplatin-treated yeast cells in 
culture presented in figure 3.7 (c) (Pearson’s correlation with the predicted profile is 0.71 for the 
probes presented and 0.57 for the whole genome) and 3.8 (d) shows the mean of the 2 repeat 
experiments presented in figure 3.7 (d) for oxaliplatin-treated yeast cells (Pearson’s correlation with the 
predicted profile is 0.70 for the probes presented and 0.55 for the whole genome). Snapshots of a 
section of chromosome 4 are presented with the genome coordinates given as figures above each 
profile and the yellow boxes show ORF positions and the grey dots show microarray feature positions. 
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Figure 3.9 - Genome plot of cisplatin and oxaliplatin treated yeast DNA in vitro with error bars 
representing +/- standard error of the mean. The log2 IP/IN ratio values for each microarray feature 
are plotted as a genome plot displaying the distribution of platinum-induced DNA damage (black 
profile) and the predicted distribution of platinum damage (red profile). The black profile is the mean 
of three biological repeat datasets of cisplatin treated yeast DNA in vitro in 3.9 (a) and for two 
biological repeats of oxaliplatin treated yeast DNA in vitro in 3.9 (b). The red profile represents the 
predicted profile of platinum damage. The error bars on the black profiles represent +/- the standard 
error of the mean of each log2 IP/IN value at each microarray feature for the biological repeat 
experiments. Snapshots of a section of chromosome 4 are presented with the genome coordinates given 
as figures above each profile and the yellow boxes show ORF positions and the grey dots show 
microarray feature positions. 
 
 
 
Correlation between experimental platinum-induced DNA damage profiles and 
predicted distributions of platinum-induced DNA damage throughout the yeast 
genome 
The platinum analogues react with nucleophilic purine bases on DNA to form 
adducts, as described in section 1.6.4, chapter 1. Studies performed in vitro examining 
cisplatin treated naked DNA have demonstrated that cisplatin forms approximately 
65% 1,2-d(GpG), 25% 1,2-d(ApG) and 5-10% 1,3-d(Gp-NpG) intrastrand crosslinks, 
and a small percentage of interstrand crosslinks and monofunctional adducts 
(Kartalou and Essigmann, 2001b). Similar adduct profiles are also seen for oxaliplatin 
and for both drugs when cells are treated in culture (Fichtinger-Schepman et al., 1987, 
Woynarowski et al., 1998). 
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 Based on this knowledge a mathematical algorithm has been applied to 
generate a theoretical or predicted microarray profile for sequence specific DNA 
damage events. This algorithm has been developed in our laboratory (PredictProfile 
function within Sandcastle suite, Dr M Bennett, PhD Thesis 2012) and has previously 
been applied to measure UV irradiation-induced CPD formation, which occur at 
defined dipyrimidine sequences (Teng et al., 2011). In this thesis the algorithm has 
been used as a model of initial DNA damage induction patterns for each platinum 
adduct across the yeast genome. Comparing the experimental microarray data with 
the predicted data based on this mathematical model offers an important measure for 
quality control, confirms that the assays are performing as expected and serves as the 
second way the microarray data output is validated.  
 For each treatment scenario the closest correlation between the experimental 
platinum-induced DNA damage profile and the predicted profile is demonstrated with 
the predicted profile for the most abundant platinum adduct product, namely the 1,2-
d(GpG) bifunctional intrastrand adduct (table 3.4). Additionally, when using the 
mathematical model to generate predicted profiles for the 1,2-d(GpG) adduct plus one 
of the other adduct products, and correlating the experimental profile with this 
combined profile, the correlation value never exceeds the correlation demonstrated 
with the 1,2-d(GpG) adduct alone. Additionally, no correlation is demonstrated 
between untreated experimental samples and predicted profiles for any adduct 
product. This validates the assay and confirms the application of the predicted model 
for DNA damage in this way to validate the microarray data. This also confirms that 
the CP9/19 antibody used is primarily recognising the 1,2-d(GpG) adduct. If the 
antibody was recognising one of the other adducts in addition to the 1,2-d(GpG) 
adduct then a higher correlation between the experimental and predicted profile for 
that individual adduct would be expected and also the correlation between the 
combined prediction and the experimental profile would expect to be higher than for 
that of the 1,2-d(GpG) alone. Neither of these situations are observed (table 3.4).  
 For each of the examples presented in figure 3.8 we present the experimental 
data and the predicted data for the induction of the 1,2-d(GpG) adduct and present 
Pearson correlation coefficient values to describe the association between these two 
datasets. For example, for the section of chromosome 4 presented in figure 3.8(a), for 
cisplatin treated DNA in vitro, the Pearson correlation co-efficient is 0.71 for the 
probes presented in the figure and 0.59 for the whole microarray dataset. The 
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correlation values for each of the other figures presented are similar and can be seen 
in the figure legend. 
 
Adduct            
cisplatin 
treated 
DNA in 
vitro 
cisplatin 
treated 
cells in 
culture 
oxaliplatin 
treated 
DNA in 
vitro 
oxaliplatin 
treated 
cells in 
culture 
untreated 
DNA in 
vitro 
untreated 
cells in 
culture 
GG 0.592 0.568 0.521 0.554 0.219 -0.022 
AG 0.029 0.120 0.013 0.122 0.066 0.000 
GNG 0.320 0.398 0.247 0.395 0.219 -0.012 
G 0.390 0.435 0.322 0.462 0.233 -0.028 
GC (ICL) 0.040 0.095 0.033 0.094 0.045 0.009 
GG + AG 0.554 0.559 0.485 0.547 0.259 -0.025 
GG + GNG 0.580 0.565 0.506 0.551 0.263 -0.022 
GG + G 0.590 0.568 0.519 0.554 0.261 -0.022 
 
Table 3.4 - Correlation values between experimental profiles and predicted profiles for platinum 
adduct formation. Pearson's product moment correlation coefficient values are presented in this table 
for the correlations between each platinum adduct, for each of the different experimental scenarios, and 
the predicted profile of platinum damage based on the mathematical model. In each case the highest 
correlation value is generated for the 1,2-d(GpG) adduct. These correlations were produced using the 
whole microarray dataset in each case. G - guanine, A - adenine, C - cytosine, ICL - Interstrand 
crosslink. 
 
 
3.4 Discussion 
 
In this chapter the development and validation of the DIP-chip assay to measure 
cisplatin and oxaliplatin-induced DNA damage genome wide in the S. cerevisiae 
organism is described and in chapter 5 these data generated using this assay in yeast 
are used for further comparative analysis. Developing the DIP-chip assay required 
method development in four key areas: induction of cisplatin and oxaliplatin-DNA 
damage in yeast cells, detection of damage induced by both drugs using the CP9/19 
antibody, the development of the DIP assay to detect this damage and the 
establishment and validation of successful microarray hybridisation. Data from the 
ISB assay, presented in figure 3.4, provided important confirmation of the first two 
key areas. It confirmed that DNA adducts could be successfully induced by both 
cisplatin and oxaliplatin following treatment of S. cerevisiae cells in culture, 
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confirming satisfactory drug uptake in yeast cells despite the presence of the cell wall. 
It also demonstrated that the CP9/19 antibody, which was raised against cisplatin-
modified DNA and previously used to detect cisplatin and carboplatin-induced DNA 
damage, could be used to detect DNA damage caused by both cisplatin and 
oxaliplatin.  
 The next important question concerned the sensitivity of the CP9/19 antibody 
for use in DIP studies. Detection of cisplatin and oxaliplatin-induced DNA damage, 
following both treatment of DNA and cells in culture, using DIP was demonstrated in 
figure 3.5. These studies demonstrated dose-dependent increases in cisplatin-induced 
DNA damage induction and the enrichment shown by qRT-PCR reflected the known 
characteristic that oxaliplatin forms fewer adducts than cisplatin at equimolar doses in 
both cellular and free DNA (Saris et al., 1996, Woynarowski et al., 1998, 
Woynarowski et al., 2000). Enrichment was comparatively lower in DNA samples 
extracted from cells treated in culture than in DNA treated in vitro which may reflect 
comparatively lower drug levels reaching the DNA when treating cells. This may be 
due to the effect of cell uptake or intracellular metabolism of the drug, or it may 
indicate lower induction of DNA damage in the context of chromatin compared with 
naked DNA. These studies confirmed that using the CP9/19 antibody and the DIP 
assay is a valid method for detecting cisplatin and oxaliplatin-induced DNA damage 
fragments in naked DNA treated in vitro and in genomic DNA extracted from cells 
treated in culture, and that DIP generates consistent and reproducible qRT-PCR data. 
 The presence of platinum adducts inhibits and blocks the function of DNA 
polymerases (Comess et al., 1992, Suo et al., 1999) and will also interfere with 
downstream microarray applications including DNA labelling, amplification and 
microarray hybridisation. Therefore, to ensure reproducible and consistent qRT-PCR 
results as well as effective sample preparation for microarray hybridisation, removal 
of the platinum-DNA adducts was important. Following platinum-DNA damage 
induction and DIP, adduct removal was achieved using the established method of 
incubating the DNA sample with 0.2 M sodium cyanide (NaCN) for 2 hours at 65°C 
(Blommaert and Saris, 1995, Welters et al., 1997). Efficient removal of adducts using 
NaCN was demonstrated in figure 3.6 where platinum-damaged DNA samples were 
treated with NaCN prior to DIP. This demonstrated a fall in enrichment level from 
roughly 10-fold to an undetectable level when the same platinum damaged DNA 
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samples were treated with NaCN prior to DIP confirming the effective removal of 
platinum adducts. 
This work established the validity of the DIP assay as an effective and valid 
method of detecting platinum damaged DNA fragments for use in downstream 
applications such as qRT-PCR and DNA microarray hybridisation. For the microarray 
preparation stage the procedure outlined in the Agilent Technologies ChIP on chip 
protocol for yeast was followed. This involved blunting of the ends of the DNA 
fragments, ligation of a common linker sequence of DNA to the ends of the 
fragments, LM-PCR followed by labelling and microarray hybridisation. 
 The LM-PCR method for amplifying DIP samples was demonstrated to be an 
effective method for providing sufficient DNA for microarray hybridisation (table 
3.2). The quality and effectiveness of microarray hybridisation, and also of the assay 
as a whole, was validated in two ways. Firstly, demonstrating a linear relationship and 
correlation between the individual microarray probe values between biological repeat 
experiments confirmed reproducibility of the assay (figure 3.7). Secondly, correlation 
between experimental microarray DNA damage profiles and predicted profiles based 
on the mathematical model of platinum-induced DNA damage confirmed the validity 
of the assay.  
 Scatter plots of the individual microarray probe values of two biological repeat 
experiments plotted against one another demonstrated a clear linear relationship, and 
in each case the Pearson product-moment correlation coefficient was used as a 
measure of the strength of this linear association between the two datasets. Since total 
log2 IP/IN values from single DIP-chip microarray datasets have been demonstrated 
to form a normal distribution (Appendix II, figure 1), and that a linear association 
between repeat DIP-chip datasets has been demonstrated in each case, then Pearson’s 
correlation was an appropriate test to apply to measure the strength of the association 
between these variables. In the context of these DIP-chip studies, where many 
potential sources exist for variation between replicate experiments from drug 
treatment through the different laboratory preparation stages, the correlation values 
obtained for these experiments are striking. Despite this, it is possible that a degree of 
inherent technical variation exists within the experimental protocol, and that even 
higher concordance might be achieved between repeat samples by further 
optimisation of the DIP-chip protocol. Conversely, it might also be possible that 
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genuine biological differences exist between repeat samples that may prevent higher 
concordance, such as the effect of chromatin on platinum-DNA adduct formation. 
 When comparing experimental platinum-damaged DNA profiles with 
predicted profiles the correlation was greatest with the predicted profile for the 1,2-
d(GpG) adduct in each case. Additionally, no improvement in correlation was 
observed when comparing with the predicted profiles for a combination of the 1,2-
d(GpG) adduct and any other adduct. Furthermore, no correlation was evident 
between untreated profiles and predicted profiles (table 3.4). This added further 
confirmatory evidence that the antibody was specific for the 1,2-d(GpG) intrastrand 
adduct specifically and was not significantly detecting the 1,2-d(ApG) adduct. The 
correlation observed between treated samples and the predicted profile for 1,2-
d(GpG) adduct distribution along with the lack of correlation between untreated 
samples and predicted profiles confirmed the validity of the experimental DIP-chip 
technique. Given the lack of correlation seen with untreated samples it also confirmed 
the antibody was recognising the platinum adduct itself and not simply the GG 
dinucleotide sequence or another, artefactual, conformational change in the DNA. 
 It is evident that the predicted model for platinum adduct formation is capable 
of generating accurate representations of global genome platinum adduct induction. 
Once again, the Pearson correlation values measuring the strength of association 
between experimental and predicted profiles are high but there are possible reasons 
for why these correlation values may not be higher. Firstly, there may be genuine 
biological reasons for why differences exist between experimental and predicted 
profiles, and this will be explored in more detail in chapter 5. For example, it is quite 
possible that regions of the genome exist where biological factors other than the DNA 
sequence are important determinants of platinum-DNA damage induction and have 
important biological implications. Such variations in adduct induction may occur due 
to structural reasons such as the presence of chromatin or due to differences in cell 
cycle states. Secondly, there may be an element of inherent variation in microarray 
experiments such that even if the predicted profile exactly reflected the biological 
picture this may not be represented by the microarray output. This is partly reflected 
in the microarray datasets presented in this chapter where averaged datasets show 
improved correlation with the predicted profile compared with single datasets, as 
averaging datasets has the effect of removing some of this variation between them. It 
is evident in figure 3.9 that the variation in the error bars for each data point on the 
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genome plots for the cisplatin treated DNA in vitro (fig. 3.9a) are smaller than those 
for oxaliplatin treated DNA (figure 3.9b). This is partly due to how the standard error 
is calculated but also reflects a reduction in some of the variation from averaging 
three datasets compared with two. As stated previously, some of these technical 
variations or shortcomings within the assay protocol may by optimised. Finally, it is 
also possible that there are factors that reduce the accuracy of the predicted profile. It 
is apparent from visual observations that the predicted profile has limitations in 
certain regions of the genome where repeat genomic sequences are prevalent, for 
example at telomeres and chromosome ends. This is supported by the fact that when 
analysing only short sections of the genome such as those presented in figure 3.8 the 
correlation value between predicted and experimental profiles increases, in each case, 
to a consistent value of around 0.71. Equally, the predicted profile is based partly on 
the known quantitative ratios of platinum adduct induction findings from independent 
experimental protocols. Studies that established and characterised platinum adduct 
formation were often performed on short oligonucleotide sequences treated in vitro, 
and did not use global genome tools such as the assay developed here. The predicted 
model is therefore based on extrapolating these findings across the genome as a 
whole.  
 The DIP-chip assay protocol could be further optimised. For instance, steps 
could be taken to improve DIP enrichment levels for what are, in this chapter, quite 
large treatment doses, which may then allow lower more clinically relevant treatment 
doses to be used. Further evaluation of the effectiveness of NaCN in repairing 
platinum adducts could be performed to ensure optimal amplification of samples 
during preparation of microarray hybridisation. Furthermore, it may also be possible 
to improve DNA amplification efficiency in the microarray preparation step. Such 
steps could improve DNA damage enrichment levels and may improve 
reproducibility between repeat samples, and may also improve correlation between 
experimental and predicted data. Each of these elements will now be explored and 
developed in chapter 4. 
 The achievement of the work presented in this chapter is the development and 
validation of the DIP-chip assay to measure cisplatin and oxaliplatin induced DNA 
damage in S. cerevisiae. This is a novel method for measuring these DNA damage 
lesions, and the assay is demonstrated to be reproducible and is validated by 
comparing against mathematical models of platinum-induced DNA damage. This 
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proves the principle that DNA damage by the platinum analogues can be successfully 
induced, detected and analysed genome-wide using this DIP-chip assay. This assay 
has a number of potential applications in the fields of basic and clinical research 
which will be discussed later in the thesis. This assay will now be developed in 
human cells and this development work will be presented in the next chapter. 
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Chapter 4 
Development of DNA immunoprecipitation-DNA 
microarray (DIP-chip) assay to measure platinum-
induced DNA damage in human fibroblast cells 
 
 
4.1 Introduction 
 
In this chapter the development of the DNA immunoprecipitation-microarray (DIP-
chip) assay to measure platinum-induced DNA damage in human cells is presented 
and described. This assay represents a major improvement and advance on other 
current techniques for measuring DNA damage since it allows the measurement of 
platinum-induced DNA damage throughout the human genome at high resolution. 
This offers far greater breadth and depth of information relating to platinum adduct 
formation in human genomes than previously possible. Measuring platinum-induced 
DNA damage profiles genome-wide offers the possibility of being able to detect 
specific signatures of DNA damage induction or its repair in clinical samples that may 
predict for response and toxicity to chemotherapy treatment. 
 Developing this assay from its application in S. cerevisiae, presented in 
chapter 3, for use in human cells presented a major challenge with a number of 
complexities to overcome. Primarily, these centred around the 300-fold increase in 
genome size encountered when moving from the yeast model organism genome to the 
human genome. When relating this to microarray hybridisation this manifests as a 
relative reduction of 300 fold in genomic copy number (i.e. fewer numbers of 
fragments representing each sequence of genomic DNA) between the yeast and 
human genomes. Such a reduction in DNA copy number results in fewer DNA 
fragments capable of binding to each microarray probe, causing reduced fluorescence 
and reduced microarray signal generated at each probe. Whilst total genomic DNA 
damage enrichment following qRT-PCR is unlikely to change between genomes of 
different size, it can be envisaged how fewer copies of each fragment within the 
enriched sample might negatively impact successful microarray hybridisation. This 
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could not be overcome simply by scaling the assay protocol up 300 fold, as this would 
be impractical. Therefore careful consideration was given at the outset to developing 
each step within the assay in order to successfully optimise and establish the DIP-chip 
assay protocol in human cells. 
 In this chapter the carefully considered and methodical stepwise approach 
undertaken that allowed these complexities to be overcome and ensured the successful 
development of the DIP-chip assay to detect platinum-induced DNA damage in 
human cells is presented. The validation of this method development is then 
demonstrated followed by an example of the applicability of the DIP-chip assay to 
measuring other DNA damage lesions of interest with the measurement of UV 
irradiation-induced CPD formation in human cells. 
 
4.1.1. Previous and current techniques for measuring platinum-
induced DNA damage in clinical samples 
Historically, many different approaches and laboratory techniques have been used to 
measure platinum-DNA adducts in digested DNA, synthetic oligonucleotides and 
cultured cells in vitro (outlined in section 3.1 of chapter 3), and adduct levels have 
been shown to correlate with cytotoxicity in vitro (Terheggen et al., 1990). Many of 
these same techniques have also been applied to clinical samples to measure adducts 
in patients and to correlate these with therapeutic response. Most measurements made 
in clinical samples, in circulating white blood cells or in cells taken from tumours, 
have been made using similar immunochemical techniques, particularly ELISA, to 
those described in sections 3.1 and 3.1.2 in chapter 3. It will now be outlined in this 
section how these techniques have long been applied to detecting platinum-DNA 
adducts at the low level seen within clinical samples. 
 The CP9/19 anti-cisplatin modified DNA monoclonal antibody, developed by 
Tilby et al, (Tilby et al., 1991) has been used in these studies and this antibody has 
been used previously to identify cisplatin and carboplatin-induced adducts in 
peripheral blood leukocytes in clinical samples (Peng et al., 1997, Ghazal-Aswad et 
al., 1999, Veal et al., 2001). In the study by Peng et al immunochemical adduct 
measurement using competitive ELISA (described in section 3.1.2) was performed to 
calculate Pt-DNA adduct levels in circulating white blood cells (WBCs) in twenty-
four children with cancer following cisplatin treatment. Plasma ultrafiltrate was also 
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analysed for unbound platinum content by atomic absorption spectrophotometry 
(AAS) to determine pharmacokinetic parameters following cisplatin and carboplatin 
therapy. This study demonstrated considerable interindividual variation in the Pt-
DNA adduct level but limited correlation was demonstrated between this level and the 
value of unbound drug present in the ultrafiltrate. Such studies were common and 
were performed primarily to assess if adducts could be detected in clinical samples 
using these techniques and to investigate the relationship between Pt-DNA adduct 
levels in cells and pharmacokinetics.  
 Platinum-DNA adduct formation in peripheral blood leucocytes has been 
shown to be predictive of tumour response to platinum-based therapy in certain 
studies. Using ELISA and the antibody developed by Poirier et al, (discussed in 
section 3.1) adducts were measured in peripheral blood leukocytes of patients with 
testicular and ovarian cancer receiving platinum-based chemotherapy treatment with 
either cisplatin or carboplatin. These studies demonstrated a positive correlation 
between the formation of DNA adducts and response to drug therapy (Reed et al., 
1986, Reed et al., 1987, Reed et al., 1988). Competitive ELISA was similarly used by 
Fichtinger-Schepman and colleagues who used separate antibodies for each of the 
individual adducts and characterised platinum adduct formation in peripheral 
leukocytes of seven cancer patients but did not relate this to therapeutic response 
(Fichtinger-Schepman et al., 1987).  
 The commonest non-immunological approach to measuring platinum adducts 
in clinical samples has been AAS. This has also been applied to human leukocyte 
DNA taken from 49 patients with a variety of different malignancies (Reed et al., 
1993), and again this study showed a significant relationship between adduct level 
and disease response. Other studies using atomic absorption spectrometry (AAS) have 
also demonstrated a clear relationship between leukocyte DNA adduct level and 
disease response in patients with a variety of solid tumours (Parker et al., 1991, 
Schellens et al., 1996).  
 Measurement of adduct levels in WBCs using an AAS technique developed by 
Ma et al (Ma et al., 1995) has been used as a means of escalating cisplatin dose in 
patients with head and neck carcinoma (Schellens et al., 2001) and non-small cell 
lung carcinoma (NSCLC) (Schellens et al., 2003). Not all studies, however, have 
confirmed a relationship between adduct levels and tumour response, with a study 
using AAS to measure platinum-DNA adducts in WBCs of patients with germ cell 
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tumours and ovarian cancer failing to demonstrate a positive correlation between 
adduct formation and clinical response (Motzer et al., 1994). It was suggested in this 
study that drug, dose and treatment schedule were important factors to consider with 
these studies. Far fewer studies have been conducted looking at oxaliplatin, and the 
generally lower level of platinum-adduct formation following oxaliplatin exposure, 
compared with cisplatin, needs to be considered. A recent study observed a positive 
correlation between oxaliplatin adducts in WBCs and clinical response using a 
technique called adsorptive stripping voltammetry (Pieck et al., 2008).  
 Measuring adducts in tumour tissue of clinical samples is more challenging 
and is limited by tumour accessibility and the amount of tissue able to be obtained by 
biopsy. For this reason surrogates such as WBCs have been more commonly used. 
Nevertheless, some studies have been published where measurements of adduct levels 
have been made in tumour tissue. ELISA assays have been performed on autopsy 
samples to measure Pt-DNA adducts in tumour tissue from patients previously treated 
with cisplatin. The first of these studies demonstrated detectable adduct levels in four 
patients for up to 22 months and that adduct levels in tumour tissue correlated with a 
response to therapy (Poirier et al., 1987). Another study demonstrated that platinum-
DNA adduct levels were similar in a variety of different tumour tissues and non-
malignant bone marrow tissues taken from the same individual and that these adducts 
persisted for up to 15 months (Poirier et al., 1992). These findings were supported by 
another study that analysed tumour tissue and normal tissue from 1 patient at autopsy 
(Reed et al., 1987). ELISA assays have also detected platinum-induced DNA adducts 
in fresh cervical tumour tissue taken 24 hours after carboplatin treatment in 3 patients 
with cervical cancer (Poirier et al., 1988).  
 An immunocytochemical method using rabbit antibodies developed by 
Terheggen et al (Terheggen et al., 1991) was applied to buccal cells taken from 
cancer patients with different tumour types following treatment with cisplatin or 
carboplatin. This study demonstrated higher immunocytochemical detection of 
carboplatin-induced adducts in responding patients compared with non-responders, 
however no such correlation was evident in the cisplatin treated group (Blommaert et 
al., 1993). The same immunocytochemical procedure was performed in a separate 
study examining cisplatin-DNA adduct levels in buccal cells of patients with NSCLC 
receiving cisplatin and demonstrated cisplatin-DNA adduct levels in these cells to be 
an independent prognostic factor (van de Vaart et al., 2000).  
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 Two studies using a 32P–postlabelling technique to quantify cisplatin 
intrastrand 1,2-d(GpG) and 1,2-d(ApG) adducts in tumour tissue have also been 
reported. Firstly, fresh tumour samples were obtained from eight testicular cancer 
patients and eight head and neck cancer patients and treated ex vivo with cisplatin, and 
higher adduct levels were demonstrated in patients exhibiting better response (Welters 
et al., 1999). A second study using this technique, took matched normal tissue (WBCs 
and buccal cells) and tumour tissue from 35 patients with head and neck cancer and 
demonstrated better disease free survival in head and neck cancer patients with higher 
adduct levels in their primary tumours (Hoebers et al., 2006). This study also 
demonstrated 4-5 fold higher adduct levels in tumours than in WBCs or buccal cells. 
In a recent paper platinum-DNA adducts were detected in circulating tumour cells 
(CTCs), collected from patients with NSCLC and treated ex vivo with cisplatin and 
the kinetics of their removal predicted for cisplatin response (Nel et al., 2013). This is 
an important concept as it raises the possibility of obtaining tumour cells by collecting 
CTCs, or also circulating tumour DNA, via a simple blood test thus removing the 
need for a potentially hazardous tumour biopsy. Whilst the study discussed here treats 
the extracted CTCs ex vivo, it may also be feasible to obtain CTCs or circulating 
tumour DNA from patients prior to and following platinum treatment to measure 
DNA adduct levels. These measurements could subsequently be related to treatment 
response to provide a strategy for predicting treatment response. 
These studies therefore demonstrate the clinical and biological relevance of 
developing an assay that can sensitively measure platinum-induced DNA damage and 
demonstrate the potential for developing such an assay as a predictive biomarker for 
therapeutic response allowing for individualisation of therapy. These studies have also 
demonstrated the feasibility of measuring cisplatin-adducts in both circulating blood 
cells and primary tumours.  
 Whilst each of the assays discussed in this section are important and relevant 
research techniques, there are certain shortcomings associated with most of the 
approaches outlined here prohibiting their widespread clinical application. For 
example, they mostly require large amounts of DNA and are therefore not appropriate 
for use in clinical samples where DNA yield is often limited. Equally, most of these 
technologies represent low resolution approaches and detect total levels of platinum-
induced damage within genomes and are therefore often trying to detect subtle 
differences between whole genome damage levels. Accurately detecting and 
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measuring these adducts in clinical samples therefore remains a clinically relevant 
area of research and the development of novel approaches and techniques for 
measuring DNA damage lesions and platinum adducts in vivo are desirable. 
 
4.1.2 Biological relevance of the 1,2-d(GpG) intrastrand crosslink 
For the DIP-chip development work presented in this chapter the CP9/19 antibody 
was employed, as for the work presented in chapter 3. Previous studies have 
demonstrated that this antibody is specific for the 1,2-d(GpG) intrastrand crosslink 
(discussed in section 3.1.2, chapter 3), and the work presented in chapter 3 of this 
thesis also supports this. Whilst the studies using AAS detect elemental platinum and 
therefore total platinum content, many of the aforementioned studies in section 4.1 
use immunochemical methods using antibodies to detect the 1,2-d(GpG), the most 
frequently occurring platinum-DNA adduct. Whilst interstrand crosslinks (ICLs) are 
known to be highly toxic, cell killing lesions, they form in very small numbers 
compared with the predominant intrastrand crosslinks and these intrastrand crosslinks 
are increasingly also being recognised as important killing lesions. 
 One fundamental observation recognising the importance of the 1,2-d(GpG) 
adduct was made when cisplatin was compared with the biologically inactive trans 
isomer of cisplatin, trans-diamine-dichloroplatinum(II) (trans-DDP). Transplatin is 
not cytotoxic and its inactivity is thought to be due to two reasons. Firstly, the trans-
chloro isomer is considered more reactive and therefore is less stable and is more 
readily deactivated (Coluccia and Natile, 2007). Secondly, and more importantly for 
this discussion, DNA adduct formation is more selective: it has been observed that 
due to steric restriction trans-DDP is unable to crosslink neighbouring bases in DNA 
and form 1,2-intrastrand crosslinks, but is able to form 1,3-intra- and interstrand 
crosslinks (Eastman and Barry, 1987, Eastman et al., 1988). Whilst these lesions are 
also toxic they form in far fewer numbers compared with the predominant 1,2-d(GpG) 
lesion. The inactivity of this agent and its inability to form the 1,2-d(GpG) intrastrand 
crosslink therefore suggests an important cytotoxic role for this crosslink. 
 Following this, a number of other observations have been made which point to 
the importance of the 1,2-d(GpG) intrastrand crosslink. Firstly, oxaliplatin is known 
to form fewer ICLs than cisplatin at equimolar doses but is known to be more toxic. 
This may point to other important properties of oxaliplatin-induced DNA adducts 
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causing greater cytotoxicity or it could point to the importance of another lesion such 
as the 1,2-d(GpG) intrastrand crosslink (Woynarowski et al., 1998, Woynarowski et 
al., 2000). Secondly, NER is known to repair 1,3-d(GNG) intrastrand adducts more 
efficiently than 1,2-d(GpG) adducts, potentially making the 1,2-d(GpG) adducts more 
biologically relevant to cytotoxicity. This differential DNA repair is due to the greater 
helical bending induced by 1,3-d(GNG) adducts enhancing binding of DNA damage 
recognition proteins. Thirdly, many of the studies discussed in section 4.1 have used 
experimental approaches to measure the 1,2-d(GpG) adduct and correlated this with 
cytotoxicity or clinical outcome, highlighting the clinical importance of this lesion. 
One such immunochemical study measuring the levels of the 1,2-d(GpG) intrastrand 
platinum adduct using the CP9/19 antibody, has demonstrated a correlation between 
response or toxicity and adduct formation in WBCs of patients treated with cisplatin 
(Veal et al., 2001). A different antibody, developed by Poirier et al and shown to 
recognise the two major intrastrand crosslinks 1,2-d(GpG) and 1,2-d(ApG) and not 
the ICLs (Poirier et al., 1982, Reed et al., 1990) has also been used extensively to 
demonstrate correlation between adduct levels in leukocytes and positive tumour 
responses in patients (Reed et al., 1987, Reed et al., 1988, Reed et al., 1986). Finally, 
studies have measured intrastrand platinum-DNA adducts using the 32P-postlabelling 
technique which have demonstrated correlation between higher intrastrand 1,2-
d(GpG) adduct levels in primary tumours following cisplatin treatment and improved 
disease free survival (Welters et al., 1999, Hoebers et al., 2006).  
 Taken together, these observations and studies point to the importance and 
relevance of the 1,2-d(GpG) intrastrand adduct to the biological activity and 
anticancer efficacy of the platinum analogues. 
 
4.1.3 Development of the DIP-chip assay in human dermal fibroblasts 
Studies in this chapter were conducted using human normal dermal fibroblast cells. 
For assay development it was considered important to use a genetically stable cell line 
with as few known genetic defects as possible. During the development phase of this 
work experimental DNA damage microarray profiles would be compared with 
predicted models of DNA damage based on the sequence of the human genome. 
Therefore a cell line containing many genetic mutations, such as a cancer cell line 
could be a potential confounding factor when trying to validate experimental profiles 
Chapter 4. Development of DIP-chip in human cells 
 
 139 
against predicted profiles for DNA damage. Alterations in the genetic sequence could 
also influence and bias microarray hybridisation. For these reasons it was decided not 
to use a cancer cell line for the assay development phase however, clearly, once the 
assay is established and there are fewer technical uncertainties the technique can be 
applied to studying cancer cells at that stage.  
 Dermal fibroblasts have been widely used by the scientific research 
community and these adherent cells grow readily in culture as monolayers. Platinum 
adduct formation has been studied in these cells using chromatography coupled with 
techniques such as ELISA and this has shown that the same platinum-DNA adduct 
products are formed in these cells and in the same ratio as previously described in 
section 1.6.4, chapter 1 (Dijt et al., 1988). These cells have also been shown to be 
sensitive to the platinum analogues with regard to cell killing (Poll et al., 1984, Dijt et 
al., 1988). For these reasons these cells were considered representative of a normal 
human cell population and appropriate for use in these assay development studies. 
 
 
4.2 Methods 
 
4.2.1 Experimental overview of DIP-chip assay 
AG16409 human dermal fibroblast cells were obtained from the Coriell Cell 
Repository (Camden, NJ, USA) and cisplatin, oxaliplatin and UV treated DNA 
samples were prepared as presented in sections 2.3 of chapter 2. An example of 
readings obtained using the Nanodrop-1000 spectrophotometer demonstrating the 
purity of extracted DNA is presented in table 4.1. Care was taken at the outset to 
ensure DNA samples were free from RNA, and if assessment of DNA purity 
suggested RNA contamination then a second incubation with RNase was performed 
(section 2.4, chapter 2 & Appendix III, figure 1). DNA was sonicated as described in 
section 2.6, chapter 2, and DNA immunoprecipitation (DIP) was conducted as 
described for yeast samples (section 3.2.2, chapter 3). Following IP, DNA samples 
were retrieved and purified using the PureLinkTM Quick PCR Purification Kit 
(Invitrogen) and eluted with 50 µl of elution buffer and then IP and IN samples were 
processed for damage removal using NaCN as described for yeast samples (section 
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3.2.3, chapter 3). DNA samples were then processed for immuno-slot-blots (ISBs) or 
for qRT-PCR and microarray preparation.  
 In the initial phase of developing this assay in human samples, paired IP and 
IN samples were prepared for microarray hybridisation in the same way as described 
for the yeast samples (section 3.2.5, chapter 3). This involved LM-PCR, DNA 
labelling, microarray hybridisation, washing and scanning. As described in section 
3.1.3, chapter 3, for the yeast microarray work, the Agilent Technologies’ two 
channel DNA microarray system was used and the Agilent Mammalian ChIP-on-chip 
protocol (Agilent Technologies Mammalian ChIP-on-chip Protocol, version 10.2), 
was followed. DNA microarrays were scanned recording the fluorescence intensities 
of both IP and IN samples at each microarray feature and Agilent Feature Extraction 
software converted these signals into numerical values. These values were then 
loaded into the R statistical programming language (R version 2.15.2) and data 
analysis conducted as described in section 3.2.6, chapter 3 and samples were 
normalised by applying the quantile normalise function as described in section 3.2.7. 
 
4.2.2 Quantitative real-time PCR (qRT-PCR) 
Following DIP, DNA samples underwent qRT-PCR, conducted as described in 
section 2.7, chapter 2. This allowed quantification of the amount of DNA in the 
platinum-treated and untreated IP and IN samples. These values represent relative 
amounts of DNA determined by the use of a standard curve (Appendix III, figure 2). 
qRT-PCR was an important quality control checkpoint, as it provided further 
assessment of the quality of the starting DNA, validated the success of the IP step and 
confirmed that DNA samples were of sufficient quality to proceed with DNA 
microarray hybridisation. qRT-PCR was also used to determine the relative amounts 
of IP DNA between untreated and platinum or UV treated samples and was conducted 
as described in section 2.7, chapter 2. Since platinum-induced DNA damage was 
likely to occur uniformly throughout the human genome the exact locus used to 
examine this damage during qRT-PCR could be chosen arbitrarily. During qRT-PCR 
damage was examined at the 28s ribosomal RNA gene, an area of repeat DNA present 
in 5 different regions, on chromosomes 13, 14, 15, 21 and 22, and therefore 
considered to be more reflective of damage across the genome as a whole than if a 
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primer for a single locus was used. An example of a typical melt curve and standard 
curve using these primers is demonstrated in Appendix III, figure 2. 
 
The 28s primer sequence:- 
Primer 
28s: 
Forward: 5ʹ′ - CGCAATACGAATGCCCCCG - 3ʹ′        
Reverse: 5ʹ′ - AGCCGCCTGGATACCGC - 3ʹ′             
 
Sample ng/ul A260 A280 260/280 260/230 
Cisplatin 0.05mM 99.67 1.993 1.090 1.83 2.00 
Cisplatin 0.1mM 91.92 1.838 0.997 1.84 2.01 
Oxaliplatin 0.5mM 112.76 2.255 1.221 1.85 2.06 
Cisplatin 1mM 104.07 2.081 1.129 1.84 2.03 
Cisplatin 1mM 98.40 1.968 1.075 1.83 2.03 
 
Table 4.1 - Concentration and purity of genomic DNA extracted from human dermal fibroblast 
cells. Example of readings using the NanoDrop-1000 spectrophotometer for genomic DNA extracted 
from human dermal fibroblast cells using the QIAGEN DNeasy blood and tissue extraction kit. mM - 
millimolar, ng/ul - nanograms per microlitre, A260 - absorbance at 260nm, A280 - absorbance at 
280nm. 
 
4.2.3 Development of custom-designed human DNA microarrays 
Platinum-induced DNA damage lesions are distributed in a sequence specific fashion, 
yet uniformly and at high frequency throughout the genome, with no known areas 
refractory to damage. When treating cells, oxaliplatin and cisplatin form ~ 0.86 and 
1.36 adducts/106 base pairs/10 µM drug/1 hour of incubation respectively 
(Woynarowski et al., 2000). This equates approximately to 1 adduct forming per 103 
base pairs for the cellular treatment conditions used in these studies. In view of these 
factors and to optimise the precision of the DNA microarray data output a high 
resolution microarray approach was considered necessary. 
 Two factors govern the resolution of DNA microarray analysis - the spatial 
distribution of the microarray features along the genome and the average length of the 
DNA fragments being applied to the microarray. Each microarray feature contains 
many identical probes capable of hybridising to DNA fragments and figure 4.1 
demonstrates the genomic region potentially measurable by a single microarray probe.  
If each microarray feature representing these genomic regions is positioned far apart 
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along the genome then regions will exist between them where gaps in the microarray 
coverage will occur. Equally, if features are placed closely together but the lengths of 
the DNA fragments being applied to the microarray are significantly longer than the 
distance between the microarray features then fragments will be able to bind many 
features positioned in a particular genomic region. Each of these situations reduce the 
microarray resolution and this point is demonstrated in figure 4.2. For a high 
resolution DNA microarray approach, and the one employed for the studies presented 
in this chapter, DNA microarray features are positioned closely together along the 
genome and the average fragment length closely matches the distance, in base pairs, 
between each feature. A spectrum of DNA fragment lengths is of course present 
within the hybridised DNA sample and therefore some of the longer fragments will 
also be able to hybridise to a single neighbouring feature, a beneficial effect in 
helping to improve microarray coverage. 
 For the DNA microarray studies presented in this chapter each microarray 
hybridisation sample contained differentially labelled paired IP and IN samples, as 
used and described for the yeast microarray studies presented in chapter 3. The IN 
samples provide a sensitive internal control for the DIP-chip assay and requires a two 
channel microarray system allowing separate signals to be measured from both the IP 
and IN samples (described in section 3.1.3, chapter 3). Again, as for the yeast studies, 
the well-established Agilent Technologies two channel microarray system was used. 
The standard, ‘off-the-shelf’, DNA microarray products available from Agilent, 
within their ChIP-on chip platform, include human Promoter microarrays and human 
ENCODE arrays. Both of these microarray options involve short regions of 
microarray probe coverage interspersed by long sections of the genome with no probe 
coverage. Whilst such arrays are suitable for certain experiments, such as gene 
expression analysis, they are unsuitable for measuring platinum-induced DNA 
damage in continuous stretches of the genome, required with these DIP-chip 
experiments. Human DIP-chip microarray experiments were initially attempted using 
a 1 x 244k Human Promoter Microarray (G4489A), and an example of the microarray 
output obtained from these arrays is shown in figure 4.2 (d). The long sections 
between the regions of microarray coverage meant that these ‘off the shelf’ options 
were unsuitable for the method development stage of this assay where microarray 
outputs from frequently occurring DNA damage lesions needed to be obtained and 
validated.  
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Figure 4.1 - Diagram demonstrating the genomic region measurable by a single microarray 
feature. Each microarray feature contains many probes of the same sequence capable of binding DNA 
fragments. DNA fragments are shown in blue. 
 
 In view of these factors, for the work presented in this chapter, high resolution 
custom-designed human DNA microarrays were developed. These were designed 
using Agilent Technologies’ ‘eArray’ facility, a web-based application enabling the 
creation of custom microarray designs. The optimal microarray analysis was deemed 
to be to investigate a short continuous region of the human genome at very high 
resolution, and therefore the Agilent Technologies’ 4x44k microarray format was 
chosen. This format meant that 1 DNA microarray comprised 44,000 features, and 
that 4 separate microarrays were included on a single glass slide, increasing the 
throughput of the microarray experiments. The microarray coverage comprised a 5 x 
106 base pair section of chromosome 17 between base position 10,000,000 and 
15,000,000, based on the most recent human genome build (UCSC hg19, 
http://genome.ucsc.edu). This gave a final genomic spatial resolution of around 150 
base pairs for the microarray. This region of chromosome 17 includes genes for a 
diverse series of cellular function including genes coding for myosin heavy chain 
skeletal muscle (MYH2, MYH13 etc.) and cytochrome c oxidase assembly proteins 
(COX2, COX10). As described in section 3.2.7 of chapter 3 a method for microarray 
normalisation is currently being developed within our laboratory using external 
reference fragments (‘spike-ins’) of E. Coli DNA. Therefore, of the 44,000 total 
microarray features included on the custom-designed human microarrays, 100 were 
substituted for microarray features complimentary to the E. coli spike-in DNA. 
 When designing the coverage of these microarrays it was again considered 
important, during the development phase of the assay, to avoid genomic regions 
containing genes often mutated in cancer cells. This could introduce a potential 
confounding factor that could bias microarray hybridisation if applied to studies using 
  Probe ≈ 
60mer 
Max genomic region measurable by probe 340nt 
   IP DNA fragment, average size 200bp 
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cancer cells, and could affect the validation of microarray profiles. This precaution 
was taken to aid the assay development stage and once the assay is established, with 
fewer technical uncertainties, the assay may be applied to cancer cells at that stage. In 
addition, it will also be possible to produce custom-designed microarrays for any 
section of the human genome at a range of different resolutions.  
 
 
Figure 4.2 - Illustration of effect of DNA microarray resolution and genome coverage on DNA 
damage DIP-chip microarray data output. This illustration demonstrates the effect of DNA 
microarray resolution on microarray data output specific to the DIP-chip DNA damage assay. In the 
diagrams in 4.2 (a-c) stars represent platinum-DNA adducts, blue and black horizontal lines represent 
DNA fragments and the red blocks represent microarray features. Below each diagram in (a-c) is a 
corresponding example of a genome plot from microarray data, where the red, black and green profiles 
represent platinum-induced DNA damage microarray profiles and the grey spots along the gene 
annotation data represent the genomic location of the microarray features. In (a) microarray features 
are widely spaced and some shorter fragments containing DNA damage in regions that fall between 
these features will fail to hybridise and therefore will not register signal. Equally, longer fragments are 
able to bind to many adjacent features. This results in the low resolution microarray output seen in the 
corresponding genome plot. If the microarray features are positioned at shorter intervals along the 
genome but DNA fragments remain long (b) then damage fragments are again able to hybridise to 
many neighbouring features meaning resolution is only marginally improved (the intermediate 
situation). Finally, in (c), positioning the microarray features at shorter intervals along the genome 
coupled with applying shorter DNA fragments to the microarray results in the high resolution approach 
demonstrated in the corresponding microarray output. In this high resolution approach certain longer 
fragments may be capable of binding two neighbouring features. 4.2 (d) gives an example of a 
platinum-induced DNA damage profile in chromosome 1 obtained using an Agilent human promoter 1 
x 244k microarray. In this instance microarray features are clustered in promoter regions with long 
sequences in between without microarray coverage. 
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4.2.4 Adapting length of DNA fragments for use with custom-
designed human DNA microarrays 
As well as microarray design and the genomic positioning of the DNA microarray 
features, the second important element for ensuring a high resolution microarray 
approach is achieved is ensuring the average DNA fragment length being hybridised 
to the microarray is approximately equal to the genomic spacing of the microarray 
features (figure 4.2). In these studies, as for yeast, DNA was fragmented using 
sonication. Studies were carefully conducted evaluating the sonication conditions 
which ensured an average DNA fragment length of around 200bp. DNA fragment 
length was analysed using the 2100 Bioanalyzer System (Agilent Technologies), a 
single software platform providing high quality electrophoretic analysis of the DNA 
samples and a digital output. The bioanalyzer is the industry standard for quality 
control and for sizing fragment length within DNA samples. 
 DNA samples were sonicated at a concentration of 100 ng/µl in a volume of 
200 µl and one cycle entailed sonicating for 30 seconds on and 30 seconds off using a 
BioRuptor sonicator (Diagenode) with power set at the ‘high’ position. The 
BioRuptor unit allows placement of up to 6 microcentrifuge tubes in a carousel for 
sonication at the same time. Sample volume, DNA concentration and the number of 
microcentrifuge tubes sonicated at the same time were all shown to be critically 
important determinants of final DNA fragment length. Figure 4.3 (a) demonstrates, 
using the 2100 Bioanalyzer, the marked difference in distribution of fragment length 
obtained between sonicating 6 microcentrifuge tubes at once compared with 4. 
Finally, the type of plastic the microcentrifuge tubes are made from is important when 
considering sonication efficiency and therefore care was taken not to alter 
microcentrifuge tube supply for the duration of these studies. 
 Figure 4.3 (b) demonstrates the difference in DNA fragment length 
distribution achieved by increasing the numbers of sonication cycles. 15 cycles of 
sonication results in mean fragment lengths of just over 300bp whilst 25 cycles of 
sonication yields a mean fragment length of a little over 200bp. The same fragmented 
DNA samples analysed using the bioanalyzer in figure 4.3 (b) are also analysed using 
agarose gel electrophoresis in figure 4.3 (c). Based on this work the final sonication 
conditions used for these studies were as follows:- 4 microcentrifuge tubes sonicated 
together, each containing 200 µl of DNA sample at a concentration of 100 ng/µl and 
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sonicated for 25 cycles of 30 seconds on, 30 seconds off at 4°C, using a BioRuptor 
sonicator (Diagenode) with the unit power set at the ‘high’ position. These same 
conditions were followed each time samples were sonicated and routine assessment of 
sonication was performed each time by agarose gel electrophoresis and an example of 
typical DNA sonication assessment by this method is shown in Appendix III, figure 3. 
 
 
 
Figure 4.3 - Studies demonstrating distribution of DNA fragment length following fragmentation 
using sonication. Graphs presented in (a) and (b) are generated using the 2100 Bioanalyzer (Agilent 
Technologies) and fragment length in base pairs is displayed on the x axis, with the frequency of each 
fragment given on the y axis. Sonication is performed in cycles and 1 cycle entails sonicating samples 
for 30 seconds on and 30 seconds off using a BioRuptor sonicator (Diagenode) with the power set at 
the ‘high’ position. 4.3 (a) demonstrates the different DNA fragment length obtained when sonicating 6 
microcentrifuge tubes at once compared with 4 tubes. In this instance samples were sonicated for 8 
cycles and most frequently occurring fragment length is over 700bp for 6 tubes compared with around 
500bp for 4 tubes. 4.3 (b) demonstrates the effect on fragment length of increasing sonication from 15 
to 25 cycles. Mean fragment length reduces from just over 300bp with 15 cycles to just over 200bp 
with 25 cycles and fragment length at these higher cycle numbers is also more evenly distributed. 4.3 
(c) presents agarose gel electrophoresis images demonstrating the fragment length of the different 
DNA samples presented in figure 4.3 (b). The number of cycles are given below each sample on the 
electrophoresis image and the first gel image is taken after running gel for 20 minutes and the second 
for 40 minutes at 75V. 1.2% agarose gel and 100bp DNA ladder used. 
a 
b 
15 cycles 25 cycles 
6 tubes 4 tubes 
c 
          15         20        25         20         15 
     15         20         25         20         15 1000bp 
500 
100 
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4.2.5 Polymerase Chain Reaction (PCR) for PCR amplicon-DNA 
microarray study 
PCR was performed to generate PCR amplicons for 6 regions of chromosome 17 to 
use for a PCR amplicon-DNA microarray assay. This assay was performed to assess 
DNA microarray hybridisation and is explained fully in section 4.3.4.1 of this chapter. 
Primers were designed for regions of chromosome 17, present on the custom-
designed human DNA microarray, as follows:- MYH13 open reading frame (ORF), 
MYH13 promoter, MYH8 ORF, MYH8 promoter, PIRT ORF and PIRT promoter. 
All primers were diluted to a stock concentration of 100 µM. 
 
The primer sequences:- 
 
Primer                                        Tm (°C)        Product length (bp) 
MYH13 ORF: 
Forward: 5ʹ′ - ACACAGACCCTCACCTCCAC - 3ʹ′     61.4 
Reverse: 5ʹ′ - CCACTCCTTTGTGACCCTGT - 3ʹ′       59.4                     210 
 
MYH13 promoter 
Forward: 5ʹ′ - CACACTCTGCTCCAGTTCCA - 3ʹ′      59.4 
Reverse: 5ʹ′ - ATGTAAATGCGTCGTAGCCC - 3ʹ′      57.3            168 
  
MYH8 ORF 
Forward: 5ʹ′ - TGATCTTGGCTCACTGCAAC - 3ʹ′       57.3 
Reverse: 5ʹ′ - CTTGAGGCCAGGAGTTTGAG - 3ʹ′      59.4          175 
 
MYH8 promoter 
Forward: 5ʹ′ - CCCGTGGTAGCAAATAAGGA - 3     57.3 
Reverse: 5ʹ′ - TGGCAAACTCTTTCATGCAC - 3ʹ′       55.3                   102 
 
PIRT ORF 
Forward: 5ʹ′ - ACCTTGTTCACCCTCCACTG - 3ʹ′       59.4 
Reverse: 5ʹ′ - GGTGGTGGTCCAGACAGACT - 3ʹ′      61.4          263 
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PIRT promoter 
Forward: 5ʹ′ - GGTAAGTCGTGTTGTGGGCT - 3ʹ′      59.4 
Reverse: 5ʹ′ - AGGACCTGGAGTTTCTGGGT - 3ʹ′       59.4        292 
 
PCR reactions were conducted using the GoTaq® DNA polymerase supplied in a 
proprietary formulation by Promega. PCR was performed in a total reaction volume 
of 50 µl and the following components were added to the PCR reaction mix:- 4 µl 
(400 ng) of template DNA, 10 µl of GoTaq® Reaction Buffer, 1 µl of dNTPs (10 mM 
each, Bioline), 4 µl of MgCl2 (25 mM), 0.25 µl of forward primer, 0.25 µl of reverse 
primer (final primer concentration in PCR mix of 0.5 µM), 0.25 µl of GoTaq® DNA 
polymerase and nuclease free water to 50 µl. 
 
PCR amplification was performed in a PTC-200, Peltier thermal cycler (MJ Research) 
with a heated lid, with the following thermal cycling conditions:- 
1. 95°C for 2 minutes 
2. 95°C for 30 seconds 
3. 60°C for 30 seconds 
4. 72°C for 30 seconds 
5. Go to step 2 x 29 times 
6. 72°C for 5 minutes 
 
Following PCR, the DNA products were purified using the PureLinkTM Quick PCR 
Purification Kit (Invitrogen) and eluted with 50 µl of elution buffer. The PCR 
products were separated and viewed by agarose gel electrophoresis and visualised 
with ethidium bromide as described (Appendix III, figure 4). 
 
4.2.6 Whole genome amplification method for DIP sample 
amplification prior to DNA microarray hybridisation 
Two alternative methods were employed in this chapter for amplifying DIP samples 
prior to microarray hybridisation:- LM-PCR, which was conducted as described in 
section 3.2.5, chapter 3 and, secondly, a proprietary whole genome amplification 
method using the GenomPlex® Complete Whole Genome Amplification Kit (WGA2, 
Sigma-Aldrich). The manufacturers protocol was followed, and the entire DIP sample 
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used for library preparation. 2 µl of 1 x library preparation buffer and 1 µl of library 
stabilization solution were added to the DIP sample, followed by mixing and 
incubating at 95°C for 2 minutes and immediately cooling on ice. 1 µl of library 
preparation enzyme was added to each sample, and samples incubated in a thermal 
cycler at 16°C for 20 minutes, 24°C for 20 minutes, 37°C for 20 minutes and 75°C for 
5 minutes before proceeding to PCR amplification. 7.5 µl of 10 X amplification 
master mix, 47.5 µl of nuclease-free H2O and 5 µl of WGA DNA polymerase were 
added to each sample, mixed and incubated in a thermal cycler as follows: 95°C for 3 
minutes, followed by 14-16 cycles of 94°C for 15 sec and 65°C for 5 minutes. 
Samples were purified using the PureLink PCR Purification Kit (Invitrogen), eluted in 
15 µl of water and DNA quantified using the NanoDrop ND-1000 Spectrophotometer. 
The expected yield was between 1-5 µg of genomic material, providing enough 
material for one microarray experiment, although a second round of amplification 
(using 10 – 20 ng of the first amplification sample) was performed if necessary. 
 
 
4.3 Results 
 
4.3.1 Immuno-slot-blot analysis of platinum-induced DNA damage 
As was the case with the work presented in chapter 3, at the outset of these studies in 
human cells ISB experiments were performed to ensure successful DNA damage 
induction and detection could be achieved following treatment of DNA in vitro and 
human dermal fibroblast cells in culture with cisplatin and oxaliplatin using the 
CP9/19 antibody. These studies were performed as described in sections 2.3 and 2.8 
of chapter 2 and the ISB band intensities were quantified using ImageQuant software. 
The purpose of these ISB experiments was therefore twofold: to ensure that the 
CP9/19 antibody would detect cisplatin and oxaliplatin-induced DNA damage 
following treatment of both DNA in vitro and cells in culture and to confirm that the 
antibody was sensitive enough to detect dose-dependent increases in platinum-
induced damage in human cells. To do this, single scouting dose titration experiments 
were performed measuring cisplatin and oxaliplatin-induced DNA damage following 
DNA in vitro and cellular treatments. Finally, a single ISB was performed to evaluate 
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if increasing dose of antibody would lead to greater damage detection and this 
experiment was performed using cisplatin treated DNA in vitro. The results of these 
experiments are presented in figure 4.4. 
 For each of the studies presented here 200 ng of DNA was used and for the 
DNA in vitro treatment study 2 µg of primary antibody was used and for the cellular 
treatment in culture study 1 µg of primary antibody was used. Following both 
treatments a dose-dependent increase in cisplatin and oxaliplatin-induced DNA 
damage detection is observed. For DNA in vitro treatments a dose titration was 
performed over a wide dose range (0.05 µM to 500 µM), demonstrating a dose-
dependent increase in damage detection for both cisplatin and oxaliplatin (figure 4.4 
(a)). A narrower dose range (5 µM to 500 µM) with fewer doses was used for cellular 
treatments in culture but again dose-dependent damage is demonstrated for both 
agents (figure 4.4 (b)). In the cellular treatment in culture study damage levels also 
appear to be generally lower than for the in vitro study, partly reflecting the different 
amounts of primary antibody used. In figure 4.4 (c) two different amounts of primary 
antibody were used demonstrating increased DNA damage detection for DNA in vitro 
cisplatin treated samples when increasing CP9/19 antibody from 1 µg to 2 µg.  
 Whilst only single experiments were performed for each of these studies they 
confirmed that platinum-induced DNA damage could be detected following cisplatin 
or oxaliplatin treatment using the CP9/19 antibody and that DNA damage could be 
successfully induced in human dermal fibroblast cells. The antibody would now be 
evaluated within human DIP experiments.  
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Figure 4.4 - Immuno-slot-blot (ISB) assays of platinum-induced DNA damage following DNA 
treated in vitro and cells treated in culture. For the DNA in vitro studies presented in this figure (a,c) 
DNA extracted from the human MDA-MB-231 cell line was used and for the cellular treatment studies 
(b) human dermal fibroblast cells were used. 4.4 (a) shows an ISB assay of cisplatin and oxaliplatin 
treated DNA in vitro using 200 ng of DNA and 2 µg of primary antibody and in 4.4 (b) an ISB assay of 
cisplatin and oxaliplatin treated cells in culture is shown using 200 ng of DNA and 1 µg of primary 
antibody. 4.4 (c) demonstrates an ISB of cisplatin treated DNA using 200 ng of DNA and 2 different 
primary antibody amounts of 1 µg and 2 µg. In each of these experiments 0.5 µl of secondary antibody 
was used (1:20,000). In each case scanned images of the ISB membrane taken by the Typhoon TRIO 
Imager are displayed and quantification of the ISB bands was performed using ImageQuant software 
and this quantification is presented in the bar graphs. 
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4.3.2 DNA Immunoprecipitation (DIP) and qRT-PCR of platinum-
induced DNA damage at 28s locus 
For each of the studies presented in this section, qRT-PCR results are presented at the 
28s gene locus and for each qRT-PCR experiment the amount of DNA in the IP and 
IN samples were calculated relative to the standard curve. As described in section 
3.3.2, chapter 3, in each case IP samples were corrected for starting amount of DNA 
by dividing by the corresponding IN sample. The ratio of the DNA amounts in the IP 
and IN samples was first calculated, and the fold increase or ‘enrichment’ in IP/IN 
ratio for cisplatin and oxaliplatin treated samples relative to untreated samples was 
calculated. For the DIP results, treated samples were therefore normalised to the 
untreated samples in each case (see table 3.1, chapter 3 or Appendix III for examples).  
 
CP9/19 antibody titration studies to determine optimal antibody amount for 
DNA immunoprecipitation experiments 
Antibody titration DIP experiments were performed to study the affinity of the 
CP9/19 antibody for both cisplatin and oxaliplatin-induced DNA damage using the 
dermal fibroblast cells. A range of antibody amounts was used in DIP experiments for 
cisplatin and oxaliplatin-induced DNA damage and the amount of DNA measured 
after IP for each antibody amount was determined by qRT-PCR. The fold change in 
IP value was then calculated over the no antibody sample for each antibody amount.  
 Two different amounts of DNA (6 µg and 4 µg for cisplatin, 4 µg and 3 µg for 
oxaliplatin) were used for these antibody titration studies and greater fold increases 
were seen with the higher DNA amount (Appendix III, figure 5 (a,b)). For cisplatin-
induced DNA damage a rapid rise in IP value is seen at low antibody amounts 
followed by a rapid decrease, whilst for oxaliplatin-induced DNA damage a steadier 
increase in IP value is evident followed by a plateau phase. The cisplatin titration 
assay demonstrated the peak IP enrichment at an antibody amount of approximately 
0.5 µg, and the oxaliplatin titration assay demonstrated the peak and plateau phase at 
an antibody amount of approximately 1.5 µg. The patterns of the enrichment for the 
antibody titration assays are very similar using the different amounts of DNA, except 
that the absolute values of IP enrichment are generally lower with the lower DNA 
amounts. Therefore, on the basis of these titration experiments 0.5 µg and 1.5 µg of 
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CP9/19 antibody were used in DIP experiments for cisplatin and oxaliplatin 
respectively. 
 A DIP titration experiment was also performed to evaluate the optimal amount 
of DNA to be used in DIP assays. These studies demonstrate peak IP enrichment 
using 6 µg of DNA for both cisplatin and oxaliplatin and therefore on the basis of 
these experiments 6 µg of DNA was used for both cisplatin and oxaliplatin-induced 
damage DIP assays (Appendix III, figure 5 (c,d)). 
 
Capturing cisplatin and oxaliplatin-induced DNA damaged fragments using DIP 
Having demonstrated activity of the CP9/19 antibody within human ISB assays, as 
well as for the antibody titration assays using DIP, it was now used in cisplatin and 
oxaliplatin dose titration DIP studies. This would allow important evaluation of the 
CP9/19 antibody and DIP assay with human DNA samples, to ensure their sensitivity 
in detecting differences in platinum-induced DNA damage related to dose. 
 For these DIP assays 6 µg of DNA was used and 0.5 µg or 1.5 µg of CP9/19 
antibody were used for cisplatin and oxaliplatin treated DNA samples respectively 
and cells were incubated with the required drug concentration for 2 hours. Stock 
concentration of the CP9/19 antibody was stated on the accompanying datasheet as 
1.47 µg/µl, therefore 0.34 µl or 1.02 µl of CP9/19 antibody was added per DNA 
sample for cisplatin and oxaliplatin DIP experiments respectively. Fibroblasts and 
MDA-MB-231 cells treated in culture were used for cisplatin and oxaliplatin dose 
titration DIP studies and these are presented in figure 4.5. Two biological repeat 
experiments of a cisplatin dose titration study using fibroblast cells show a dose-
dependent increase in enrichment (4.5 (a)), which is also reflected in a single dose 
titration experiment using the MDA-MB-231 cell line (4.5 (b)). Mean values for these 
three replicate experiments are presented in figure 4.5 (c). Results from three replicate 
oxaliplatin dose titration DIP experiments are shown in figure 4.5 (d). These replicate 
experiments were conducted in parallel using the same volumes and amounts of DNA 
and therefore single input samples were used for each dose level. A single oxaliplatin 
dose titration DIP assay was performed using the MDA-MB-231 cell line treated with 
different doses to the previous study (4.5 (e)). In this oxaliplatin study samples were 
not processed with NaCN prior to qRT-PCR. Finally, figure 4.5 (f) presents the mean 
values for the three replicate cisplatin (4.5 (a,b)) and oxaliplatin treated (4.5 (d)) DIP 
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studies on one graph. In each case the error bars represent the standard error of the 
mean and these demonstrate the variation of the assay. 
 The results presented in figure 4.5 reflect those seen in yeast cells, and again 
confirm that the CP9/19 antibody is valid within DIP studies and is recognising both 
cisplatin and oxaliplatin-induced DNA damage in human cells following treatment in 
a dose-dependent manner. Once again, cisplatin shows greater amounts of DNA 
damage than oxaliplatin at equimolar doses and results from these assays demonstrate 
the DIP assay to be valid and reproducible. 
 
 
Figure 4.5 - DNA immunoprecipitation studies capturing cisplatin and oxaliplatin-induced DNA 
damage using the CP9/19 antibody. Data from dose titration DIP studies of cisplatin and oxaliplatin 
treated human dermal fibroblasts and MDA-MB-231 cells are shown using DNA extracted 
immediately post treatment. Fold enrichment of treated samples relative to untreated (U) are shown. In 
4.5 (a) data presented are means of 2 biological repeat DIP dose titration studies of cisplatin treated 
fibroblasts, (b) demonstrates data from a single DIP study in the MDA-MB-231 cell line and (c) 
presents the mean of these three replicate studies. 4.5 (d) demonstrates the mean of 3 replicate DIP 
studies for oxaliplatin treated fibroblasts using single input samples, (e) represents a single dose 
titration study for oxaliplatin treated MDA-MB-231 cells and (f) presents the data from these replicate 
DIP studies for cisplatin and oxaliplatin treated cells. In each case the error bars represent +/- standard 
error of the mean. 
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Removing platinum-induced adducts from DNA with sodium cyanide 
Platinum-treated DNA samples were incubated with NaCN as described in section 
3.2.3, chapter 3. To assess the effectiveness of NaCN in removing platinum adducts 
from cisplatin or oxaliplatin treated human DNA, samples were incubated with NaCN 
in two different scenarios. Firstly, qRT-PCR measurements were compared for 
cisplatin and oxaliplatin treated samples that underwent adduct reversal with NaCN 
following DIP but before qRT-PCR (figure 4.6 (a-c)). This demonstrates improved 
PCR efficiency for both cisplatin and oxaliplatin following NaCN incubation, 
indicating effective adduct removal. Greater change is seen in cisplatin-induced 
damage compared with oxaliplatin possibly reflecting the fewer adducts associated 
with oxaliplatin treated samples compared with cisplatin. In 4.6 (a) differences in the 
fold change in IP is shown between the same cisplatin-treated MDA-MB-231 DNA 
samples treated with or without NaCN. 4.6 (b) shows the difference in fold 
enrichment of IP/IN values for the same oxaliplatin-treated MDA-MB-231 DNA 
samples treated with or without NaCN. In 4.6 (c) three replicate samples for cisplatin 
and oxaliplatin-treated fibroblasts treated with or without NaCN prior to qRT-PCR 
are shown. Secondly, platinum treated DNA samples were incubated with NaCN prior 
to DIP to confirm the removal of platinum adducts from treated samples pre-DIP. 
Figure 4.6 (d) compares the enrichment seen in cisplatin and oxaliplatin treated DNA 
samples with or without NaCN incubation prior to DIP. This demonstrates that the 
enrichment level seen following DIP falls after incubating platinum-damaged DNA 
samples with NaCN. A smaller fall in enrichment is seen with oxaliplatin treated 
samples compared with cisplatin, probably reflecting the lower initial enrichment 
levels seen with oxaliplatin.  
 These results support those seen with yeast DNA (figure 3.6, chapter 3) and 
taken together, these studies demonstrate and confirm the principle of reversal of 
platinum adducts using NaCN. 
 
Chapter 4. Development of DIP-chip in human cells 
 
 156 
 
Figure 4.6 - Studies demonstrating effectiveness of sodium cyanide (NaCN) in removing platinum 
adducts from platinum-treated human DNA samples. In 4.6 (a) and (b) cisplatin and oxaliplatin 
treated MDA-MB-231 cell samples underwent DIP and qRT-PCR enrichment was compared between 
samples treated with or without NaCN following DIP. Improved qRT-PCR enrichment following 
NaCN treatment is shown for both cisplatin (a) and oxaliplatin (b). 4.6 (c) makes similar comparisons 
for cisplatin-treated and oxaliplatin-treated fibroblast cell samples and results shown are averages of 
three replicate samples and the bars represent standard error of the mean. 4.6 (d) shows that DIP 
studies demonstrate no enrichment between untreated and platinum treated samples for DNA samples 
that have been treated with NaCN pre-DIP. The same DNA samples not treated with NaCN 
demonstrate good enrichment for platinum damage. 
 
 
4.3.3 Preliminary human DIP-chip studies of platinum-induced DNA 
damage 
Similar to the yeast studies presented in chapter 3, DIP is shown to be a consistent and 
reproducible method for capturing platinum-induced DNA damage fragments from 
human cells and these samples may now be processed for DNA microarray studies. 
As described in section 4.1, the fundamental challenge to preparing human DNA 
samples for microarray hybridisation compared with yeast was overcoming the added 
complexity of the 300-fold increase in genome size, and the resultant reduction in 
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copy number of each DNA fragment within each unit mass of DNA examined. 
Initially, the same sample preparation technique for DNA microarray hybridisation 
was followed as outlined for the yeast studies in section 3.2.5 of chapter 3. This 
involved LM-PCR, DNA labelling and microarray hybridisation as described in the 
Agilent Technologies Mammalian ChIP-on-chip Protocol, version 10.2. 
 Using this technique with human DNA samples the amount of DNA obtained 
following LM-PCR (table 4.2) and the amount of labelled DNA obtained following 
labelling (table 4.3) were similar to those obtained for yeast DNA (tables 3.2, 3.3, 
chapter 3). However, whilst the values following LM-PCR and labelling compared 
favourably with yeast data, and lay within the parameters stated by the microarray 
manufacturer, the overall DIP-chip assay for these human samples failed. The two 
validation tests of microarray data presented in section 3.3.3, chapter 3, were not 
satisfied using this technique. Firstly, reproducible data between biological repeats 
was not shown and, secondly, no correlation was demonstrated between experimental 
data and predicted data profiles (generated using the PredictProfile function within 
Sandcastle). Examples from failed microarray experiments are given in figure 4.7. In 
this figure scatter plots demonstrate no association between two biological repeat 
datasets from failed microarray experiments analysing cisplatin and oxaliplatin treated 
DNA in vitro. Also presented in figure 4.7 (c) is an example of a genome plot of 
cisplatin treated DNA in vitro from one of these preliminary microarray studies which 
demonstrates sharp peaks and troughs suggestive of non-specific microarray 
hybridisation of DNA fragments with DNA microarray probes. 
 
 
Sample ng/µl A260 A280 260/280 260/230 
Untreated IN 255.53 5.111 2.910 1.76 2.24 
Untreated IP 215.68 4.314 2.428 1.78 2.19 
Cisplatin IN 240.86 4.817 2.806 1.72 2.22 
Cisplatin IP 265.97 5.319 2.986 1.78 2.22 
 
Table 4.2 - DNA concentration measured following LM-PCR using the NanoDrop-1000 
Spectrophotometer. DNA concentration was measured following LM-PCR for IP and IN samples for 
untreated human DNA and human DNA treated in vitro with cisplatin. Samples are in 13 µl. A260 - 
absorbance at 260nm, A280 - absorbance at 280nm. 
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Sample Dye 1 Dye 1 pmol/µl Dye 2 Dye 2 pmol/µl ng/µl 
Untreated IN Cy3 1.76 Cy5 0.95 74.68 
Untreated IP Cy3 0.56 Cy5 3.06 67.13 
Cisplatin IN Cy3 1.88 Cy5 1.01 75.87 
Cisplatin IP Cy3 0.55 Cy5 3.08 71.46 
 
Table 4.3 - DNA labelling efficiency assessed using MicroArray Measurement Module on the 
NanoDrop-1000 Spectrophotometer. The DNA samples presented in table 4.2 were differentially 
labelled with Cy3 and Cy5 fluorophores using the BioPrime Total Genomic Labelling Module 
(Invitrogen). IP samples were labelled with Cy5 fluorophore and IN with Cy3. Samples are in 50 µl. 
 
 
 
 
Figure 4.7 - Examples of preliminary data output from failed human DNA microarray 
experiments. 4.7 (a) & (b) show scatter plots displaying the association between biological repeat 
microarray datasets for cisplatin and oxaliplatin treated fibroblast DNA in vitro respectively. In each 
plot log2 values of the IP/IN ratios at each microarray feature are plotted for two biological repeat 
microarray datasets, showing no association for cisplatin or oxaliplatin treated human DNA in vitro. In 
4.7 (c) the log2 IP/IN ratio values for each microarray feature for a single cisplatin-treated DNA dataset 
are plotted as a genome plot displaying the distribution of cisplatin-induced DNA damage in a section 
of chromosome 17. This demonstrates sharp peaks and troughs diagnostic for non-specific microarray 
hybridisation. 
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 Since the spectrophotometer assessments of DNA amounts following the LM-
PCR and labelling stages appeared satisfactory, and since the previous step of the 
protocol, namely DIP, had been validated it was considered that the cause of the 
failed microarray output lay at the next step of the microarray preparation protocol – 
the hybridisation stage. Measures were therefore taken to increase the amount of 
DNA being applied to the microarray to try and improve microarray hybridisation and 
this was achieved in three ways. Firstly, by increasing the DNA template for LM-PCR 
by pooling two DIP samples prior to LM-PCR, secondly by prolonging the labelling 
incubation time from two to three hours to increase the amount of labelled DNA and, 
thirdly by combining two labelled IP samples at the final post labelling stage prior to 
hybridisation. This is possible as after sample amplification the samples are diluted 
and therefore multiple labelled IP DNA samples can be generated from a single 
amplified IP sample.  
 The net result from these changes were to improve the signal achieved 
following scanning of the microarray suggesting improved hybridisation (figure 4.8 
(a-c)). However, despite this improvement in signal intensity no significant 
improvement was seen in the sensitivity and validity of the microarray data output. 
The ‘box and whisker’ plots presented in figure 4.8 (a-c) represent the total 
microarray signal intensity for each microarray channel, with the red channel 
representing the Cy5 labelled IP channel and the green channel representing the Cy3 
labelled IN channel. In each box plot, the box represents the “interquartile range” 
(central 50% of the data between the upper and lower quartiles), the band inside the 
box represents the median value and the whiskers represent the extremes of the range 
of the signals, and the spots represent outliers. These plots demonstrate the increased 
microarray signal intensity achieved by prolonging the labelling time or increasing the 
amount of hybridised DNA. 
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  a        standard conditions                                 b     prolonged labelling time                            c    two IP samples combined 
   
Figure 4.8 - Signal intensities recorded from microarray experiments. In 4.8 (a-c) box and whisker 
plots demonstrate the total signal recorded from each channel of single microarray experiments. Log2 
signal values are plotted and in each case the red box represents the IP channel whilst the green box 
represents the IN channel. In 4.8 (a) the signal values for single IP and IN samples are demonstrated, 
4.8 (b) shows the signal has been boosted by prolonging the labelling incubation time from two to three 
hours and 4.8 (c) shows further increased signal when two labelled IP samples are combined prior to 
microarray hybridisation. In each case the box represents the interquartile range, the bar within the box 
represents the median value and the whiskers represent the extremes of the range of the signals, and the 
spots represent outliers. Note is made of the different scale in each plot. 
 
 The observation that improved microarray signal was achieved by increasing 
the DNA amount applied to the microarray suggested that microarray hybridisation 
might not be the major limiting factor in producing reliable microarray output. This 
was further examined by applying technical repeat samples to different microarrays, 
(i.e two samples were taken from the same LM-PCR sample and labelled and 
hybridised separately). By plotting the microarray output from these technical repeat 
samples as scatter plots a clear linear relationship is demonstrated between these 
microarray datasets (figure 4.9 (a,b)), albeit with no association between either dataset 
and predicted profiles of DNA damage. The close association observed here between 
microarray output from two technical repeat samples was a significant step forward in 
our understanding as it demonstrated that if similar samples were applied to two 
separate microarrays, i.e hybridised independently, then consistent microarray output 
was achieved. This indicated that microarray hybridisation was indeed working 
consistently and reproducibly and that therefore the problem with the preliminary 
microarray studies lay upstream of the hybridisation step. 
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Figure 4.9 - Correlation between technical repeat microarray samples. 4.9 (a) and (b) plot log2 
values of the IP/IN ratios at each microarray feature for two technical repeat microarray datasets 
against each other. These scatter plots display a linear association between technical repeat microarray 
datasets for cisplatin (a) and oxaliplatin (b) treated fibroblasts respectively suggesting that microarray 
hybridisation is reproducible. 
 
4.3.4 Development of human DNA damage microarray technique 
 
4.3.4.1 PCR amplicon study to evaluate microarray hybridisation 
Establishing and confirming reproducible microarray hybridisation was a key step in 
the development of the human DNA microarray assay and suggested the problem 
encountered with the preliminary microarray work lay prior to hybridisation in the 
microarray sample preparation. Demonstrating reproducible microarray hybridisation 
was such a key step that it was considered important to investigate this in more detail. 
We reasoned that a detailed understanding of the hybridisation stage could highlight 
where the deficiencies lay in the DIP-chip protocol that were currently preventing 
effective microarray data output. To investigate microarray hybridisation in more 
detail a microarray study analysing individual PCR amplicons, was performed. 
 For this PCR amplicon microarray study six PCR products, or amplicons, for 
regions of chromosome 17 covered by the microarray were generated as described in 
section 4.2.5 of this chapter. Processing and applying these amplicons for microarray 
hybridisation would hopefully demonstrate peaks within the microarray data output 
corresponding to the relevant regions within the genome, thus confirming that 
accurate signals could be produced using the custom-designed human DNA 
microarrays. Generating large pools of DNA for each PCR amplicon meant that DNA 
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amplification would not be required meaning that the labelling and hybridisation steps 
within the microarray protocol could be isolated for further scrutiny. 
 Primers were designed for six genetic loci of chromosome 17 present on the 
custom-designed human microarray and PCR was conducted as described in section 
4.2.5. Amplicons were purified using the PureLinkTM Quick PCR Purification Kit 
(Invitrogen) and directly labelled and hybridised to the microarrays as described in 
section 3.2.5 of chapter 3. Four different strategies were employed for these 
experiments using either a single or a two channel microarray approach and either 
including a background genomic DNA sample, which was taken from IN DNA 
samples, or not. For the single-channel microarray approach two different methods 
were used; the DNA amplicons were either mixed together and directly labelled with 
a single fluorophore, Cy5, and hybridised to the microarray, or IN DNA was also 
added to the six DNA amplicons and the sample labelled with a single fluorophore, 
Cy5, before hybridising. Similarly, for the two-channel microarray approach, two 
different methods were used; the DNA amplicons were either directly labelled with 
Cy5 in one channel and in a second channel IN DNA was labelled with Cy3, or IN 
DNA was added to the DNA amplicons in one channel and labelled with Cy5 and in 
the second channel IN DNA sample was labelled with Cy3. 
 Results from these studies were very informative. Analysing the single 
channel data demonstrated that signal peaks corresponding to the relevant genetic 
location were present but difficult to distinguish (figure 4.10 (a,b), marked X). For 
these single channel studies, very high signal levels were seen throughout the 
microarray data suggesting significant non-specific microarray hybridisation. When 
background genomic DNA was added in a separate two channel array, distinct peaks 
and signals appeared in the data corresponding to the appropriate locations (figure 
4.10 (c,d), marked X). The background signal level was also lower and, as a 
consequence, peaks relating to each amplicon were more defined. This study 
highlighted the critically important role of the IN sample in the second channel in 
reducing background signals obtained with DNA microarray studies. It suggested that 
the background genomic DNA IN sample balances non-specific microarray 
hybridisation and confirmed that two channel microarray analysis, e.g analysing IP/IN 
signal ratios, corrects much of the background “noise” related to experimental 
microarray variability. This study confirmed that the labelling and hybridisation steps 
of the DNA microarray protocol were performing efficiently and consistently. 
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Figure 4.10 Genome plots of microarray data from PCR amplicon studies. X locates the promoter 
regions of MYH13 (a) and MYH8 (b), PIRT promoter and ORF (c) and MYH13 ORF (d). 4.10 (a) and 
(b) demonstrate genome plots for three microarray studies for single channel, labelled PCR amplicon 
studies. In these cases the general level of signal throughout the genome is very high and the peaks 
corresponding to the amplicon locations are barely discernible. 4.10 (c) shows three profiles 
corresponding to the two channel microarray datasets demonstrating signal peaks corresponding to the 
PIRT promoter and PIRT ORF location. In 4.10 (d) two profiles corresponding to two channel 
microarray datasets containing labelled PCR amplicons in one channel and background genomic DNA 
in the second channel are presented demonstrating a peak at the MYH13 ORF location. 
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 These studies suggested that if peaks related to DNA damage events were to 
be detected within experimental human DIP-chip microarray outputs then improved 
microarray signal specifically related to these DNA damage events had to be 
achieved. If these signals could be improved then the DIP-chip microarray assay 
should be sufficiently sensitive to be able to generate profiles representative of DNA 
damage patterns in human samples. To achieve this the situation modelled in the PCR 
amplicon study had to be replicated in the DIP-chip assays, with a greatly enriched IP 
DNA sample being generated for microarray hybridisation, and thus an improved 
signal to noise ratio. For this to be achieved, two key areas of the protocol were 
highlighted for optimisation:- 
 
1) Improvement in quality and enrichment of the DNA sample achieved following 
DIP by reducing detection of undamaged DNA fragments and improving the overall 
DNA yield.  
2) Development of a more effective method of amplifying the DIP sample prior to 
microarray hybridisation. 
 
4.3.4.2 Optimisation of DIP protocol to improve quality and enrichment of the 
DNA sample 
 
Optimisation of DIP to improve specificity of CP9/19-epitope reaction 
To reduce detection of undamaged DNA fragments using the CP9/19 antibody during 
DIP, non-specific binding of DNA fragments needed to be limited to an absolute 
minimum. One method of ensuring improved antibody-epitope specificity within IP 
reactions is by limiting the low affinity antibody-DNA reactions. Increasing salt 
(NaCl) concentration in the post IP wash buffer can increase the stringency of these 
washes and reduce the low affinity non-specific antibody reactions occurring between 
antibody and undamaged DNA fragments (www.abcam.com/chip, 2011).  
 Therefore in the DIP assay presented in this work the post antibody-DNA 
incubation wash step was modified to include a higher NaCl concentration in the 
wash buffer: FA/SDS + 1 M NaCl instead of FA/SDS + 0.5 M NaCl. This step 
demonstrated an obvious improvement in the enrichment seen with cisplatin treated 
DNA, but a less clear improvement was seen for oxaliplatin treated samples (figure 
4.11 (a)), suggesting reduced non-specific or background DNA-antibody interaction. 
Chapter 4. Development of DIP-chip in human cells 
 
 165 
Alternative purification of DIP samples and pooling of DIP samples to improve 
overall DNA yield 
It was observed following purification of the PCR amplicons for the PCR amplicon 
microarray study, using the PureLinkTM Quick PCR Purification Kit (Invitrogen), that 
a significant amount of DNA was lost during this purification step. Therefore, if a 
similar proportion of DNA was lost when using the same purification method for DIP 
samples this could significantly reduce the yield of the DIP sample. It was also 
recognised that the presence of NaCN could adversely affect the function of the 
Invitrogen column purification system, causing further loss of DNA. For these 
reasons, and to increase the yield of DNA within the DIP sample, the method 
employed for DIP sample purification was changed from using the PureLinkTM Quick 
PCR Purification Kit (Invitrogen) to using a phenol chloroform extraction method. 
The combination of the phenol-chloroform extraction method for purification and 
higher concentration NaCl washes, along with ensuring good quality starting DNA 
material, led to a considerable increase in the overall level of enrichment seen in DIP 
samples for cisplatin (figure 4.11 (b)).  
 Finally, to increase the overall DNA yield in the DIP sample, multiple samples 
were processed in parallel and two samples pooled prior to the qRT-PCR stage. The 
effect of the pooling of two cisplatin-treated DIP samples prior to qRT-PCR on the 
enrichment is seen in figure 4.11 (c). Each of these protocol optimisations were 
included in final DIP assays examining both cisplatin and oxaliplatin-induced DNA 
damage, for both DNA in vitro and cellular treatments, and are presented in figure 
4.11 (d). These assays included single DIP samples for each cisplatin treated DNA in 
vitro replicate, 2 pooled DIP samples for the cisplatin cellular treatment replicates and 
three pooled samples for the oxaliplatin treated replicate samples. This final optimised 
assay represented a significant improvement in the sensitivity of the DIP assay and 
provided a greatly enriched DIP sample for DNA microarray preparation. 
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Figure 4.11 - Optimisation of DIP protocol to improve quality and enrichment of the DIP sample. 
In each graph in this figure the fold enrichment of treated human dermal fibroblast samples relative to 
untreated, determined by qRT-PCR, are shown and in each case the error bars represent +/- standard 
error of the mean. 4.11 (a) displays data from DIP studies of cisplatin and oxaliplatin treated fibroblasts 
and data presented are means of 3 biological replicate studies. Improvement is seen in cisplatin 
enrichment with higher concentration of NaCl used to wash dynabeads following the DNA-antibody-
bead incubation. Minimal improvement is seen in oxaliplatin enrichment. In 4.11 (b) fibroblasts are 
treated with 250 µM cisplatin for 24 hours. DIP studies here are performed using higher concentration 
NaCl washes and demonstrate the additional improvement achieved in qRT-PCR enrichment by the 
addition of NaCN treatment and phenol chloroform extraction. In figures 4.11 (c & d) fibroblasts are 
treated with 2.5 mM cisplatin or oxaliplatin for 2 hours and DIP samples are processed using the 
optimised protocol comprising 1 mM NaCl washes, NaCN treatment and phenol chloroform extraction. 
Figure 4.11 (c) shows the improvement in qRT-PCR enrichment achieved following these 
optimisations and demonstrates the further additional benefit achieved by pooling two DIP samples 
prior to qRT-PCR. Figure 4.11 (d) demonstrates qRT-PCR enrichment for 2.5 mM cisplatin and 
oxaliplatin DIP samples incorporating each of these optimisations to the DIP protocol and each column 
represents 2 replicate values apart from the oxaliplatin cellular treated samples in culture, which 
represent 4 replicates. For these samples the cisplatin in vitro DIP samples represent single DIP 
samples, cisplatin cellular treated samples represent two DIP samples pooled prior to qRT-PCR and the 
oxaliplatin treated samples represent three pooled samples prior to qRT-PCR. These optimisations lead 
to a large increase in the fold enrichment seen, demonstrating a significant increase in sensitivity of this 
assay. 
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4.3.4.3 Alternative method of amplifying the DIP sample prior to microarray 
hybridisation using whole genome amplification 
Having significantly improved the sensitivity of the DIP assay, attention now turned 
to another key element in developing the microarray assay in the human context - 
developing a more effective method for amplifying DIP samples prior to microarray 
hybridisation. Whilst LM-PCR was an effective method for DIP sample amplification 
in the yeast organism, it might be less effective for amplifying human DIP samples. 
For example with LM-PCR, it is very likely that linker ligation is less effective in 
human DIP samples given the lower DNA fragment copy number in these samples.  
 An alternative method for DIP sample amplification was developed using the 
proprietary whole genome amplification method, GenomPlex® Complete Whole 
Genome Amplification Kit (WGA2, Sigma-Aldrich) as described in section 4.2.6. 
This kit uses an amplification method based on random fragmentation of genomic 
DNA and conversion of the resulting small fragments into PCR-amplifiable 
OmniPlex® library molecules flanked by universal priming sites and has been used by 
other groups for DNA sample amplification in ChIP-chip studies (O'Geen et al., 
2006). The OmniPlex library is then PCR amplified using universal oligonucleotide 
primers to generate a representative amplification of human genomic DNA. The 
WGA DNA Polymerase has been produced with the aim of reducing background 
DNA in the reaction, and providing improved accuracy and specificity and the single 
round of amplification, compared with LM-PCR, results in reduced amplification 
bias. 
 
Assessment of whole genome amplification 
DIP samples were amplified using the WGA2 kit and following amplification DNA 
was measured using the NanoDrop-1000 spectrophotometer. DNA amounts greater 
than 5 µg were consistently achieved following WGA, which was higher than seen 
with LM-PCR (table 4.4). Samples were diluted to 250 ng/µl and this allowed 
multiple samples to be processed for DNA labelling from the same starting 
amplification sample. This enabled multiple labelled IP DNA samples to be combined 
prior to microarray hybridisation as a further means to boosting the microarray 
hybridisation signal. DNA samples were processed for labelling in the same manner 
as previously described in section 3.2.5, chapter 3, except that samples were now 
labelled for three hours at 37°C instead of two. Significantly higher values were now 
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achieved for labelled DNA following WGA than after LM-PCR, suggesting far 
greater labelling efficiency (table 4.5). This suggested that WGA was more effective 
than LM-PCR in amplifying DNA within the DIP samples and produced samples that 
were labelled more efficiently than before. 
 
 
Sample ng/µl A260 A280 260/280 260/230 
Cisplatin IN 224.82 4.496 2.430 1.85 2.07 
Cisplatin IP 344.64 6.893 3.665 1.88 2.11 
Oxaliplatin IN 365.55 7.311 3.885 1.88 2.45 
Oxaliplatin IP 386.45 5.056 2.687 1.88 2.38 
 
Table 4.4 - DNA concentration measured following WGA using the NanoDrop-1000 
Spectrophotometer. DNA concentration was measured following WGA for cisplatin and oxaliplatin 
IP and IN samples treated in vitro. Samples are in 15 µl. A260 - absorbance at 260 nm, A280 - 
absorbance at 280nm. 
 
 
 
Sample Dye 1 Dye 1 
pmol/µl 
Dye 2 Dye 2 
pmol/µl 
ng/µl 
Cisplatin IN Cy3 3.58 Cy5 0.09 101.65 
Cisplatin IP Cy3 0.83 Cy5 6.45 90.93 
Oxaliplatin IN Cy3 3.42 Cy5 0.01 97.01 
Oxaliplatin IP Cy3 0.63 Cy5 5.47 95.10 
 
Table 4.5 - DNA labelling efficiency of WGA samplers assessed using MicroArray Measurement 
Module on the NanoDrop-1000 Spectrophotometer - The same DNA samples as presented in table 
4.4 are diluted to 250 ng/µl and differentially labelled with Cy3 and Cy5 fluorophores using the 
BioPrime Total Genomic Labelling Module (Invitrogen). IP samples were labelled with Cy5 
fluorophore and IN with Cy3. Samples are in 50 µl. 
 
4.3.5 DIP-chip microarray data measuring and locating platinum-
induced DNA adducts in human cells 
Having optimised the DIP protocol and developed an improved DNA amplification 
method, each of these new steps - higher concentration NaCl washes, purification 
using the phenol-chloroform technique, pooling of DIP samples, WGA, prolonged 
DNA labelling and combining labelled samples prior to microarray hybridisation - 
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were now incorporated into the human DIP-chip protocol. These new steps, allied to 
the previously described important elements of ensuring good quality starting DNA 
material and platinum adduct repair with NaCN now ensured successful human DNA 
microarray outcomes. 
 As described in sections 3.2.5 and 3.2.6 of chapter 3, and section 4.2.1 in this 
chapter DNA microarrays were scanned and the image converted to numerical values 
using Feature Extraction software. The ratio of the signals for the IP and IN channels 
at each microarray feature is calculated, producing single numerical values for each 
feature, and log2 IP/IN values are plotted in the scatter plots and genome plots 
presented here. 2.5 mM cisplatin and 2.5 mM oxaliplatin treatments were used for 
both the DNA in vitro and cellular treatment samples for these microarray studies. 
Using the steps outlined previously for validating microarray data output, scatter plots 
now demonstrate linear associations between biological replicate samples for both 
cisplatin and oxaliplatin treated DNA in vitro (Pearson's product moment correlation 
coefficient 0.88 and 0.60 respectively) and cisplatin and oxaliplatin treated human 
cells in culture (Pearson's correlation 0.83 and 0.74 respectively) (figures 4.12, 4.13). 
This now confirms good reproducibility between biological repeat samples and the 
correlation values observed between cisplatin repeats are stronger than between 
oxaliplatin repeats. 
 Genome profiles of the microarray data are presented, demonstrating platinum 
adduct profiles for sections of chromosome 17 and peaks represent regions of high 
platinum levels and troughs represent low platinum levels (figures 4.12, 4.13). In the 
case of cisplatin treated DNA in vitro the microarray data presented are the average of 
three replicate experiments, in each other case the data represent the average of two 
biological repeats. In each genome plot presented (figs 4.12 and 14.13) the black 
profile represents the experimental platinum damage profile whereas the red profile 
represents the predicted distribution for the 1,2-d(GpG) bifunctional intrastrand 
adduct based on the mathematical algorithm (PredictProfile function, within 
Sandcastle suite) described in section 3.3.3, chapter 3. It is evident from these profiles 
that, in each case, as for yeast, the global pattern of platinum induced DNA damage is 
heterogeneous. 
 In each case the closest association for the experimental platinum-induced 
damage profile is with the predicted profile for the 1,2-d(GpG) bifunctional 
intrastrand adduct. For the section of chromosome 17 presented in figure 4.12, for 
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cisplatin treated DNA in vitro, the Pearson correlation co-efficient is 0.76 for the 
probes presented in the figure and 0.73 for the genome as a whole. The correlation 
values for each of the other profiles can be seen in the figure legends of figure 4.12 
and 4.13 and in table 4.6.  
 An alternative to these linear genome plots for displaying the genomic DNA 
damage data is to use the Circos software package to allow circular visualisation of 
the data in the form of Circos plots (Circos, 2013). Circos plots were originally 
designed for visualising genomic data and allow complete genomic datasets to be 
visualised in a single figure with the circular layout ideal for exploring relationships 
between different genomic locations. These plots also allow different layers of 
cellular information such as genomic, transcriptional or epigenetic information to be 
incorporated together in single images. An example of how the data from cisplatin-
induced DNA damage treated in vitro can be displayed as a Circos plot is 
demonstrated in figure 4.14, where the damage profile can be seen as the green trace. 
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Figure 4.12 - DNA microarray data for normal dermal fibroblast DNA treated in vitro with 2.5 
mM cisplatin or oxaliplatin. Scatter plots demonstrate the association between replicate microarray 
datasets. Log2 IP/IN values are presented and these plots are displayed as ‘heat plots’ whereby the 
darker blue regions represent the greater density of data. These datasets demonstrate a linear 
relationship, with the majority of values congregated along or near the line of x = y. 4.12 (a) displays 
the values at each microarray feature for two replicate experiments of cisplatin treated DNA (Pearson's 
product moment correlation coefficient (r) = 0.89) and 4.12 (b) for two biological repeats of oxaliplatin 
treated DNA (r = 0.6). 4.12 (c) and (d) show genome plots where log2 IP/IN ratios are plotted for a 
section of chromosome 17 showing the genomic distribution of platinum-induced DNA damage (black 
profile) and the predicted distribution for damage (red profile) in this region. 4.12 (c) shows the mean 
of 3 replicate experiments for cisplatin-treated DNA (Pearson’s correlation with the predicted trace is 
0.76 for the region plotted, 0.73 for the whole microarray). 4.12 (d) shows the mean of the 2 repeat 
experiments for oxaliplatin-treated DNA presented in (b) (correlation with the predicted trace is 0.55 
for region plotted and 0.42 for the whole microarray). The three cisplatin treated replicate samples each 
comprised a single DIP sample. For the first cisplatin treated replicate a single labelled IP sample was 
hybridised to the microarray, for the second replicate two labelled samples were combined and for the 
third replicate sample three labelled samples were combined prior to microarray hybridisation. The 
oxaliplatin treated samples are biological repeats each using three pooled DIP samples and in both 
cases two labelled IP samples were combined prior to hybridisation. The yellow boxes show ORF 
positions and the grey dots show microarray feature positions. 
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Figure 4.13 - DNA microarray data for normal dermal fibroblast cells treated in culture with 2.5 
mM cisplatin or oxaliplatin. Scatter plots demonstrate the association between biological repeat 
microarray datasets. Log2 IP/IN values are presented and these plots are displayed as ‘heat plots’ 
whereby the darker blue regions represent the greater density of data. These datasets demonstrate a 
linear relationship with the majority of values congregated along or near the line of x = y. 4.13 (a) 
displays the values at each microarray feature for two biological repeats of cisplatin treated human 
fibroblast cells (Pearson's product moment correlation coefficient (r) = 0.83) and 4.13 (b) for two 
biological repeats of oxaliplatin treated cells (r = 0.74). 4.13 (c) and (d) show genome plots where log2 
IP/IN ratios are plotted for a section of chromosome 17 showing the genomic distribution of platinum-
induced DNA damage (black profile) and the predicted distribution for damage (red profile) in this 
region. 4.13 (c) shows the mean of the 2 repeat experiments for cisplatin-treated cells presented in (a) 
(Pearson’s correlation with the predicted trace is 0.74 for the region plotted, 0.69 for the whole 
microarray), 4.13 (d) shows the mean of the 2 repeat experiments for oxaliplatin-treated cells presented 
in (b) (correlation with the predicted trace is 0.55 for the region plotted and 0.44 for the whole 
microarray). For the cisplatin treated samples 2 DIP samples were pooled and single labelled samples 
were applied to the microarray. The oxaliplatin treated samples each comprised three pooled DIP 
samples and in both cases two labelled IP samples were combined prior to hybridisation. The grey dots 
along the genome plot show microarray feature positions.  
-4 -3 -2 -1 0 1 2 3
-3
-2
-1
0
1
2
average12$ratios
a
ve
ra
g
e
3
4
$
ra
tio
s
a b 
c 
Chr. 17
lo
g2
 B
in
di
ng
-1
.5
-0
.5
0.
5
14800000 14805000 14810000 14815000 14820000 14825000
Chr. 17
lo
g2
 B
in
di
ng
-1
.5
-0
.5
0.
5
14825000 14830000 14835000 14840000 14845000 14850000
RPL23AP76
Chr. 17
lo
g2
 B
in
di
ng
-1
.5
-0
.5
0.
5
14850000 14855000 14860000 14865000 14870000 14875000
Chr. 17
lo
g2
 B
in
di
ng
-1
.5
-0
.5
0.
5
14875000 14880000 14885000 14890000 14895000 14900000
Chr. 17
lo
g2
 B
in
di
ng
0.
0
1.
0
2.
0
14800000 14805000 14810000 14815000 14820000 14825000
Chr. 17
lo
g2
 B
in
di
ng
0.
0
1.
0
2.
0
14825000 14830000 14835000 14840000 14845000 14850000
RPL23AP76
Chr. 17
lo
g2
 B
in
di
ng
0.
0
1.
0
2.
0
14850000 14855000 14860000 14865000 14870000 14875000
Chr. 17
lo
g2
 B
in
di
ng
0.
0
1.
0
2.
0
14875000 14880000 14885000 14890000 14895000 14900000
d 
ci
sp
la
ti
n 
tr
ea
te
d 
ce
ll
s 
da
ta
se
t 1
 (
lo
g 2
 I
P
/I
N
) 
cisplatin treated cells dataset 2 (log2 IP/IN) 
-2 0 2 4 6
-2
0
2
4
6
normoxvivo$ratios[, 1]
no
rm
ox
vi
vo
$r
at
io
s[
, 2
]
ox
al
ip
la
ti
n 
tr
ea
te
d 
ce
ll
s 
da
ta
se
t 1
 (
lo
g 2
 I
P
/I
N
) 
oxaliplatin treated cells dataset 2 (log2 IP/IN) 
r = 0.83 r = 0.74 
Chapter 4. Development of DIP-chip in human cells 
 
 173 
 
 
 
Figure 4.14 - Circos plot demonstrating the whole microarray damage dataset for the 5 x 106 
base pair section of chromosome 17 included on the custom-designed human microarray. The 
green and red line plot represents the cisplatin induced DNA damage in vitro pattern with the green 
representing the positive values and red representing the negative values of the data respectively. The 
position of each microarray feature is shown around the outside of the Circos plot, with the features 
represented as almost continuous grey dots. 
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Adduct            
cisplatin 
treated 
DNA in vitro 
cisplatin 
treated cells 
in culture 
oxaliplatin 
treated 
DNA in vitro 
oxaliplatin 
treated cells 
in culture 
untreated 
DNA in 
vitro 
GG 0.732 0.690 0.417 0.441 0.154 
AG 0.446 0.512 0.276 0.275 0.106 
GNG 0.689 0.660 0.358 0.402 0.146 
G 0.695 0.680 0.398 0.403 0.208 
GC (ICL) 0.085 0.113 0.054 0.007 0.041 
GG + AG 0.709 0.680 0.413 0.427 0.160 
GG + GNG 0.736 0.691 0.416 0.441 0.158 
GG + G 0.732 0.687 0.418 0.440 0.157 
 
Table 4.6 - Correlation values between experimental profiles and predicted profiles for platinum 
adduct formation. Pearson's product moment correlation coefficient values are presented in this table 
for the correlations between each platinum adduct, for each of the different experimental scenarios, and 
the predicted profile for platinum damage based on the mathematical model. In each case the highest 
correlation value is generated for the 1,2-d(GpG) adduct. These correlations were produced using the 
whole microarray dataset in each case. G - guanine, A - adenine, C - cytosine, ICL - Interstrand 
crosslink. 
 
 
4.3.6 Measuring and locating UV-induced CPD formation in human 
fibroblasts using DIP-chip 
Following successful development and validation of the DIP-chip assay for measuring 
platinum-induced DNA damage in human fibroblasts it was now of interest to 
evaluate how robust the DIP-chip methodology was, by assessing its performance 
when measuring an alternative mode of DNA damage. For this study UV irradiation-
induced CPD formation was studied and the preparation of UV damaged human DNA 
in vitro and cellular treated DNA samples was performed as described in sections 
2.3.4 and 2.3.5, chapter 2. Samples were processed for CPD DIP using the same 
protocol as explained in section 3.2.2, chapter 3, but using an anti-thymine dimer 
antibody (KTM53, Kamiya Biomedical Company, Seattle) along with Pan Mouse IgG 
Dynabeads.  
 The anti-thymine dimer antibody has been widely used and well characterised 
in our laboratory, and the optimal amount of this antibody for DIP-chip experiments 
using yeast has previously been determined as 2 µl. Equally, final antibody washes 
have been characterised as optimal using 500 µl of FA/SDS + 500 mM NaCl. These 
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conditions for CPD IP were therefore used for the studies presented here and 6 µg of 
DNA was again used. Detailed assessment and optimisation of DIP was not 
performed, as the goal from these studies was to ensure that the DIP-chip method was 
robust enough to be transferred and applied to detecting other forms of DNA damage 
without further modification.  
 Similar to work examining the platinum adducts, CPDs also needed removal 
prior to qRT-PCR, WGA and microarray hybridisation and this was achieved using 
the proprietary PreCR DNA repair kit (New England Biolabs) - a kit that removes 
many DNA damages including CPDs. 40 µl of IP and IN samples were processed for 
repair using this kit as per the manufacturer’s instructions. Following repair, DNA 
was retrieved using phenol-chloroform extraction and ethanol precipitation and 
resuspended in 10 µl. Beyond this, samples were prepared for microarray 
hybridisation in the same fashion as previously described using WGA and labelling. 
For each of these studies of in vitro and cellular treated samples 3 DIP samples were 
pooled prior to qRT-PCR and single labelled IP samples were applied the DNA 
microarrays. 
 Results demonstrating enrichment following DIP for UV-induced DNA 
damage are displayed in Appendix III, figure 6. Samples were processed for 
microarray hybridisation and again good reproducibility was seen between biological 
repeat studies with a Pearson’s correlation of 0.83 and 0.78 between repeat DNA in 
vitro treatment samples and repeat cellular treated DNA samples respectively. The 
formation of CPDs is also sequence specific and based on this sequence information 
and the known quantitative ratios of CPD formation, again, a predicted distribution 
for CPD induction was generated in the same manner as for platinum damage (see 
section 3.3.3, chapter 3, also CPD formation discussed in detail in section 5.3.1, 
chapter 5) and experimental CPD profiles are compared to this predicted profile 
(figure 4.15). Genome profiles demonstrate CPD formation to be heterogeneous and 
correlation between experimental and predicted profiles for CPD formation is 0.69 
and 0.65 for in vitro and cellular treated DNA respectively for the sections of 
chromosome 17 presented in figure 4.15. 
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Figure 4.15 - DNA microarray data for normal dermal fibroblast DNA treated in vitro with 300 
J/m2 UV irradiation or cells treated in culture with 50 J/m2 UV irradiation. Scatter plots 
demonstrate the association between biological repeat microarray datasets. Log2 IP/IN values are 
presented and these plots are presented as ‘heat plots’ whereby the darker blue regions represent the 
greater density of data. These datasets demonstrate a linear association with the majority of values 
congregated along or near the line of x = y. 4.15 (a) displays the values at each microarray feature for 
two biological repeats of UV treated DNA (Pearson's product moment correlation coefficient (r) = 
0.83) and 4.15 (b) for two biological repeats of UV treated human fibroblast cells (r = 0.78). 4.15 (c) 
and (d) show genome plots where log2 IP/IN ratios are plotted for a section of chromosome 17 showing 
the genomic distribution of UV-induced CPD formation (black profile) and the predicted distribution 
for damage (red profile) in this region. 4.15 (c) shows the mean of the 2 repeat experiments for the UV-
treated DNA presented in (a) (correlation with the predicted trace is 0.69 for the region plotted and 
0.61 for the whole microarray) and 4.15 (d) shows the mean of the 2 repeat experiments for the UV-
treated cells presented in (b) (correlation with the predicted trace is 0.65 for the region plotted and 0.56 
for the whole microarray). In each case three DIP samples were pooled prior to qRT-PCR and single 
labelled IP samples were applied to the microarray. The grey dots along the genome plots show the 
microarray feature positions. 
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4.4 Discussion 
 
In this chapter the development of the DIP-chip assay in human cells is described in 
detail, culminating in the validation of this technique to successfully measure both 
platinum-induced DNA damage and UV-induced CPD formation. The work in this 
chapter started with scouting experiments using ISB assays to make preliminary 
assessments of the ability to detect and induce cisplatin and oxaliplatin-induced DNA 
damage in the human dermal fibroblast cell line used in these studies. The results of 
these ISB assays indicate that the CP9/19 antibody is able to demonstrate dose 
dependency over a wide range of doses with both cisplatin and oxaliplatin (figure 
4.4). Again, CP9/19 is shown to detect adducts induced by both cisplatin and 
oxaliplatin following both in vitro and cellular treatments. The antibody also 
demonstrates appropriate antibody kinetics within IP studies confirming its ability to 
perform within the context of human DIP assays for both cisplatin and oxaliplatin. 
The results of the DIP assays themselves also confirm dose dependency for the 
detection of both cisplatin and oxaliplatin following cellular treatment and again 
demonstrate the known adduct formation differential, with oxaliplatin forming fewer 
adducts compared to cisplatin at equimolar doses (figure 4.5). 
 Efficient removal of platinum adducts is demonstrated using NaCN in two 
settings, by incubating DNA samples with NaCN prior to or after DIP. In each of 
these two studies effective removal of platinum adducts using NaCN is confirmed, an 
important step prior to qRT-PCR and sample preparation for microarray hybridisation 
(figure 4.6). Taken together with the results seen with yeast DNA, these results were 
considered confirmatory of successful adduct reversal using NaCN. 
 Whilst the CP9/19 antibody and DIP assay were demonstrated to be valid in 
detecting differences related to dose and drug, the initial dose titration assays using 
DIP resulted in modest enrichment amounts despite relatively large drug doses. This 
suggested that despite this sensitivity there was scope for the assay to be optimised to 
improve enrichment levels and allow lower drug doses to be utilised, making the 
assay more clinically relevant. The optimisation steps, outlined in section 4.3.4.2, 
resulted in significant improvements in enrichment levels and there are different 
explanations for this. Firstly, a change made to the washes of the DNA/antibody 
complexes reduced non-specific antibody binding. This ensured that the level of DNA 
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detected within untreated samples was significantly lower resulting in greater 
enrichment between treated and untreated samples. Secondly, by changing the method 
used for recovering the DNA following DIP from the column-based purification 
method to the phenol-chloroform technique the DNA yield within the DIP samples 
was increased. It is also possible that the presence of NaCN in the sample interferes 
with the membrane of the purification columns causing the DNA within the DIP 
sample to bind less avidly to it and leading to greater DNA loss. At this stage of the 
assay the DNA amount within the DIP sample is very low and therefore any loss of 
DNA at this point will be critical for the outcome of the assay. Whilst the DNA 
purification columns were successfully used to recover DIP samples within the yeast 
DIP-chip assay presented in chapter 3, it is likely that some loss of DNA within the 
yeast DNA sample could be tolerated given the smaller genome and the 
corresponding increased copy number of each fragment. Finally, to improve the yield 
and enrichment of DIP samples replicate DIP samples were processed in parallel and 
pooled prior to qRT-PCR. 
 Having proven the principle in the yeast model organism that a DNA 
microarray approach could be used to measure DNA damage events such as these was 
enormously helpful. Without this precedent it may have been concluded, when the 
initial human microarray assays were unsuccessful, that being able to sensitively 
detect platinum-DNA damage lesions at high resolution in the human genome would 
be too challenging. The fundamental complexity and challenge of developing this 
assay in human cells was represented by the increase in genome size between yeast 
and human samples and the effect of this on being able to detect affinity captured 
DNA damage on the microarrays. This posed a series of challenges to be overcome 
and required systematic and methodical characterisation of each step of the DIP-chip 
protocol in developing a successful assay. Following this development work, the 
overall conclusion is that no single step by itself was responsible for the successful 
development of the human DIP-chip assay but rather a number of key steps needed to 
be established for the assay to perform consistently, reproducibly and, in terms of 
correlating with predicted models, as expected. These steps will now be discussed. 
 Firstly, for measuring DNA damage events that are occurring uniformly and at 
high frequency throughout the human genome using DNA microarrays, a high 
resolution approach is essential. Therefore, the development of custom-designed high 
resolution microarrays and carefully matching the DNA fragment length and array 
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resolution was crucial. Secondly, the quality and purity of the starting DNA sample, 
i.e good concentration of DNA and free from RNA, was critically important for 
accurate and reproducible functioning of the DIP assay. Thirdly, the sensitivity and 
consistency of the DIP assay is critical for capturing the DNA fragments of interest. 
Following DIP, the importance of optimising the recovery of the DIP sample is clear, 
and the studies presented here confirm the phenol-chloroform technique to be more 
effective than the proprietary column-based method for this (figure 4.11). The final 
critical step for achieving successful human microarray hybridisation was to replace 
the LM-PCR step with an alternative method for amplifying the DIP sample prior to 
DNA labelling and hybridisation.  
 For DNA amplification the GenomPlex® Complete Whole Genome 
Amplification Kit (WGA2, Sigma-Aldrich) was used instead of the LM-PCR method 
used for yeast samples. These two methods offer alternative means of amplifying 
whole samples of genomic DNA to yield amplified products representative of the 
starting sample. WGA has been used by other groups for ChIP-chip studies who 
compared it directly to LM-PCR and demonstrated improved signal to noise ratios 
particularly when using high resolution microarrays (O'Geen et al., 2006). WGA2 
employs a PCR-based method using degenerate oligonucleotides coupled with 
universal adaptors, or defined termini, which anneal arbitrarily and evenly throughout 
the sample. This annealing step is referred to as ‘library preparation’, and the library 
is then amplified using primers targeting the defined universal sequence. This method 
is different from LM-PCR which ligates common linker DNA sequences to the ends 
of DNA fragments, and uses primers designed to recognise the linker sequences.  
 Following the PCR amplicon studies presented in this chapter it became 
apparent that the preliminary human microarray studies using LM-PCR amplification 
were resulting in very high background levels such that the damaged DNA fragments 
of interest could not be distinguished from this background noise when applied to 
microarrays. This could not be resolved by simply increasing the starting DNA 
amount for LM-PCR or by increasing the post-LM-PCR DNA amount being applied 
to the microarray and suggested a lack of sensitivity related to LM-PCR in human 
samples. It is likely that the efficiency of the linker ligation step falls when lower 
DNA copy number exists accounting for the reduced efficiency of LM-PCR in human 
samples compared with yeast. The added amplification bias associated with the two 
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sequential rounds of amplification (15 cycles, 25 cycles) employed in LM-PCR, 
compared with only one round using the WGA2 kit is also likely to be important. 
 Careful characterisation and optimisation of these key aspects of the DIP-chip 
protocol have allowed this assay to be successfully developed in human cells. The 
human microarray data output has been validated and the correlation coefficients 
between experimental and predicted profiles for DNA damage presented in table 4.6 
indicate that the data output from the microarray is a good reflection of damage 
induction throughout the genome. This confirms the efficacy of the microarrays in 
detecting genome wide DNA damage events. Comparing with the yeast microarray 
data presented in chapter 3 the human microarray outputs are more reproducible and 
higher correlation values are evident between experimental and predicted data for 
cisplatin samples but slightly lower correlation for oxaliplatin. As seen in yeast, in 
each case, the highest correlation is seen with the predicted profile for the 1,2-d(GpG) 
adduct universally. Correlation values in the human datasets are a little higher for the 
other adduct products than seen in the yeast work, but in each case these correlations 
never exceed that seen with the 1,2-d(GpG) adduct. Possible reasons for why these 
correlation values may not be higher include bioinformatic and experimental, and 
were discussed in the discussion of chapter 3 and apply again here. One observation is 
that the correlation values are similar between in vitro and cellular treatment 
conditions suggesting that damage induction may not be significantly affected by 
chromatin structure for the lesions examined. For these assays high doses of drug 
were used and it is possible that the effect of chromatin structure on damage induction 
could be more prominent at lower drug doses. Alternatively, it is possible that the 
importance of chromatin structure will be more apparent when repair of the damage is 
investigated. These questions will be investigated in more detail in chapter 6. 
 The major achievement of the work presented in this chapter is the technical 
development and robust validation of a novel and sophisticated laboratory assay able 
to detect and measure genomic DNA damage events at high resolution within the 
human genome. This has been developed using the platinum analogue chemotherapy 
agents as a paradigm but has the potential to be applied to other DNA damaging 
lesions as long as a suitable antibody exists to detect that damage. This rigour has 
been demonstrated using the measurement of UV-induced CPD damage as an 
example (figure 4.15). The DIP protocol optimisation steps presented here are critical 
steps as these now increase the sensitivity of the assay considerably from that 
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presented in chapter 3, allowing sufficient sensitivity for potentially detecting 
platinum-DNA adducts in clinical samples. The potential basic scientific and 
translational clinical research applications of this assay are broad and these will be 
discussed in detail in the final discussion in chapter 7. 
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Chapter 5 
Comparative analyses of platinum-induced and UV-
induced DNA damage datasets generated using DIP-
chip in Saccharomyces cerevisiae and human 
fibroblast cells 
 
 
5.1 Introduction  
 
In the previous two chapters the methods for developing the DIP-chip assay, first in S. 
cerevisiae then in human dermal fibroblast cells, have been described in detail. In this 
chapter the genomic platinum-induced DNA damage datasets generated in both 
organisms are now analysed in more depth. Comparative analyses are performed 
between platinum-induced DNA damage datasets and UV-induced DNA damage 
datasets in both S. cerevisiae and human cells. These analyses are useful as they allow 
these datasets to be examined within different biological contexts, and also provide 
further validation of the DIP-chip methodology and the datasets developed so far. The 
work presented in this chapter provides examples of how these genome-wide studies 
may be analysed and how comparisons may be made between different datasets to 
allow differences between them to be detected. Finally it is also demonstrated how 
analysing these genome-wide datasets in particular biological contexts allows patterns 
to emerge allowing interesting and important observations to be made. 
 A number of different bioinformatic approaches are used in this chapter to 
perform the analyses presented and these are described in each relevant section. In the 
first part of this chapter (section 5.3.1) the cisplatin and oxaliplatin-induced DNA 
damage datasets generated in S. cerevisiae in chapter 3 are analysed and in the second 
part (section 5.3.2) the cisplatin, oxaliplatin and UV-induced DNA damage datasets 
generated in human dermal fibroblast cells in chapter 4 are analysed.  
 The validation analyses presented in chapters 3 and 4 have predominantly 
concentrated on examining experimental datasets for how similar these are to one 
another, however, for comparative analysis it is more relevant to examine the 
Chapter 5. Comparative analysis of DNA damage 
 
 183 
differences between these datasets and the reasons for these. The basic and clinical 
research applications of this assay are likely to depend on the ability to sensitively 
detect differences between DNA damage induced genomic profiles, for example 
between DNA damage profiles from repair proficient and repair deficient cell lines or 
between DNA damage profiles from a patient responding to chemotherapy versus a 
non-responder. The previous chapters have demonstrated how datasets can be 
compared and analysed by examining individual short sections of the genome. A far 
more powerful approach however is to perform comparative analysis on the whole 
genomic dataset and in this chapter examples are given for how this can be achieved.  
 
 
5.2 Methods 
 
The methods employed for generating the DIP-chip microarray datasets presented in 
this chapter are described in chapter 3 for S. cerevisiae yeast cells and in chapter 4 for 
human dermal fibroblast cells. Cisplatin, oxaliplatin and UV-treated cells are analysed 
for both yeast and human cells and the methods for cell treatments and DNA 
preparation are described in chapter 2. 
 
5.2.1 DIP-chip DNA microarray datasets used for analysis  
The analysis presented in this chapter was performed using the DIP-chip microarray 
datasets generated in yeast S. cerevisiae cells presented in chapter 3, and human 
dermal fibroblast cells presented in chapter 4. 
 In this chapter, for the analysis performed in yeast cells (presented in section 
5.3.1) cisplatin and oxaliplatin-induced DNA damage experimental profiles generated 
form cells treated in culture are used. In each case the mean of two datasets is used. 
Similar DIP-chip DNA damage datasets have also been generated analysing UV-
induced CPD formation. The UV-induced CPD microarray datasets have been 
generated and provided by a research colleague, Dr Shirong Yu. For these datasets, 
yeast cells were treated in culture with 100 J/m2 UV irradiation and DNA extracted 
immediately and processed for DIP-chip as described in chapter 3. DIP was 
conducted using an anti-thymine dimer antibody and the same format DNA 
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microarrays were used. For these UV-treated datasets the mean of four repeat datasets 
is used.  
 For the analysis performed in human fibroblast cells, presented in section 
5.3.2 of this chapter, the experimental DNA damage datasets generated from cisplatin, 
oxaliplatin and UV treated cells in culture are presented. In each case the results 
presented represent the means of two biological repeat experiments. 
  
5.2.2 Analysis of yeast and human DIP-chip DNA microarray 
datasets 
Microarray data analysis was conducted as described in section 3.2.6, chapter 3, using 
the R statistical programming language (R version 2.15.2). All of the analysis 
presented in this chapter was conducted using R and analysed using Sandcastle, a 
suite of tools written in R which allows data to be analysed using bioinformatic 
methods developed by Dr M Bennett, PhD thesis 2012. Sandcastle allows all of the 
analyses performed in this chapter to be conducted and also allows the compilation of 
each the graphical outputs presented here. The Sandcastle software and full 
documentation are available for download from http://reedlab.cf.ac.uk. 
 
 
5.3 Results  
 
The results presented here are divided into two sections. In section 5.3.1 results from 
the analysis of yeast datasets are presented and in section 5.3.2 results from the 
analysis of human datasets are presented. 
 
5.3.1 Analysis of DIP-chip datasets generated in S. cerevisiae 
The validated platinum-induced DNA damage microarray datasets generated in S. 
cerevisiae and presented in chapter 3, and the UV treated datasets generated by Dr 
Yu, were used for the microarray data analysis presented in this section. Initially, 
comparative analysis was performed between cisplatin and oxaliplatin-induced DNA 
damage, followed by cisplatin and UV radiation-induced CPD datasets. Subsequently, 
outlier detection methodology is presented for analysing and detecting differences 
between whole microarray datasets. 
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5.3.1.1 Comparative observations between cisplatin, oxaliplatin and UV-induced 
DNA damage profiles in S. cerevisiae 
To assess the similarities between these different DNA damage profiles, these are 
now directly compared in this section. Firstly, the mean of two cisplatin-treated 
datasets was compared with the mean of two oxaliplatin-treated datasets. Plotting the 
log2 IP/IN ratio of these two datasets against each other as a scatter plot demonstrates 
a linear relationship (Pearson’s product moment correlation coefficient r = 0.703) and 
equally, the genome plots of these two datasets follow very similar genome profiles 
(figure 5.1). This suggests very similar patterns of initial adduct formation with these 
drugs, not an unexpected finding given that the sequence specificity of these drugs is 
the same. The degree of similarity demonstrated here acts as further validation for the 
functioning of this assay. 
 Cisplatin adduct formation was then compared with UV CPD formation. The 
formation of CPDs is also sequence specific and the quantitative ratio of CPD 
formation after UV irradiation at TT:TC:CT:CC sequences is roughly 68:16:13:3 
respectively, as measured in plasmid DNA and DNA from human cells (Mitchell et 
al., 1992) (Tornaletti et al., 1993). Based on this sequence information and these 
quantitative ratios the mathematical algorithm (PredictProfile function within 
Sandcastle suite) generating predicted profiles of sequence specific DNA damage 
events, was applied. This generated a theoretical genomic distribution of UV-induced 
CPD damage in the same way as was done for platinum-induced DNA damage (see 
section 3.3.3, chapter 3) (Teng et al., 2011). In this case the UV-induced CPD profiles 
match the predicted profile for CPD formation with a Pearson’s correlation of 0.62.  
 Given that cisplatin adducts form at purine dinucleotide sequences and CPDs 
form at pyrimidine dinucleotide sequences and also that experimental cisplatin 
profiles represent GG intrastrand adducts whilst the experimental CPD profiles 
represent CPD formation at predominantly TT and TC sequences limited association 
would be expected between these datasets. This is demonstrated in a scatter plot in 
figure 5.2 (a) where the log2 IP/IN ratios of cisplatin and UV datasets plotted against 
each other confirm a lack of association (r = -0.3). Furthermore, when the genome 
plots of UV-induced CPD formation and cisplatin-induced adduct formation are 
plotted together the peaks and troughs of each profile often oppose one another and in 
certain regions the two profiles demonstrate reverse patterns to each other (figure 5.2 
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(b)). This result is interesting as it further demonstrates the validity of this technique 
in being able to reflect the biology of the DNA damage lesions forming at opposing 
sites in DNA. The same reverse pattern is seen when the oxaliplatin-induced DNA 
damage profile is plotted with UV-induced CPD formation (figure 5.2 (c)). 
 
 
 
 
Figure 5.1 - Data comparing cisplatin- and oxaliplatin-induced DNA damage in yeast cells 
treated in culture. In each case the cisplatin and oxaliplatin datasets represent mean values of 2 
biological repeat samples. 5.1 (a) presents a scatter plot as a ‘heat plot’ whereby the darker blue regions 
represent the greater density of data and the black line represents the line of x = y. Log2 IP/IN values 
for each microarray feature are plotted and this scatter plot demonstrates a linear association between 
cisplatin and oxaliplatin microarray datasets (Pearson’s product moment correlation coefficient 0.703). 
In 5.1 (b) and (c) the log2 IP/IN ratios are plotted as genome plots demonstrating the distribution of 
platinum-induced DNA damage in two sections of chromosome 4. These profiles display the 
distribution of cisplatin-induced DNA damage (black profile) and oxaliplatin-induced DNA damage 
(red profile) and the two profiles can be seen to match each other closely. The yellow boxes show ORF 
positions and the grey dots show microarray feature positions. 
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Figure 5.2 - Data comparing platinum- and UV-induced DNA damage in yeast cells treated in 
culture. In each case the cisplatin dataset represents the mean values of 2 biological repeat samples, 
whilst the UV treated dataset represents the mean values of 4 biological repeat samples. 5.2 (a) presents 
a scatter plot as a ‘heat plot’ whereby the darker blue regions represent the greater density of data and 
the black line represents the line of x = y. Log2 IP/IN values for each microarray feature are plotted and 
this plot demonstrates no association between cisplatin and UV-induced CPD microarray datasets 
(Pearson’s product moment correlation coefficient -0.3). In 5.2 (b) the log2 IP/IN ratios are plotted as a 
genome plot demonstrating the distribution of cisplatin-induced DNA damage (black profile) and UV-
induced CPD formation (red profile) in chromosome 4. In 5.2 (c) the log2 IP/IN ratios are plotted as a 
genome plot demonstrating the distribution of oxaliplatin-induced DNA damage (black profile) and 
UV-induced CPD formation (red profile) in chromosome 4. In each of these genome plots, in certain 
regions, the CPD distribution can be seen to be the reverse of the platinum-induced DNA damage 
profile. The yellow boxes show ORF positions and the grey dots show microarray feature positions. 
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5.3.1.2 Comparative analysis of genome-wide platinum-induced DNA 
damage datasets using outlier detection methodology 
In section 5.3.1.1 visual observations were made by comparing the short sections of 
the different genome-wide DNA damage datasets presented in figure 5.1 and 5.2. In 
this section an approach is described for analysing and detecting differences between 
datasets using the microarray data as a whole. Analyses are presented examining 
differences between whole microarray datasets for cisplatin and oxaliplatin-induced 
DNA damage and for platinum-induced DNA damage and the predicted model for 
platinum adduct formation, using outlier detection methodology. This also allows 
some of the ideas outlined in the discussion of chapter 3 regarding differences 
between the experimental profiles and the predicted profiles to be explored in more 
detail. 
 Firstly, variation between experimental profiles for cisplatin and oxaliplatin-
induced adduct formation from cells treated in culture was examined. This was done 
to validate the findings presented in figure 5.1, where a linear relationship between 
these variables is shown and the profiles are very similar for the section of 
chromosome 4 presented. Secondly, variation between experimental platinum-
induced DNA damage profiles and the predicted microarray profiles generated using 
the PredictProfile function within Sandcastle, was examined to further characterise 
the differences between these datasets. Possible explanations for why differences 
occur between the experimental and predicted profiles were outlined in the discussion 
in chapter 3. Considering these ideas briefly again here, these include variations in 
either the experimental or predicted microarray datasets individually or a combination 
of both. Whichever is the case, it is likely that the majority of the variation occurring 
between these two datasets is as a result of random inherent technical microarray 
variability, random variations in locations of the genomic damage induction or 
inaccuracies in the predicted profile. If the variation between these datasets is 
predominantly due to these random variations then it is reasonable to assume that the 
majority of the differences between experimental and predicted profiles will follow a 
normal distribution. Conversely, there may be regions of the genome where genuine 
biological reasons account for some of the variation in experimental profiles, causing 
higher or lower levels of DNA damage induction following treatment of cells in 
culture. Such variation caused by biological processes may occur non-randomly and 
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could represent regions of ‘hot’ or ‘cold’ spots of DNA damage. These key regions of 
non-random variation may lie outside the normal distribution and may be detected 
using outlier detection methodology, and this will be discussed here. 
 To identify these genomic regions, firstly, the differences between the 
experimental DNA damage and predicted DNA damage values were calculated by 
subtracting one dataset from the other. Differences between the averaged cisplatin-
induced DNA damage datasets and the predicted profile for 1,2d(GpG) adducts are 
shown as a histogram in figure 5.3. The overlying normal distribution curve is added 
to the histogram using the mean and standard deviation calculated from the difference 
values (0 and 0.3 respectively). This shows that the majority of the calculated 
difference values approximate the normal distribution. This highlights, as expected, 
that most of these differences are occurring randomly throughout the genome and that 
most of the DNA damage events are occurring at expected rates and are not 
associated with ‘hot’ or ‘cold’ spots of DNA damage.  
 
 
   
Figure 5.3 - Histogram of the differences between cisplatin-induced DNA damage datasets and 
the predicted profile for 1,2d(GpG) intrastrand crosslink. Differences represent log2 IP/IN ratio 
values and the y axis displays the relative proportions of each difference value. The red line shows the 
normal distribution calculated from the mean and standard deviation of the difference values. 
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 To examine these calculated differences in more detail, and to detect any 
values that deviate from the normal distribution, the differences were plotted as a Q-Q 
plot whereby the differences are plotted as quantiles against a normally distributed 
theoretical set of quantiles. For outlier detection, the “extremevalues” package (van 
der Loo, 2010) was used within the ‘R’ statistical software programme (version 
2.15.2). This expresses the differences between datasets as quantiles, estimates their 
underlying distribution and uses outlier detection to define the outlying difference 
values not drawn from the normal distribution. Examples of the outlier detection are 
shown in figure 5.4 where the differences between cisplatin and oxaliplatin-induced 
DNA damage from cells treated in culture are presented (fig. 5.4 (a)), along with the 
differences between experimental and predicted profiles for cisplatin (fig. 5.4 (b)) and 
oxaliplatin (fig. 5.4 (c)) treated datasets and in each case these differences are plotted 
as Q-Q plots. 
 In each of these Q-Q plots (figure 5.4 (a-c)) it is evident that the majority of 
the differences lie along the black line (x = y) approximating a normal distribution. In 
each case however, these plots demonstrate values at either end of this range, detected 
by the outlier detection software, which deviate from the normal distribution and are 
highlighted in red. These are the outlying differences. Figure 5.4 (a) shows a Q-Q plot 
of the differences between the averaged cisplatin and oxaliplatin treated datasets 
(shown previously in figure 5.1) and only 14 microarray features are detected as 
outlying differences between the two datasets, confirming the overall similarity and 
consistency between these datasets. Figures 5.4 (b,c) show Q-Q plots of the 
differences between cisplatin and oxaliplatin treated datasets respectively with the 
predicted models for platinum induced DNA damage. 61 and 44 microarray features 
(~0.14% and 0.09% of all microarray features) were detected as outlying differences 
for the cisplatin and oxaliplatin datasets respectively. In both cases, the majority of 
outlying differences deviating from the normal distribution have higher values, 
indicating greater DNA damage in the experimental datasets than prediction. 
 The positions of these outlying features were then located and marked on 
genome plots with a red cross and some examples of these are given in the genome 
plots below the corresponding Q-Q plot in figure 5.4 (whole genome plots 
demonstrating outlying features can be seen in the electronic appendix, chapter 5). 
For both cisplatin and oxaliplatin these outlying differences occur, almost exclusively, 
at individual microarray features scattered throughout the genome, rather than 
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clustered together in certain regions. Whilst these findings of small numbers of 
individual sites of difference scattered throughout the genome do not suggest that 
regions within the genome of ‘hot’ or ‘cold’ spots of DNA damage occur due to 
genuine biological changes in damage induction at different genomic locations, 
further testing with replicate samples would be required to investigate this further. 
Furthermore, these data could be analysed and combined with other, more robust, 
outlier detection methods to further evaluate these findings. This ability to detect 
variations in DNA damage levels between experimental datasets and predicted values 
could have important biological implications. 
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Figure 5.4 - Global genome comparative analysis between microarray datasets using outlier 
detection methodology. In each case in this figure, data generated from treating cells in culture are 
presented. In 5.4 (a), (b) and (c) Q-Q plots are presented and in each case quantiles representing 
differences between datasets are plotted against a theoretical normal distribution. In 5.4 (a) differences 
are calculated between the averaged cisplatin and oxaliplatin treated datasets. In 5.4 (b) differences are 
calculated between the averaged treated cisplatin datasets and the predicted profile and in 5.4 (c) 
differences are calculated between the averaged treated oxaliplatin datasets and the predicted profile. In 
each case the difference quantiles and theoretical normal distribution quantiles are shown as dots. The 
black line of x = y represents normally distributed data and the majority of the difference values lie 
along this line. Some values deviate from this line, with most of these deviating from the line at the 
high end and the red dots represent the outlying differences detected by outlier methodology. In 5.4 (a), 
(b) and (c) 14, 61 and 44 features are recognised as outliers respectively. The genomic location of these 
outliers can then be demonstrated on genome plots by red crosses on the gene annotation data. Some 
examples of the genomic locations of these outliers are demonstrated in the figure with two snapshots 
of genome profiles with the outliers marked by red crosses given below the corresponding Q-Q plot. In 
each genome plot the black profile represents the predicted dataset, whilst the red profile represents the 
platinum treated profile. 
 
 
 
 
a c
VPS3
PUF6
ITR1
SEC20
RPL37B
SAM2
LPP1
SPG3
PSP1
YDR506C
tL(CAA)D
GIN4
GNP1
YDR510C−A
EMI1
YDR514C
EMI2
URC2
SPS2
SPS1
AGE1
YDR524C−B
YDR524C−A
YDR526C
SNR84
QCR7
APA2
KRE28
LCD1
PLM2
YDR509W
SMT3
ACN9
GRX2
SLF1
GRH1
EUG1
FPR2
YDR521W
YDR524W−C
API2
SNA2
RBA50
HLR1
CAB1
● ● ● ● ● ● ● ● ● ● ● ●●●●● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ●● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ● ●● ●● ● ● ●● ●● ●●● ●●● ● ● ● ●● ● ● ● ●● ●● ● ● ●● ● ● ● ● ●●● ● ●● ● ● ● ● ●● ● ● ●● ●● ● ● ●● ●● ● ● ●● ●●●● ● ● ● ● ● ●●● ●● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ●● ●● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ●●●● ● ●●● ● ● ● ●● ●● ●● ●● ● ● ● ● ●Chr. 4
lo
g2
 B
in
di
ng
0
1
2
3
4
5
1440000 1450000 1460000 1470000 1480000 1490000 1500000
KRE28
HSP31
FIT1
YDR535C
YDR537C
IRC4
YDR541C
YDR543C
YDR544C
YDR545C−A
STL1
PAD1
FDC1
PAU10
YRF1−1
● ●● ● ●●● ●● ● ● ●● ● ● ● ● ● ●● ● ● ●●● ●● ● ● ● ● ● ●● ● ● ●● ● ●● ●●● ● ● ● ●● ● ● ●● ●● ● ● ● ● ●●● ● ● ●●● ● ● ●● ● ● ●●● ●● ● ● ● ●●● ● ● ● ●● ● ●● ●●Chr. 4
lo
g2
 B
in
di
ng
0
1
2
3
4
5
1500000 1510000 1520000 1530000 1540000 1550000 1560000
YEL077C
YEL076C−A
YEL076C
YEL075C
YEL073C
HXT13
YEL068C
YEL067C
AVT2
CAN1
CIN8
PRB1
SOM1
YEL057C
POL5
SNR80
RPL12A
MAK10
RML2
YEL077W−A
YEL075W−A
YEL074W
RMD6
DLD3
DSF1
HPA3
SIT1
NPR2
HHY1
PCM1
HAT2
YEL053W−A
AFG1
VMA8
YEL050W−A
● ● ● ●● ●●● ●● ●●● ● ● ●● ● ●● ● ● ●● ●● ● ●●● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ●●● ●● ●● ● ● ●● ● ●●● ● ● ● ●●● ● ●● ●●● ●●● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ●● ● ● ● ● ●● ● ●●●● ●● ●● ● ● ●●●●●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ●● ●● ● ●●● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ●●● ● ● ● ●Chr. 5
lo
g2
 B
in
di
ng
0
1
2
3
4
5
0 10000 20000 30000 40000 50000 60000
RML2
tG(GCC)E
TCA17
YEL047C
GLY1
YEL045C
CYC7
RAD23
ANP1
UTR5
YEL034C−A
YEL032C−A
YEL030C−A
BUD16
YEL025C
YEL023C
YEL020C−B
RPR1
YEL020C
SNR67
SNR53
PAU2
IES6
YEL043W
GDA1
YEF1
UTR2
UTR4
HYP2
MTC7
tS(AGA)E
MCM3
SPF1
ECM10
YEL028W
IMT4
VMA3
SNU13
RIP1
GEA2
URA3
TIM9
● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ●●● ●● ● ●● ●● ●● ● ● ●● ●● ● ●● ●● ● ●●● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ●● ● ●● ● ● ● ● ● ●● ●●● ● ● ● ●● ● ● ●● ●● ● ●● ● ●● ● ● ● ●● ●● ● ● ● ●● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●Chr. 5
lo
g2
 B
in
di
ng
0
1
2
3
4
5
60000 70000 80000 90000 100000 110000 120000
Theoretical quantiles 
D
if
fe
re
nc
e 
qu
an
ti
le
s 
Theoretical quantiles 
b 
D
if
fe
re
nc
e 
qu
an
ti
le
s 
Theoretical quantiles 
D
if
fe
re
nc
e 
qu
an
ti
le
s 
Chr. 5 
NTH2
RER2
GPI18
DSF2
FLR1
HHF1
IPP1
YBR012C
YBR013C
GRX7
MNN2
KAP104
GAL7
GAL10
CHS3
OLA1
ETR1
YBR027C
YPK3
CDS1
COQ1
RCR1
UGA2
HHT1
YBR012W−A
YBR012W−B
tT(AGU)B
YBR016W
GAL1
FUR4
POA1
SCO2
RKM3
● ●●● ● ● ● ● ● ●●● ● ● ●● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ●●● ● ●●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●●● ● ●●●● ●●● ● ●● ●●● ● ● ● ●●● ●● ● ● ● ●● ● ● ● ●● ●●● ● ●●● ●● ● ● ● ●●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ●● ● ●● ● ● ●●● ● ● ●●●● ● ● ● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
5
240000 250000 260000 270000 280000 290000 300000
HMT1
PDX3
SNR161
CSG2
SCO1
CST26
QDR3
TCM62
tV(UAC)B
GIP1
ZTA1
REB1
REG2
RFS1
YBR053C
PRP6
YBR056C−B
MUM2
UBP14
TSC3
AKL1
RPL4A
YBR032W
EDS1
TLC1
CHS2
ATP3
FIG1
FAT1
FMP23
RPS11B
YBR051W
YRO2
tL(UAA)B2
YBR056W
tQ(UUG)B
YBR056W−A
● ● ●● ● ● ● ● ● ● ●●● ● ●● ● ● ●●● ● ● ● ● ●● ● ● ●●●● ●● ● ●● ● ●●● ● ● ● ●● ● ● ● ● ● ●●●● ● ● ● ● ● ●● ● ●●● ●● ●●● ● ● ●●● ● ● ●● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ●● ●●● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ●● ● ●●● ● ●● ● ●●●● ●●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●●●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ● ● ● ●● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
5
300000 310000 320000 330000 340000 350000 360000
AKL1
ORC2
TRM7
YBR062C
YBR063C
ECM2
NRG2
TIP1
BAP2
TAT1
ALG14
YBR072C−A
YBR076C−A
SLM4
RPG1
SEC18
SPT7
UBC4
RPL19A
YBR085C−A
YBR064W
YBR071W
HSP26
RDH54
YBR074W
ECM8
ECM33
tR(UCU)B
tD(GUC)B
TEC1
MIS1
AAC3
● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●●●● ● ● ● ● ●●● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ●● ●● ● ● ● ● ● ●● ●● ●●● ● ● ● ● ● ●● ●● ● ●●● ●● ● ● ● ● ● ● ● ● ●●●●● ● ●● ● ● ● ●●● ● ● ●●●● ● ● ●●●● ●●●●● ● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ●● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
5
360000 370000 380000 390000 400000 410000 420000
IST2
POL30
NHP6B
YBR090C
TIM12
PHO3
PHO5
RXT2
YBR099C
FES1
EXO84
YBR103C−A
VID24
IML3
CMD1
YSA1
CYC8
LYS2
YBR116C
TKL2
RFC5
YBR089W
PBY1
YBR096W
VPS15
MMS4
SIF2
YMC2
PHO88
AIM3
YBR109W−A
ALG1
SUS1
YBR113W
RAD16
TEF2
MUD1
● ● ● ● ● ● ● ● ●● ● ● ● ●●●● ●● ●● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ●● ●● ● ● ●● ●●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ●● ● ●●● ● ●● ●● ● ● ● ● ● ● ●● ●●● ●●●● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ●● ●● ● ● ● ● ●● ●● ● ● ●● ● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
5
420000 430000 440000 450000 460000 470000 480000
Chr. 2 Chr. 2 
NTH2
RER2
GPI18
DSF2
FLR1
HHF1
IPP1
YBR012C
YBR013C
GRX7
MNN2
KAP104
GAL7
GAL10
CHS3
OLA1
ETR1
YBR027C
YPK3
CDS1
COQ1
RCR1
UGA2
HHT1
YBR012W−A
YBR012W−B
tT(AGU)B
YBR016W
GAL1
FUR4
POA1
SCO2
RKM3
● ●●● ● ● ● ● ● ●●● ● ● ●● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ●●● ● ●●● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●●● ● ●●●● ●●● ● ●● ●●● ● ● ● ●●● ●● ● ● ● ●● ● ● ● ●● ●●● ● ●●● ●● ● ● ● ●●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ●● ● ●● ● ● ●●● ● ● ●● ●● ● ● ● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
240000 250000 260000 270000 280000 290000 300000
HMT1
PDX3
SNR161
CSG2
SCO1
CST26
QDR3
TCM62
tV(UAC)B
GIP1
ZTA1
REB1
REG2
RFS1
YBR053C
PRP6
YBR056C−B
MUM2
UBP14
TSC3
AKL1
RPL4A
YBR032W
EDS1
TLC1
CHS2
ATP3
FIG1
FAT1
FMP23
RPS11B
YBR051W
YRO2
tL(UAA)B2
YBR056W
tQ(UUG)B
YBR056W−A
● ● ●● ● ● ● ● ● ● ●●● ● ●● ● ● ●●● ● ● ● ● ●● ● ● ●●●● ●● ● ●● ● ●●● ● ● ● ●● ● ● ● ● ● ●●●● ● ● ● ● ● ●● ● ●●● ●● ●●● ● ● ●●● ● ● ●● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ●● ●●● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ●● ● ●●● ● ●● ● ●●●● ●●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●●●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ● ● ● ●● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
300000 310000 320000 330000 340000 350000 360000
AKL1
ORC2
TRM7
YBR062C
YBR063C
ECM2
NRG2
TIP1 BAP2
TAT1
ALG14
YBR072C−A
YBR076C−A
SLM4
RPG1
SEC18
SPT7
UBC4
RPL19A
YBR085C−A
YBR064W
YBR071W
HSP26
RDH54
YBR074W
ECM8
ECM33
tR(UCU)B
tD(GUC)B
TEC1
MIS1
AAC3
● ● ●● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●●●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●●●● ● ● ●● ●● ● ● ● ● ● ●● ●● ●●● ● ● ● ● ● ●● ●● ● ●●● ●● ● ● ● ● ● ● ● ● ●●●●● ● ●● ● ● ● ●●● ● ● ●●●● ● ● ●●●● ●●●●● ● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ●● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
360000 370000 380000 390000 400000 410000 420000
IST2 POL30
NHP6B
YBR090C
TIM12
PHO3
PHO5
RXT2
YBR099C
FES1
EXO84
YBR103C−A
VID24
IML3
CMD1
YSA1
CYC8
LYS2
YBR116C
TKL2
RFC5
YBR089W
PBY1
YBR096W
VPS15
MMS4 SIF2
YMC2
PHO88
AIM3
YBR109W−A
ALG1
SUS1
YBR113W
RAD16
TEF2
MUD1
● ● ● ● ● ● ● ● ●● ● ● ● ●●●● ●● ●● ● ● ● ● ● ● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ●● ●● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ●● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●Chr. 2
lo
g2
 B
in
di
ng
0
1
2
3
4
420000 430000 440000 450000 6 000 470000 480000
CDC40
ESF1
YDR366C
XRS2
YDR370C
YDR371C−A
VPS74
YDR374C
BCS1
LSM6
YDR379C−A
YDR381C−A
NKP1
ATO3
YDR387C
UBA2
SUF3
YDR391C
ESC2
tK(CUU)D1
SEM1
YDR365W−B
YDR365W−A
KEI1
YPR1
CTS2
FRQ1
YDR374W−A
ARH1
ATP17
RGA2
ARO10
YRA1
RPP2B
EFT2
MUS81
RVS167
SAC7
SPT3
SHE9
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●●● ● ● ●● ●● ● ●● ●●●●●● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ●● ●●●● ● ● ● ● ●● ●● ● ● ● ●● ● ●● ● ●●● ●● ● ●● ●● ● ● ●● ●●●● ●●● ●● ●● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●Chr. 4
log
2 B
ind
ing
0
1
2
3
4
1200000 1210000 12 00 1230000 1240000 1250000 1260000
NCB2
DIT2 RPB7
TRS120
ADE8
STE14
DFM1
YDR413C
ERD1
YDR415C
YDR417C
SIP1 CAD1
DYN2
SHE9
RPT3
SXM1
YDR396W
UTP5
HPT1
URH1
YDR401W
DIT1
MRP20
PDR15
YDR406W−A
SIZ1
RRP17
SYF1
RPL12B
RAD30
tS(AGA)D3
HKR1
ARO80
●● ● ● ● ●● ● ● ● ●●● ●● ● ● ●● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ● ●● ●●●●● ● ●● ● ● ●● ● ●●● ●●● ● ● ●●● ● ● ●● ● ● ● ●●●●● ● ● ● ● ●● ●● ● ● ● ● ●● ●● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ●● ● ●●● ● ● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ●Chr. 4
log
2 B
ind
ing
0
1
2
3
4
1260000 1270000 1280000 1290000 1300000 1310000 1320000
YDR426C
BNA7
TIF35
CYM1
PPM1
APT2
SSN2
YDR445C
tK(CUU)D2
RPS17B
UTP6
YHP1
TSA2
GUK1
YDR455C
SNX41
RPN9
YDR431W
NPL3
YDR433W
GPI17
PPZ2
GPI19
THI74
LRS4
DOT1
YDR442W
YDR444W
ECM11
ADA2
RPS18A
PPN1
NHX1
TOM1
● ● ●● ●●● ● ● ● ● ●● ● ● ●● ● ● ● ●●● ● ● ● ● ●● ●● ●●● ● ●● ● ● ● ●●●● ● ● ●● ● ● ● ●●● ● ●● ●● ● ●●● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ●● ● ●●● ● ● ● ● ● ●● ●● ● ● ● ●●● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●●●● ●● ● ● ● ● ● ●● ● ●● ●●● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ● ●● ● ●● ●●● ● ● ●● ●● ● ● ● ● ●●● ● ●● ●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ●Chr. 4
log
2 B
ind
ing
0
1
2
3
4
1320000 1330000 1340000 1350000 1360000 1370000 1380000
HEH2
PFA5
YDR461C−A
YDR464C−A
RMT2
YDR467C
TLG1
UGO1
PRP3
JIP4 YDR476C
PEX29
PHO8
CWC21
VPS72
VPS60
RIB3 PAC11
PKH1
YDR491C
VPS3
TFB3
MFA1
MRPL28
STP1
SPP41
PKH3
SDC1
RPL27B
SNR13
TRS31
SNF1
SNM1
DIG2
KRE2
VPS52
SLD5 IZH1
MZM1
RSM28
● ●● ●● ● ● ●● ● ● ● ●● ●● ●● ● ● ● ● ● ● ●● ● ●● ●●●● ● ● ● ● ● ● ● ● ● ● ●● ●● ●●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ●● ●● ● ●●● ●● ● ● ● ●●● ● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ● ●● ●●● ●●● ● ● ● ●● ● ●●●● ● ● ● ● ●● ● ● ●● ● ●●●●● ● ● ●● ● ● ● ● ● ●● ● ●● ● ●● ●●● ● ● ● ●●● ● ● ● ● ● ● ● ●●●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●Chr. 4
log
2 B
ind
ing
0
1
2
3
4
1380000 1390000 1400000 1410000 1420000 1430000 1440000
Chapter 5. Comparative analysis of DNA damage 
 
 193 
5.3.2 Analysis of DIP-chip datasets generated in human fibroblast 
cells 
The validated platinum- and UV-induced DNA damage microarray datasets generated 
in human fibroblast cells and presented in chapter 4 were used for the microarray data 
analyses presented in this section. Initially, comparative analysis was performed using 
the cisplatin-, oxaliplatin-, and UV-induced DNA damage datasets. Subsequently, a 
method is presented for analysing whole microarray datasets by examining and 
comparing DNA damage induction at repeat sequences of DNA. 
 
5.3.2.1 Comparative observations between cisplatin, oxaliplatin and UV-induced 
DNA damage profiles in human fibroblast cells 
Having generated and validated human microarray data measuring cisplatin, 
oxaliplatin and UV radiation-induced DNA damage in chapter 4, these datasets were 
now used to perform a comparative analysis (as performed in section 5.3.1.1). In each 
case DNA damage datasets generated from fibroblasts treated in culture were used. 
 Firstly, the mean of two cisplatin-treated datasets was compared with the 
mean of two oxaliplatin-treated datasets. Plotting the log2 IP/IN ratio of these two 
datasets against each other as a scatter plot demonstrates a linear association between 
them (Pearson’s product moment correlation coefficient, r = 0.60, figure 5.5 (a)) and 
equally, the genome plots of these two datasets follow similar distributions (figure 5.5 
(b,c)). These observations concur with those made in yeast cells (presented in section 
5.3.1.1), and again suggest similar distributions of DNA damage induction with these 
two drugs and further validates the human DIP-chip assay. Visual assessment of the 
profiles in figure 5.5 (b,c) also demonstrates that even when analysing profiles that 
appear similar over short sections of the genome such as these, it is possible to 
identify some regions where difference in DNA damage induction occurs.  
 As previously discussed, given the different sequence specificity of cisplatin 
and UV induced DNA damage, limited association between these datasets would be 
expected. This is demonstrated in figure 5.6 (a) where a scatter plot of the log2 IP/IN 
ratios of both datasets plotted against each other shows no association (Pearson’s 
correlation coefficient, r = -0.24). Once again, when genome plots of UV-induced 
CPD and cisplatin-induced adducts are plotted together the opposing trend of these 
profiles is evident (figure 5.6 (b)). This opposing pattern is also evident when the two 
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predicted profiles for these different damages are plotted for the same region of 
chromosome 17 (figure 5.6 (c)). This was further interrogated by analysing the 
nucleotide composition in two regions highlighted in figure 5.6 (b). Two regions of 
chromosome 17, one between coordinates 14,906,000 and 14,907,000 and one 
between coordinates 14,908,500 and 14,909,000 (based on the latest human genome 
build, UCSC hg19, http://genome.ucsc.edu) were analysed to examine regions of high 
UV-induced and cisplatin-induced DNA damage respectively. These regions were 
selected for this analysis as examples of regions where clear differences were 
apparent, by visual assessment, in both the experimental and predicted profiles. This 
demonstrated a relative preponderance of TT dinucleotide sequences, compared to 
GG (ratio 3:1) in the high UV damage region and a preponderance of GG 
dinucleotide sequences in the high cisplatin damage region. These ratios were 
calculated based on the nucleotide sequence of a single strand of DNA in these 
regions, and these are given in the electronic appendix, chapter 5. These differential 
levels are reflected in both the experimental and predicted profiles in these regions, 
serving as further validation of the information conveyed in these profiles and 
demonstrating their ability to reflect the biology behind DNA damage induction.  
 These comparisons demonstrate how general patterns between datasets are 
evident, as would be expected based on nucleotide sequence and on generating 
predicted profiles of DNA damage. What also begins to emerge here, even by 
analysing these short sections of the genome, is that certain regions of difference also 
exist where these predicted profiles of DNA damage are not followed. An example of 
how these differences may then be examined for the whole microarray data was given 
with the outlier detection example in section 5.3.1.2 in this chapter. Analysis of these 
differences demonstrates how these microarray approaches could potentially be 
applied to detecting differences between damage profiles derived from different 
clinical samples. These are very simple illustrations of some comparisons that can be 
made between different genomic datasets and demonstrate their validity when placed 
in biological context. This also highlights how analysing the differences, where 
predicted patterns of DNA damage are not followed, across whole genomes will 
enable powerful analysis of DNA damage and repair on a previously unattainable 
scale, offering insight into how these events are organised and orchestrated 
throughout the genome. 
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Figure 5.5 - Comparison of cisplatin and oxaliplatin-induced platinum adduct formation in 
fibroblast cells treated in culture. Both cisplatin and oxaliplatin datasets represent average values of 
the 2 biological repeat samples presented in chapter 4. 5.5 (a) presents a scatter plot as a ‘heat plot’ 
whereby the darker blue regions represent the greater density of data. The line on the scatter plot 
represents the ‘line of best fit’. Log2 IP/IN values for each microarray feature are plotted demonstrating 
a linear association between cisplatin and oxaliplatin microarray datasets, (Pearson’s product moment 
correlation coefficient 0.60). In 5.5 (b) and (c) the log2 IP/IN ratios are plotted as a genome plot 
demonstrating the distribution of platinum-induced DNA damage in two sections of chromosome 17. 
These profiles display the distribution of cisplatin-induced DNA damage (black profile) and 
oxaliplatin-induced DNA damage (red profile). 
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Figure 5.6 - Comparison of cisplatin and UV-induced DNA damage in fibroblast cells treated in 
culture. Both cisplatin and the UV datasets represent average values of 2 biological repeat samples. 5.6 
(a) presents a scatter plot as a ‘heat plot’ whereby the darker blue regions represent the greater density 
of data. The line of x = y is shown on the scatter plot. Log2 IP/IN values for each microarray feature are 
plotted demonstrating no association between cisplatin and oxaliplatin microarray datasets (Pearson’s 
product moment correlation coefficient -0.24). In 5.6 (b) the log2 IP/IN ratios are plotted as a genome 
plot demonstrating the distribution of cisplatin-induced (black profile) and UV-induced (red profile) 
DNA damage in a section of chromosome 17. The ratio of different dinucleotide sequences are 
demonstrated in the boxes for the two genomic sections highlighted - one between coordinates 
14,906,000 and 14,907,000 and one between coordinates 14,908,500 and 14,909,000 (based on the 
latest human genome build, UCSC hg19, http://genome.ucsc.edu). In 5.6 (c) the predicted profiles for 
cisplatin-induced (black profile) and UV-induced (red profile) DNA damage are displayed for the same 
region of chromosome 17. 
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5.3.2.2 Examining CPD and cisplatin adduct formation in the context of repeated 
DNA sequences 
The previous sections have demonstrated how datasets may be compared and 
analysed by examining individual short sections of the genome. As described 
previously, a more powerful approach is to perform comparative analysis using whole 
microarray datasets, and the outlier detection method was one example of this. In this 
section another illustration of how this can be achieved is presented, where whole 
array cisplatin and UV-induced DNA damage datasets are analysed in the context of 
repeat DNA sequences. This analysis was prompted by the recent publication of an 
important article in this field of research. 
 Recently, a high-resolution approach to measuring CPD formation in 
telomerase (tert)-immortalised human fibroblasts was reported (Zavala et al., 2013). 
This technique also involved using DIP-chip, but employed a single-channel 
microarray method using Affymetrix Human Tiling 2.0R Array A microarrays to 
examine chromosomes 1 and 6. The authors applied a TileProbe program to normalise 
probe intensities and used computer software to identify CPD peaks (for further 
comparisons between this method and ours, see table 5.1). 
 CPD hotspots were defined based on individual microarray probe signal 
intensities (log2 IP/IN) showing at least a 3-fold enrichment between treated and 
untreated samples. They then observed associations between locations of CPD 
hotspots and certain regions of DNA repeat sequences in chromosomes 1 and 6 and 
noted that CPD hotspots frequently formed in regions abutting repeat elements of 
DNA sequence. Their analysis suggested that >86% of CPD hotspots were associated 
with long interspersed nuclear elements (LINEs), short interspersed nuclear elements 
(SINEs) and long terminal repeats (LTRs). 
 Genomes contain many repeat DNA sequences occurring in multiple copies 
throughout, and in humans repeat elements account for over 50% of the genome (de 
Koning et al., 2011). The length of each individual repeat sequence can vary from 
highly repetitive sequences of 6 - 10 base pairs, such as those seen in telomeres, to 
whole genes which can exist as tandem clusters. Repeat DNA sequences form three 
major types; tandem repeats which lie adjacent to one another and occur in regions 
such as microsatellites and telomeres, and terminal repeats and interspersed repetitive 
DNA sequences which are spread throughout the genome. Interspersed repeat 
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sequences include transposons, LINEs, and SINEs and in mammals the majority of 
LINEs and SINEs are represented by L1 and Alu elements respectively,  
 The Alu family of SINEs are about 300 base pairs long and represent the most 
abundant interspersed repeat in the human genome. These occur roughly every 3300 
base pairs in the human genome, giving an approximate total copy number of 
1,000,000 (Hasler and Strub, 2006). Alu elements are derived from 7SL RNA and 
these are GC rich and characterised by many GG and TT sequences (NCBIGenbank). 
In the paper by Zavala et al. the majority of CPD hotspots are shown to form at SINE 
elements (~76%). The L1 family of LINEs can be up to 6-8,000 base pairs long, and 
occur approximately every 28,000 base pairs in the human genome with a total copy 
number of around 100,000. Characteristics of L1 repeat elements are that these are 
AT rich regions with many A-rich stretches and high CpG dinucleotide content at 
terminals (Hattori et al., 1986, Hohjoh et al., 1990). 
 Clearly, the work by Zavala et al. was of great interest and relevance to the 
work presented here and therefore the DNA damage datasets presented in this chapter 
were analysed in the context of repeated DNA sequences in the same manner. Limited 
data validation had been presented in their study and it was of particular interest to see 
how the predicted models for DNA damage induction presented and used in this 
thesis would relate to DNA damage formation in these regions. 
 Repeat genomic elements were determined using RepeatMasker software in 
the same way as done by Zavala et al. This software screens DNA sequences for 
interspersed and low complexity DNA sequences, and a library for each repeat 
sequence included in the section of chromosome 17 covered by the custom designed 
human microarray was constructed using data based on the latest human genome 
build, UCSC hg19, http://genome.ucsc.edu. Notably, Zavala et al. used the previous 
genome build, version hg18. The experimental UV and cisplatin-induced DNA 
damage profiles, generated in this thesis, were then plotted in each of these repeat 
sequences. 
 In figures 5.7 & 5.8 these data are presented as profile plots, demonstrating the 
distribution of cisplatin and UV-induced DNA damage induction across each repeated 
sequence of DNA including a 5,000 base pair genomic region upstream and 
downstream of this. For each repeated region of DNA presented in these figures the 
experimental DNA damage profile is plotted along with the corresponding predicted 
profile. In the figures, the dashed line represents the mean of each damage profile in 
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that repeated region and the shaded area represents the standard error of this mean. 
The repeat region examined is given in the figure and the legend. 
 Zavala et al. suggested that CPD hotspots were not randomly distributed 
within the genome, but were occurring more prevalently in DNA sequences 
neighbouring repeat DNA elements, particularly Alu repeat sequences. They 
hypothesised that these repeat elements not only had distinctive sequence features but 
also a unique chromatin environment, conferred by enriched nucleosome occupancy. 
It is evident from the data presented in figure 5.7 that CPDs indeed form 
preferentially at Alu sequences, but that this is largely explained by the pattern of the 
predicted profile based on the known sequence of this region. Furthermore, no 
consistent pattern of increased CPD induction at each DNA repeat element is seen. 
For example, high levels of CPD induction are evident at the L1 repeat element but 
lower levels at the ERV-MaLR repeat. Indeed, in each case, apart from the simple 
repeat sequences and regions of low complexity, DNA damage levels follow the 
predicted profiles consistently. This suggests that CPDs form predominantly based on 
sequence specificity rather than due to features of the chromatin structure, as 
speculated by the authors. 
 Cisplatin-induced DNA damage at these repeat sequences generally follows 
the same pattern of reflecting the predicted profile, again suggesting the main 
determinant of their formation is the nucleotide sequence. Interestingly, it is also 
demonstrated in some regions such as the Alu repeat elements, characterised by GG 
and TT rich segments, that patterns of cisplatin and UV-induced damage appear 
similar. Conversely, in other regions such as L1, characterised by AT and A rich 
regions, high UV damage and low cisplatin damage is evident. Such opposing DNA 
damage induction patterns between UV and cisplatin are also seen in the ERV-MaLR 
repeat region, again probably reflecting different nucleotide content here, although the 
sequence is unobtainable. Cisplatin-induced damage in the simple repeat and low 
complexity regions do not appear to follow the predicted pattern of DNA damage, 
again indicating a region where the expected pattern of damage is not evident.  
 The same analysis is repeated comparing cisplatin adduct induction in each of 
the repeat DNA elements, following treatment of naked DNA in vitro and genomic 
DNA treated in culture (figure 5.8). This shows no difference between the two 
treatment types in any of the repeat regions. It was suggested by Zavala et al. that 
CPD hotspot formation was occurring preferentially at repeat DNA elements as these 
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offered a favourable chromatin environment. Our analysis demonstrates that 
nucleosome positioning or chromatin structure does not significantly affect cisplatin-
induced DNA damage patterns in these particular regions of repeat DNA sequences. 
Whilst UV-induced CPD formation has not been examined in this manner, it is 
unlikely that significant differences would be seen with UV given the findings 
demonstrated here with cisplatin.  
 
 
	   (Zavala	  et	  al.,	  2013)	   This	  thesis	  
Cells	   Tert-­‐immortalised	  human	  fibroblasts	   Tert-­‐immortalised	  human	  fibroblasts	  
Experimental	  
method	  
DIP-­‐chip	   DIP-­‐chip	  
DNA	  microarray	  
platform	  
Affymetrix	  one-­‐channel	  Tiling	  microarrays	   Agilent	  custom-­‐designed	  high	  resolution	  two	  channel	  microarrays	  
Coverage	   Chromosome	  1	  and	  6	   5	  x	  106	  base	  pair	  segment	  of	  chromosome	  17	  
Normalisation	   TileProbe	  Programme	   Quantile	  normalisation	  
Microarray	  
validation	  
Nil	   1)	  Correlation	  between	  variables	  for	  repeat	  experiments	  2)	  Correlation	  with	  predicted	  models	  of	  DNA	  damage	  using	  mathematical	  models	  	  
Definition	  of	  
repeated	  DNA	  
sequence	  
RepeatMarker	  software	  UCSC	  hg18	   RepeatMarker	  software	  UCSC	  hg19	  
 
Table 5.1 - Comparison between DIP-chip experimental systems. Features of the DIP-chip 
experimental methodology are compared and contrasted between methods used in the published paper 
(Zavala et al., 2013) and those developed and applied in this thesis.  
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Figure 5.7 - CPD and cisplatin DNA damage induction in the context of repeated DNA sequences. 
Profile plots demonstrating the distribution of DNA damage induction for UV (5.7 (a), this page) and 
cisplatin (5.7 (b), next page) treated human fibroblast cells, plotted in the context of different repetitive 
DNA sequences. For each group of repeat DNA sequences the profile of DNA damage across each 
repeated sequence of DNA, and a 5000 base pair region upstream and downstream of this, is plotted. 
The profiles for UV-induced CPD formation are presented on this page (5.7 (a)) and the profiles for 
cisplatin-induced adduct formation are presented on the next page (5.7 (b)). RepeatMasker computer 
software compiled 8 repeat DNA sequences and UV and cisplatin-induced DNA damage was measured 
in these different regions. For each group, the number in brackets represents the number of DNA 
damage profiles analysed within each repeat sequence, the dashed lines represent the mean values of 
these damage profiles, and the shaded area represents +/- standard error of the mean. In each case the 
red plots represent the experimental DNA damage profiles whilst the green plot represents the 
predicted profiles for DNA damage. Repeat sequences presented are as follows. SINEs:- Alu repeats 
(Alu) and Mammalian-wide interspersed repeat (MIR). LINEs:- L1 and L2. LTRs:- Endoplasmic 
retrovirus mammalian apparent LTR (ERV-MaLR). hAT Transposons:- hAT-Charlie elements. Low 
complexity regions of the genome and simple repeat (di- to pentameric and hexameric repeats) 
sequences are also presented. 
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Figure 5.8 – Cisplatin-DNA damage induction after cellular treatment in culture and after DNA 
treatment in vitro, in the context of repeated DNA sequences. Profile plots demonstrating the 
distribution of cisplatin-induced DNA damage in human fibroblast cells treated in culture (5.8 (a), this 
page) and in DNA treated in vitro (5.8 (b), next page), plotted in the context of different repetitive 
DNA sequences. For each group of repeat DNA sequences the profile of DNA damage across the 
repeated sequence of DNA, and a 5000 base pair region upstream and downstream of this, is plotted. 
The profiles for cisplatin treated cells in culture are shown on this page (5.8 (a)) and profiles for 
cisplatin treated DNA in vitro are shown on the next page (5.8 (b)). RepeatMasker computer software 
compiled 8 repeat DNA sequences and cisplatin-induced DNA damage was measured in these different 
regions. For each group, the dashed lines represent the mean values of these damage profiles, and the 
shaded area represents +/- standard error of the mean. In each case, the red plots represent the 
experimental DNA damage profiles whilst the green plot represents the predicted profiles for DNA 
damage and the repeat sequences presented are as described for figure 5.7. 
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5.4 Discussion 
 
In chapters 3 and 4, the method development and validation of the DIP-chip technique 
was presented in yeast and human cells. In this chapter the aim was to analyse these 
data, firstly to allow biologically relevant comparisons and observations to be made 
between datasets and secondly to illustrate and provide examples of different 
analytical strategies that can be taken to compare datasets and detect differences 
between them.  
 Comparisons were initially made between cisplatin and oxaliplatin treated 
microarray profiles in both yeast and human cells, and these demonstrated similarities 
between cisplatin and oxaliplatin-induced DNA damage profiles (figures 5.1 and 5.5). 
Comparisons then made between cisplatin-induced DNA damage datasets and UV-
induced DNA damage datasets in yeast and human cells allowed interesting 
observations to be made between the damage profiles of these two different 
genotoxins (figures 5.2 and 5.6). Simply looking at one or other of these profiles in 
isolation may give the appearance of an arbitrary data profile, leaving the impression 
that conclusions or observations could be difficult to draw from this single profile. 
However, as demonstrated with the analysis presented in figure 5.2, when the profiles 
from cisplatin and UV-treated DNA are simply plotted together a clear pattern 
becomes apparent, whereby the DNA damage profiles appear to oppose one another 
in certain regions. This pattern can be explained by the biology, and the known 
sequence specific DNA damage induction pattern.  
 This very simple approach highlights how, by analysing or plotting these 
genome-wide datasets in particular contexts, that meaningful and powerful biological 
information can be detected. These comparative analyses provide further confidence 
and validation for the performance and reproducibility of the DIP-chip assay for the 
detection of platinum- and UV-induced DNA damage in yeast and human cells. This 
validation is provided by the demonstration that cisplatin and oxaliplatin-induced 
DNA damage profiles in culture follow each other closely and also by the 
demonstration that the cisplatin-induced DNA damage profile opposes the UV-
induced CPD profile in regions, reflecting the different sequence specificity of these 
damage types. Furthermore, analysis of the nucleotide sequence in regions of 
differential DNA damage patterns confirms the expected nucleotide composition 
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based on the damage seen, i.e GG>TT in regions of predominantly cisplatin damage 
and the reverse in CPD rich regions. These findings also correlate with predicted 
profiles for DNA damage, thus providing biological validation of the bioinformatic 
process and development of the predicted model. 
 Much of the validation work up to this point has concentrated on proving and 
demonstrating how similar microarray profiles are to one another but, ultimately, as 
stated in the introduction, when applying these techniques to research questions it will 
be important to be able to detect differences between microarray profiles. The reasons 
why the experimental and predicted platinum-induced DNA damage profiles don’t 
match more precisely were discussed in the context of yeast cell treatments in section 
3.4, chapter 3. Therefore, with this in mind, an approach employing outlier detection 
methodology was used to compare the experimental and predicted DNA damage 
datasets in yeast to identify and examine regions of significant difference between the 
two.  
 The purpose of this technique was to identify and locate regions of the genome 
where differences between the experimental and predicted genomic profiles occur, 
beyond simple random experimental variation. Such regions may have important 
biological implications and could represent regions where other factors, beyond DNA 
sequence, are important considerations for platinum adduct formation leading to ‘hot’ 
or ‘cold’ spots of DNA damage induction. In the examples in figure 5.4, 61 and 44 
outlying differences were detected between cisplatin and oxaliplatin damage 
induction and predicted profiles (the locations of some of these outlying features are 
highlighted in figure 5.4 with red crosses and the whole genome plots for these 
outliers are given in the electronic appendix). These outlying differences 
predominantly occur due to increased DNA damage levels occurring in experimental 
profiles compared with predicted. Analysing the genomic positions of these outlying 
features demonstrates that generally they are dispersed throughout the genome, tend 
to occur individually and often occur at the beginning and ends of chromosomes. 
Genuine biological reasons may account for the detected outlying differences seen in 
these regions and further investigation would be required to establish this. However, 
the principle that this is an approach that could be taken to make comparisons 
between experimental and predicted datasets appears valid and is an illustration of 
how comparisons can be made between these global genome datasets. This approach 
could be used to detect differences between such datasets obtained from clinical 
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samples, and could be a way for allowing genomic datasets to be distilled down to a 
small number of potentially key regions of interest. 
 Another illustration is given in this chapter for how whole microarray datasets 
may be examined for differences. This is done by analysing the UV and cisplatin 
DNA damage induction microarray data within the context of sites of repeat regions 
of DNA and this analysis was prompted by a recent publication (Zavala et al., 2013). 
Whilst this paper has some clear shortcomings, it was encouraging to see other 
research groups with interests in the same field and to note similar approaches being 
adopted to the studies presented here. It was also reassuring to see some of the key 
technical development principles, highlighted as being critically important in chapter 
4, also being applied in this publication. For example, studies were employed using 
dermal fibroblasts and a combination of DIP with DNA microarray analysis using 
high-resolution microarrays to concentrate on a small portion of the genome at high 
resolution. As mentioned, there were also some shortcomings, such as their use of the 
one-channel Affymetrix microarray platform with IP and IN samples applied to 
seperate microarrays, coupled with the lack of clear microarray data validation. As 
discussed in chapters 3 and 4, for the DIP-chip technique developed in this thesis, the 
two-channel microarray system provides an important internal experimental control to 
reduce some of the inherent variability present in microarray experiments. This is 
considered particularly advantageous for microarray work analysing these frequently 
occurring DNA damage events. 
 The conclusion reached in the publication by Zavala et al. that CPD hotspots 
form at DNA repeat sequences, provided an opportunity to analyse the data generated 
in human cells and presented in chapter 4 in a way not previously envisaged. In so 
doing this provides another clear illustration of how information can be obtained from 
these global genomic dataset when analysed in a particular biological context. As 
stated, one of the shortcomings of the work presented by Zavala et al. is the lack of 
microarray data validation and by applying the predicted profiles for DNA damage 
presented in this thesis it becomes evident that the CPD hotspots are simply 
reflections of predicted damage profiles occurring at these regions based on DNA 
sequence. To highlight this point, cisplatin-induced damage profiles were examined in 
the same regions. In repeat DNA regions with a mixed nucleotide composition, such 
as the Alu repeats, the DNA damage profile patterns are the same for UV and 
cisplatin. However for the L1 repeat elements, for example, where there is a 
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preponderance of AT-rich and A-rich DNA sequences, UV-induced damage is high, 
and cisplatin is low, in both experimental and predicted profiles (figure 5.7). 
Conversely, by analysing different DNA repeat regions, certain unexpected patterns 
of DNA damage induction are demonstrated, such as in the simple repeats and regions 
of low complexity, where differences between predicted and experimental patterns are 
clearly demonstrated. It is likely that if the genomic data is taken as a whole, and not 
restricted to examining these repeat regions, that other regions where such differences 
exist will become apparent. The conclusion from this work is therefore that generally, 
DNA damage patterns within DNA repeat sequence is primarily determined by 
nucleotide sequence but with some notable exceptions in the simple repeat and low 
complexity repeat DNA elements. 
 These two analyses illustrate how these microarray approaches may be utilised 
to detect differences between DNA damage profiles within different samples. The 
ability to make such comparisons will be necessary if this assay is to be applied 
clinically, and we envisage that similar approaches to these could be applied to 
identify differences in DNA damage induction patterns between clinical samples. 
What is encouraging is from examining even very short sections of the whole dataset, 
such as those presented in figures 5.1 and 5.5, is that whilst these datasets are similar, 
certain regions of difference can be detected. We surmise based on the examples 
presented in this chapter using outlier detection, and by analysing DNA damage in the 
context of repeat sequences, that by analysing microarray datasets as a whole key 
differences between such datasets will emerge. We anticipate that these differences 
will be able to be detected and that from these differences certain DNA damage 
signatures will be apparent within genomes that may be predictive for biological 
characteristics, such as response or toxicity to platinum agents. 
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Chapter 6 
Measuring histone H3 K14 acetylation changes in 
response to exposure to platinum analogues in 
Saccharomyces cerevisiae 
 
 
6.1 Introduction 
 
In chapters 3 and 4 genomic DNA damage profiles were measured following 
cisplatin, oxaliplatin and UV exposure in yeast cells and human fibroblasts. In this 
chapter, associated global changes occurring in the epigenome are examined by 
measuring histone H3 acetylation following exposure to platinum analogues. Whilst 
histone modification, coupled with chromatin remodelling, is an essential component 
of the response to DNA damaging agents and is necessary for efficient repair of the 
DNA damage, it is also clear from studies that will be outlined here that histone 
modification can also influence the degree of initial platinum damage induction. 
Acetylation of histone H3 at lysines 9 (K9) and 14 (K14) is necessary for repair of 
UV induced CPDs in yeast (Yu et al., 2011). In this chapter, acetylation of histone H3 
at lysine 14 (H3 K14) is examined genome-wide, for the first time, using ChIP-chip in 
Saccharomyces cerevisiae following treatment with cisplatin or oxaliplatin. 
 Firstly, global histone H3 K14 acetylation is examined in untreated cells and 
characterised following exposure to cisplatin and oxaliplatin. Secondly, comparisons 
are made between cisplatin-induced DNA damage following treatment in vitro and in 
culture and these studies are compared with untreated H3 K14 acetylation to 
investigate the influence of chromatin on initial platinum adduct formation genome-
wide. Previous research work, discussed in section 6.1.3, has suggested that 
chromatin configuration affects cisplatin adduct formation by reducing drug 
accessibility to DNA when in its highly condensed form. If platinum drugs bind more 
favourably to an open form of chromatin, then this raises the possibility of altering 
chromatin configuration pharmacologically to make it more susceptible to cisplatin 
damage and therefore potentiating its effect. Studies presented in this section of the 
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thesis are therefore conducted to test the hypothesis that regions of the genome 
exhibiting low histone acetylation are highly compacted and are less accessible to 
cisplatin, leading to lower levels of cisplatin-induced DNA damage in these regions. 
Thirdly, global histone H3 acetylation is examined following cisplatin and UV 
treatment of cells in culture to allow comparisons to be made between epigenetic 
responses to these different types of DNA damage, and the organisation of their 
repair, following exposure to these two different genotoxins. A variety of different 
comparative analyses are employed in this chapter and these are discussed in the 
relevant results section.  
 
6.1.1 Chromatin structure and its role in DNA metabolic processes 
In the eukaryotic nucleus DNA does not exist in the naked form, it is wound tightly 
around positively charged histone proteins forming nucleosomes. Nucleosomes 
consist of a nucleosome core particle (NCP) consisting of 146 bp of DNA wrapped 
around a histone octamer containing one (H3-H4)2 tetramer plus two H2A-H2B 
dimers and a 20-90 bp linker region of DNA (discussed in section 1.1.3, chapter 1). 
Nucleosomes undergo further organisation into chromatin, allowing compaction and 
higher-order structural arrangement forming chromosomes (Felsenfeld and Groudine, 
2003). This sophisticated level of organisation means DNA exists in a highly 
compacted and structured form within cell nuclei. DNA metabolic processes such as 
replication, transcription and repair occur in the context of chromatin and therefore 
the physical properties of chromatin are fundamentally important for the successful 
completion of these processes. Whilst the compacted chromatin structure can limit 
accessibility to DNA binding proteins chromatin also plays an active, participatory 
role in the regulation of these processes (Clapier and Cairns, 2009, Teng et al., 2009).  
 The organisation of DNA into chromatin alters the physical and dynamic 
properties of DNA and also alters the reactivity of DNA toward a variety of external 
agents (Millard, 1996). Physical agents such as the platinum analogues modify 
cellular DNA in the context of chromatin and platinum-induced DNA damage levels 
and adduct formation have been shown to be different in chromosomal DNA 
compared with naked DNA (Jung and Lippard, 2007). Equally, chromatin structure 
and metabolism and DNA metabolic processes such as DNA repair are 
mechanistically intertwined and alteration of chromatin properties and chromatin 
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remodelling can significantly affect DNA repair processes (Teng et al., 2009). For 
non-physical sources of DNA damage, such as UV irradiation, the chromatin structure 
affects the frequency of the different damage photoproducts differently. Firstly, CPDs 
form with a regular periodicity in NCP DNA and are strongly affected by nucleosome 
structure whilst the pyrimidine-(6-4)-pyrimidone photoproducts (6-4PPs) are 
randomly distributed and form preferentially in the internucleosomal DNA regions 
and are therefore less affected by nucleosome structure (Gale and Smerdon, 1990). 
 Studies have previously been conducted investigating the effect of the NCP on 
the efficiency of removal of platinum adducts. These have compared repair of 
platinated DNA between free DNA and mononucleosome DNA and have 
demonstrated that repair efficiency of cisplatin adducts is greater in free DNA (Wang 
et al., 2003). Also, to investigate the role of histone modification in repair of 
platinum-DNA adducts, native mononucleosomes composed of post-transcriptionally 
modified histones and recombinant mononucleosomes containing unmodified 
histones were prepared. This demonstrated improved repair efficiency in nucleosomes 
with acetylated histones (Wang et al., 2003). 
 
6.1.2 Histone Modification 
Histone proteins are subject to a number of post-translational modifications (PTMs) 
that can alter their secondary structure and interaction with DNA and other proteins. 
These modifications include acetylation, phosphorylation, methylation, 
ubiquitination, sumoylation, deimination and poly-ADP ribosylation (Yang and Seto, 
2008). These occur mainly at the amino-terminal ‘tails’ of the histone proteins but 
recent evidence has confirmed PTMs occurring at the globular domains also 
(Tropberger and Schneider, 2013, Tropberger et al., 2013). Histone modification is a 
dynamic process affecting chromosome function and can promote DNA metabolic 
processes such as DNA transcription and repair (Margueron and Reinberg, 2010). 
 
Histone Acetylation 
Histone acetylation is regulated through histone acetyltransferases (HATs), which 
promote acetylation, and histone deacetylases (HDAC), which promote acetyl 
disassembly. HATs catalyse the transfer of acetyl groups from acetyl-CoA to lysine 
amino acids in the amino-terminal of the histone tails. Histones are positively charged 
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- promoting affinity with negatively charged DNA - and acetylation at the lysine 
residues of the amino-terminal tails of the histones neutralises the negative charge, 
reducing histone-DNA interaction. 
 The association between histone acetylation and transcriptional activity in 
eukaryotic cells has long been made (Allfrey et al., 1964). Mechanistic evidence 
supporting this link between acetylation and transcription is provided by different 
sources. Firstly, studies have shown a lack of histone tail acetylation in inactive 
heterochromatin (Margueron and Reinberg, 2010). Secondly, when lysine residues in 
the amino-terminal of H4 are substituted by arginine (which cannot be acetylated) 
transcriptional activity is markedly reduced (Durrin et al., 1991). Thirdly, treatment of 
mammalian cells with potent inhibitors of histone deacetylase activity results in 
increased gene expression (Yoshida et al., 1995). More recently, the connection 
between histone acetylation and transcription was highlighted when known 
transcription regulators were also demonstrated to have HAT activity (Struhl, 1998). 
 An important strategy for evaluating the effect of histone acetylation has been 
to block acetylating and deacetylating enzymes using enzyme inhibitors or cell strains 
or organisms with inactivating mutations in these genes. An example is the yeast 
organism S. cerevisiae where the Gcn5 protein has been closely studied. In S. 
cerevisiae the Gcn5 protein acts as a transcriptional regulator of a diverse range of 
genes, and the subsequent demonstration of its HAT activity was an important 
indicator of the connection between acetylation and transcription (Brownell et al., 
1996). This connection was highlighted further when it was demonstrated that 
transcription required promoter histone acetylation and the HAT activity of the Gcn5 
protein (Kuo et al., 1998). HATs are classified as type A or B and Gcn5 is an example 
of a type A HAT. Type A HATs are nuclear in origin, active on chromosomal 
histones and play a role in transcription, and type B HATs are cytoplasmic in origin 
and mainly involved in the acetylation of newly synthesised histones prior to their 
assembly with newly replicated DNA in chromatin (Kornberg and Lorch, 1999). 
 These results demonstrating Gcn5 HAT activity in yeast are also reflected 
with mammalian transcription factors (Struhl, 1998). For example, the human protein 
p300/CBP was initially described as a human transcriptional coactivator for many 
different transcriptional factors, before it was demonstrated to have intrinsic HAT 
activity (Bannister and Kouzarides, 1996). As well as its proven histone acetylase 
activity p300/CBP is associated with the RNA polymerase II haloenzyme, suggesting 
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a more general component of the transcriptional machinery. This connection between 
recruitment of transcriptional and acetylation machinery provides another important 
mechanism and further evidence for the association between these processes. Equally, 
p300/CBP interacts with a number of DNA binding proteins involved in transducing 
signals for a number of diverse cellular processes such as DNA repair, cellular 
differentiation, cell cycle control and apoptosis. 
 
Histone Deacetylation 
Reversible acetylation of histone tails is a balance between the competing effects of 
histone acetyltransferases (HATs) and histone deacetylases (HDACs). Since histones 
were the first identified targets of deacetylases, these proteins were termed histone 
deacetylases. Many non-histone proteins including transcription factors, hormone 
receptors and signal transducers have subsequently been identified as being subject to 
reversible acetylation by HATs and HDACs (Spange et al., 2009). As stated, in 
general, histone acetylation promotes a more open chromatin structure, allowing 
transcriptional activation, and therefore HDACs can act as transcriptional repressors 
and promote chromatin condensation.  
 Similar to the connection between acetylation and transcription, the link 
between deacetylation and gene repression has also been established, and like the 
discovery that transcription factors also demonstrate HAT activity, it has been 
demonstrated that gene repressors possess deacetylase activity (Grunstein, 1997). This 
was most clearly demonstrated with the isolation of human histone deacetylase, 
HDAC1, whose sequence is very similar to the yeast negative regulatory protein Rpd3 
(Kornberg and Lorch, 1999). Many deacetylases have subsequently been identified in 
yeast and human cells. The mammalian HDAC protein family comprises 18 members 
and is generally divided into four classes based on the sequence homology with yeast 
counterparts. Class 1 HDACs (HDAC1, -2, -3 and -8) are homologues of the yeast 
Rpd3 protein. They are ubiquitously expressed and, with the exception of HDAC3, 
display a primarily nuclear localisation. Class II HDACs can be further divided into 
class IIa (comprising HDAC4, -5, -7, -9) and class IIb HDACs (HDAC6 and -10) and 
share homology with yeast Hda1. HDAC11 shares sequence homology with Rpd3 
and Hda1 and is classified as a class IV HDAC. Class III HDACs (comprising SIRT 
1-7) are homologues of the yeast SIR2 protein. HDACs may be further categorised 
into two families according to function, with class III HDACs being NAD+ dependent 
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and class I,II and IV being zinc dependent. Further categorising can be made based on 
the cellular processes mediated by these proteins. For example the NAD+ dependent 
proteins tend to mediate processes such as drug resistance, angiogenesis, cell 
differentiation, proliferation and apoptosis. Class II and IV HDACs are expressed 
only in certain tissues and are present in both nucleus and cytoplasm whilst class I 
HDACs are distributed in all tissues (Buchwald et al., 2009). These deacetylases 
function as part of large multiprotein complexes with co-activating, co-repressing and 
chromatin-remodelling proteins, having important functional consequences, including 
allowing them to deacetylate nucleosomes, which the individual HDAC cannot do. 
 
6.1.3 Platinum adduct formation in chromatin 
Most of the early work, characterising the sequence specificity of platinum-DNA 
interactions (discussed in chapters 3 and 4) was performed in free DNA and these 
findings were subsequently corroborated in cellular DNA. Knowledge of the sequence 
specificity of platinum adduct formation is clearly fundamentally important and has 
been the cornerstone for the work presented in chapters 3,4 and 5. The study of these 
interactions with nucleosomal DNA, or chromatin, has been less widely investigated. 
Establishing the impact of chromatin structure on platinum-DNA interactions and 
characterising how this affects platinum adduct induction genome-wide will be 
equally as important as defining the sequence specificity. 
 Early research using isolated nucleosomes to characterise cisplatin-DNA 
interactions in the presence of nucleosome core proteins, and to examine the effect of 
histone proteins on platinum adduct formation confirmed that the vast majority of 
adducts involved only DNA, with few DNA-histone interactions (Lippard and 
Hoeschele, 1979). Studies using reconstituted nucleosomes also demonstrated the 
linker DNA region as the preferred target for platinum analogues (Foka and Paoletti, 
1986, Millard and Wilkes, 2000, Galea and Murray, 2002), although at higher doses 
this preference was not observed (Foka and Paoletti, 1986). The preference for linker 
DNA over the NCP is attributed to the conformational constraint imparted by the 
histones within the core to physical agents such as drugs, impeding their interaction 
with DNA (Millard, 1996). NCP and histone octamer association can therefore 
modulate DNA platination and, furthermore, a recent study has identified methionine 
residues within the histone octamer core as a site of preferential platinum adduct 
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formation, identifying such residues as a possible platinum reservoir influencing 
adduct transfer to DNA (Wu et al., 2008).  
 The overall level of platinum adduct induction has been shown to be 
influenced by the degree and nature of PTM of the histones. The combination of the 
HDACi arginine butyrate and cisplatin has been shown to lead to greater adduct 
formation and a corresponding greater cytotoxicity in human cancer cell lines (Bubley 
et al., 1996). Inhibition of HDAC leads to hyperacetylation of histone proteins and 
promotes chromatin relaxation and unfolding (Marchion and Munster, 2007). This 
suggested that platinum drugs bind more favourably to an open form of chromatin, 
and that chromatin configuration affects cisplatin adduct formation by reducing the 
accessibility of the drug to DNA when it exists in its highly condensed form. This 
introduces the possibility of altering chromatin configuration pharmacologically, to 
make it more susceptible to cisplatin damage and therefore potentiate its effect. The 
influence of histone acetylation on initial platinum adduct induction has not 
previously been examined genome-wide and in this chapter the hypothesis that 
regions of the genome that exhibit low histone acetylation are highly compacted and 
are therefore less accessible to cisplatin, leading to lower levels of cisplatin-induced 
DNA damage in these regions, is examined genome-wide using ChIP-chip. 
 
6.1.4 Histone acetylation following exposure to platinum therapy 
As well as influencing initial platinum adduct formation, histone acetylation is also a 
prominent histone modification taking place in response to platinum treatment, which 
may be linked to repair of platinum adducts. Cisplatin treatment has been shown to 
induce histone H3 phosphorylation mediated by the mitogen-activated protein kinase 
(MAPK) pathway as well as histone H4 hyperacetylation by Western blotting of cell 
extracts from different cancer cell lines (Wang and Lippard, 2004).  
 Histone acetylation is biologically relevant to the action of platinum 
analogues, as different HDACi have demonstrated synergistic interaction with 
oxaliplatin inhibiting the survival of human colorectal cancer cells in vitro (Flis et al., 
2009). Subsequent studies have demonstrated synergy between different HDACi and 
cisplatin in many different cancer types including non-small cell and small cell lung 
carcinoma, head and neck squamous cell carcinoma, glioblastoma and soft tissue 
sarcoma (Lopez et al., 2009, Erlich et al., 2009, Bangert et al., 2011, Luchenko et al., 
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2011). These studies have also shown synergy with other common chemotherapy 
agents including the anthracycline doxorubicin and the topoisomerase inhibitors 
topotecan and etoposide. These findings may indicate that greater histone acetylation 
prior to treatment potentiates platinum-DNA adduct formation or that histone 
deacetylation following platinum exposure is important for adduct repair, or both. 
These studies again highlight the potential important role and influence of basal 
histone acetylation on DNA damage induction and treatment efficacy. 
 
 
6.2 Methods 
 
6.2.1 Preparation of platinum-treated yeast chromatin 
Wild-type yeast BY4742 cells were grown to logarithmic-phase and treated with 250 
µM cisplatin or oxaliplatin for 4 hours in PBS, as described in section 2.2.2, chapter 
2. Following treatment, cells were collected by centrifugation at 5000rpm for 5 
minutes and resuspended in YPD for the required repair time. Cells were then 
crosslinked and chromatin extracted and prepared as described in section 2.2.5, 
chapter 2. Chromatin was sonicated for 8 cycles of 30 seconds on and 30 seconds off 
as described in section 2.6, chapter 2 and sonication was confirmed by agarose gel 
electrophoresis. 
 
6.2.2 Chromatin immunoprecipitation of histone H3K14 acetylation 
Yeast chromatin extracted from cells treated in culture with platinum analogues was 
used for chromatin immunoprecipitation (ChIP) using the anti-acetyl-histone H3 
(lysine14) antibody (Millipore, 07-353). 50 µl of Dynabeads (Sheep anti-Rabbit IgG, 
Invitrogen) per sample were washed three times using 500 µl PBS-BSA (0.1%). 
Washed Dynabeads were resuspended in 50 µl of PBS-BSA (0.1%) per sample and 2 
µl of anti-acetyl-histone H3 (lysine14) antibody was added per 50 µl of Dynabeads 
for detection of histone H3 K14 acetylation. Dynabeads and antibody were incubated 
at 30°C for 30 minutes at 1300rpm in a thermomixer (Eppendorf). Dynabeads were 
collected, washed three times with 500 µl of chilled PBS-BSA (0.1%) and 
resuspended in 50 µl of PBS-BSA (0.1%) per sample. 30 µl of 10 X PBS-BSA (10 
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mg/ml) and 125 µl of sonicated chromatin were added to each sample containing the 
Dynabeads, and the final volume made up to 300 µl with PBS. Samples were 
incubated at 21°C for 3 hours at 1300rpm in a thermomixer. Following incubation, 
samples underwent a series of washes as follows: first wash with 500 µl of freshly 
prepared FA/SDS buffer. This was followed by three washes with 500 µl of FA/SDS 
+ 500 mM NaCl, one wash with 500 µl of LiCl solution and one wash with 500 µl of 
cold TE. Chromatin was eluted from the Dynabeads in 125 µl of pronase buffer at 
65°C at 900rpm for 30 min. 6.25 µl of pronase (20 mg/ml) was added to each sample 
and incubated at 65°C in a waterbath overnight. IN samples of 25 µl of sonicated 
chromatin were made up to 100 µl with TE buffer followed by the addition of 25 µl of 
5 x pronase buffer and 6.25 µl of pronase (20 mg/ml) and incubated overnight as the 
IP samples. Following overnight incubation, IP and IN samples were processed for 
damage removal with sodium cyanide as discussed in section 3.2.3, chapter 3, and 5 
µl of DNase-free RNase A (10 mg/ml) was added during this process. DNA was 
purified using the PureLinkTM Quick PCR Purification Kit (Invitrogen) and eluted 
with 50 µl elution buffer. 
 
6.2.3 Quantitative real-time PCR (qRT-PCR) 
Following ChIP, qRT-PCR was conducted as described in section 2.7, chapter 2. This 
allowed quantification of the amount of DNA in the platinum-treated and untreated IP 
and IN samples at different repair times. qRT-PCR was performed examining 3 
different regions based on the work of Dr Katie Evans, PhD thesis 2011. The primers 
used were for the MFA2 promoter, PSK1 promoter and POL30. These had previously 
been shown (Dr K Evans PhD thesis) to correspond to regions of medium, high and 
low acetylation respectively when applied to UV-induced acetylation using a H3 
K9K14 antibody. 
 
The primer sequences:- 
MFA2 promoter: 
Forward: 5ʹ′ - AAAGCAGCATGTTTTCATTTGAAACA - 3ʹ′ 
Reverse: 5ʹ′ - TATGGGCGTCCTATGCATGCAC - 3ʹ′ 
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PSK1 promoter: 
Forward: 5ʹ′ - TGATTACATGCTAAGGAAGTGGTG - 3ʹ′ 
Reverse: 5ʹ′ - GCACTTTGTAACGTTGATTTCC - 3ʹ′ 
 
POL30: 
Forward: 5ʹ′ - AACACACCGGATTCCATCAT - 3ʹ′ 
Reverse: 5ʹ′ - TTGGGACAAGTCACGAACAA - 3ʹ′ 
 
6.2.4 Sample preparation for DNA microarray hybridisation 
Following ChIP, samples were prepared for DNA microarray hybridisation as 
described in sections 3.2.5 in chapter 3 and as described in the Agilent Technologies 
Yeast ChIP on chip protocol (Agilent Technologies Yeast ChIP-on-chip Analysis 
Protocol, version 9.2). As for DIP samples, ChIP does not yield sufficient DNA for 
use in microarray experiments and therefore these samples must be amplified as 
discussed previously. The steps required are the same as those used for preparing 
yeast DIP samples for microarray hybridisation and include blunting of the ends of 
the DNA fragments followed by ligation of common linker sequences of DNA to the 
ends of these fragments, ligation-mediated PCR amplification, DNA labelling and 
hybridisation to yeast microarrays. For these studies, Yeast Whole Genome ChIP-on-
chip Microarrays, 4x44K format, were used (Agilent Technologies, Catalogue 
number G4493A). 
 
6.2.5 Normalisation of ChIP-chip datasets 
The ChIP-chip datasets presented in this chapter were normalised using a novel 
normalisation technique for analysing such datasets and developed by Dr M Bennett, 
PhD thesis, 2012. Normalisation is required to allow comparisons to be made between 
datasets that in their raw state have essentially unrelated and arbitrary values. This 
normalisation process involves four steps - a ‘clean-up’ step followed by quantile 
normalisation, shifting and scaling of the data. This normalisation procedure is 
described in detail in the aforementioned thesis and the relevant section from Dr 
Bennett’s thesis is included in the electronic appendix.  
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6.3 Results 
 
6.3.1 Antibody titration study using the histone H3 K14 acetylation 
antibody for ChIP 
An antibody titration ChIP study was performed using the anti-H3 K14 acetylation 
antibody and cisplatin treated chromatin at the 1-hour repair time (Appendix IV, 
figure 1). A range of antibody volumes, from 0 to 5 µl, was examined by qRT-PCR 
and the fold increase in ChIP was calculated for each antibody amount relative to the 
no antibody sample. This demonstrated that the fold change in ChIP increased up to 
peak enrichment of approximately 1 µl of antibody, following which a plateau phase 
was apparent where no further ChIP DNA was obtained despite additional antibody. 
As a result of these findings, 2 µl of H3 K14 antibody, an amount within the plateau 
phase, was used for ChIP studies. 
 
6.3.2 ChIP and qRT-PCR of histone H3 K14 acetylation at the MFA2 
promoter locus following cisplatin treatment  
Following ChIP, histone acetylation enrichment was assessed with qRT-PCR, using 
primers for the MFA2 promoter. H3 K14 acetylation was assessed in untreated cells, 
immediately following cisplatin treatment (0 hours) and at 1 and 2-hour repair times 
following treatment. The ratio of IP to IN values was calculated and data is presented 
and displayed as the fold increase or ‘enrichment’ of the IP/IN ratio at different repair 
times relative to untreated cells. This confirmed that H3 K14 acetylation was highest 
after 1 hour with a very slight fall at 2 hours (figure 6.1). qRT-PCR serves to confirm 
the success of the ChIP experiment and confirms that samples are of sufficient quality 
to proceed with preparing for microarray hybridisation.  
 
6.3.3 Genome-wide measurement of cisplatin-induced histone H3 
K14 acetylation using DNA microarrays (ChIP-chip) 
Cisplatin-induced histone H3 K14 acetylation ChIP samples were prepared for DNA 
microarray hybridisation. A single sample measuring H3 K14 acetylation in untreated 
cells and 3 biological replicate samples measuring H3 K14 acetylation at 1-hour 
repair time in cisplatin treated cells were applied to DNA microarrays. Normalised 
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datasets for the three replicates for cisplatin treated cells, along with the untreated 
sample, are presented in the genome plots in figure 6.2. In figure 6.2 (a) 3 replicates 
for H3 K14 acetylation in cisplatin treated cells are presented, and the black profile 
represents the untreated sample. In figure 6.2 (b) the three replicate cisplatin treated 
samples have been averaged - producing the single red profile – and again, the black 
profile represents the untreated sample. Whilst only a single untreated dataset has 
been applied to microarrays, these genomic profiles clearly indicate that cisplatin 
treated samples have higher H3 K14 acetylation values than the untreated sample 
throughout the genome. They also show a very high concordance between the three 
replicate cisplatin treated samples, indicating a consistent acetylation response 
following cisplatin exposure. Such concordance would therefore also likely to be 
demonstrated between multiple untreated acetylation profiles. 
 As well as these two acetylation values - the untreated histone H3 K14 
acetylation and the cisplatin treated histone H3 K14 acetylation - a third value was 
determined, namely the cisplatin-induced histone H3 K14 acetylation. This was 
calculated by subtracting the untreated histone H3 K14 acetylation values (log2 IP/IN) 
from the average value of the three cisplatin treated H3 K14 acetylation datasets (log2 
IP/IN). By accounting for the starting, untreated, level of acetylation, the cisplatin-
induced acetylation value reflects the true change in acetylation occurring at each 
microarray feature due to cisplatin exposure and allows the identification of the 
genomic regions undergoing the most or least cisplatin-induced acetylation (figure 6.2 
(c)). 
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Figure 6.1 - Chromatin immunoprecipitation and qRT-PCR of histone H3 K14 acetylation at the 
MFA2 promoter locus following cisplatin treatment in Saccharomyces cerevisiae. Yeast cells were 
incubated with 250 µM cisplatin for 4 hours in PBS and cells were either harvested immediately post 
treatment (0 hour), or were transferred back to YPD following incubation with cisplatin and allowed to 
incubate for 1 or 2 hours. Untreated yeast cells were also transferred to PBS for 4 hours and harvested 
immediately post incubation as for the 0 hour samples. Data shown are means of four biological 
replicate samples for 0 hour samples, means of five biological replicate samples for 1 hour samples, 
and means of three biological replicate samples for 2 hour samples. Error bars represent +/- standard 
error of the mean. The asterix indicates a significant difference between H3 K14 acetylation levels in 
untreated and 1 hour repair cisplatin-treated samples (p<0.05, Paired t-test, result given with raw data 
in electronic appendix, chapter 6). 
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Figure 6.2 - Genome plots demonstrating histone H3 K14 acetylation in wild type yeast cells 
following treatment with 250 µM cisplatin for 4 hours and allowed to repair in YPD for 1 hour. 
In 6.2 (a) the black profile represents normalised H3 K14 acetylation in untreated yeast wild type cells. 
The blue, green and red profiles in 6.2 (a) represent three normalised biological replicate samples 
measuring H3 K14 acetylation in cisplatin treated cells and almost overlie each other. Figure 6.2 (b) 
shows the average of the three biological replicates for H3 K14 acetylation in cisplatin treated yeast 
cells represented by the red profile, and again the black profile represents the untreated sample. Figure 
6.2 (c) demonstrates the cisplatin-induced histone H3 K14 acetylation, a value achieved by subtracting 
the untreated log2 IP/IN value (pre-cisplatin treatment) from the averaged post-cisplatin treatment log2 
IP/IN values (shown in 6.2 (b)). This profile represents the overall cisplatin-induced change in histone 
H3 K14 acetylation. For each of these profiles, data is plotted for a section of chromosome 4 from co-
ordinates 1450000 to 1500000. The genes are represented by yellow boxes, with the arrows indicating 
the direction of transcription. The microarray features are represented as grey dots.  
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6.3.4 Validation of ChIP-chip histone H3 K14 acetylation data 
To validate the microarray data presented in figure 6.2, qRT-PCR was performed at 
three different genomic locations allowing comparisons to be made between 
enrichment detected by qRT-PCR and the microarray values at these locations. qRT-
PCR was conducted using primers for the MFA2 promoter, PSK1 promoter and 
POL30 genomic locations as detailed in section 2.7, chapter 2 and in section 6.2.3 
above. The amount of DNA measured after ChIP in the IP and IN samples was 
determined by qRT-PCR. The microarray data generates log2 values for the IP and IN 
samples based on their relative fluorescence values at each probe, which are 
converted to numerical values by the feature extraction software. By calculating the 
IP/IN ratio for both the qRT-PCR and microarray data and using the fold change or 
‘enrichment’ in the IP/IN ratio of treated samples relative to untreated for both 
sources then their data can be compared. This was used as a method for validating the 
microarray data output and ensuring that the normalisation procedure applied to these 
datasets was working appropriately. 
 Enrichment in H3 K14 acetylation between untreated and the one hour repair 
samples was calculated using qRT-PCR for the MFA2, PSK1 and POL30 primers, 
and this was compared with the enrichment between the same samples obtained from 
the microarray data. For the three cisplatin treated replicate microarray samples 
presented in figure 6.2 (a) enrichment relative to the untreated sample was calculated 
at each microarray feature corresponding to the three qRT-PCR primers, and the 
average of these values was taken. This procedure was performed on the microarray 
data at 3 different stages of data processing - firstly, using the raw microarray data, 
secondly, using partially normalised (quantile normalisation) microarray data and, 
thirdly, using the microarray data subject to the full normalisation procedure. These 
data are presented in figure 6.3 and they demonstrate that qRT-PCR data are very 
different to the raw and partially normalised microarray data output (p<0.05, two-
tailed t test, data presented in electronic appendix, file name ‘Figure 6.3 - Raw data 
for qRT-PCR and microarray validation’) but that qRT-PCR data and the fully 
normalised microarray data correspond closely. This validates the ChIP-chip 
normalisation method applied here, confirming its applicability for normalising the 
platinum-induced histone H3 K14 acetylation microarray datasets generated in these 
studies. Further analysis of these microarray data could now be performed. 
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Figure 6.3 - Validation of the histone H3 K14 acetylation ChIP-chip data. The fold increase in 
cisplatin-induced histone H3 K14 acetylation at the one hour repair time relative to the untreated value 
was calculated using qRT-PCR and DNA microarrays at three different genomic locations - the MFA2 
promoter, POL30 and PSK1. Comparison was made between the qRT-PCR data and the microarray 
data at three different stages of microarray data processing. Firstly the raw microarray data, secondly 
quantile normalised data and thirdly the fully normalised microarray data. This demonstrates a 
statistically significant difference between the qRT-PCR data and the non-normalised microarray data 
whilst the normalised microarray and qRT-PCR data correspond closely to one another. Note is also 
made of the different scales used for the y axis for each graph, again highlighting the validity of the 
normalisation procedure. In each case, microarray values are means for three biological replicate 
datasets. qRT-PCR values are averages of five replicates for MFA2 and two replicates for PSK1 and 
POL30. The error bars represent +/- standard error of the mean. The asterix indicates a significant 
difference between H3 K14 acetylation enrichment levels (p<0.05, two-tailed t-test). Raw data in 
electronic appendix, file name ‘figure 6.3 - Raw data for qRT-PCR and microarray validation’, chapter 
6. 
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6.3.5 Global genome analysis of histone H3 K14 acetylation following 
cisplatin treatment 
Western blots have previously demonstrated global increases in histone H4 
acetylation following cisplatin treatment (Wang and Lippard, 2004), however, the 
ChIP-chip method applied here is advantageous as it allows acetylation following 
cisplatin treatment to be measured globally and at different regions of the genome at 
high resolution. It is evident from the genome plots presented in figure 6.2 that 
cisplatin treated samples generally have higher acetylation values than untreated 
samples. To appreciate the acetylation change following cisplatin treatment across the 
whole microarray dataset the values from each microarray feature (log2 IP/IN) for the 
untreated sample and the averaged cisplatin treated samples have been plotted on a 
scatter plot. This demonstrates the majority of probe values to be greater following 
acetylation (figure 6.4 (a)).  
 Additionally, this pattern of increased acetylation can be examined further by 
analysing the microarray data in a different context, allowing global analysis of 
histone acetylation changes. The microarray data can be analysed utilising the gene 
annotation data to examine the acetylation profiles collectively across each open 
reading frame (ORF). This type of analysis is described as a profile plot and can be 
performed using a function within the Sandcastle bioinformatic package. In figure 6.4 
(b) the average profile of H3 K14 acetylation across all ORFs greater than 1000 
nucleotides in length (n=3608), including a 1000 bp region up and downstream of 
this, before and after cisplatin treatment are presented. This again demonstrates the 
greater acetylation occurring in these regions in the cisplatin treated samples. It also 
indicates that, collectively, histone H3 K14 acetylation is higher in the end of the 
promoter regions of genes with lower acetylation levels within the ORFs and 
downstream regions (figure 6.4 (b)). This pattern of differential acetylation across 
genes is evident for both pre and post-cisplatin treatment but is more marked in the 
post-treatment group.  
 These three different analyses - genome plots, scatter plots and profile plots - 
each demonstrate the trend of increasing histone H3 K14 acetylation following 
cisplatin treatment and the gene profile plots (figure 6.4 (b)) demonstrate the 
differential acetylation within the different gene domains.  
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Figure 6.4 - Examining histone H3 K14 acetylation following cisplatin exposure. Figure 6.4 (a) 
demonstrates a scatter plot of the untreated H3 K14 acetylation values in yeast cells (x axis) versus the 
post-cisplatin treated H3 K14 acetylation values (y axis) with each microarray probe value (log2 IP/IN) 
for the 2 separate arrays plotted. The relative density of data within the plot is demonstrated with the 
darker shade of blue representing greater data density and conversely the lighter shade representing less 
dense data areas. The line of y = x is shown. Figure 6.4 (b) presents a profile plot of H3 K14 acetylation 
in the untreated sample (green profile) and in the averaged cisplatin-treated samples (average 3 
replicates, red profile). In this plot, the dashed red line represents the mean value of the cisplatin-
treated acetylation profiles for all ORFs over 1000 nucleotides in length throughout the yeast genome 
(n=3608), the green profile represents the untreated acetylation profiles, and the shaded area represents 
+/- standard error of the mean. This highlights the differential level of acetylation occurring across 
genes globally, with a consistent peak of acetylation occurring at the end of the promoter regions 
before falling within the ORF. 
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6.3.6 Analysis of oxaliplatin-induced histone H3 K14 acetylation 
using ChIP-chip 
Previous published studies examining platinum induced epigenetic responses had only 
been performed with cisplatin, and one element of interest in this thesis was to 
investigate histone acetylation following oxaliplatin treatment to determine whether 
acetylation changes between platinum analogues were similar. Therefore, a single 
experiment was conducted examining oxaliplatin-induced histone H3 K14 acetylation 
in yeast cells. A single ChIP experiment was performed examining oxaliplatin-
induced H3 K14 acetylation at the MFA2 promoter (Appendix IV, figure 2). This 
demonstrates a similar fold enrichment of acetylation at 1 hour, compared with 
cisplatin, however in this instance, acetylation appears to increase further at the 2-
hour repair time. 
 The one hour repair oxaliplatin-treated sample was applied to microarrays and 
the genome plot of this is displayed in figure 6.5 (a). This demonstrates a similar 
pattern compared with cisplatin-treated acetylation, with higher H3 K14 acetylation 
values than the untreated samples generally evident throughout the genome. 
Furthermore, comparing between the oxaliplatin treated and the averaged cisplatin 
treated acetylation profile presented in figure 6.2 (b), it is evident that the profiles are 
almost identical (figure 6.5 (b)). Further analysis of oxaliplatin-treated histone H3 
K14 acetylation by a scatter plot and a gene profile plot, as described for cisplatin 
treated samples in section 6.3.5, also show similar patterns of increased global H3 
K14 acetylation following oxaliplatin treatment compared to cisplatin. The gene 
profile plot presented in figure 6.5 (d) has the oxaliplatin treated acetylation profile 
included (green profile), in addition to the cisplatin and untreated profiles presented 
previously and this reveals a similar pattern of greater acetylation in promoter regions 
with reduced levels within the ORF. 
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Figure 6.5 - Histone H3 K14 acetylation in wild type yeast cells following oxaliplatin treatment. 
Yeast cells were treated with 250 µM oxaliplatin for 4 hours and allowed to repair in YPD for 1 hour. 
In figure 6.5 (a) the black profile represents H3 K14 acetylation in untreated yeast cells and the red 
profile represents a single sample measuring histone H3 K14 acetylation in oxaliplatin treated cells. In 
figure 6.5 (b) the red profile represents H3 K14 acetylation in oxaliplatin treated cells whilst the black 
profile represents averaged H3 K14 acetylation from the three biological replicates for cisplatin treated 
cells presented previously in figure 6.2 (b). For these genome plots data is presented for a section of 
chromosome 4 from co-ordinates 1450000 to 1500000. The gene annotation data is represented by the 
yellow boxes, and the individual microarray features are represented as grey dots. Figure 6.5 (c) 
presents a scatter plot of the untreated H3 K14 acetylation values in yeast cells (x axis) versus the 
oxaliplatin treated H3 K14 acetylation values (y axis) with each microarray probe value (log2 IP/IN) 
for the 2 separate arrays plotted. The relative density of data is demonstrated with the darker shade of 
blue representing greater data density and conversely the lighter shade representing less dense data 
areas. Figure 6.5 (d) presents a gene profile plot, as per figure 6.4 (b) demonstrating cisplatin treated 
H3 K14 acetylation (average 3 replicates, red profile), oxaliplatin treated H3 K14 acetylation (green 
profile) and the untreated acetylation level (blue profile). For each of these the dashed lines represent 
the mean values of the acetylation profiles for all ORFs over 1000 nucleotides in length throughout the 
yeast genome (n=3608), and the shaded area represents +/- standard error of the mean. This highlights 
the differential level of acetylation occurring across genes globally, with a consistent peak of 
acetylation occurring at the end of the promoter regions before falling within the open reading frame 
(ORF). 
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6.3.7 Comparison of cisplatin-induced DNA damage between 
cisplatin-treated naked DNA and cellular treated DNA and 
integration with histone H3 K14 acetylation 
An approach to analysing and integrating genomic cisplatin-induced DNA damage 
and epigenetic datasets has been developed and is presented in this section. DNA 
damage profiles for yeast DNA samples treated in vitro and for cells treated in culture 
with cisplatin are examined for variation and differences and these regions of 
difference then compared with untreated histone H3 K14 acetylation. This was 
performed to analyse the influence of chromatin on initial platinum adduct formation 
and to examine the impact of histone acetylation on DNA adduct formation. This 
could provide mechanistic insight for platinum adduct formation in the context of 
chromatin and provide opportunities for therapeutic potentiation of these agents. For 
this section the in vitro and cellular treated cisplatin DNA damage datasets presented 
in chapter 3 were used along with the untreated and cisplatin treated acetylation 
datasets.   
 As discussed in section 5.3.1.2, chapter 5, the assumption is made that the 
greatest cause of variation between the in vitro and cellular cisplatin-treated datasets 
will occur as a result of inherent technical variability within the microarray protocol. 
If the variation between these datasets is predominantly due to these random 
variations then it is reasonable to assume that the differences between the two datasets 
will follow a normal distribution. In figure 6.6, the cellular treated microarray values 
are subtracted from the in vitro treated dataset and the difference values plotted as a 
histogram, and the majority of these calculated differences are demonstrated to 
approximate a normal distribution. Whilst most of the variation between these 
datasets is random, some of the variation may occur non-randomly and represent 
meaningful signals due to biological processes, such as the presence of chromatin. 
These key regions of non-random variation may lie outside this normal distribution 
and may be detected using outlier detection methodology.  
 The process applied in this section is the same as outlined in section 5.3.1.2, 
chapter 5. Firstly, the differences between the datasets treated in vitro and datasets 
treated in culture are calculated, and these are presented in figure 6.6. The overlying 
normal distribution curve is added to the histogram using the mean and standard 
deviation calculated from the difference values (0 and 0.24 respectively). These 
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differences are then represented as quantiles and plotted against a normally distributed 
theoretical set of quantiles on a Q-Q plot using the “extremevalues” package within 
the ‘R’ statistical software programme (refer to section 5.3.1.2 for further description 
of this method). Figure 6.7 shows the differences between cisplatin-induced DNA 
damage in vitro and DNA damage following cellular treatment plotted as a Q-Q plot. 
This plot demonstrates that the majority of the calculated differences presented in 
figure 6.6 lie along the black line approximating a normal distribution, however 
certain microarray features at each end of this range are identified which deviate from 
the normal distribution, representing large calculated differences (figure 6.7 (a)). The 
points lying above the line represent outlying features where greater DNA damage is 
occurring in the in vitro treated sample, with fewer outlying values lying below the 
line representing features where damage is greater in the cellular treated samples. The 
outlier detection identified 93 outlying microarray features in total, which deviate 
from the normal distribution, and these are highlighted on the Q-Q plot as red dots 
(figure 6.7 (b)).  
 
 
  
Figure 6.6 - Histogram of the differences between cisplatin-induced DNA damage datasets 
treated in vitro and in culture. Differences represent log2 IP/IN ratio values and the y axis displays 
the relative proportions of each difference value. The red line represents a normal distribution 
calculated from the mean and standard deviation of the difference values. 
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Figure 6.7 - Q-Q plots of differences between cisplatin-induced adduct formation in yeast DNA 
treated in vitro and in yeast cells treated in culture. In both cases the difference and theoretical 
quantiles are plotted as dots, and the black line represents normally distributed data. The majority of 
the differences lie along the black line indicating that the majority of these difference values are 
normally distributed, however some values deviate from the line, with a small deviation at the low end 
and a larger deviation at the high end (6.7 (a)). Using outlier detection methodology outlying 
differences between cisplatin treated yeast DNA in vitro and cisplatin treated yeast cells are detected 
and these are highlighted in red (6.7 (b)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-4 -2 0 2 4
-3
-2
-1
0
1
2
Normal Q-Q Plot
Theoretical Quantiles
S
am
pl
e 
Q
ua
nt
ile
s
-1.0 -0.5 0.0 0.5
-3
-2
-1
0
1
2
QQ plot with outliers, Method I 
 normal distribution, R2 = 1
Predicted
O
bs
er
ve
d
Theoretical quantiles 
D
if
fe
re
nc
e 
qu
an
til
es
 
D
if
fe
re
nc
e 
qu
an
til
es
 
Theoretical quantiles 
a b 
Chapter 6. Histone acetylation following platinum exposure 
 
 232 
 These outlying differences are then located on a genome plot (figure 6.8, 
whole genome available in the electronic appendix). Snapshots of this dataset are 
presented in figure 6.8 and these genome plots support the findings of the Q-Q plot 
that most of the outlying differences identified are due to increased damage in the in 
vitro treated sample compared with samples treated in culture (figure 6.8).  
 These observations, made from analysing the Q-Q plots and genome plots, 
were confirmed by plotting histograms of the log2 IP/IN values for each microarray 
feature and comparing values at outlying features with the whole microarray data. 
These histograms demonstrate that the distribution of whole microarray values for 
cisplatin in vitro treatments and cellular cisplatin treatments in culture are similar 
(figure 6.9 (a)), but that the distributions of values plotted only for the outlying 
features are very different, with greater values evident in the in vitro group (figure 6.9 
(b)). This confirms that genomic regions of differential cisplatin-induced DNA 
damage between DNA treated in vitro and genomic DNA treated in culture have been 
identified. Furthermore, when cisplatin in vitro treatment values are compared 
between outlying features and the whole microarray values these confirm higher 
values at the outlying features compared with the whole microarray values (figure 6.9 
(c)). When whole microarray and outlier values are compared following cisplatin 
treatment in culture the difference is more subtle but a trend toward lower values at 
the outlying features is evident (figure 6.9 (d)). 
 The Kolmogorov-Smirnov statistical test (K-S test) is a non-parametric 
statistical test used to make comparisons between data distributions and to measure 
how different two datasets are. This test produces a D statistic which can have a value 
of 0 to 1, where 0 represents no difference between datasets and 1 represents the 
largest difference possible, along with a p-value for the D statistic. This test was 
applied to further examine differences between the log2 IP/IN distributions of the 
histograms plotted in figure 6.9. In particular, it was applied to assess the difference 
between the log2 IP/IN values for platinum-DNA adduct formation for in vitro and 
cellular cisplatin-treated samples at the outlying microarray features compared with 
the whole microarray datasets. The D statistic is presented in figure 6.9 for each pair 
of histograms being compared. Comparing the whole microarray log2 IP/IN 
distributions for in vitro and cellular treated microarray datasets gives a low value for 
the D statistic, D = 0.06, confirming the overall similarity between these datasets. The 
significant p-value in this instance may reflect the large number of microarray values 
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(~44,000) compared between these two datasets. Conversely, comparing between in 
vitro and cellular treated log2 IP/IN distributions at the outlying microarray features 
demonstrates greater values in the in vitro treated dataset with D = 0.88. To examine 
these differences further, in vitro log2 IP/IN values were compared between the whole 
microarray dataset and the outlying features, which again confirmed greater values at 
outlying features, with a D = 0.92. The same analysis was performed with the datasets 
generated in cells treated in culture and this demonstrates a trend toward lower values 
at the outlying features compared with the whole array dataset with a D = 0.34. In 
each case here the p-value < 0.0001 confirms a statistically significant difference 
between the two datasets. In summary therefore, these D values support the 
observations made by analysing the Q-Q plots and genome plots and they confirm 
that difference occurs in cisplatin-induced DNA adduct formation between the in vitro 
and cellular treated datasets at the outlying microarray features identified. 
 Finally, the untreated histone H3 K14 acetylation dataset was compared with 
the cisplatin-induced DNA damage in vitro and cellular treated datasets. Plotting 
these three profiles together as genome plots did not reveal an obvious pattern related 
to the untreated sample and these plots were then examined at the outlying microarray 
features identified in the previous section and presented in figure 6.8. There was a 
suggestion from these genome plots of a trend toward lower untreated histone H3 
acetylation values at the outlying microarray features compared with the whole 
microarray dataset, suggesting that high DNA damage following in vitro treatment 
compared with cellular treatment coincide with regions of lower levels of untreated 
H3 K14 acetylation. This was investigated by comparing histograms of untreated 
histone acetylation log2 IP/IN values at the outlying features compared with the whole 
microarray dataset. The K-S test was used to compare these two distributions and, 
again, a trend toward lower acetylation values at outlying features was apparent, 
albeit with a low, non-statistically significant, value for the D statistic (D = 0.24, p = 
0.08, figure 6.10). Overall, therefore, whilst these findings may suggest a trend that 
could be further investigated, they do not support the hypothesis presented in the 
introduction to this chapter, namely that regions of the genome exhibiting low histone 
acetylation are highly compacted and are therefore less accessible to cisplatin and 
therefore demonstrate lower values for cisplatin-induced DNA damage following 
cellular treatments in culture compared with in vitro. 
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Figure 6.8 - Genome plots of cisplatin-induced DNA damage locating the microarray features 
detected in figure 6.7 as outlying differences. Presented are snapshots of whole genome data for 
chromosome 1, 2 and 14 and in each case the black profile represents cisplatin-induced DNA damage 
in vitro and the red profile represents cisplatin-induced DNA damage from cellular treatment in 
culture. Red crosses along the gene annotation data identify the microarray features and genomic 
locations where the outlying differences between these two datasets, detected in figure 6.7, are located. 
In each of the examples given in this figure, regions of outlying difference are demonstrated due to 
greater cisplatin-induced adduct formation occurring following in vitro treatment compared with 
cellular treatment in culture. Whole genome plot available in the electronic appendix. 
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Figure 6.9 - Histograms presenting microarray values of cisplatin-induced DNA damage and 
untreated histone H3 acetylation. In 6.10 (a-d) cisplatin-induced DNA damage microarray values 
(log2 IP/IN) are plotted as histograms. Values are either plotted for the whole microarray dataset or for 
the outlying features detected in figure 6.7. D represents the K-S test statistic, as discussed in the text. 
D values close to 1 represent large differences between distributions whilst values close to 0 represent 
no difference. 
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Figure 6.10. Microarray data for cisplatin-induced DNA damage and untreated histone H3 K14 
acetylation. In 6.10 (a) a genome plot for a section of chromosome 14 is presented and the black 
profile represents cisplatin-induced DNA damage in vitro, the red profile represents cisplatin-induced 
DNA damage in cells treated in culture and the green profile represents untreated histone H3 K14 
acetylation. Red crosses along the gene annotation data identify the microarray features and genomic 
locations where the outlying differences between the two cisplatin treated datasets (detected and 
presented in figure 6.7 & 6.8) are located. In this figure, regions of outlying difference demonstrating 
greater cisplatin-induced adduct formation occurring following in vitro treatment compared with 
cellular treatment are shown. Whole genome plot presented in electronic appendix. In 6.10 (b) 
untreated histone H3 K14 acetylation microarray values (log2 IP/IN) are plotted as histograms. Values 
are plotted for the whole microarray dataset and for the outlying features detected in figure 6.7. D 
represents the K-S test statistic, as discussed in the text. D values of 1 represent large differences 
between distributions whilst values of 0 represent no difference. 
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YAR066W
YAR068W
PHO11
IMD1
YAR075W
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lo
g2
 B
in
di
ng
0
2
4
6
8
180000 190000 200000 210000 220000 230000 240000
TOR2
MNN4
PTK1
PEX1
YKT6
MST1
SDS22
ACP1
PXA2
YKL187C
MTR2
YKL183C−A
COY1
STE3
LST4
YKL202W
tN(GUU)K
MIA40
DPH2
CNB1
tL(UAA)K
HYM1
ASH1
SPE1
LOT5
FAS1
PRS1
RPL17A
YKL177W
ZRT3
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lo
g2
 B
in
di
ng
0
2
4
6
8
60000 70000 80000 90000 100000 110000 120000
TPO5
YKL169C
KKQ8
MRP49
TPK3
YKL165C−A
MCD4
tE(UUC)K
PIR1
YKL162C−A
YKL162C
KDX1
RCN1
YKL156C−A
RSM22
tR(UCU)K
GPM1
YKL151C
DBR1
SDH1
YKL147C
RPC25
ZRT3
SNU114
EBP2
NNK1
MRPL38
PIR3
ELF1
APE2
RPS27A
SRP102
YKL153W
MCR1
AVT3
RPT1
YKL145W−A
LTV1
MRP8
SDH3
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lo
g2
 B
in
di
ng
0
2
4
6
8
120000 130000 140000 150000 160000 170000 180000
HSK3
MRPL31
APL2
OCT1
YKL133C
RMA1
SHE2
MYO3
PMU1
SRP21
VPH2
PRR1
YKL115C
APN1
RAD27
YKL111C
KTI12
YKL106C−A
YKL105C
SDH3
TGL1
CTK1
CMC1
YKL136W
YKL131W
tK(CUU)K
PGM1
YPK1
RRN3
SSH4
YKL123W
DGR2
OAC1
YKL118W
tA(AGC)K1
SBA1
ABF1
HAP4
SLD2
YKL107W
AAT1
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lo
g2
 B
in
di
ng
0
2
4
6
8
180000 190000 200000 210000 220000 230000 240000
YKL105C
GFA1
LAP4
YKL102C
YKL100C
UTP11
YKL097C
YKL096C−B
BUD2
YKL091C
CYT2
RRP14
PSY1
YKL075C
MUD2
HSL1
YKL100W−A
MTC2
CWP2
CWP1
YJU2
YJU3
MBR1
CUE2
MIF2
CAB3
SRX1
MDH1
HOT13
YKL083W
TEF4
SNR38
VMA5
SMY1
DHR2
YKL077W
LHS1
STB6
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lo
g2
 B
in
di
ng
0
2
4
6
8
240000 250000 260000 270000 280000 290000 300000
Chr. 11 
Chr. 14 
ACC1
ATP23
MRPL50
YNR025C
SEC12
YNR029C
SSK2
HUB1
ARC35
MRPS12
RSM19
ZRG17
COQ2
MSO1
LYS9
BRE5
POP2
TIM23
AIM38
ARE2
YNR021W
SNF12
MPP6
BUD17
CPR8
ALG12
PPG1
ABZ1
SOL1
YNR034W−A
DBP6
YNR040W
YNR042W
MVD1
AGA1
PET494
TRM112
FPK1
YNR048W
SNR49
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lo
g2
 B
in
di
ng
0
2
4
6
8
660000 670000 680000 690000 700000 710000 720000
POP2
NOG2
SNR191
ESF2
tL(UAA)N
HOL1
BIO5
BIO4
YNR061C
YNR062C
YNR064C
YNR065C
YNR066C
DSE4
YNR068C
BSC5
YNR071C
YNR073C
AIF1
BIO3
MNT4
FRE4
YNR063W
PDR18
HXT17
COS10
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lo
g2
 B
in
di
ng
0
2
4
6
8
720000 730000 740000 750000 760000 770000 780000
YNR075C−A
YNR077C
COS10
PAU6
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lo
g2
 B
in
di
ng
0
2
4
6
8
780000 790000 800000 810000 820000 830000 840000
YOL166C
AAD15
PAU20
YOL159C−A
YOL159C
ENB1
IMA2
HPF1
YOL153C
YOL150C
SPT20
PEX11
CTR9
RIB4
YOL166W−A
YOL164W−A
BDS1
YOL163W
YOL162W
YOL160W
HXT11
YOL155W−A
ZPS1
FRE7
GRE2
DCP1
PSF3
NOP8
RRP40
PPM2
ARG8
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lo
g2
 B
in
di
ng
0
2
4
6
8
0 10000 20000 30000 40000 50000 60000
TOR2
MNN4
PTK1
PEX1
YKT6
MST1
SDS22
ACP1
PXA2
YKL187C
MTR2
YKL183C−A
COY1
STE3
LST4
YKL202W
tN(GUU)K
MIA40
DPH2
CNB1
tL(UAA)K
HYM1
ASH1
SPE1
LOT5
FAS1
PRS1
RPL17A
YKL177W
ZRT3
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lo
g2
 B
in
di
ng
0
2
4
6
8
60000 7000 80000 90000 100000 110000 120000
TPO5
YKL169C
KKQ8
MRP49
TPK3
YKL165C−A
MCD4
tE(UUC)K
PIR1
YKL162C−A
YKL162C
KDX1
RCN1
YKL156C−A
RSM22
tR(UCU)K
GPM1
YKL151C
DBR1
SDH1
YKL147C
RPC25
ZRT3
SNU114
EBP2
NNK1
MRPL38
PIR3
ELF1
APE2
RPS27A
SRP102
YKL153W
MCR1
AVT3
RPT1
YKL145W−A
LTV1
MRP8
SDH3
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lo
g2
 B
in
di
ng
0
2
4
6
8
120000 130000 140000 150000 160000 170000 180000
HSK3
MRPL31
APL2
OCT1
YKL133C
RMA1
SHE2
MYO3
PMU1
SRP21
VPH2
PRR1
YKL115C
APN1
RAD27
YKL111C
KTI12
YKL106C−A
YKL105C
SDH3
TGL1
CTK1
CMC1
YKL136W
YKL131W
tK(CUU)K
PGM1
YPK1
RRN3
SSH4
YKL123W
DGR2
OAC1
YKL118W
tA(AGC)K1
SBA1
ABF1
HAP4
SLD2
YKL107W
AAT1
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lo
g2
 B
in
di
ng
0
2
4
6
8
180000 190000 200000 210000 220000 230000 240000
YKL105C
GFA1
LAP4
YKL102C
YKL100C
UTP11
YKL097C
YKL096C−B
BUD2
YKL091C
CYT2
RRP14
PSY1
YKL075C
MUD2
HSL1
YKL100W−A
MTC2
CWP2
CWP1
YJU2
YJU3
MBR1
CUE2
MIF2
CAB3
SRX1
MDH1
HOT13
YKL083W
TEF4
SNR38
VMA5
SMY1
DHR2
YKL077W
LHS1
STB6
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lo
g2
 B
in
di
ng
0
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6.3.8 Comparative analysis of cisplatin and UV-induced histone 
acetylation 
In chapter 5 comparisons were made between genomic cisplatin and UV-induced 
DNA damage profiles in S. cerevisiae, and in this section the epigenetic histone 
acetylation profiles following these treatments are now compared. Histone acetylation 
datasets following UV treatment were generated by Dr Katie Evans, PhD 2011, and, 
importantly, the UV-induced acetylation datasets were generated using a different 
antibody, the Anti-acetyl-Histone H3 antibody (Millipore 06-599). This antibody 
recognises histone H3 acetylation at lysine 9 and 14 residues (H3 K9K14), compared 
with the histone H3 K14 antibody used for the platinum acetylation studies presented 
in this chapter, which recognises acetylation at the lysine 14 residue only.  
 The ChIP-chip normalisation method formed by Dr Mark Bennett was 
developed to allow comparisons to be made between differences in a single factor 
within microarray datasets (e.g. histone acetylation) as a result of changes in an 
experimental condition (e.g. repair time). This normalisation method does not allow 
comparisons to be made between microarray datasets with additional sources of 
experimental variation such as those introduced by a different antibody. Datasets 
generated using different antibodies can have many other variations related to the 
antibody binding characteristics which may account for the differences seen between 
datasets even following normalisation. Therefore, whilst making direct quantitative 
comparisons between the two datasets in this instance would violate the assumptions 
made that are integral to the ChIP-chip normalisation procedure, and would not be 
valid, the overall patterns of the profiles themselves may still be compared to allow 
broad comparisons to be made between the different acetylation profiles. Making 
such comparisons between histone acetylation changes in cells following exposure to 
these two different genotoxins was of great interest and would also allow comparisons 
to be made between the genomic DNA damage datasets and the epigenetic histone 
acetylation changes. 
 For the comparisons presented in this section H3 K9K14 acetylation 
microarray datasets following UV treatment and untreated samples were used, and H3 
K14 acetylation microarray datasets for acetylation following cisplatin treatment and 
the untreated acetylation sample were used. For both UV and cisplatin treated 
samples, acetylation was measured at one hour repair following treatment. 
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6.3.8.1 ChIP-chip microarray data comparing histone H3 acetylation following 
treatment with cisplatin or UV 
A scatter plot of the untreated H3 K9K14 acetylation data against the untreated H3 
K14 acetylation data is presented in figure 6.11 (a), demonstrating a linear 
relationship with a Pearson correlation coefficient value of 0.74. Corresponding 
genome plots of these untreated datasets are presented in figure 6.11 (c), 
demonstrating untreated H3 K14 acetylation (black profile) and untreated H3 K9K14 
acetylation (red profile). The genome profiles and scatter plots indicate similarity in 
the untreated level of histone acetylation detected showing that the two different 
antibodies produce similar measurements of untreated histone H3 acetylation. 
 The treated acetylation profiles were then compared and a scatter plot of H3 
K14 acetylation in cisplatin treated cells against H3 K9K14 acetylation in UV treated 
cells also demonstrates a linear relationship, with a higher Pearson correlation 
coefficient of 0.91 demonstrated (figure 6.11 (b)). This scatter plot suggests greater 
acetylation levels in cisplatin treated samples, however, to confirm this observation, 
this would need to be tested using the same antibody. The genome plots demonstrate a 
similar profile for H3 K14 acetylation following cisplatin treatment compared with 
H3 K9K14 acetylation following UV treatment, and again, as suggested by the scatter 
plot, the acetylation profile in the cisplatin treated group appears higher (figure 6.11 
(d)). This genome plot (figure 6.11 (d)) demonstrates that peaks and troughs of 
acetylation coincide and to allow this pattern to be visualised more clearly a scaling 
multiplication factor is applied to the UV treated acetylation dataset which confirms 
that the distribution of the two acetylation profiles are very similar and almost overlie 
one another (figure 6.11 (e)). This observation is supported by the high Pearson 
correlation value of 0.91. 
 The cisplatin and UV-induced acetylation values were then calculated by 
subtracting the untreated acetylation data from the relevant treated acetylation data. 
The cisplatin-induced acetylation and UV-induced acetylation profiles are presented 
in figure 6.11 (f), and whilst these profiles do not show the same similarity compared 
to the treated acetylation data (seen in figure 6.11 (e)) a relationship between the two 
values is again evident with overlying peaks and troughs demonstrated in this short 
section of the genome. These qualitative observations suggest that despite the 
different antibodies used for these experiments the regions of histone H3 acetylation 
following exposure to these different genotoxins are remarkably similar.  
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Figure 6.11 – Microarray data comparing histone acetylation following treatment with either UV 
or cisplatin. In figure 6.11 (a,b) log2 IP/IN values are plotted as scatter plots, firstly of untreated H3 
K14 against untreated H3 K9K14 acetylation (Pearson’s correlation 0.74) and secondly, of H3 K14 
acetylation following cisplatin treatment against H3 K9K14 acetylation following UV treatment 
(Pearson’s correlation 0.91). In both cases the line plotted is the line of y = x. Figure 6.11 (c) presents a 
genome plot of the untreated datasets plotted in 6.11 (a), with untreated H3 K14 acetylation shown as 
the black profile and untreated H3 K9K14 acetylation as the red profile. In each of the genome plots 
presented in figures 6.11 (d-f) the black profile represents cisplatin treated samples and the red profile 
represents UV treated samples. Figure 6.11 (d) presents a genome plot of the cisplatin and UV treated 
histone acetylation datasets presented in 6.11 (b). Figure 6.11 (e) presents the same profiles as shown 
in figure 6.11 (d) except that a multiplication scaling factor has been applied to the UV acetylation data 
to increase the scale of the data to allow better visualisation. Figure 6.11 (f) shows the cisplatin-
induced acetylation (cisplatin treated acetylation minus the untreated acetylation) (black profile) and 
the UV-induced acetylation (red profile). 
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6.3.8.2 Comparisons of global histone acetylation enrichment between cisplatin 
and UV treated cells 
In this section analysis of the whole epigenetic microarray datasets is presented, 
evaluating histone acetylation profiles globally. The purpose of this work was to 
identify, examine and compare genome-wide the regions of the cisplatin and UV 
treated datasets where histone H3 acetylation was highest, or enriched. This was 
performed using the ‘enrichment detection’ function within Sandcastle, which 
allowed enriched portions of microarray datasets to be distinguished from the 
background. For this analysis, cisplatin-treated and UV-treated acetylation values 
were used, rather than the induced acetylation values presented in figure 6.11 (f).  
 Out of the approximately 44,000 microarray features included on the 
microarray, the enrichment detection identified 33,015 microarray features enriched 
for histone H3 K14 acetylation following cisplatin treatment and 29,080 microarray 
features enriched for histone H3 K9K14 acetylation following UV treatment. 
Combining the analysis to detect features enriched following both cisplatin and UV 
treatment identified 28,684 microarray features and the positions of some of these are 
located with red crosses on the genome plot for a section of chromosome 4 in figure 
6.12 (a) (whole genome plot in file titled ‘Figure 6.12’ in electronic appendix). This 
indicates that 99% of the features enriched following UV treatment are also enriched 
following cisplatin and 87% of the features enriched following cisplatin treatment are 
also enriched following UV (figure 6.12 (d)).  
 It is interesting to note that greater numbers of features are identified by 
enrichment detection following cisplatin treatment compared with UV given that the 
antibody used for UV studies recognises K9 and K14 acetylation compared with K14 
alone for cisplatin. This increased identification of enriched features demonstrating 
acetylation following cisplatin treatment may reflect the generally higher values 
evident within the cisplatin treated microarray data, which may reflect differences in 
the degree of acetylation related to the dose of cisplatin compared with UV. Another 
explanation is that the power of detection of the enrichment detection procedure is 
greater when more datasets are included and five datasets were analysed for 
acetylation following UV compared to three for acetylation following cisplatin. This 
means that the enrichment detection is able to identify acetylation in trough regions 
and at peaks more precisely following UV than following cisplatin and may be more 
accurately identifying certain regions as being non-enriched. There may, therefore, be 
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a degree of over-identification of regions as enriched following cisplatin treatment. A 
final explanation could be that one antibody is more efficient at recognising histone 
acetylation than the other. 
 
 
           
 
Figure 6.12 – Genome plot demonstrating histone H3 acetylation following cisplatin treatment 
and UV irradiation. For each of the genome plots presented, the black profiles represent acetylation 
following cisplatin treatment and the red profiles represent acetylation following UV treatment. 
Enrichment detection software identified microarray features that are enriched for histone H3 
acetylation following both cisplatin and UV treatment and these enriched microarray features are 
located by red crosses along the gene annotation data for a section of chromosome 4 in figure 6.12 (a) 
(n=28,684). In figure 6.12 (b) the same profiles are plotted for a section of chromosome 6 and on this 
occasion the red crosses highlight features identified as enriched for acetylation following UV but not 
cisplatin (n=396). Figure 6.12 (c) again shows the same profiles for a section of chromosome 1, now 
the red crosses highlight features which are enriched for acetylation following cisplatin but not UV 
(n=4331). Whole genome plots of the three different profiles are presented in the electronic appendix. 
Figure 6.12 (d) outlines, in a Venn diagram, the numbers of microarray features detected as enriched 
following cisplatin or UV treatment or both.  
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 In this section the differential regions detected as enriched for H3 acetylation 
following treatment with one genotoxin but not the other are examined in more detail 
and the K-S test is again used to compare between the distributions of the different 
histograms presented. This test was previously described in section 6.3.7, and the D 
statistic is presented as a measure of the difference between the datasets presented in 
the histograms in figures 6.13 and 6.14. D values close to 1 represent large differences 
whilst values close to 0 represent no difference. 
 Examining the 1% of features where acetylation enrichment is detected 
following UV treatment but not following cisplatin identifies 396 features. As stated 
previously, many of the features identified show low levels of acetylation following 
UV, and an example of some of these are located by red crosses on the genome plot 
for a section of chromosome 6 presented in figure 6.12 (b). Acetylation levels at these 
enriched regions were examined by plotting the log2 IP/IN ratios for each of the 396 
features as a histogram. This demonstrates a trend toward lower values for both UV 
and cisplatin acetylation at these points compared with the microarray data as a whole 
(figure 6.13 (a-b)). D values suggest differences between the acetylation values at the 
enriched regions compared with the whole microarray values (D = 0.50, D = 0.73, 
p<0.0001), but less difference between the two enriched regions (D = 0.2, p<0.0001). 
These 396 points therefore reflect regions where both acetylation following UV and 
following cisplatin are low and the increased power of detection for the UV samples 
is leading, in some instances, to these values being preferentially detected for 
acetylation following UV compared with cisplatin. These findings therefore are likely 
to be a reflection of the increased power of detection with more samples rather than a 
reflection of significantly different H3 acetylation levels.  
 In support of this is the observation that when these 396 features are located 
throughout the genome they are typically scattered evenly throughout the genome 
rather than being clustered in certain regions (whole genome plot available in file 
titled ‘Figure 6.12’ in electronic appendix). A further observation here is that many of 
the 396 features identified occur at the end of genes or in downstream regions (some 
of these are evident in figure 6.12 (b)). This, again, is likely to be a reflection of 
genomic regions where acetylation levels are lower, since regions at ends of genes 
and downstream regions have previously been demonstrated to be associated with 
lower acetylation levels on the profile plots previously presented in figure 6.4 (b).  
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 The same analysis was performed for the 4331 microarray features identified 
as enriched following cisplatin treatment but not UV. This time, most of the features 
identified demonstrate noticeably higher acetylation levels following cisplatin 
treatment compared with UV and an example of some of these are located by red 
crosses on the section of chromosome 1 presented in figure 6.12 (c) (whole genome 
plot available in electronic appendix). Once again, this observation is supported by 
analysing the log2 IP/IN ratios at each of the 4331 features identified and plotting 
these as histograms (6.13 (c,d)). These histograms confirm higher acetylation values 
following cisplatin treatment compared with following UV in these regions (D = 0.91, 
p<0.0001). 
 Finally, the features identified as differentially enriched for acetylation 
following UV and cisplatin treatment were examined for DNA damage at these sites. 
Log2 IP/IN ratios for cisplatin and UV-induced DNA damage from the S. cerevisiae 
cellular genomic datasets treated in culture presented in chapter 3 were analysed at 
these sites, and the DNA damage levels at these features are presented in the form of 
histograms in figure 6.14. No difference is observed in the distribution of cisplatin or 
UV-induced DNA damage at the enriched sites compared with the microarray 
datasets as a whole and the low values of the D statistic are presented in figure 6.14. 
The damage levels at these features for both genotoxins are therefore representative of 
the whole genomic DNA damage data. 
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Figure 6.13 – Histograms presenting microarray values from studies of histone acetylation 
following UV and cisplatin treatment. In each histogram presented here the values plotted are the 
log2 IP/IN ratio acetylation values obtained from the relevant DNA microarray study. Enrichment 
detection identifies 396 features where histone acetylation is enriched after UV but not cisplatin. In 
6.13 (a) and (b) comparisons are made between histone acetylation values at these 396 features and the 
whole microarray datasets for UV and cisplatin treatment respectively. In both cases the values at the 
enriched features are lower than for the total microarray data and the D statistic is given in the figure. 
Comparing between histone acetylation values in the enriched regions following UV and cisplatin 
demonstrates similar distributions with a D value of 0.20. Likewise, enrichment detection identifies 
4331 features where histone acetylation occurs after cisplatin but not UV. In 6.13 (c) and (d) 
comparisons are made between histone acetylation values at these 4331 features and the whole 
microarray datasets for UV and cisplatin treatment respectively. In this case the values at these features 
are generally higher after cisplatin compared with UV with a D statistic of 0.91 Note the different scale 
of x axis for these histograms. 
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Figure 6.14 – Histograms presenting microarray values of genomic DNA damage from S. 
cerevisiae cells treated in culture with cisplatin or UV irradiation. In each histogram presented here 
the values plotted are the log2 IP/IN ratio values obtained from the relevant DNA microarray study. In 
figures 6.14 (a) and (b) the microarray values of cisplatin- and UV-induced DNA damage are 
compared between the 396 enriched features of acetylation discussed in figure 6.12 and the whole 
microarray dataset. In figures 6.14 (c) and (d) the microarray values of cisplatin- and UV-induced 
DNA damage are compared between the 4331 enriched features of acetylation discussed in figure 6.12 
and the whole microarray dataset. In each case the distribution of microarray values for DNA damage 
is the same at the enriched features as for the whole microarray data, highlighted by the low value for 
the D statistic in each case. 
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6.4 Discussion 
 
In this chapter studies were conducted in the yeast model organism S. cerevisiae. This 
organism processes chromatin similarly to human cells and histones H3 and H4 are 
highly conserved between eukaryotes and are known to have similar function in all 
eukaryotes. Histone acetylation in response to UV irradiation in yeast has previously 
been investigated and is well characterised and some of the mechanisms behind these 
responses are now also beginning to be understood. In comparison to UV, histone 
acetylation in response to exposure to platinum analogues has been much less widely 
investigated although histone H4 acetylation has been demonstrated by Western 
blotting to be a prominent histone modification taking place in response to platinum 
treatment (Wang and Lippard, 2004). Evaluating untreated histone acetylation as well 
as changes in acetylation genome-wide with ChIP-chip following exposure to 
platinum agents will therefore provide new insight into the formation of platinum 
adducts in the context of chromatin as well as their processing.  
 It has recently been demonstrated in yeast and human cells that histone 
acetylation promotes the chromatin remodelling necessary for efficient repair of UV-
induced DNA damage (Yu et al., 2011, Guo et al., 2011). Whilst much of the previous 
work has been performed characterising acetylation responses to UV irradiation and 
how this influences the NER machinery, it is likely that since NER is also critical for 
the repair of platinum adducts that histone acetylation will play a similarly prominent 
role in the repair of platinum adducts. Evaluating, and understanding, DNA damage 
formation in the context of chromatin as well as chromatin remodelling in response to 
platinum-induced damage (and also other DNA damaging agents) is an increasingly 
important area of research as it may well reveal potential new targets and therapeutic 
strategies for the potentiation of current therapies.  
 Two strategies were employed in this chapter to evaluate these key areas of 
adduct formation in chromatin and to characterise acetylation responses. Firstly, 
differences were analysed between cisplatin-induced DNA damage profiles in naked 
DNA and chromatin before integrating these findings with untreated histone H3 K14 
acetylation. Secondly, comparisons were performed between acetylation responses 
following exposure to two different genotoxic agents, initially of the same class, 
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cisplatin and oxaliplatin, and subsequently, between two different classes of 
genotoxins, the chemical genotoxin cisplatin and physical genotoxin UV. 
 In this chapter standard ChIP-chip methodology has been used to determine 
cisplatin and oxaliplatin-induced histone H3 K14 acetylation at high-resolution 
genome-wide in yeast cells. Reproducible qRT-PCR data is obtained using the histone 
H3 K14 antibody and this demonstrates that histone H3 K14 acetylation following 
cisplatin treatment increases most by the one hour repair time following cisplatin 
exposure, relative to the untreated sample (figure 6.1). Histone acetylation following 
oxaliplatin treatment appears to still be increasing at two hours repair time, however 
this represents a single experiment and therefore the significance of this is uncertain. 
This acetylation pattern needs to be further characterised by performing more 
experimental replicates but this pattern could represent certain differences in the 
repair of oxaliplatin adducts compared with cisplatin. 
 Microarray data presented in this chapter are normalised using the ChIP-chip 
normalisation technique developed by Dr Mark Bennett (PhD thesis, 2012). This 
normalisation technique was initially developed to analyse ChIP-chip datasets in yeast 
cells examining histone acetylation changes and DNA repair factor binding following 
exposure to UV irradiation, and the procedure was previously demonstrated to be 
valid for these datasets by comparisons made between microarray and qRT-PCR data. 
In the work presented in this chapter the same approach was used to validate histone 
acetylation yeast microarray datasets following platinum treatment (figure 6.3). 
 The genomic regions chosen for qRT-PCR analysis for microarray validation 
were based on previous work examining histone H3 acetylation following UV 
treatment (Dr K Evans, PhD thesis 2012). This work demonstrated differential 
acetylation levels following UV treatment in three separate genomic locations, with 
the greatest level of UV-induced acetylation present at POL30, followed by PSK1 
then MFA2. The work presented in this chapter demonstrates the same pattern of 
differential acetylation following cisplatin exposure when examining H3 K14 
acetylation in these genomic locations by qRT-PCR (figure 6.3). When analysing the 
microarray data at these locations the same pattern is also evident and a very close 
concordance is evident between the enrichment values obtained by qRT-PCR and 
from microarray data at the PSK1 and MFA2 regions but with slightly less 
concordance at the POL30 region. However, the normalised microarray data at 
POL30 is still more representative of the qRT-PCR data than the non-normalised or 
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quantile normalised data. This demonstrates the normalisation technique to be 
appropriate for normalising these datasets and confirms the ChIP-chip microarray 
data output to be valid. This therefore indicates that ChIP-chip is a valid approach to 
examining changes in histone H3 K14 acetylation in response to platinum analogue 
treatment. 
 The work presented in this chapter confirms histone H3 K14 acetylation to be 
a prominent histone modification following exposure to platinum analogues. The data 
presented in figures 6.2 and 6.5 confirm a global increase in acetylation across the 
genome following cisplatin or oxaliplatin exposure and collectively these data suggest 
that the majority of the genome has higher H3 K14 acetylation following either of 
these treatments. Furthermore, by collectively analysing the acetylation profiles 
across individual genes increased acetylation within promoters is evident with a fall in 
acetylation level within the gene ORF (figures 6.4 and 6.5).  
 One area of particular interest was to develop an approach to being able to 
evaluate platinum-DNA adduct formation in the context of chromatin. This was 
achieved by making comparisons between cisplatin-induced DNA damage induction 
following in vitro treatment and cellular treatment in culture and comparing these 
differences with the untreated histone H3 acetylation profile. To make these 
comparisons, firstly the differences were calculated between the damage datasets then 
outlier detection methodology was applied to detect regions of large, or outlying, 
difference between these datasets. This approach relies on the assumption that small 
differences occur between these datasets, which may be the result of technical 
experimental variation and are normally distributed, but in some regions larger key 
differences may exist as a result of biological processes such as the effect of 
chromatin structure on cisplatin adduct formation. 
 Using this method certain regions of large difference between these datasets 
were detected, which were almost exclusively as a result of greater damage being 
induced in in vitro samples compared with the cellular treated samples (figures 6.7 
and 6.8). Analysing histograms of the individual microarray feature values confirm 
that the outlying regions are associated with greater values for in vitro samples and 
lower values for the cellular treated samples when compared with whole microarray 
datasets in each case (figure 6.9). When integrating these data with untreated histone 
acetylation data a trend was demonstrated that these differences were occurring in 
regions of low histone H3 acetylation (figure 6.10). Whilst this does demonstrate a 
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trend it doesn’t confirm the hypothesis outlined at the beginning of this chapter - that 
differences occur between these datasets in regions of the genome exhibiting low 
histone acetylation, as these are highly compacted and protected from cisplatin-
induced DNA damage, therefore leading to lower levels of DNA damage when 
treating cells in culture. It is also important to say that only one epigenetic factor has 
been investigated here and that greater sensitivity to this type of analysis may be 
achieved by including analysis from histone acetylation at other residues or other 
epigenetic histone modifications such as histone methylation. Nevertheless, these are 
important observations, which provide a basis for further more rigorous investigations 
of this area using greater numbers of replicate samples. This approach would be well 
suited to investigating the hypothesis that DNA damage using chemical agents such 
as cisplatin occurs more readily in less compacted regions of chromatin which would 
support the notion of being able to potentiate the effect of these drugs by altering 
chromatin configuration prior to treatment, with an agent such as a HDACi. 
 The work presented in figures 6.2 and 6.5 demonstrates that histone H3 
acetylation response is remarkably consistent both between separate biological 
replicate samples of cisplatin treated yeast cells and also between different classes of 
platinum analogue. Whilst only a single ChIP-chip sample for oxaliplatin treated 
yeast was generated, and further replicate samples would therefore be required to 
confirm this finding, the consistency demonstrated between acetylation profiles for 
cisplatin and oxaliplatin is striking. This intriguing finding of such consistency in 
global histone H3 K14 acetylation response within classes of genotoxins raised the 
question what about such responses in different classes of genotoxins. This question 
was addressed in this chapter by comparing histone H3 acetylation between cisplatin 
and the physical genotoxin UV irradiation. 
 Comparisons were therefore performed between histone H3 acetylation in 
yeast cells following exposure to cisplatin or UV irradiation. Different antibodies 
were used within the ChIP-chip protocol for each genotoxin, namely the histone H3 
K9K14 antibody was used for the UV acetylation work and the H3 K14 antibody for 
the cisplatin acetylation work. Therefore, these comparisons were performed with the 
limitations of comparing datasets generated using different antibodies taken into 
account. However, despite the different antibody used, this comparison revealed very 
similar patterns of histone acetylation following exposure to these two different 
genotoxins. Whilst there are caveats to this analysis in view of the different antibodies 
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used for the ChIP-chip experiments, and whilst fully quantitative comparisons could 
not be made because of this, it was still possible for comparisons to be made of the 
sites of acetylation between the two and to analyse the global acetylation patterns in 
each case. To allow the acetylation patterns to be better appreciated visually a 
multiplication scaling factor was applied to the UV dataset, a valid step since this was 
only performed to allow improved visual representation of the pattern and not for 
making quantitative comparisons. Indeed, the striking similarity demonstrated 
between the two acetylation profiles following this scaling is clearly evident. 
 The conclusion from these comparative studies is that very similar acetylation 
patterns are induced following exposure to cisplatin, oxaliplatin and UV irradiation. 
This suggests that acetylation response may not necessarily be specific to the 
genotoxin itself but is more specific for the organisation of repair of the DNA damage 
induced by that genotoxin. For example, repair of both CPDs and cisplatin adducts 
predominantly involve NER and organisation of NER may explain the similarity 
demonstrated here between acetylation patterns. Whilst the similarity evident between 
cisplatin and UV-induced acetylation in these profiles may suggest that trying to 
identify different epigenetic signatures related to H3 acetylation predictive of 
response may be challenging. It is also entirely possible that the pattern detected here 
could represent the signature of, for example, a repair proficient yeast cell whilst 
analysis in a repair-deficient strain may reveal different H3 acetylation profiles. This 
needs further characterisation in different cell strains. A further technical observation 
in this case is that the histone H3 K9K14 antibody may demonstrate a bias for 
recognising acetylation predominantly at lysine 9. 
 The rationale for applying these ChIP-chip assays in the yeast model organism 
was the same as for developing the DNA damage DIP-chip assays initially in yeast. 
Namely, the simpler model system with smaller genome and the well-established 
technique and method meant there were fewer uncertainties and challenges to 
overcome when developing the assay. Applying these ChIP-chip assays in yeast also 
meant that comparative analytical approaches could be developed to examine these 
epigenetic histone modification datasets with the genomic DNA damage datasets that 
had already been generated (presented in chapter 3). At the time of performing these 
assays the methodology for developing the DIP-chip technique for measuring 
genomic DNA damage in human cells was still being developed and therefore such 
comparative analyses were not possible in the human context at that time. Data 
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acquired from these studies in yeast could also be applied and compared to a variety 
of other datasets already generated in yeast cells within our research group, such as 
those examining UV-induced histone modification. Again, this would not be possible 
in the human context. Clearly, these assays could also be applied to other species, 
such as human cells and now that the DIP-chip assay has been developed and 
validated in human cells, as described in chapter 4, genomic DNA damage datasets 
now also exist in human cells for comparative analysis. 
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Chapter 7 
Discussion and future work 
 
 
The main achievement of the research work presented in this thesis has been to 
develop a novel technique combining DNA immunoprecipitation with DNA 
microarrays to enable valid genomic measurements of DNA damage to be made in 
human cells. In this thesis the technical development and validation of this technique 
has been presented and the assay has been applied to measuring DNA damage lesions 
from the chemical genotoxins cisplatin and oxaliplatin in addition to the physical 
genotoxic agent UV irradiation. The real value of this technique is that it allows DNA 
damage events to be measured and located at high resolution and precision within the 
human genome providing a huge depth of information from single assays. 
 This technique involves capturing DNA damage lesions of interest using DNA 
immunoprecipitation employing an antibody specific to the damage lesion, coupled 
with genome wide location analysis of the damage lesions using DNA microarrays 
(DIP-chip). This concept was first described to examine UV-induced CPD induction 
in S. cerevisiae following exposure to UV light irradiation (Teng et al., 2011). As 
presented in this thesis the DIP-chip assay has now been developed and adapted 
allowing it to be applied in human cells to examine different modes of DNA damage 
at high resolution. This represents a significant technological advance, refinement and 
improvement of the original method. This also represents significant progress in the 
application of DNA microarray-based technology and now offers a novel technique 
and approach to examining global patterns of DNA damage in human cells. In this 
thesis the DIP-chip assay has been used to measure cisplatin and oxaliplatin-induced 
DNA damage in S. cerevisiae (chapter 3) as well as cisplatin, oxaliplatin and UV 
irradiation-induced DNA damage in human cells (chapter 4). Comparisons between 
these different damage profiles have demonstrated overall similarity between cisplatin 
and oxaliplatin-induced DNA damage profiles and the contrast between platinum and 
UV-induced DNA damage profiles (sections 5.3.1.1 and 5.3.2.1 chapter 5). The 
power of the assay has been demonstrated in a variety of settings, for example with 
the demonstration of the outlier detection method to detect regions of different DNA 
damage between samples (section 6.3.7, chapter 6), and the demonstration of 
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differential DNA damage patterns in different regions of repeat DNA sequences 
(section 5.3.2.2, chapter 5). 
 In addition to the technical laboratory development of the assay itself, several 
novel bioinformatic analytical methods have been presented and applied in this thesis 
for validating, analysing and visualising the genome-wide DNA damage datasets. The 
bioinformatic tools have been developed in parallel with the laboratory assay 
development. These are all included within the Sandcastle software package, which is 
available for download with full documentation from http://reedlab.cf.ac.uk. These 
bioinformatic tools have been applied to the comprehensive validation work 
conducted in the development of this assay and presented in chapters 3 and 4, as well 
as for performing the comparative analyses presented in chapters 5 and 6. One of the 
key validating steps for the DIP-chip work presented in this thesis was the 
development of predicted profiles for DNA damage formation based upon the known 
characteristics of platinum or UV-induced DNA damage induction and knowledge of 
the genomic sequence. As well as providing important validation of the method, these 
analyses also provide illustrations of how this novel assay may be applied to both 
basic and clinical research questions. For example, comparing experimental 
microarray profiles versus predicted profiles for DNA damage provided a way of 
detecting areas of genomic damage in experimental samples that deviate from the 
predicted pattern of DNA damage induction (section 5.3.1.2, chapter 5). The same 
technique may be further developed and applied to clinical samples to allow 
comparisons of DNA damage profiles to be made between different groups of 
patients. For example, this could provide a method for detecting outlying values and 
therefore detect potential key differences between DNA damage profiles that classify 
groups of individuals receiving the same chemotherapeutic regimens. 
 The development of this assay represents a significant improvement on the 
existing technologies for measuring DNA damage, discussed in chapter 1. Such 
technologies can measure DNA damage at low resolution throughout the genome, 
using immuno-slot-blots (Perdiz et al., 2000) or at very high, individual nucleotide, 
resolution in single gene loci using high resolution gels (Teng et al., 1997). The DIP-
chip assay provides, for the first time, a technology that simultaneously offers both 
sensitivity and resolution in measuring and locating DNA damage induction across 
long sections of the entire human genome. This now offers a phenotypic or functional 
assay capable of examining the DNA damage lesions directly, examining for regions 
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of preferential DNA damage induction and repair. This assay has significant potential 
relevance in the fields of genotoxicity testing, translational clinical research and 
personalised medicine as well as in basic, mechanistic, laboratory studies. This assay 
may now be developed and applied to clinical samples to begin to characterise genetic 
DNA damage signatures as predictive biomarkers of response or toxicity to these 
DNA damaging agents, which may then be applied to allow individualisation of 
chemotherapeutic agents. Equally, characterising unintended drug-DNA interactions 
using this technology will also offer a valuable and robust tool for genotoxicity testing 
of novel drug compounds.  
 As discussed in the introduction, it is recognised that inactivation of MMR 
proteins can have profound biological consequences including increased rates of 
genome-wide point mutations arising from unrepaired DNA synthesis errors. This 
loss of MMR activity can lead to cells developing a mutator phenotype, a hypothesis 
whereby mutations are required in genes that control DNA fidelity to allow the 
greatly increased mutation rates required for the initiation and promotion of 
carcinogenesis (Loeb et al., 2003). This is one example highlighting how defective 
DNA repair can result in the genome instability required for carcinogenesis, and 
highlights how a functional, phenotypic assay such as the DIP-chip assay presented 
here, may be employed to measure DNA damage as a means to assessing variation in 
interindividual DNA repair capacity. 
 The approach taken to developing this assay, as described in this thesis, was to 
initially establish the assay in the model yeast organism S.cerevisiae. This allowed a 
number of the fundamental characteristics of the assay development to be appreciated 
and established. These elements included induction of cisplatin and oxaliplatin-DNA 
damage in yeast cells, the detection of damage induced by both drugs using the 
CP9/19 antibody, development of the DIP assay to detect this damage and the 
establishment and bioinformatic validation of successful microarray hybridisation. 
Successfully developing the assay in yeast cells proved the principle that taking a 
microarray approach to measuring platinum-induced DNA damage was feasible, and 
achieving this gave confidence, and the necessary evidence, to proceed to develop the 
assay in human cells. 
 The fundamental difference with developing the assay in human compared 
with yeast cells was the increased genome scale encountered in human cells, which 
represented a significant and complex challenge to overcome. This complexity was 
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governed by the 300-fold increase in genome size and the associated relative 
reduction of each DNA fragment (copy number) within the DIP or microarray 
hybridisation sample. This reduction in DNA fragment copy number would make 
each of the microarray preparation steps less efficient, and ultimately would manifest 
as reduced labelled DNA for microarray hybridisation and therefore reduced 
fluorescence at each microarray probe. This challenge could not be overcome simply 
by scaling up amounts of DNA 300-fold, which would not be feasible and would 
make the protocol impractical. Therefore, for the successful development of this assay 
in human cells a number of key technical steps were taken to enrich the human DNA 
samples being applied to microarrays so that they would reflect the yeast system as 
far as possible. This was achieved as outlined in chapter 4, and involved a number of 
key methodological developments to enrich the DIP samples and to increase the 
quality of DNA being applied to the microarrays. 
 These developments comprised optimising the DIP stage of the protocol such 
that detection of background, undamaged DNA fragments was minimised, and 
optimisation of DNA retrieval following DIP, using a phenol-chloroform step to 
purify and extract the DNA, to maximise the amount of immunoprecipitated DNA 
recovered following DIP. Despite these optimisations the DIP sample still required 
amplification to provide sufficient DNA amount for hybridisation to DNA 
microarrays. Whilst the LM-PCR method was satisfactory for amplifying yeast 
samples it was concluded that LM-PCR may not be as efficient for amplifying human 
DNA samples since the efficiency of the linker ligation step may fall significantly in 
the face of the reduced copy number within human samples. Therefore, replacing the 
LM-PCR method of genome amplification with the GenomPlex® Complete Whole 
Genome Amplification Kit (WGA2, Sigma-Aldrich) method for amplification 
represented the final key methodological development prior to microarray 
hybridisation. 
 At the outset of these studies the development of custom-designed DNA 
microarrays to allow a short continuous section of the human genome to be examined 
at high resolution was critically important. These arrays provided coverage of a short 
section of the genome on a microarray, and allowed high resolution microarray 
studies to be performed. These microarrays also ensured high experimental 
throughput since four separate microarrays could be included on one glass slide. 
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 Finally, stringent data validation of the microarray output was a pivotal step 
for developing this technique and provided confidence that the assay was functioning 
reliably and reproducibly. Data validation was assessed in two ways in both yeast and 
human cells. Firstly, replicate datasets were plotted against each other as scatter plots 
to assess the association and correlation between them to establish reproducibility. 
Secondly, generating theoretical models for platinum and UV-induced DNA damage 
provided a key way of validating the success of the DIP-chip assay by providing a 
standard for experimental profiles to be compared against. Further confirmation of the 
technique was then provided by demonstrating similarity between cisplatin and 
oxaliplatin-induced damage profiles and by demonstrating the contrasting profiles of 
UV and platinum-induced DNA damage.  
 Following the development of the DIP-chip assay in human cells to measure 
platinum-induced DNA damage, its successful application to measuring another mode 
of DNA damage, namely UV-induced CPD formation demonstrated the assay to be 
robust. This demonstrated how, having methodically developed and validated the 
DIP-chip assay to measure platinum-induced DNA damage, this work can be 
considered as a paradigm for examining and measuring DNA damage profiles of 
other DNA damaging agents. This is providing that specific antibodies against that 
damage are available or that other means of affinity capture of the feature can be 
established. 
 The purpose of this work was to develop an assay that could be applied to 
clinical samples to detect differences in platinum adduct formation between patients. 
Whilst many different cellular processes affect overall platinum-DNA adduct levels 
such as drug uptake, drug efflux and detoxification, ultimately it is the extent of the 
platinum-DNA adducts, and their repair, that is pivotal to the action and clinical 
efficacy of the platinum analogues. As discussed in section 4.1, chapter 4, many 
studies have demonstrated that platinum-DNA adduct levels formed in both tumour 
tissue and white blood cells correspond to clinical response to treatment. Many 
studies have also measured surrogate markers for the repair of the platinum-DNA 
damage itself such as ERCC1, a protein involved in the NER pathway, to try and 
predict response to the platinum analogues. Whilst these studies have merit and 
demonstrate the continued clinical relevance of this area of research, to be able to 
directly measure and locate the DNA damage lesions themselves using this assay 
provides a significant advance in providing a novel phenotypic assay.  
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 We envisage that by applying this assay to clinical samples, differences will 
be detected in platinum-DNA adduct formation and repair between patients, and that 
distinct signatures or patterns of DNA damage or repair may be identified that may 
differentiate responder patients from non-responders for example. This translational 
research application could lead to the assay being used as a predictive biomarker for 
treatment response and for treatment stratification. This is an important element of the 
modern model of healthcare termed personalised medicine, whereby medical 
treatments are tailored to individual patients based on the likelihood of clinical 
response.  
 There are many approaches that could be taken to develop and apply the DIP-
chip assay presented in this thesis to clinical samples. The first logical approach 
would be to take whole blood samples from cancer patients following treatment with 
platinum agents, isolate the peripheral blood mononuclear cells (PBMCs) and extract 
their DNA for DIP-chip experiments. This could be preceded by scouting experiments 
whereby PBMCs are isolated from normal subjects, treated ex vivo with cisplatin and 
processed for DIP-chip. These experiments would ensure that the DIP-chip method 
developed in this thesis could be applied to clinical samples and could also be used to 
establish the lower limit of detectability of the assay when applying to such samples 
(see later discussion). These studies would also evaluate if cisplatin-induced DNA 
damage profiles generated from PBMCs reflect those generated in cultured cells and 
presented in this thesis. Using PBMCs would be reasonable since previous studies, 
outlined in section 4.1, chapter 4, have shown that platinum-DNA adduct formation in 
peripheral blood leucocytes is predictive of tumour response to platinum-based 
therapy. It is therefore possible that studies using PBMCs may themselves reveal 
signatures predictive of tumour response and toxicity, without needing to sample 
tumour tissue. 
 In addition to these studies, paired DNA samples could be collected from 
tumour tissue and leucocytes from cancer patients treated with platinum analogues to 
compare DNA damage profiles between the two sources. Comparisons of adduct 
formation and repair between PBMCs and tumour tissue could highlight differences 
in DNA repair capabilities between somatic cells (PBMCs) and cancer cells offering 
important insights into carcinogenesis. Clearly, the main barrier to such a study would 
be the difficulty in accessing tumour tissue and in obtaining tumour samples from 
patients following platinum treatment. However, such tissues would be available, for 
Chapter 7. Discussion and future work 
 
 258 
example from patients with head and neck, bladder and oesophageal cancer which are 
commonly treated with neo-adjuvant (treatment prior to surgery) cisplatin 
chemotherapy. Cisplatin-treated tumour tissue would therefore be available from 
these surgical samples. An important consideration in these cases would be the timing 
of surgery, however, surgery is normally performed within 3-6 weeks of completion 
of chemotherapy treatment and multiple cycles of chemotherapy are administered 
prior to surgery. It has previously been shown that platinum-DNA adducts persist for 
many months following treatment having been detected at autopsy in patients who 
had received cisplatin between 7-15 months prior to death (Poirier et al., 1992). The 
same study also demonstrated similar adduct levels in tumour tissues and bone 
marrow. If such studies analysing paired tumour and PBMC samples demonstrated 
similar adduct profiles this would support using PBMCs as a surrogate for tumour 
tissue in further studies. 
 Another consideration here is whether the quality and quantity of DNA 
obtained from these tissue samples would be sufficient for use in microarray assays. 
This would have to be evaluated but it is possible that the DNA yield from tumour 
tissue would not be of sufficient quantity for a microarray-based approach to be taken, 
and may require a DNA sequencing approach using the latest next generation 
sequencing techniques. 
 One potential elegant solution to obtaining tumour DNA could be the use of 
circulating free tumour DNA, or circulating tumour cells. This would allow the 
retrieval of fresh tumour DNA non-invasively through a simple blood test. The timing 
of the blood test following treatment could be controlled and several repeat samples 
could be taken at different times, allowing the repair of adducts within tumours to be 
investigated closely. Another possible source of tumour cells from patients following 
platinum treatment could be within ascitic fluid - although the numbers of tumour 
cells available in ascites may be prohibitively small. 
 Initially, for these studies two predefined patient groups could be identified 
that demonstrate response or non-response to these agents and tumour and PBMC 
DNA obtained and compared between these patients to see if key differences in 
damage induction can be detected between these groups. This may be achieved by 
using the outlier detection method outlined in chapter 4. It is possible that key 
discriminatory differences will be observed in the damage induction patterns, 
alternatively, such differences may only be apparent when analysing the repair of this 
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damage. The outlier detection approach could be applied to demonstrate key areas of 
difference in DNA damage between samples. Equally, detailed evaluation of the 
repair of the damage may be required, requiring a quantitative approach. Whether 
detailed quantification of DNA repair will be required or whether detection of regions 
of platinum-DNA damage induction will be discriminatory is unclear at present. 
 At present the DIP-chip assay has been developed using a custom-designed 
DNA microarray to examine a short section of chromosome 17 at very high 
resolution. Examining only a section of the genome allows very high resolution to be 
achieved and also allows four microarrays to be printed on each glass slide. It is 
likely, given the heterogeneous pattern of damage induction observed in this region, 
that this section of the genome is representative of the genome as a whole and 
consequently, examining this section of the genome alone may be sufficient to 
demonstrate the aforementioned differences between samples. Therefore, by 
designing the high-resolution human arrays in this way we may have developed an 
approach that allows the coverage of the microarray to be reduced whilst maintaining 
the sensitivity, resolution and depth of information obtained. This would be an 
advantageous and pragmatic outcome as it would reduce DNA requirements, 
potentially making the microarray approach more applicable to analysing clinical 
samples, and having four microarrays per slide increases the throughput of the assay 
by allowing greater numbers of samples to be analysed at once. Another outcome of 
this work might be that following microarray analysis, either of a short section of the 
genome or of the whole genome, that the genomic data output can be distilled down 
to certain key discriminatory regions. Clinical samples could then be analysed only 
for these pre-defined discriminatory regions. Customised DNA microarrays, DNA 
sequencing or, possibly even PCR- based approaches could then be used to only 
analyse these specific key regions, and again this would vastly increase the 
throughput of the assay, increasing its potential clinical utility. 
 This remains a highly relevant area of clinical cancer research with clear 
potential applications for this assay in addressing fundamental questions such as 
predicting response and toxicity to these agents and in individual treatment 
stratification. Many other therapeutic anticancer agents, such as the alkylating agents, 
act by damaging DNA at specific nucleotides or specific nucleotide sequences. The 
platinum analogues may therefore be viewed as a paradigm as this approach and the 
assay could be applied to detecting DNA damage from a variety of chemotherapeutic 
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DNA-damaging agents and could be used for a wide variety of tumour types. 
Cisplatin is also very commonly used in combination with radiotherapy as a 
radiosensitising agent. A further very interesting clinical application of this assay 
would therefore be to investigate how DNA damage levels of agents such as cisplatin 
are affected by concurrent radiotherapy treatment. 
 Another potential application of this work is to correlate genomic DNA 
damage induction with other elements of genetic and cellular metabolism such as 
epigenetic or transcriptional information. For example, histone H3 acetylation was 
measured in response to cisplatin or UV-induced DNA damage and presented in 
chapter 6 and, interestingly, striking similarities were evident between epigenetic 
histone acetylation responses to UV and platinum induced DNA damage. The Circos 
plot presented in figure 4.14 allows the complete DNA damage dataset from the 
custom-designed human microarrays to be visualised in a single figure. By looking at 
such plots one can easily imagine how these other elements of information could be 
integrated into these plots and also how information from, for example, DNA repair 
and DNA repair factor binding could also be incorporated. It is possible that by 
studying other biological parameters following exposure to these agents, rather than 
the DNA damage itself, that characteristic signatures capable of predicting response 
and outcome to treatment may also be revealed. Measuring epigenetic modifications 
such as histone acetylation and assimilating this with information derived from 
genomic DNA damage spectra may reveal the mechanisms biological systems employ 
in response to genetic damage and thus provide a mechanistic systems view of 
genome stability and the response to DNA damage. Such approaches are likely to 
provide important insights for characterising the organisation of DNA repair 
mechanisms as well as having the potential to reveal strategies for enhancing or 
potentiating initial damage induction.  
 This assay could also be used for more basic research applications. For 
example, correlating DNA damage and repair with DNA repair factor binding could 
provide important mechanistic information for the organisation of DNA repair within 
the cell. Characterising DNA repair factor and transcription factor binding could also 
be informative for investigating the mechanisms of cell killing and how apoptosis is 
induced. These basic research applications could help highlight novel drug targets and 
the epigenetic studies could provide mechanisms for potentiating drug efficacy. DNA 
damage induction and its repair could also be investigated using wild type and repair-
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deficient cell lines to further characterise DNA repair mechanisms. In this thesis data 
was presented comparing platinum-induced and UV-induced DNA damage profiles 
and similarly powerful analysis could be performed comparing DNA repair patterns 
between these agents. 
 For the future direction of this work, a number of important steps will need to 
be characterised before this assay may be applied as a clinical test. One important area 
of this work will be to establish the lower limit of detection of the DIP-chip assay. 
This is an important detail prior to clinical application since overall DNA damage 
levels and DNA amounts obtained from clinical samples may be limited. During the 
technical development of this assay, described in chapters 3 and 4, high drug doses 
were utilised to ensure high levels of DNA damage were generated which, in turn, 
increased the amount of DNA detected during DIP. This enriched the DIP sample 
ensuring that good amounts of DNA could be processed for microarray hybridisation. 
Optimisation of the DIP assay, performed in human DNA samples and outlined in 
chapter 4, has however increased the assay sensitivity significantly, and consequently 
it is likely that DNA amount, DNA damage level and drug dose may now be reduced 
without compromising microarray outcome. The logical approach to establishing this 
lower limit would initially be to repeat dose titration DIP assays using reducing dose 
levels, followed by DNA amount titration DIP assays using reducing amounts and 
correlating each of these changes with microarray validity. When applying this assay 
to clinical samples it is likely that natural variation in DNA damage spectra will be 
encountered between individuals. The fundamental challenge will then lie in 
extracting and validating the biologically meaningful variation, or DNA damage 
signatures, from the background noise between samples and it may be possible to do 
this using the outlier detection method presented in this thesis. 
 When considering the low amounts of DNA available from clinical samples, it 
is envisaged that using DNA sequencing rather than microarrays may be necessary. 
As discussed in section 1.8.7 of chapter 1, there are a number of recognised benefits 
to using DNA sequencing over microarrays, including lower DNA requirements, 
higher throughput, greater genomic coverage and higher resolution. For example, to 
cover the whole human genome at the resolution used for the human microarray work 
presented in this thesis would require the use of around 300 microarrays. 
Furthermore, by using DNA sequencing genomic coverage is no longer limited to, or 
restricted by, a fixed number of probes or sequences imprinted on a DNA microarray. 
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A number of alternative sequencing platforms, including next generation sequencing, 
have now been established with consequent improved access to machines and reduced 
cost. Therefore, it is likely that another key future development of the work presented 
in this thesis will be to establish DNA sequencing approaches allied to the DIP 
element of the assay. 
 Despite the obvious attraction and potential benefits to adopting a DIP-
sequencing (DIP-seq) approach, this is not to say that the microarray approach 
becomes redundant. Microarrays remain a well-established, robust and reliable 
laboratory technique, widely used and validated in both laboratory research and 
industry. In fact, given the clear technical development established in this thesis, 
along with better awareness of the bioinformatic challenges associated with DNA 
microarrays, it is likely that DNA microarrays will continue to play an important role 
in many areas of basic laboratory research. 
 Another area where microarrays may continue to provide a rapid, simple and 
important application is in the field of genotoxicity testing. At present, genotoxicity 
testing often involves low resolution assessments of the efficacy and toxicity of new 
compounds and these are often still made based on crude laboratory assays or by 
using animal models. For instance, if information is not required for entire genomes 
but rather for a selected number of genes, for example those with known roles in 
cancer, then using the DIP-chip microarray assay may offer a simple and robust 
screening solution for measuring genomic damage following exposure to novel 
therapeutic agents. There is also the potential for the damage detection DIP-chip assay 
to be applied as an alternative to animal-based genetic toxicology in this field.  
 An area where the DIP-chip assay may be further developed is microarray 
data normalisation. In the work presented in this thesis, samples have been normalised 
by applying quantile normalisation. This is a suitable approach for normalising DIP-
chip datasets and allows comparisons to be made between biological replicates. Many 
such comparative analyses have been presented in chapters 3-5 of this thesis and these 
have proven to be useful and powerful techniques for analysing this genomic data and 
have established a number of significant findings that offer considerable insight into 
the induction of these DNA damage lesions. Semi-quantitative analysis such as the 
outlier detection approach presented in chapter 3 and 5 provide sufficient sensitivity 
to detect meaningful differences in DNA damage induction between samples and such 
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an approach could be applied to identifying characteristic patterns of damage or 
signatures predictive of response in clinical samples. 
 For performing quantitative comparisons however, for example between 
microarray datasets from different treatment conditions or different repair times, a 
robust and novel normalisation method will be required as, currently, no standard 
method for normalising DIP-chip microarray datasets exists. A validated 
normalisation procedure has been applied to the histone acetylation ChIP-chip 
datasets presented in chapter 6 which relies on the presence of a background sub-
population within the microarray data. As discussed in section 3.2.7 of chapter 3, in 
the case of DIP-chip damage datasets, the whole genome is a potential site for DNA 
damage and therefore the whole genome is potentially enriched. Consequently, for 
DIP-chip datasets no background subpopulation exists, and the solution currently 
being developed by our research group is to add artificial DNA fragments to the 
hybridisation DNA mix (termed spike-ins) to fulfil the role of the background, 
undamaged, sub-population. In this instance varying concentrations of E. Coli DNA 
will be added, which have corresponding E. Coli probes included on the custom-
designed DNA microarrays. Successfully establishing such a normalisation technique 
would make the DIP-chip assay a genuinely quantitative assay capable of allowing 
formal and robust comparisons to be made between DNA damage and repair samples. 
 Finally, as discussed in section 1.4.9, chapter 1, recent advances in next 
generation sequencing technologies are now enabling genome-wide mutation analyses 
and the sequencing of individual cancer genomes. Studies applying these technologies 
are providing remarkable insight into the acquisition of mutation in cancer genomes 
and, by revealing the presence of mutational signatures embedded within the genomes 
of cancer cells, are making fundamental observations on cancer development (Nik-
Zainal et al., 2012a, Nik-Zainal et al., 2012b, Alexandrov et al., 2013a). Some of the 
mutational signatures identified can be attributed to known genotoxins and the results 
of these analyses appear to reveal the life history of mutagen exposure of an 
individual to these genotoxins. These mutations are likely to reflect the associated 
DNA repair capacity of the genome in question, and it would therefore be desirable, 
to be able to detect and measure the early mutation-determining events, such as the 
DNA damage and repair spectra with a view to correlating these with mutational end-
points. The DIP-chip DNA damage assay described here could be used to further 
refine our understanding of the mechanisms of mutation, offering the possibility of 
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identifying predictive DNA damage signatures associated with these mutational end-
points. This might enable these early signatures to be used as predictive markers for 
subsequent end-points including cancer predisposition and the response to drug 
treatments of diseases. 
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Appendix I - Liquid and solid media 
 
1. Growth media 
YPD (1 L) 
10 g Bacto Yeast Extract 
20 g Bacto Peptone 
20 g Glucose 
Made up to 1000 ml with H2O. Autoclave at 125°C for 15 minutes. 
 
 
2. Stock Solutions for DNA and chromatin preparation 
PBS (1 L) 
NaCL      8 g 
KCl      0.2 g 
Na2HPO4.2H H20    1.8 g 
KH2PO4     0.24 g 
H2O      800 ml 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4.2H2O, 2 mM KH2PO4) 
Adjust the pH to 7.4. Add H2O to 1 L.  
Autoclave at 125°C for 15 minutes. 
 
1 M Tris 
Tris base       121.1 g 
H2O            800 ml 
Adjust the pH to the desired value (7.6 or 8.0) by adding concentrated HCl.  
Add H2O to make 1 L. 
 
0.5 M EDTA (pH 8.0) 
EDTA . Na2 . 2H20    186.1 g 
H2O      800 ml 
pH was adjusted with NaOH to pH 8.0. 
Add approximately 100 ml H2O to make 1 L  
Autoclave at 125°C for 15 minutes. 
 
10 x Tris-EDTA (TE) Buffer (400 ml) 
40 ml 1 M Tris-HCl (pH 7.5) 
8 ml 0.5 M EDTA (pH 8.0) 
352 ml of H20 
 
Sorbitol TE (1L) (Kept in cold room) 
Sorbitol     165 g 
Tris . HCl 1M (pH 8.0)   100 ml 
EDTA 0.5 M      200 ml 
(0.9 M sorbitol, 0.1 M Tris-HCl [pH 8.0], 0.1 M EDTA) 
Add 500 ml H20 to dissolve the sorbitol. Adjust the final volume to 1 L.  
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3 M Sodium acetate (pH 5.2) (400 ml) 
Sodium acetate . 3H20        163.24 g 
H2O              300 ml 
Adjust the pH to 5.2 with acetic acid.  
Add H2O to make 400 ml  
Use filter to sterilise. 
 
5 M NaCL (400 ml) 
Dissolve 116.9 g of NaCl in 350 ml of H20. Adjust the volume to 400 ml with H20. 
Sterilise by autoclaving. 
 
10% SDS (Sodium dodecyl sulfate) (1 L) 
Dissolve 100g of SDS in 800 ml of distilled H20. Add distilled H20 to make a total 
volume of 1 L. 
 
20% SDS (Sodium dodecyl sulfate) (500 ml) 
Dissolve 100 g of SDS in 350 ml of distilled H20. Add dissolved H20 to make a total 
volume of 500 ml. 
 
DNA Lysis Buffer (1 L) 
Urea          240 g 
NaCl          11.69 g 
CDTA          5 g 
SDS                          5 g 
1 M Tris-HCl (pH 8.0)       100 ml 
(4 M urea, 200 mM NaCl, 100 mM Tris-HCl [pH 8.0], 10 mM CDTA, 0.5% SDS) 
Add 700 ml of H2O to dissolve the chemicals and then adjust the final volume to 1 L.  
 
FA/SDS Buffer + PMSF 
HEPES-KOH (pH 7.5)        50 mM 
NaCl           150 mM 
EDTA           1 mM 
Triton-X 100          1% 
Sodium Deoxycholate         0.1% 
SDS                  0.1% 
PMSF          1 mM *Added just before use 
 
PMSF (Phenylmethylsulfonyl fluoride)  
1.75 g of the serine protease inhibitor PMSF is dissolved in 100 ml 100% ethanol to 
make 100 mM PMSF in 100 ml. Stored at 4°C. 
 
 
3. Solutions for gel electrophoresis 
50 x TAE (Tris-acetate) (1 L) 
Tris base     242 g 
Sodium Acetate . 3 H20   136 g 
0.5 M EDTA     200 ml 
H2O                                500 ml 
Adjust to pH 7.2 with acetic acid.  
Add H2O to make 1 L. 
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Non-denaturing loading buffer (10 ml)  
Ficoll 10%     1 g 
SDS 0.5%     0.5 ml of 10% solution 
Bromophenol Blue 0.06%       6 mg 
Made up in 1 x TAE solution. 
 
 
4. Solutions for immuno-slot-blots 
10 x TBST 
Tris-Base (1 M, pH 8.0)        100 ml 
NaCl (5 M)                    300 ml 
Tween 20                     5 ml 
Add H2O to make 1 L 
(containing 100 mM Tris-base [pH 8], 500 mM NaCl, Tween 20 made in H2O) 
 
 
5. Solutions for ChIP and DIP 
FA/SDS Buffer + PMSF 
HEPES-KOH (pH 7.5)   50 mM 
NaCl      150 mM 
EDTA      1 mM 
Triton X-100     1% 
Sodium Deoxycholate    0.1% 
SDS      0.1% 
PMSF      1 mM *Added just before use 
The NaCl concentration can be adjusted from 150 mM to 500 mM or 1000 mM 
depending on different protein-antibody binding characteristics. 
 
PMSF (Phenylmethylsulfonyl fluoride)  
1.75g of the serine protease inhibitor PMSF is dissolved in 100ml 100% ethanol to 
make 100 mM PMSF in 100ml. Stored at 4°C.  
 
5 x Pronase Buffer (100 ml) 
1 M Tris (pH 7.5)    12.5 ml 
0.5 M EDTA     5 ml 
10% SDS     25 ml 
Add H2O to make 100 ml. 
(125 mM Tris pH 7.5, 25 mM EDTA, 2.5% SDS) 
1x Pronase Buffer – 25 mM Tris pH 7.5, 5 mM EDTA, 0.5% SDS 
 
LiCl Buffer (500 ml) 
1 M Tris-Cl (pH 8.0)    5 ml 
5 M LiCl     25 ml 
0.5 M EDTA     1 ml 
NP40      2.5 ml 
10% Sodium Deoxycholate   25 ml 
10 mM Tris-Cl (pH 8.0), 250 mM LiCl, 1 mM ETDA, 0.5% NP40, 0.5% Sodium 
Deoxycholate) 
Add H2O to make 500 ml. 
Appendix II 
 
 268 
Appendix II – Raw data and supplementary figure for 
chapter 3 
 
Figure 3.4 Platinum ISB result 
 
Cisplatin Oxaliplatin 
Untreated 151004.89 124975.36 
0.5mM 692461.80 758706.89 
1mM 768418.04 766763.28 
 
 
Figure 3.5 (a) Cisplatin treated DNA in vitro 
 
 IP 
Fold 
enrichment Mean SD SE 
Experiment 1 U 0.00018 1    
 0.05mM 0.00104 5.8427    
 0.1mM 0.00318 17.8652    
 0.5mM 0.00266 14.9438    
 1mM 0.01 56.1798    
 2mM 0.0166 93.2584    
       
Experiment 2 U 0.00018 1    
 0.05mM 0.00089 4.9719    
 0.1mM 0.00284 15.9551    
 0.5mM 0.00257 14.4382    
 1mM 0.00938 52.6966    
 2mM 0.0162 91.0112    
       
Experiment 3 U 0.00018 1 1 0 0 
 0.05mM 0.00089 4.9719 5.26 0.50 0.29 
 0.1mM 0.00265 14.8876 16.24 1.50 0.87 
 0.5mM 0.00285 16.0112 15.13 0.80 0.46 
 1mM 0.00981 55.1123 54.66 1.78 1.03 
 2mM 0.0114 64.0449 82.77 16.26 9.39 
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Figure 3.5 (a) Oxaliplatin treated DNA in vitro 
  IP Fold enrichment Mean SD SE 
Experiment 1 U 0.0073 1    
 0.05mM 0.0132 1.8207    
 0.1mM 0.0541 7.4621    
 0.5mM 0.109 15.0345    
 1mM 0.281 38.7586    
 2mM 0.229 31.5862    
       
Experiment 2 U 0.0073 1    
 0.05mM 0.0124 1.7103    
 0.1mM 0.0582 8.0276    
 0.5mM 0.085 11.7241    
 1mM 0.246 33.9310    
 2mM 0.241 33.2414    
       
Experiment 3 U 0.0073 1 1 0 0 
 0.05mM 0.0106 1.4620 1.66 0.18 0.10 
 0.1mM 0.059 8.1379 7.88 0.36 0.21 
 0.5mM 0.106 14.6207 13.79 1.80 1.04 
 1mM 0.209 28.8276 33.84 4.97 2.87 
 2mM 0.161 22.2069 29.01 5.95 3.44 
 
 
Figure 3.5 (b) - Cisplatin treated cells in culture 
    
    
 
 
IP IN IP/IN 
Fold 
enrichment 
 
Mean 
 
SD 
 
SE 
Experiment 1 Untreated 0.000012 0.000964 0.0124 1 1   
 0.5mM 0.000212 0.003420 0.0620 4.9798 4.98   
 1mM 0.000095 0.000729 0.1303 10.4688    
 
     
   
Experiment 2 Untreated 0.000014 0.001100 0.0124 1    
 1mM 0.000069 0.000908 0.0763 6.1730    
 
     
   
 Untreated 0.000014 0.001100 0.0124 1    
 1mM 0.000076 0.001340 0.0569 4.5995 7.08 3.04 1.75 
 
     
   
Experiment 3 Untreated 0.000044 0.000988 0.0447 1    
 2.5mM 0.000508 0.001160 0.4379 9.7890    
 
     
   
 Untreated 0.000044 0.000988 0.0447 1    
 2.5mM 0.000605 0.001160 0.5216 11.6582 10.72 1.32 0.93 
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Figure 3.5 (b) - Oxaliplatin treated cells in culture 
 
 
IP IN IP/IN 
Fold 
enrichment 
 
Mean 
 
SD 
 
SE 
Experiment 1 Untreated 0.000015 0.000988 0.0147 1    
 2.5mM 0.000076 0.000964 0.0787 5.3648    
 5mM 0.000182 0.001120 0.1625 11.0724    
 
 
       
Experiment 2 Untreated 0.000015 0.000988 0.0147 1 1 0 0 
 2.5mM  0.000095 0.000964 0.0984 6.7078 6.04 0.95 0.67 
 5mM 0.000137 0.001120 0.1223 8.3347 9.70 1.94 1.37 
 
 
Figure 3.6 – NACN repair studies 
NACN pre-IP 
 
IP IN IP/IN Fold enrichment 
Cisplatin Untreated 0.000249 0.000837 0.2975 1 
 1mM 0.000301 0.001400 0.2150 0.72 
 2.5mM 0.002250 0.004470 0.5034 1.69 
 
 
    
Oxaliplatin Untreated 0.000473 0.002430 0.1947 1 
 5mM 0.000565 0.002850 0.1982 1.01 
 
 
NACN pre-IP No NACN pre-IP 
Cisplatin 1mM 0.723 6.17 
Cisplatin 2.5mM 1.692 9.79 
Oxaliplatin 5mM 1.018 11.07 
 
 
 
	  
Figure	  1	  -­‐	  Example	  of	  density	  curves	  showing	  the	  distribution	  of	  the	  total	  log2	  IP/IN	  ratios	  
for	   two	   separate	   microarray	   datasets.	   (a)	   shows	   the	   typical	   normal	   distribution	   of	   the	  microarray	   log2	   IP/IN	   ratio	   values	   from	   a	   cisplatin-­‐induced	   DNA	   damage	   microarray	   dataset,	  with	   no	   discernable	   background	   subpopulation.	   (b)	   shows	   a	   typical	   distribution	   of	   the	  microarray	  log2	  IP/IN	  ratio	  values	  from	  a	  histone	  H3K14	  acetylation	  dataset	  demonstrating	  the	  bimodal	  positively	   skewed	  distribution	  of	   signals	   representing	   the	  background	  population	   and	  the	  separate	  enriched	  population.	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Appendix III - Raw data and supplementary figures for chapter 4 
 
 
Figure	   1	   -­‐	   Extracted	   human	   DNA	   examined	   by	   agarose	   gel	   electrophoresis.	   DNA	   was	  extracted	   from	   human	   dermal	   fibroblast	   cells	   using	   the	   QIAGEN	   DNeasy	   blood	   and	   tissue	  extraction	   kit	   and	   assessed	   by	   agarose	   gel	   electrophoresis	   using	   1%	   agarose	   gel.	   In	   (a)	   five	  samples	  of	  extracted	  DNA	  contaminated	  with	  RNA	  are	  presented.	  RNA	  can	  be	  seen	  as	  a	  second	  faint	  band	  below	  the	  brighter	  DNA	  band.	  First	  image	  is	  taken	  after	  running	  gel	  for	  10	  minutes	  at	  75V	  and	  the	  second	  after	  40	  minutes	  at	  75V.	  In	  (b)	  an	  example	  of	  pure	  genomic	  DNA	  is	  presented	  with	   DNA	   visible	   as	  white	   bands	   and	   no	   second	   RNA	   bands	   visible.	   First	   image	   is	   taken	   after	  running	  gel	  for	  15	  minutes	  at	  75V	  and	  the	  second	  after	  45	  minutes	  at	  75V.	  	  
 
 
	  
Figure	  2	   -­‐	  Melt	   curve	  and	  standard	  curve	   for	   typical	  qRT-­‐PCR	  experiment	  using	  primers	  
for	  28s	  gene.	  This	  demonstrates	  qRT-­‐PCR	  data	  from	  a	  DIP	  experiment	  of	  a	  NaCN	  repair	  study	  of	  cisplatin	  and	  oxaliplatin	  treated	  human	  DNA.	  In	  (a)	  a	  typical	  example	  of	  a	  melt	  curve	  produced	  using	   these	  primers	   is	   shown.	  The	   single,	   sharp	  peak	   represents	   a	   single	  melting	   temperature,	  confirming	   the	   formation	   of	   a	   single	   PCR	   product.	   In	   (b)	   the	   standard	   curve	   for	   this	   PCR	  experiment	   is	   shown.	   Four	   standards	   are	   displayed	   as	   green	   spots	   representing	   serial	   10-­‐fold	  DNA	  dilutions	  plotted	  from	  -­‐1	  to	  -­‐4	  on	  the	  x	  axis.	  The	  sample	  values	  are	  then	  calculated	  relative	  to	   these	  standards	  and	  are	   represented	  by	   the	  green	  crosses	  plotted	  along	   the	  standard	  curve.	  Samples	  containing	  relatively	  little	  DNA,	  such	  as	  an	  untreated	  IP	  sample	  will	  lie	  to	  the	  lower	  end,	  left,	  of	  the	  curve,	  whilst	  samples	  containing	  relatively	  high	  amounts	  of	  DNA	  will	  lie	  at	  the	  higher	  end,	  right,	  of	  the	  curve.	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Figure	   3	   -­‐	   Typical	   agarose	   gel	   electrophoresis	   studies	   demonstrating	   DNA	   sample	  
fragment	   length	   following	  sonication.	  1.2%	  agarose	  gel	  used.	  In	  (a),	  (b)	  and	  (c)	  the	  same	  five	  DNA	  samples	  are	  displayed	  having	  undergone	  25	  cycles	  of	  sonication	  and	  gel	  images	  taken	  after	  running	   gel	   for	   20,	   40	   and	   60	  minutes	   at	   75V	   respectively.	   FastRuler™	   low	   range	  DNA	   ladder	  (Fermentas)	  is	  used	  with	  the	  fragment	  lengths	  in	  base	  pairs	  given	  displayed	  on	  image	  (b).	  
 
 
 
 
	  
Figure	  4	  -­‐	  Agarose	  gel	  electrophoresis	  demonstrating	  the	  PCR	  amplicons	  for	  different	  gene	  
loci	   of	   chromosome	  17.	  PCR	  amplicons	  were	  generated	  as	  outlined	  in	  section	  4.2.5.	   In	  the	  gel	  image	  presented	  lane	  1	  represents	  the	  product	  for	  PIRT	  open	  reading	  frame	  (ORF),	  lane	  2	  -­‐	  PIRT	  promoter,	  lane	  3	  -­‐	  MYH13	  ORF,	  lane	  4	  -­‐	  MYH13	  promoter,	  lane	  5	  -­‐	  MYH8	  ORF	  and	  lane	  6	  -­‐	  MYH8	  promoter.	  1%	  agarose	  used,	  gel	  ran	  for	  40	  minutes	  at	  75V.	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Figure	  5	  -­‐	  Titration	  assays	  using	  CP9/19	  antibody	  in	  DIP	  experiments.	  Examples	  of	  antibody	  titration	   DIP	   assays	   for	   cisplatin	   (a)	   and	   oxaliplatin	   (b)	   respectively	   using	   CP9/19	   antibody.	  Examples	   are	   given	   in	   each	   case	   of	   titrations	   using	   different	   DNA	   amounts.	   Fold	   increase	  represents	   the	   relative	   amount	   of	   immunoprecipitated	   DNA	   using	   different	   antibody	   amounts	  over	  the	  zero	  antibody	  determined	  by	  qRT-­‐PCR.	  0.5	  mM	  cisplatin	  treated	  fibroblasts	  were	  used	  for	  the	  cisplatin	  antibody	  titrations	  and	  1.25	  mM	  and	  1	  mM	  oxaliplatin	  treated	  fibroblasts	  were	  used	  for	  the	  4	  and	  3	  µg	  oxaliplatin	  antibody	  titrations	  respectively.	  Figure	  5	  (c)	  &	  (d)	  show	  DIP	  assays	   for	  different	  DNA	  amounts	  using	  cisplatin	  and	  oxaliplatin	  damaged	  DNA	  extracted	   from	  cells	  treated	  in	  culture	  respectively.	  For	  the	  DIP	  studies	  using	  different	  DNA	  amounts	  0.5	  µg	  and	  1.5	  µg	  of	  CP9/19	  antibody	  were	  used	  for	  the	  cisplatin	  and	  oxaliplatin	  studies	  respectively	  and	  0.5	  mM	  cisplatin	  and	  1.25	  mM	  oxaliplatin	   treatments	  were	  used.	   In	  each	  case	  cells	  were	   incubated	  with	  drug	  for	  2	  hours.	  
 
   
Figure	   6	   -­‐	   DNA	   immunoprecipitation	   studies	   capturing	   UV-­‐induced	   DNA	   damage	   using	  
anti-­‐thymine	   dimer	   antibody.	   This	   figure	   displays	   the	   data	   from	   a	   single	   DIP	   study	   of	   UV	  treated	   human	   DNA	   in	   vitro	   and	   UV	   treated	   cells	   in	   culture.	   Human	   dermal	   fibroblasts	   were	  exposed	  to	  50	  J/m2	  whilst	  naked	  DNA	  was	  exposed	  to	  300	  J/m2.	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Figure 4.4 (a) ISB of platinum treated DNA in vitro  
 
 
Cisplatin Oxaliplatin 
Untreated 126430.485 65523.216 
0.05 µM 119325.736 93907.215 
0.5 µM 56248.278 376832.52 
5 µM 285305.586 982842.912 
50 µM 741404.334 1132257.324 
100 µM 1055693.783 895278.642 
250 µM 1118655.328 1177822.036 
500 µM 1168652.007 1138800.685 
	  
Figure 4.4 (b) ISB of platinum treated cells in culture 
 
 
Cisplatin Oxaliplatin 
Untreated 99636.741 99636.741 
5 µM 159820.242 91648.797 
125 µM 581723.478 235275.505 
500 µM 626209.589 516942.893 
 
 
Figure 4.4 (c) ISB of platinum treated DNA in vitro 
 
Cisplatin 1µg 2µg 
Untreated 49621.258 126430.485 
50 µM 442724.158 741404.334 
100 µM 418519.226 1055693.783 
500 µM 618624.803 1168652.007 
 
 
Figure 4.5 (a-c,f) DIP studies of cisplatin-induced DNA damage using CP9/19 
antibody 
 
 
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Experiment 1 Untreated 0.0007 0.0254 0.0269 1.0000    
Fibroblasts 0.05 mM 0.0026 0.0193 0.1337 4.9695    
 0.1 mM 0.0030 0.0246 0.1207 4.4882    
 0.5 mM 0.0104 0.0254 0.4094 15.221    
 1 mM 0.0266 0.0226 1.1770 43.754    
         
Experiment 2 Untreated 0.0004 0.0153 0.0248 1 1 0 0 
Fibroblasts 0.05 mM 0.0009 0.0213 0.0423 1.7057 3.338 2.3078 1.6319 
 0.1 mM 0.0027 0.0200 0.1325 5.3489 4.9186 0.6087 0.4304 
 0.5 mM 0.0080 0.0173 0.4636 18.714 16.968 2.4702 1.7467 
 1 mM 0.0222 0.0221 1.0045 40.552 42.153 2.2643 1.6011 
         
Experiment 3 Untreated 0.0007 0.0254 0.0269 1 1 0 0 
MDA-MB- 0.05 mM 0.0042 0.0166 0.2518 9.3644 5.3465 3.8432 2.2189 
231 cells 0.1 mM 0.0029 0.0203 0.1443 5.3677 5.0683 0.5025 0.2901 
 0.5 mM 0.0163 0.0224 0.7277 27.061 20.332 6.0837 3.5124 
 1 mM 0.0261 0.0228 1.1447 42.572 42.292 1.6192 0.9349 
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Figure 4.5 (d,f) DIP studies of oxaliplatin-induced DNA damage using CP9/19 
antibody 
 
 
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Experiment 1 Untreated 0.00006 0.0021 0.0306 1.0000    
 0.05 mM 0.00009 0.0023 0.0382 1.2477    
 0.1 mM 0.00011 0.0022 0.0478 1.5595    
 0.5 mM 0.00010 0.0019 0.0512 1.6725    
 1 mM 0.00080 0.0029 0.2754 8.9919    
         
Experiment 2 Untreated 0.00006 0.0021 0.0283 1.0000    
 0.05 mM 0.00009 0.0023 0.0407 1.4370    
 0.1 mM 0.00011 0.0022 0.0473 1.6692    
 0.5 mM 0.00022 0.0019 0.1155 4.0744    
 1 mM 0.00047 0.0029 0.1612 5.6878    
         
Experiment 3 Untreated 0.00007 0.0021 0.0318 1.0000 1.000 0 0 
 0.05 mM 0.00008 0.0023 0.0342 1.0748 1.253 0.181 0.105 
 0.1 mM 0.00009 0.0022 0.0389 1.2243 1.484 0.232 0.133 
 0.5 mM 0.00027 0.0019 0.1444 4.5410 3.429 1.539 0.889 
 1 mM 0.00067 0.0029 0.2322 7.3021 7.327 1.652 0.953 
 
Figure 4.5 (e) DIP studies of oxaliplatin-induced DNA damage using CP9/19 
antibody 
 
 
IP IN IP/IN Fold enrichment 
Untreated 0.0009 0.0177 0.0481 1.0000 
1 mM 0.0062 0.0269 0.2316 4.8114 
2 mM 0.0094 0.0227 0.4132 8.5844 
3 mM 0.0116 0.0219 0.5297 11.0039 
4 mM 0.0162 0.0205 0.7902 16.4170 
 
 
Figure 4.6 (a) NaCN removal of cisplatin-induced adducts in MDA-MB-231 cells 
	   	  No NACN treatment IP Fold increase 
Untreated 0.0007 1.0000 
50 µM 0.0005 0.6929 
100 µM 0.0009 1.3434 
500 µM 0.0053 8.0939 
1000 µM 0.0161 24.6975 
   NACN treatment before qRT-PCR  IP Fold increase 
Untreated 0.0005 1.0000 
50 µM 0.0046 8.5806 
100 µM 0.0042 7.7825 
500 µM 0.0104 19.2949 
1000 µM 0.0286 53.0420 
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Figure 4.6 (b) - NaCN removal of oxaliplatin-induced adducts in MDA-MB-231 
cells 
 
No NACN treatment before qRT-PCR     
 
IP IN IP/IN Fold enrichment 
Untreated 0.0009 0.0177 0.0481 1 
I mM 0.0062 0.0269 0.2316 4.81 
2 mM 0.0094 0.0227 0.4132 8.58 
3 mM 0.0116 0.0219 0.5297 11.00 
4 mM 0.0162 0.0205 0.7902 16.42 
     
NACN treatment before qRT-PCR     
 
IP IN IP/IN Fold enrichment 
Untreated 0.0005 0.0213 0.0225 1 
1 mM 0.0015 0.0276 0.0536 2.38 
2 mM 0.0050 0.0044 1.1222 49.80 
3 mM 0.0118 0.0080 1.4732 65.37 
4 mM 0.0118 0.0049 2.4033 106.64 
 
 
Figure 4.6 (c) - NaCN removal of cisplatin-induced adducts in fibroblasts 
 
NACN treatment 
before qRT-PCR 
 
 
      
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Untreated (1) 0.00038 0.01530 0.02477 1 
  
 
Cisplatin 0.5 mM (1) 0.00802 0.01730 0.46358 18.714 
  
 
       
 
Untreated (2) 0.00070 0.01530 0.04556 1 
  
 
Cisplatin 0.5 mM (2) 0.00813 0.01730 0.46994 10.316 
  
 
       
 
Untreated (3) 0.00044 0.01530 0.02902 1 1 0 0 
Cisplatin 0.5 mM (3) 0.00905 0.01730 0.52312 18.027 15.69 4.66 2.69 
        
No NACN treatment        
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Untreated (1) 0.00005 0.0027 0.0189 1.0000    
Cisplatin 0.5 mM (1) 0.0002 0.0022 0.1064 5.6375    
        
Untreated (2) 0.00004 0.0027 0.0164 1.0000    
Cisplatin 0.5 mM (2) 0.0005 0.0022 0.2178 13.2579    
        
Untreated (3) 0.00033 0.0027 0.1233 1.0000 1 0 0 
Cisplatin 0.5 mM (3) 0.0003 0.0022 0.1521 1.2331 6.71 6.08 3.51 
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Figure 4.6 (c) - NaCN removal of oxaliplatin-induced adducts in fibroblasts 
 
NACN treatment 
before qRT-PCR 
       
 
IP IN IP/IN  Fold 
enrichment 
 Mean SD SE 
Untreated (1) 0.00006 0.00206 0.03063 1.00000 
  
 
Oxaliplatin 1 mM (1) 0.00080 0.00289 0.27543 8.99193 
  
 
       
 
Untreated (2) 0.00006 0.00206 0.02835 1.00000 
  
 
Oxaliplatin 1 mM (2) 0.00047 0.00289 0.16125 5.68778 
  
 
       
 
Untreated (3) 0.00007 0.00206 0.03180 1.00000 1 0 0 
Oxaliplatin 1 mM (3) 0.00067 0.00289 0.23218 7.30215 7.32 1.65 0.95 
        
No NACN treatment        
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Untreated (1) 0.00005 0.00266 0.01887 1.00000    
Oxaliplatin 1 mM (1) 0.00038 0.00280 0.13536 7.17231    
        
Untreated (2) 0.00004 0.00266 0.01643 1.00000    
Oxaliplatin 1 mM (2) 0.00043 0.00280 0.15500 9.43478    
        
Untreated (3) 0.00033 0.00266 0.12331 1.00000 1 0 0 
Oxaliplatin 1 mM (3) 0.00020 0.00280 0.07107 0.57637 5.73 4.60 2.66 
 
 
Figure 4.6 (d) - NaCN removal of platinum-induced adducts prior to DIP 
 
Cisplatin 
    
 
 
IP IN IP/IN 
Fold 
enrichment 
Previous 
enrichment with 
same samples 
Untreated 0.00003 0.00174 0.01908 1  
Cisplatin  0.00007 0.00136 0.05059 2.65 27.06 
     
 
Oxaliplatin 
    
 
 
IP IN IP/IN 
Fold 
enrichment 
 
Untreated 0.00003 0.00144 0.01771 1  
Oxaliplatin 0.00002 0.00030 0.05268 2.98 6.77 
 
 
 
 
 
 
Appendix III 
 
 278 
Figure 4.11 (a) - DIP studies comparing different concentration sodium chloride 
washes 
 
1 mM NaCl 
washes 
 
 
      
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Untreated (1) 0.000047 0.0027 0.0176 1.0000 
  
 
cisplatin 1mM (1) 0.00294 0.0032 0.9304 52.9938 
  
 
       
 
Untreated (2) 0.000023 0.0027 0.0086 1.0000 
  
 
cisplatin 1mM (2) 0.00508 0.0032 1.6076 186.7337 
  
 
       
 
Untreated (3) 0.000064 0.0027 0.0239 1.0000 1 0 0 
cisplatin 1mM (3) 0.00290 0.0032 0.9177 38.4431 92.72 81.74 47.19 
        
Untreated (1) 0.00007 0.00266 0.02816 1.00000    
oxaliplatin 1mM (1) 0.00052 0.00280 0.18393 6.53204    
        
Untreated (2) 0.00005 0.00266 0.01906 1.00000    
oxaliplatin 1mM (2) 0.00042 0.00280 0.14929 7.83235    
        
Untreated (3) 0.00006 0.00266 0.02218 1.00000 1 0 0 
oxaliplatin 1mM (3) 0.00048 0.00280 0.17143 7.72881 7.36 0.72 0.42 
        
0.5 mM NaCl washes        
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
Untreated (1) 0.0004 0.0153 0.0248 1.0000    
cisplatin 1mM (1) 0.0222 0.0221 1.0045 40.5521    
        
Untreated (2) 0.0007 0.0153 0.0456 1.0000    
cisplatin 1mM (2) 0.0268 0.0221 1.2127 26.6196    
        
Untreated (3) 0.0004 0.0153 0.0290 1.0000 1 0 0 
cisplatin 1mM (3) 0.0486 0.0221 2.1991 75.7796 47.65 25.34 14.62 
        
Untreated (1) 0.0001 0.0021 0.0306 1.0000    
oxaliplatin 1mM (1) 0.0008 0.0029 0.2754 8.9919    
        
Untreated (2) 0.0001 0.0021 0.0283 1.0000    
oxaliplatin 1mM (2) 0.0005 0.0029 0.1612 5.6878    
        
Untreated (3) 0.0001 0.0021 0.0318 1.0000 1 0 0 
oxaliplatin 1mM (3) 0.0007 0.0029 0.2322 7.3021 7.32 1.65 0.95 
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Figure 4.11 (b) - DIP studies demonstrating effect of different protocol changes 
on qRT-PCR enrichment	  
 
 
IP IN IP/IN Fold 
enrichment 
Mean SD SE 
NaCN treatment        
No cisplatin treatment 0.0000522 0.00279 0.01874  
  
 
Cisplatin + NACN 
treatment 0.0008032 0.00267 0.30120 16.07315 
  
 
Cisplatin + NACN 
treatment 2 0.0009354 0.00267 0.35076 18.71793 17.40 1.87 1.32 
       
 
Phenol Chloroform 
extraction     
  
 
No cisplatin treatment 0.0000522 0.00409 0.01277 1.00000 
  
 
Cisplatin + NACN 
treatment + Phenol 
Chlor extraction 1 IP 
0.0019567 0.00256 0.76520 59.94134 
  
 
Cisplatin + NACN 
treatment + Phenol 
Chlor extraction 2 IP 
0.0014912 0.00256 0.58319 45.68347 
52.81 10.08 7.13 
        
No NACN treatment        
No cisplatin treatment 0.0000524 0.00238 0.02205 1.00000    
Cisplatin + No NaCN 0.0006321 0.00255 0.24750 11.22708    
Cisplatin + No NaCN 0.0001857 0.00255 0.07270 3.29762    
Cisplatin + No NaCN 0.0005621 0.00255 0.22009 9.98368    
Cisplatin + No NaCN 0.0003498 0.00255 0.13695 6.21243 7.68 3.62 1.81 
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Figure 4.11 (c,d) - Optimisation of DIP protocol to improve quality and 
enrichment of the DIP sample 
 
Cisplatin in vitro 
Experiment 1 
IP IN IP/IN Fold 
enrichment 
Mean SD SE  
Untreated  0.00010 0.00090 0.1145 1.00     
Cisplatin 2.5 mM 0.02898 0.00047 62.152 542.69     
cisplatin 2 IP 
samples 0.05054 0.00047 108.37 946.25 
    
         
Cisplatin in vitro 
Experiment 2 
        
Untreated  0.0001 0.0015 0.0491 1.00     
Cisplatin 2.5 mM 0.0210 0.0006 35.470 722.16 632.4 126.9 89.74  
cisplatin 2 IP 
samples 0.0353 0.0006 59.597 1213.35 1080 188.9 133.5 
 
         
Cisplatin treated in 
culture  
IP IN IP/IN Fold 
enrichment 
Mean 2 
replicates 
Mean SD SE 
Untreated 0.00002 0.0012 0.0196 1.00     
Cisplatin 1a 2.5 mM 0.01263 0.0011 11.509 587.26     
Cisplatin 1b 2.5 mM 0.01313 0.0011 11.96 610.27 598.8    
Cisplatin 2a 2.5 mM 0.01240 0.0010 12.423 633.93     
Cisplatin 2b 2.5 mM 0.01206 0.0010 12.081 616.45 625.1 611.9 18.68 13.21 
         
Oxaliplatin in vitro 
Experiment 1 
IP IN IP/IN Fold 
enrichment 
Mean 2 
replicates 
Mean SD SE 
Untreated 0.00006 0.00033 0.1787      
Oxaliplatin 2.5 mM 0.00322 0.00005 63.044 352.85     
         
Oxaliplatin in vitro 
Experiment 2     
    
Untreated 0.00017 0.00115 0.1510 1.0000     
Oxaliplatin 2.5 mM 0.00847 0.00009 90.222 597.66     
Oxaliplatin 2.5 mM 0.00656 0.00009 69.905 463.08 530.37 441.6 125.5 88.76 
         
Oxaliplatin in 
culture 
Experiment 1 
IP IN IP/IN Fold enrichment 
Mean 2 
replicates 
Mean SD SE 
Untreated 0.00017 0.00115 0.1510 1.0000     
Oxaliplatin 2.5 mM 0.02618 0.00099 26.43 175.06     
Oxaliplatin 2.5 mM 0.02402 0.00099 24.25 160.64     
         
Oxaliplatin in 
culture 
Experiment 2 
    
    
Untreated 0.00008 0.00127 0.0652 1.0000     
Oxaliplatin 1a 2.5 
mM 
0.01239 0.00114 10.869 166.68     
Oxaliplatin 1b 2.5 
mM 
0.01005 0.00114 8.8017 134.98 150.83    
Oxaliplatin 2a 2.5 
mM 
0.01162 0.00120 9.6877 148.57     
Oxaliplatin 2b 2.5 
mM 
0.00429 0.00120 3.5744 54.81 101.69 147.0 31.84 15.92 
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Appendix IV - Data and supplementary figures for chapter 6 
 
 
  
Figure 1 - Example of an antibody titration study using qRT-PCR and using the histone H3 K14 
antibody for ChIP studies. Different volumes of H3 K14 antibody were added, from 0 to 5µl, and the 
fold increase in IP calculated relative to the 0 antibody control. Fold increase represents the relative 
amount of immunoprecipitated DNA using different antibody amounts determined by qRT-PCR using 
primers for MFA2. The fold increase with additional antibody amounts reaches a plateau at 1µl 
antibody amount. Following this, 2µl of the H3 K14 antibody was used as the optimal amount for ChIP 
experiments. For this study histone H3 K14 acetylation at 1 hour following cisplatin treatment were 
used. 
 
 
 
 
IP Fold increase 
0 µl 0.00019 1.00000 
0.5 µl 0.00151 7.90576 
1 µl 0.00190 9.94764 
2 µl 0.00186 9.73822 
3 µl 0.00207 10.83770 
5 µl 0.00194 10.15707 
 
Table 1 - Data for histone H3 K14 acetylation antibody titration  
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Figure	  2	  -­‐	  Chromatin	  immunoprecipitation	  and	  qRT-­‐PCR	  of	  histone	  H3	  K14	  acetylation	  at	  
the	   MFA2	   promoter	   locus	   following	   oxaliplatin	   treatment	   in	   Saccharomyces	   cerevisiae.	  Yeast	   cells	   were	   incubated	   with	   250	   μM	   oxaliplatin	   for	   4	   hours	   in	   PBS	   and	   cells	   were	   either	  harvested	   immediately	   post	   treatment	   (0	   hour),	   or	   were	   transferred	   back	   to	   YPD	   following	  incubation	  with	  oxaliplatin	  and	  allowed	  to	  incubate	  for	  1	  or	  2	  hours.	  Untreated	  yeast	  cells	  were	  also	  transferred	  to	  PBS	  for	  4	  hours	  and	  harvested	  immediately	  post	  incubation	  as	  for	  the	  0	  hour	  samples.	   Data	   shown,	   in	   each	   case,	   are	   values	   for	   single	   experimental	   samples.	   Raw	   qRT-­‐PCR	  data	  is	  given	  in	  e-­‐appendix,	  chapter	  6.	  
 
 
 
	  
IP	   IN	   IP/IN	   Fold	  enrichment	  
U	   0.001000	   0.001020	   0.980392	   1.000000	  
0	  hour	   0.000788	   0.000876	   0.899543	   0.917534	  
1	  hour	   0.00291	   0.000681	   4.273127753	   4.358590308	  
2	  hour	   0.00796	   0.000446	   17.84753363	   18.2044843	  
	  
Table	  2	   -­‐	  qRT-­‐PCR	  data	  for	  oxaliplatin	  treated	  ChIP	  of	  histone	  H3	  K14	  acetylation	  at	  the	  MFA2	  promoter	  locus	  following	  oxaliplatin	  treatment	  in	  Saccharomyces	  cerevisiae.	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Figure 6.1 – Data for cisplatin-induced histone H3 K14 acetylation using ChIP 
 
 
Experiment 1 
    
 
 
 
 
 
IP IN IP/IN 
Fold 
enrichment 
 
Mean 
 
SE 
U 0.00039 0.00110 0.35636 1.00000 	   	  
1 hour 0.00057 0.00019 2.96859 8.33022 	   	  
     
	   	  
Experiment 2 
    
	   	  
 
IP IN IP/IN 
Fold 
enrichment 
	   	  
U 0.00037 0.00110 0.33909 1.00000 	   	  
0 hour 0.00040 0.00128 0.30938 0.91237 	   	  
1 hour 0.00083 0.00020 4.20305 12.39504 	   	  
     
	   	  
Experiment 3 
    
	   	  
 
IP IN IP/IN 
Fold 
enrichment 
	   	  
U 0.00051 0.00153 0.33595 1.00000 	   	  
0 hour 0.00024 0.00091 0.26821 0.79837 	   	  
1 hour 0.00026 0.00023 1.12069 3.33591 	   	  
2 hour 0.00055 0.00040 1.36160 4.05300 	   	  
     
	   	  
Experiment 4 
    
	   	  
 
IP IN IP/IN 
Fold 
enrichment 
	   	  
U 0.000850 0.000976 0.870902 1.000000 	   	  
0 hour 0.000821 0.000889 0.923510 1.060406 	   	  
1 hour 0.002510 0.000671 3.740686 4.295187 	   	  
2 hour 0.003900 0.000522 7.471264 8.578769 	   	  
     
	   	  
Experiment 5 
    
	   	  
 
IP IN IP/IN 
Fold 
enrichment 
  
U 0.000967 0.000907 1.066152 1.000000 1  
0 hour 0.000739 0.000840 0.879762 0.825175 0.91 0.07 
1 hour 0.002910 0.000684 4.254386 3.990412 6.46 1.73 
2 hour 0.003570 0.000657 5.433790 5.096636 5.93 1.36 
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Figure 6.3 – Validation of histone H3 K14 acetylation ChIP chip data 
 
qRT-PCR data is given in this appendix. MFA2 data as presented in previous table. 
PSK1 and POL30 data are presented in this table. The microarray raw data values and 
statistical values are presented in sheet 2 of the Excel file in the electronic appendix 
entitled ‘Figure 6.3 - Raw data for qRT-PCR and microarray validation’. 
 
 
Histone	  H3	  K14	  Acetylation	  at	  PSK1	  
	   	  
	   	  
	   	   	   	   	  
	   	  
Experiment	  1	  
	   	   	  
	  
Mean	  
	  
SE	  
	  
IP	   IN	   IP/IN	  
	  
	   	  
U	   0.00016	   0.00117	   0.13419	   1.00000	   	   	  
0	  hour	   0.00023	   0.00067	   0.33976	   2.53199	   	   	  
1	  hour	   0.00031	   0.00014	   2.24638	   16.74052	   	   	  
	   	   	   	   	  
	   	  
	   	   	   	   	  
	   	  
Experiment	  2	  
	   	   	  
	   	  
	  
IP	   IN	   IP/IN	  
	  
	   	  
U	   0.00018	   0.00297	   0.05892	   1.00000	   1.0000	   0.0000	  
0	  hour	   0.00010	   0.00054	   0.17874	   3.03353	   2.78	   0.25	  
1	  hour	   0.00019	   0.00023	   0.80342	   13.63516	   15.19	   1.55	  
	   	   	   	   	  
	   	  
Histone	  H3	  K14	  Acetylation	  at	  POL30	  	  
	   	  
	   	  
	   	   	   	   	  
	   	  
Experiment	  1	  
	   	   	   	  
	   	  
	  
IP	   IN	   IP/IN	  
	  
	   	  
U	   0.000263	   0.001230	   0.21382	   1.00000	   	   	  
0	  hour	   0.000391	   0.001090	   0.35872	   1.67764	   	   	  
1	  hour	   0.001350	   0.000141	   9.57447	   44.77793	   	   	  
	   	   	   	   	  
	   	  
Experiment	  2	  
	   	   	   	  
	   	  
	  
IP	   IN	   IP/IN	  
	  
	   	  
U	   0.000380	   0.001160	   0.32759	   1.00000	   1.0000	   0.0000	  
0	  hour	   0.000261	   0.000739	   0.35318	   1.07813	   1.38	   0.30	  
1	  hour	   0.000378	   0.000388	   0.97423	   2.97396	   23.88	   20.90	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